<SEC-DOCUMENT>0001628280-22-008988.txt : 20220412
<SEC-HEADER>0001628280-22-008988.hdr.sgml : 20220412
<ACCEPTANCE-DATETIME>20220412161419
ACCESSION NUMBER:		0001628280-22-008988
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20220412
DATE AS OF CHANGE:		20220412

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Context Therapeutics Inc.
		CENTRAL INDEX KEY:			0001842952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				863738787
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261599
		FILM NUMBER:		22822420

	BUSINESS ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		267-225-7416

	MAIL ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Context Therapeutics LLC
		DATE OF NAME CHANGE:	20210128
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>contexttherapeutics424b3-p.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i47e1006ae0674fccb030b14d141d1ccd_7"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed Pursuant to Rule 424(b)(3)<br>Registration No. 333-261599</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROSPECTUS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">10,000,000 Shares </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Common Stock </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="image_26.jpg" src="image_26.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption &#8220;Selling Stockholders&#8221; on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">110</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of up to 10,000,000 shares of our common stock. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling stockholders or their permitted transferees or other successors-in-interest may, but are not required to, sell the shares of our common stock offered by this prospectus from time to time in a number of different ways and at varying prices as determined by the prevailing market price for shares or in negotiated transactions. See &#8220;Plan of Distribution&#8221; on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">125</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of how the selling stockholders may dispose of the shares covered by this prospectus. We do not know when or in what amount the selling stockholders may offer the shares for sale. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not selling any shares of our common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling stockholders. We have agreed to pay certain expenses related to the registration of the offer and sale of the shares of common stock pursuant to the registration statement of which this prospectus forms a part. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;CNTX.&#8221; On April 1, 2022, the last reported closing sale price of our common stock on the Nasdaq Capital Market was $2.40 per share. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; under the federal securities laws and have elected to comply with certain reduced public company reporting requirements. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of this prospectus to read about factors you should consider before buying shares of our common stock. </font></div><div style="margin-bottom:16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The date of this prospectus is April 12, 2022 </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PROSPECTUS SUMMARY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DIVIDEND POLICY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">BUSINESS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">57</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MANAGEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">92</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXECUTIVE COMPENSATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PRINCIPAL STOCKHOLDERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">108</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SELLING STOCKHOLDERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">110</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">TRANSACTIONS WITH RELATED PERSONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">115</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SHARES ELIGIBLE FOR FUTURE SALE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">119</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY&#8217;S COMMON STOCK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">121</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">125</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">127</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">127</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">127</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.  The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investors outside the United States&#58; We have not taken any action to permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock, and the distribution of this prospectus outside the United States. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDUSTRY AND MARKET DATA </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from independent industry analysts and publications, as well as our own estimates and research. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates are derived from publicly available information released by third party sources, as well as data from our internal research, and are based on such data and our knowledge of our industry, which we believe to be reasonable. The independent industry publications used in this prospectus were not prepared on our behalf. While we are not aware of any misstatements regarding any information presented in this prospectus, forecasts, assumptions, expectations, beliefs, estimates and projects involve risk and uncertainties and are subject to change based on various factors, including those described under the headings &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221; </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_16"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRADEMARKS AND TRADE NAMES </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this prospectus are listed without the&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_19"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENT PRESENTATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC, and which resulted in all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converting into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. In this prospectus, we refer to this transaction as the &#8220;reorganization.&#8221; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights information that we present more fully in the rest of this prospectus. This summary does not contain all of the information you should consider before buying our shares in this offering. This summary contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; You should read the entire prospectus carefully, including the &#8220;Risk Factors&#8221; section and the financial statements and the notes to those statements. Unless the context requires otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Context Therapeutics,&#8221; &#8220;Context,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer, prior to the reorganization discussed herein, to Context Therapeutics LLC and its consolidated subsidiaries, and after the reorganization, to Context Therapeutics Inc. and its consolidated subsidiaries. </font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE COMPANY</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context Therapeutics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, our founders and management team have decades of experience identifying and characterizing the mechanisms that drive cancer initiation and subsequent relapse in women with cancer and who have been associated with the development of products such as Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus) to treat such cancers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers. Our first program and lead product candidate,&#160;onapristone extended release (ONA-XR), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers. ONA-XR is a selective and potentially potent antagonist of the progesterone receptor (PR), a receptor that is activated by the hormone progesterone and that has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, that are prescribed to treat female hormone-dependent cancers. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate  ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b&#47;2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate  ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021 MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in women with second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4&#47;6 and&#47;or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate  a sub-study of its Phase 2 trial in 2L&#47;3L metastatic breast cancer, that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors. Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancers, including ovarian and endometrial tumors, and absent from healthy adult tissues. We expect to select a candidate to support IND-enabling studies for  CLDN6xCD3 bsAb in the second half of 2022. Beyond these two product candidates, we continue to evaluate opportunities to expand our pipeline. We believe our team and capabilities uniquely position us to be a leader in developing novel therapies to address female cancers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context retains worldwide development and commercialization rights for ONA-XR outside of Greater China and retains full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. Our product candidates are shown in the table below&#58; </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="a20220323_pipelineslide.jpg" src="a20220323_pipelineslide.jpg" style="height:351px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop and commercialize innovative and differentiated oncology products that address significant unmet medical needs in the field of female cancers. The key components of our strategy to achieve this goal include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leveraging the insights, experience and networks of our management team and advisors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">focusing on drugs and programs that have the opportunity to be first or second in market based on current competition&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing clinical development and obtaining regulatory approval for ONA-XR for the treatment of breast, ovarian and endometrial cancer&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancing our second program, CLDN6xCD3 bsAb, as rapidly as reasonably possible through preclinical and clinical development&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating opportunities to accelerate development timelines and enhance the commercial potential of our programs in collaboration with third parties, which may entail the potential out-licensing of our product candidates, including our lead product candidate ONA-XR&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licensing or acquiring additional drug candidates to build a fully integrated company focused on female cancers. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus on Female Hormone-Dependent Cancers </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 70% of women with breast, ovarian and endometrial cancer have hormone-dependent cancer. The hormones estrogen and progesterone drive cancer progression in these patients, but anti-estrogens are the only antihormonal therapy that is FDA approved and available to clinicians. Treatment of these patients to date, therefore, has consisted of anti-estrogens alone or in combination with drugs that enhance the antitumor activity of anti-estrogens, including inhibitors of CDK4&#47;6 or PI3K&#945;. Given the broad use of anti-estrogens, anti-estrogen resistance is now a major clinical challenge. Treatment options for anti-estrogen resistance are limited, provide modest therapeutic benefit and are associated with side effects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estrogen and progesterone are master regulators of normal female sex organ development and function, acting via estrogen receptors (&#8220;ER&#8221;) and progesterone receptors (&#8220;PR&#8221;). In hormone-dependent cancers, ER and PR are often hyperactive, constantly pushing breast, ovary, and endometrial tissues to grow, divide and metastasize. To block this hormone-mediated growth, patients are administered anti-estrogen therapy (fulvestrant, letrozole, anastrozole or tamoxifen) to block ER signaling and may be used in combination with inhibitors of CDK4&#47;6 or PI3K&#945;. The cancer cells respond to this selective pressure of ER inhibition, however, by further activating progesterone signaling as a compensatory mechanism, along with other resistance mechanisms that can induce PR signaling, including ER ligand binding mutations (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), growth factor signaling and enrichment of cancer stem cells. Over time, all patients become resistant to anti-estrogens due to direct or indirect compensatory signaling mediated by the PR and other factors. Therefore, PR and proteins that regulate PR represent ideal drug targets to address anti-estrogen resistance.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Anti-estrogen Resistance Mechanisms </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="image_5.jpg" src="image_5.jpg" style="height:332px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a portfolio of novel agents targeting multiple resistance mechanisms by leveraging our specialized expertise in hormone-dependent cancers. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline and Development </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PR antagonist program&#58; ONA-XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONA-XR is currently being evaluated in three Phase 2 trials, and one Phase 1b&#47;2 trial in women with primary or metastatic breast, ovarian, and endometrial cancers. These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help inform which patients may be most suitable for treatment with ONA-XR, we are evaluating multiple biomarker assays, including tools to monitor activated progesterone receptor as well as a PR gene activation signature that measures PR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. We expect to report preliminary data from two of our ongoing trials in mid-2022 and from the other two trials in the second half of 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLDN6xCD3 bispecific antibody program </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in ovarian and endometrial tumors and absent from healthy adult tissues. The structural complexity of CLDN6 and its similarity to proteins expressed on healthy tissue, particularly Claudin 9 (CLDN9), have limited its exploitation for targeted oncology therapies. Several pharmaceutical companies are developing anti-CLDN6 antibodies and&#47;or bispecific antibodies. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other preclinical programs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product candidates, we are leveraging our knowledge in female cancers to pursue discovery stage research programs. We continue to evaluate new opportunities to expand our pipeline in female cancers.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Management Team </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team to develop novel products to treat female cancers. Members of our management team have experience leading organizations that have advanced multiple oncology therapeutics from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization. Our team&#8217;s select accomplishments include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Executive Officer co-founded Context in 2015 and was previously a venture capitalist at Osage University Partners, where he led multiple oncology investments for the firm that resulted in successful public offerings or acquisitions. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Financial Officer previously served as Chief Financial Officer of Millendo Therapeutics, a publicly-traded biopharmaceutical company.  Prior to Millendo, our CFO served as Director of Technical Accounting at PAREXEL International and began her career as an auditor at Ernst &#38; Young.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Legal Officer previously served as Vice President, Deputy General Counsel and Assistant Corporate Secretary of OptiNose, a publicly-traded specialty pharmaceutical company. Prior to OptiNose, he served as Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Medical Officer previously held the same position at H3 Biomedicine, where he led the early phase development for an oral selective estrogen receptor covalent antagonist (SERCA). During his career, he has either led or supported global drug development programs for several novel oncology drugs, including Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus), resulting in successful global registrations. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our management team has been involved in several multimillion-dollar strategic transactions, including as part of the leadership teams at Celgene and Novartis Therapeutics. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supported by our advisors who are leading experts in female cancers. Our arrangements with these individuals do not entitle us to any of their existing or future intellectual property derived from their independent research or research with other third parties beyond what has previously been licensed to us. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Financing </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January through April 2021, we entered into unit purchase agreements with certain investors, under which we sold an aggregate of 738,445 Series&#160;A convertible preferred units, at a per price share of $7.168, for an aggregate purchase price of approximately $5.3 million, and issued 184,597 warrants to purchase common member units at an exercise price of $7.168 (the &#8220;Series A Financing&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Integral Transaction </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of CLDN6xCD3 bsAb. Under the terms of the agreement, we will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6xCD3 bsAb candidates. We paid an upfront license fee of $0.3 million and granted Integral 418,559 Series A Units with a fair market value of approximately $2.8 million. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3 million, sales milestone payments totaling up to $130 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. See &#8220;Business&#8212;Our Collaboration and License Agreements&#8221; for more information. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tyligand Successful Completion </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August of 2021, Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) achieved &#8220;successful completion&#8221; under the Tyligand Process Development Agreement after successfully optimizing the ONA-XR manufacturing process. As a result, we have entered into a license agreement whereby we have granted Tyligand an exclusive license to develop and commercialize ONA-XR in the People&#8217;s Republic of China, including Hong Kong and Macau, subject to Tyligand paying us a mid-single digit royalty of net sales of ONA-XR in such countries. We have retained our global exclusive rights for ONA-XR for the remainder of the world. As a result of the completion of this milestone, Tyligand was granted a warrant (which is no longer outstanding) and we paid Tyligand $800,000. Tyligand will be eligible to receive manufacturing and development milestone payments totaling up to $5.0 million upon the achievement of certain future milestones. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reorganization </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC, and which resulted in all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converting into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the board of managers of Context Therapeutics LLC have become the directors of Context Therapeutics Inc.&#8217;s board of directors, and the officers of Context Therapeutics LLC have become the officers of Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements included elsewhere in this prospectus are those of Context Therapeutics Inc. (formerly Context Therapeutics LLC) and its subsidiaries.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2021 Private Placement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2021, we entered into a securities purchase agreement for a private placement (the &#8220;Private Placement&#8221;) with a select group of accredited investors, which we collectively refer to as the Purchasers. Pursuant to the securities purchase agreement, the Purchasers purchased 5,000,000 shares of our common stock, par value $0.001 per share, together with warrants to purchase 5,000,000 shares of common stock. The purchase price for each share of common stock and accompanying warrant was $6.25 per unit, for an aggregate purchase price of $31,250,000. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. The closing of the purchase and sale of the securities occurred on December 6, 2021.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a registration rights agreement with the Purchasers requiring us to register the resale of the shares. We were required to, and did, prepare and file a registration statement with the SEC no later than 10 days following the date of the Private Placement. In connection with the Private Placement, we terminated that certain Investors&#8217; Rights Agreement that we entered into in connection with the Series A Financing.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section titled &#8220;Risk Factors.&#8221; You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never been profitable and may never achieve or maintain profitability. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have not initiated or completed any large-scale or pivotal clinical trials and have no products approved for commercial sale. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on a central team consisting of a limited number of employees who provide various administrative, research and development, and other services across our organization, which presents operational challenges that may adversely affect our business. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional capital to finance our operations. If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts or we might have to obtain funds through arrangements, such as out-licensing our product candidates, with collaborative partners or others that may require us to relinquish rights to our technologies or product candidates that we would otherwise not relinquish. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of our first program and lead product candidate, ONA-XR, which is currently in early stage clinical trials. If we are unable to complete development of, obtain approval for and commercialize ONA-XR for one or more indications in a timely manner, our business, financial condition, results of operations and prospects would be materially and adversely affected. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our prospects depend in part upon discovering, developing and commercializing additional product candidates. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our innovative therapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the FDA, European Medicines Agency (the &#8220;EMA&#8221;) and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical development, and these third parties may not perform satisfactorily, which may substantially harm our business. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property as well as to operate without infringing the intellectual property rights of third parties. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be impacted. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate History </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC, and which resulted in all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converting into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. We were previously organized as a limited liability company in Delaware in April 2015 under the name &#8220;Context Therapeutics LLC.&#8221; Our principal executive offices are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103. Our telephone number is (267) 225-7416. Our website address is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.contexttherapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Information contained on the website is not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have three wholly-owned subsidiaries&#58; Context Therapeutics LLC, which was formed in the State of Delaware in April of 2015, Context Therapeutics Ireland Limited, which was incorporated under the Companies Act 2014 in Ireland in April 2018, and Context Biopharma, Inc., which was incorporated in the State of Delaware in December 2017. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implications of Being an Emerging Growth Company </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We  qualify as an &#8220;emerging growth company&#8221; under the Jumpstart Our Business Act of 2012, as amended, or the JOBS Act. As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have an auditor report on our internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (i.e., certain audit matters)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submit certain executive compensation matters to stockholder advisory votes, such as &#8220;say-on-pay&#8221; and &#8220;say-on-frequency&#8221;&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of October 19, 2026 or (i)&#160;the last day of the first fiscal year in which our total annual gross revenues exceed $1.07&#160;billion, (ii)&#160;the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which would occur if the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter, or (iii)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the preceding three-year period. </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE OFFERING</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuer </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Context Therapeutics Inc.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offered by the Selling Stockholders </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10,000,000 shares of common stock.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock to be outstanding immediately after this offering </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,966,053 shares of common stock.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of proceeds </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not receive any proceeds from the sale of shares in this offering. See the section titled &#8220;Selling Stockholders&#8221; for additional information. </font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk factors </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing in our common stock involves a high degree of risk and purchasers of our common stock may lose part or all of their investment. See &#8220;Risk Factors&#8221; for a discussion of factors you should carefully consider before deciding to invest in our common stock.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq trading symbol </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;CNTX.&#8221;</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of our common stock to be outstanding immediately after this offering is based on 15,966,053 shares of our common stock outstanding as of March 18, 2022, assumes the issuance of all of the shares issuable upon exercise of the Warrants sold in the Private Placement and excludes the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,180,222 shares of common stock issuable upon the exercise of options outstanding as of March 18, 2022, at a weighted-average exercise price of $3.48 per share&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">707,817 shares of common stock reserved for issuance under our 2021 Incentive Plan, as more fully described in &#8220;Executive Compensation &#8212; 2021 Incentive Plan&#8221; as of March 18, 2022&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">860,000 shares of common stock issuable upon the exercise of warrants outstanding as of March 18, 2022, at a weighted average exercise price of $7.82,</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY FINANCIAL INFORMATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our consolidated financial data for our business. We have derived the summary consolidated statement of operations data for the years ended December&#160;31, 2021 and 2020 from our audited consolidated financial statements included elsewhere in this prospectus. Our financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. Our historical results are not necessarily indicative of our future results. You should read this data together with our consolidated financial statements and related notes appearing elsewhere in this prospectus and the information contained under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations Data</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,087,832&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805,067&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632,920&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,525,819)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,572,168)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,240)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,224)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,877,857&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,872&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,635,197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,221,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,305,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033,415&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,272,335&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with general economic and business risks and all of the other information contained in this prospectus, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes, before making a decision to invest in our common stock. Our business, results of operations, financial condition or prospects could also be harmed by risks and uncertainties that are not presently known to us or that we currently believe are not material. If any of the risks actually occur, our business, results of operations, financial condition and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks described below. See &#34;Special Note Regarding Forward-Looking Statements.&#34;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never been profitable and may never achieve or maintain profitability. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not commercialized any products and have yet to generate any revenue from product sales. The amount of our future net losses will depend, in part, on our expenses and our ability to generate revenues. Our current and future product candidates will require substantial additional development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our current research and development programs, including conducting laboratory, preclinical and clinical studies for product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate clinical trials for product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire or develop additional research programs or product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that may successfully complete development&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop and refine the manufacturing process for our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional manufacturers or suppliers of pharmaceutical or biological materials or product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our anti-hormonal resistance therapies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other technologies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain new and existing personnel&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our facilities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first program and lead product candidate, ONA-XR, is currently in Phase 2 clinical trials. No clinical studies have begun on our second program, CLDN6xCD3 bsAb. It will be several years, if ever, before we obtain regulatory approval for a therapeutic product candidate, at which time any revenues for such product candidate will depend upon many factors, including, market conditions, costs and effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, and the terms of any collaboration or other strategic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement we may have with respect to such product candidate and levels of reimbursement from third-party payors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, including through the potential out-licensing of our product candidates, or if revenues from any product candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability or sustain profitability, which would have an adverse effect on the value of our common stock which would be materially adversely affected. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of identifying product candidates and conducting preclinical and clinical trials is time consuming, expensive, uncertain and takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical trials of, and seek marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution efforts. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and&#47;or commercialization efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and&#47;or commercialization efforts or we might have to obtain funds through arrangements, such as out-licensing our product candidates, with collaborative partners or others that may require us to relinquish rights to our technologies or product candidates that we otherwise would not relinquish. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were founded in 2015 and spent the first three years of our company&#8217;s history developing and refining our therapeutic approach, and only since then have we focused our efforts on advancing the development of product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is a highly speculative endeavor and entails substantial upfront capital expenditures. There is significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our product candidates and the therapeutic approach we are using are new and unproven. We have commenced Phase 2 human clinical trials for one of our product candidates, but have not demonstrated an ability to initiate clinical trials for our other product candidates or successfully complete any clinical trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to do any of the foregoing on our behalf. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. Our limited operating history, particularly in light of the rapidly evolving nature of the biopharmaceutical industries and the female cancer therapeutics field, may make it difficult to evaluate our technology and business prospects or to predict our future performance. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. The successful completion of a clinical trial with regard to any of our product candidates is not assured despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs and product candidates may not yield any commercially viable products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by the ongoing coronavirus pandemic. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel Coronavirus (&#8220;COVID-19&#8221;) has evolved into a global pandemic. The extent to which the COVID-19 pandemic impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain the virus or treat its impact, among others. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should COVID-19 continue to spread, our business operations could be delayed or interrupted. For instance, our research and development may be affected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our research activities, including clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infections and deaths related to the pandemic have disrupted and may continue to disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and&#47;or approval. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a shelter-in-place order or other mandated local travel restrictions, our employees and consultants conducting research and development or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. New or renewed restrictions may be implemented in response to evolving conditions, new variants of the virus (including the Omicron variant) and overall uncertainty about the timing of widespread availability of vaccines. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our governing documents designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of state law actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware) will be the sole and exclusive forum for&#58; (1) any derivative action or proceeding brought on our behalf&#59; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders&#59; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended &#38; restated certificate of incorporation or amended &#38; restated bylaws&#59; (4) any action to interpret, apply, enforce or determine the validity of our amended &#38; restated certificate of incorporation or amended &#38; restated bylaws&#59; or (5) any action asserting a claim governed by the internal affairs doctrine. In addition, our amended &#38; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision shall not apply to claims seeking to enforce any liability or duty created by the Exchange Act. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Product Candidates </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the successful development, regulatory approval and commercialization of our therapeutic product candidates, ONA-XR and CLDN6xCD3 bsAb, which are in the early stages of development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of ONA-XR and CLDN6xCD3 bsAb, as well as other product candidates derived from our anti-hormone resistant therapy approach, which may never occur. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may also become dependent on other product candidates that we may develop or acquire&#59; however, not all of our product candidates have been tested in humans and given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy of a female cancer treatment sufficient to warrant approval for commercialization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;), to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise any additional required capital on acceptable terms, or at all&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete IND-enabling studies and successfully submit an IND&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely completion of our preclinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consistently provide for manufacturing of our product candidates on a timely basis&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&#8220;cGMPs&#8221;)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our lead product candidates or any future product candidates or approved products, if any&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our anti-hormone resistant therapy approach&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop a commercial strategy and thereafter commercialize our current product candidates or any future product candidates in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others, including through the potential out-licensing of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience of our treatment or dosing regimen&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient demand for our current or future product candidates, if approved&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and enforce intellectual property rights in and to our product candidates&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidate or any future product candidates to continue our business or achieve profitability. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our innovative therapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foundational science and product development approach are based on the selective targeting of female cancers, including by inhibiting progesterone receptor binding to chromatin, and by inhibiting CLDN6, in each case to elicit meaningful anticancer activity. We believe that this approach may offer an improved therapeutic effect by downregulating PR effector functions associated with anti-estrogen resistant and inhibit tumor growth, as well as redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to develop therapeutics that effectively target anti-hormone treatment resistance and inhibit membrane protein targets is both preliminary and limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, we cannot assure you that even if we are able to develop cancer therapeutic candidates capable of addressing anti-estrogen resistance or redirecting T-cell-mediated lysis toward malignant cells, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, no regulatory authority has granted approval for a cancer therapy based on a selective targeting of PR+ or Claudin 6 positive cancers. As such, we believe the FDA has limited experience with evaluating our approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our ongoing clinical trials for ONA-XR and future clinical trials for our other product candidates are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies. Interim or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serious adverse events or undesirable side effects caused by ONA-XR, CLDN6xCD3 bsAb or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with ONA-XR to date, at high doses have experienced adverse events that include, but are not limited to, fatigue, liver enzyme elevations and nausea. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable side effects arise in the development of our product candidates, we, the FDA or the institutional review boards at the institutions in which our studies are conducted, or the data safety monitoring board, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products using our proprietary technologies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Besides our ONA-XR product candidate, all of our current product candidates and product development programs are still in the IND validation process. We may be unsuccessful in advancing those product candidates into clinical development or in identifying and developing additional product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biopharmaceutical development activities, including that&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates, including through the potential out-licensing of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to enter into collaborative arrangements to facilitate development of product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may be covered by third parties&#8217; patents or other exclusive rights&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate&#8217;s benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do commence additional clinical trials of product candidates and continue to identify new product candidates, such product candidates may never be approved. Failure to successfully identify and develop new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease operations. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborators or ourselves fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price of our common stock may decline. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability and professional indemnity exposure related to the testing in clinical trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the deterioration of a patient&#8217;s condition, patient injury or even death. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage when we expand our clinical trials and if our collaborators or ourselves successfully commercialize any products. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Organization, Structure and Operations </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on a central team consisting of a limited number of employees and consultants who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we had seven full-time employees. We also have three consultants who we rely on for research and development, business development and other services. While we believe this structure enables us to reduce certain infrastructure costs, the small size of our centralized team may limit our ability to devote adequate personnel, time and resources to support the operations of our business, including our research and development activities, and the management of financial, accounting and reporting matters. If our centralized team fails to provide adequate administrative, research and development, or other services across our entire organization, our business, financial condition and results of operations could be harmed. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our Chief Executive Officer, Chief Financial Officer, Chief Legal Officer, Chief Medical Officer, and other key executives and to attract, retain and motivate qualified personnel. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Martin Lehr, our Chief Executive Officer, Jennifer Minai-Azary, our Chief Financial Officer, Alex Levit, our Chief Legal Officer, and Tarek Sahmoud, our Chief Medical Officer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have formal employment agreements and consulting agreements with substantially all of our executive officers, these agreements do not prevent them from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and, if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel, will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to significantly expand our organization, and our future financial performance, ability to develop and commercialize product candidates alone or with collaborators and ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the biopharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give rise to operational mistakes, loss of business opportunities, loss of employees, consultants and contractors and reduced productivity. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. As a public company it may be more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance coverage is becoming increasingly expensive, and in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. We do not know if we </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working with collaborators poses several significant risks, including the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited availability of resource allocation and other developmental decisions made by our collaborators about the product candidates that we seek to develop with them may result in the delay or termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any product candidates that may receive approval&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, product candidates that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. If our collaborations, including those in which we may out-license our product candidates, do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive the expected deliverables or services from our collaborators, nor receive any future funding or milestone or royalty payments under the collaboration. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive the funding or expected deliverables or services from our collaborators, we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop such product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may need to raise additional capital to pursue further development or commercialization of the applicable product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which we operate. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our reputation and business prospects, delay or prevent the development and commercialization of product candidates and inhibit or preclude our ability to realize any revenues. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied on and we expect to continue to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied on and we expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;) to conduct preclinical studies and clinical trials for our product candidates. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have designed and intend to design future trials for our product candidates either alone or with collaborators, third parties may conduct some parts of or all of the trials. As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on third parties for the supply of various pharmaceutical and biological materials and the manufacture of product supplies that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all. If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur additional costs in procuring such materials. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and expect that we will rely on outside vendors, including vendors outside the United States, for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and&#47;or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators&#8217; potential products. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements, including the potential out-licensing of our product candidates, for the development and potential commercialization of current and future product candidates or the development of ancillary technologies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product, an assessment of the opportunities and risks of our product candidate, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and industry and market conditions generally. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, including out-licensing our lead product candidate, ONA-XR, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. Such collaborations may also impact our ability to control the nature, timing and cadence of developing and commercializing the product candidates subject to such collaborations. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics and pharmaceuticals, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of anti-estrogen resistance inhibition therapies for cancer. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often makes decisions consistent with the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory authorization to begin a trial, if applicable&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of financial resources to commence and complete the planned trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining approval at each clinical trial site by an independent institutional review board, or IRB&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting suitable patients to participate in a trial&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites deviating from trial protocol or dropping out of a trial&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any patient safety concerns that arise during the course of a trial&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that CLDN6xCD3 bsAb will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the Biologics Price Competition and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the Biologics Price Competition and Innovation Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that CLDN6xCD3 bsAb, if approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when our ongoing Phase 2 clinical trials for ONA-XR and planned clinical trials for our other initial product candidates are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. If the results from our clinical trials are sufficiently compelling, we intend to discuss with the FDA submission of a BLA or NDA, as applicable for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA or NDA, as applicable for the relevant product candidate. For example, the FDA may require that we conduct a comparative trial against an approved therapy, which would significantly delay our development timelines and require substantially more resources. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe an accelerated approval strategy is warranted given the limited alternatives for patients that our initial product candidates target, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or NDA, as applicable, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and&#47;or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical studies to assess new safety risks&#59; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of progesterone receptor and protein inhibitors as potential cancer treatments are recent developments and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which our product candidates are approved&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the labeling approved by the FDA&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of our product candidates as well as competitive products&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors and government authorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare&#160;&#38; Medicaid Services, or the CMS, revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of drugs and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the pharmaceutical and biotechnology industries, which includes biologics, are the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturers and importers of certain biologics with annual sales of more than $5 million made to or covered by specified federal healthcare programs are required to pay an annual, nondeductible fee according to their market share of all such sales&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% of the average manufacturer price for most branded drugs, biologics,and biosimilars and to 13.0% for generic drug, and cap of the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted, or injected&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program, commonly referred to as the &#8220;340B Program&#59;&#8221; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians, also known as the &#8220;Physician Payments Sunshine Act&#59;&#8221; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act of 2017, repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage that is commonly referred to as the &#8220;individual mandate.&#8221; In December&#160;2019, a U.S. District Court upheld a ruling that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In November 2020, the Supreme Court of the United States heard oral arguments in the appeal of this case.  While the Supreme </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court issued its ruling in July 2021, in part finding that the plaintiff&#8217;s lacked standing, it is unclear how this and other efforts to challenge, repeal, or replace the ACA, or how future changes in the Presidency, Congress or Senate, will impact the ACA or our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted which, among other things, have reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new laws or any other similar laws introduced in the future, as well as regulatory actions that may be taken by CMS, may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additionally, individual states in the United States have passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing and costs. Similar developments have occurred outside of the United States, including in the European Union where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some European Union member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. It is also possible that additional governmental action is taken in response to address the COVID-19 pandemic. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, particularly as a result of the recent presidential election, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our business position. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office (the USPTO) and its foreign counterparts are sometimes uncertain and could change in the future. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or designed around. U.S. patents and patent applications may also be subject to interference or derivation proceedings, and U.S. patents may be subject to reexamination, post-grant review and&#47;or inter parties review proceedings in the USPTO. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even if not challenged, our patents and patent applications may not adequately protect our technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications that we hold with respect to our product candidates or potential products is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product candidates or potential products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and&#47;or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and&#47;or applications. We rely on our outside counsel and employ an outside firm to pay these fees due to USPTO and non-US patent agencies. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market which would have a material adverse effect on our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our current and future research and development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators&#8217; ability to commercialize future product candidates. Any such outcome could have a material adverse effect on our business. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, trade secret and other intellectual property rights protection and contractual restrictions to protect ONA-XR, CLDN6xCD3 bsAb and other product candidates. Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to ONA-XR, CLDN6xCD3 bsAb and other product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect ONA-XR, CLDN6xCD3 bsAb and other product candidates from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets cover them. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain and maintain patent protection for ONA-XR, CLDN6xCD3 bsAb and other product candidates is uncertain due to a number of factors, including the following factors&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have been the first to invent the technology covered by our pending patent applications or issued patents&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compositions and methods may not be patentable&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any or all of our pending patent applications may not result in issued patents&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop identical, similar or alternative technologies, products or compositions, or methods of use thereof&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not seek or obtain patent protection in countries and jurisdictions that may eventually provide us a significant business opportunity&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide not to maintain or pursue patents and patent applications that, at some point in time, may cover our products, potential products, or product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged by third parties&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our representatives or their agents may fail to apply for patents in a timely fashion&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">despite our efforts to enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership and chain of title in patents and patent applications, an inventorship or ownership dispute could arise that may permit one or more third parties to practice our technologies or enforce our patent rights, including possible efforts to enforce patent rights against us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we have or obtain patents covering ONA-XR, CLDN6xCD3 bsAb or any other product candidates or compositions, others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that may cover ONA-XR, CLDN6xCD3 bsAb or any other product candidates or compositions. These patent applications may have priority over patent applications filed by us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available&#59; however the life of a patent, and the protection it affords, is limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without patent protection for current or future product candidates, we may be open to competition from generic or biosimilar versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we also try to protect our trade secrets, know-how and other proprietary information through non-disclosure and confidentiality provisions in our agreements with parties who have access to them, such as our employees, consultants and research partners. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets, know-how and&#47;or other proprietary information in the event of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized uses or disclosure or other breaches of the provisions, and we may not be able to prevent such unauthorized uses or disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure and uses is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. In addition, monitoring unauthorized disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the United States may be less willing to protect trade secrets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we may rely on third parties to manufacture our potential product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our current and potential product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, are used inappropriately to create new inventions or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Additionally, we may need to outsource and rely on third parties for many aspects of the development, sales and marketing of any products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to do so, we or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially extending the term of marketing exclusivity for such product candidates, our business may be harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology is common, including patent infringement lawsuits, and such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings before the USPTO and corresponding international patent offices. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous United States, EU and other internationally issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from a third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators might also be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators&#8217; ability to further develop or commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our or our collaborators&#8217; ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or our collaborators obtain a license. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and&#47;or being interpreted narrowly and could put our patent applications at risk of not issuing and&#47;or could impact the validity or enforceability positions of our other patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, and the laws of other countries, could diminish the value of patents in general, thereby impairing our ability to protect our products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO, and the courts and regulatory agencies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Market for Our Common Stock </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock may be volatile or may decline regardless of our operating performance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock is likely to be volatile, in part because our shares have been traded publicly for a short time. In addition, the market price of our common stock may fluctuate significantly in response to several factors, most of which we cannot control, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quarterly variations in our operating results compared to market expectations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity about us, the industries we participate in or individual scandals&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of new offerings or significant price reductions by us or our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock price performance of our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in stock market prices and volumes&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in senior management or key personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates by securities analysts&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market&#8217;s reaction to our reduced disclosure as a result of being an &#8220;emerging growth company&#8221; under the JOBS Act&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative earnings or other announcements by us or our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defaults on indebtedness, incurrence of additional indebtedness, or issuances of additional capital stock&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic, legal and regulatory factors unrelated to our performance&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors listed in this &#8220;Risk Factors&#8221; section. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility in the market price of our common stock may prevent investors from being able to sell their shares at or above their purchase price. As a result, you may suffer a loss on your investment. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, the market price for our common stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock to decline. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to advance or complete the development and commercialization of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for ONA-XR, CLDN6xCD3 bsAb or any other future product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical development plans we establish for ONA-XR, CLDN6xCD3 bsAb and any other future product candidates&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obligation to make milestone, royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">number and characteristics of product candidates that we discover or in-license and develop&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effects of competing technological and market developments&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of the implementation of commercial-scale manufacturing activities&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares for return on your investment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on any class of our stock to date and we do not anticipate paying cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may issue additional debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may attempt to increase our capital resources by entering into additional debt or debt-like financing that is secured by all or up to all of our assets, or issuing debt or equity securities, which could include issuances of commercial paper, medium-term notes, senior notes, subordinated notes or shares. In the event of our liquidation, our lenders and holders of our debt securities would receive a distribution of our available assets before distributions to our stockholders. In addition, any additional preferred stock, if issued by our company, may have a preference with respect to distributions and upon liquidation, which could further limit our ability to make distributions to our stockholders. Because our decision to incur debt and issue securities in our future offerings will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings and debt financing. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. Thus, you will bear the risk of our future offerings reducing the value of your common stock and diluting your interest in our company. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to publicly report on an ongoing basis as an &#8220;emerging growth company&#8221; (as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth companies, including but not limited to&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until October 19, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of any June&#160;30 before that time, we would cease to be an emerging growth company as of the following December 31. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result in less active trading or more volatility in the price of our common stock. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, as well as the Sarbanes-Oxley Act and the rules and regulations of the stock market on which our common stock is listed. The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting. Commencing with our fiscal year ending December 31, 2022, we will be required, under Section 404 of the Sarbanes-Oxley Act, to include in our Form 10-K filing a report by management on, among other things, the effectiveness of our internal control over financial reporting as of December 31, 2022. As an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event material weaknesses have been identified in our internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with the requirements of being a public company, we have undertaken and will need to undertake additional actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing and maintaining internal control can divert our management&#8217;s attention from other matters that are important to the operation of our business. In addition, when evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we identify any material weaknesses in our internal controls over financial reporting or we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting once we are no longer an emerging growth company, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors may lose confidence in the accuracy and completeness of our financial reports. As a result, the market price of our common stock could be materially adversely affected.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and&#47;or debt financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our technologies, research programs, product development activities, product candidates and&#47;or future revenue streams, license our technologies and&#47;or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are restricted from resale but may be sold into the market in the near future. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that the holders of a large number of shares intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 18, 2022, there were 15,966,053 outstanding shares of our common stock. Various shareholders who held shares of our common stock before our October 2021 initial public offering are currently restricted from selling their shares for a 180-day period, which ends as of the end of the day April 17, 2022, pursuant to contractual lock-up agreements with the underwriters. Furthermore, the directors and certain officers of the Company are restricted from selling their shares for a 365-day period, which ends at the close of the market on October 19, 2022, pursuant to contractual lock-up agreements with the underwriters. The representatives of the underwriters may, in their sole discretion and at any time or from time to time before the termination of the 180-day period or 365-day period, respectively, release all or any portion of the securities subject to lock-up agreements. Additionally, these shares are also eligible for sale without registration under Rule 144, subject to volume limitations applicable to affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur increased costs as a result of becoming a public company and in the administration of our organizational structure. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred significant legal, accounting, insurance, and other expenses, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with the Sarbanes-Oxley Act and related rules implemented by the SEC and ongoing periodic expenses in connection with the administration of our organizational structure. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. We expect these rules and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although we are currently unable to estimate these costs with any significant degree of certainty. In estimating these costs however, we took into account expenses related to insurance, legal, accounting, and compliance activities, as well as other expenses not currently incurred. These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and non-income taxes in the United States and Ireland, as well as the tax laws and regulations related to such matters. Tax accounting and compliance often involves complex issues, and judgment and interpretation is required in determining our provision for income taxes and other tax liabilities as well as the application of tax laws and regulations. We could become subject to income and non-income taxes in non-US jurisdictions other than Ireland as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that all transactions with related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of such transfer pricing rules, as well as of withholding taxes, goods and services taxes, sales taxes and other taxes is not always clear and we may be subject to tax audits relating to such rules or taxes. We believe that our tax positions are reasonable, and our tax provisions and reserves are adequate to cover any potential liability. We are also currently not subject to any tax audits. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, various items cannot be accurately forecasted and future events may be treated as discrete to the period in which they occur. In addition, the Internal Revenue Service or other taxing authorities may disagree with our positions. In addition, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us (possibly with retroactive effect). If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, or existing tax laws, statutes, rules, regulations or ordinances are so interpreted, changed or modified, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures or security breaches. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. If we or a third party with which we have relationships were to experience a system failure, accident or security breach such an event could cause interruptions in our or their operations, or it could result in delays and&#47;or material disruptions of our research and development programs. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties with which we have relationships collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, consultants and contractors, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#8217; security </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions, and any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost or stolen. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural or manmade disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities could be setback or delayed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaster recovery and business continuity plan(s) we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may now and in the future employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees and consultants. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited to, the sections entitled &#8220;Prospectus Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business.&#8221; These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation of preliminary results for our investigator-sponsored trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of preclinical studies and clinical trials for ONA-XR, CLDN6 bsAb, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope and likelihood of U.S. and foreign regulatory filings and approvals, including timing of Investigational New Drug applications and final FDA approval of ONA-XR, CLDN6 bsAb and any other future product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance ONA-XR, CLDN6 bsAb, and any other future product candidates, and successfully complete, clinical studies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization, and marketing capabilities, implementations thereof, and strategy&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus, sales strategy, and our ability to grow a sales team&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business and operations, including clinical trials, manufacturing suppliers, collaborators, use of contract research organizations and employees&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the approval and use of our product candidates in combination with other drugs&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies that are or may become available&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development of our product candidates, including additional indications we may pursue&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, Europe and other jurisdictions&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ONA-XR, CLDN6 bsAb, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of ONA-XR, CLDN6 bsAb and other product candidates we may develop, if approved&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of ONA-XR, CLDN6 bsAb and other product candidates we may develop&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current plans to seek additional capital in the future through equity and&#47;or debt financings, partnerships, collaborations, or other sources and the availability of such future sources of capital&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of laws and regulations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing cash and cash equivalents and the proceeds from this offer&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221;. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading &#8220;Risk Factors&#8221; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus also contains certain data and information, which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications includes projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Although we are a public company and have ongoing disclosure obligations under United States federal securities laws, we do not intend to update or otherwise revise the forward-looking statements in this prospectus, whether as a result of new information, future events or otherwise. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIVIDEND POLICY </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and, therefore, we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with the section titled &#8220;Prospectus Summary &#8211; Summary Financial Information&#8221; in this prospectus and our financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, and the potential impacts of the ongoing COVID-19 pandemic, contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described below. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. Prior to the reorganization we operated as Context Therapeutics LLC. Based on this being a transaction between entities under common control the carryover basis of accounting was used to record the assets, liabilities, and equity of Context Therapeutics LLC. Further, as a common control transaction the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, including breast, ovarian, and endometrial (uterine) cancer. Our first program and lead product candidate, ONA-XR, builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers. ONA-XR is a potent and selective antagonist of the progesterone receptor, which has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, across female hormone-dependent cancers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in April 2015 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We operate as one business segment and have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. We have funded our operations primarily through the sale of convertible debt, convertible preferred stock and common stock. Our net loss was $10.5 million for the year ended December&#160;31, 2021. As of December&#160;31, 2021, we had an accumulated deficit of $29.3 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which we issued and sold 5,750,000 shares at a public offering price of $5.00 per share. We received gross proceeds of approximately $28.8 million as a result of the offering. In December 2021, we sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement for gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into 2024. Currently, our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, in connection with the closing of our initial public offering, we have incurred and continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">did not incur as a private company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenses on other research and development activities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur net operating losses for at least the next several&#160;years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our ongoing and planned research and development of our first program and lead product candidate ONA-XR&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue nonclinical studies and initiate clinical trials for our anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) product and for any additional product candidates that we may pursue&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, hire and retain additional executive officers, clinical, scientific, quality control, and manufacturing management and administrative personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operations in the United States and to other geographies&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings and&#47;or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 Pandemic and its Impacts on Our Business </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic instability and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s ongoing or planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations (&#8220;CROs&#8221;), and&#47;or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development Expense </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expense consists of initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under Accounting Standards Codification Topic 805, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquired in-process research and development expense reflects the cash paid and&#47;or the estimated fair value of the equity consideration given. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses have consisted primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel expenses, including salaries, benefits and share-based compensation expense for our employees and consultants engaged in research and development functions&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties, including pursuant to agreements with clinical research organizations, or CROs, that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and clinical studies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses, milestone-based payments, and the cost of acquiring and manufacturing preclinical study and clinical trial materials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants who assist with research and development activities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses for facility costs, including rent, utilities and maintenance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track outsourced development costs and other external research and development costs to specific product candidates on a program-by-program basis, fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including share-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses have consisted primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and business development functions. General and administrative expense also includes corporate facility costs not otherwise included in research and development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense, including rent, utilities and insurance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the Securities and Exchange Commission, or SEC, insurance and investor relations costs. If any of our current or future product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense has consisted primarily of interest related to our convertible promissory notes that converted to Series A stock in 2020 and 2021. All of the outstanding Convertible Promissory Notes were converted as of February 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the years ended December&#160;31, 2021 and 2020&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change &#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805,067&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641,501&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163,566&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702,253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,525,819)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,572,168)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,953,651)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,240)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,224)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,984&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,877,857&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,868,540)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,101,335)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expense of $3.1 million for the year ended December&#160;31, 2021 reflects the fair value of consideration paid&#47;issued under the collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. There was no such consideration paid&#47;issued under collaboration arrangements in 2020. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $2.2 million from $1.6 million for the year ended December&#160;31, 2020 to $3.8 million&#160;for the year ended December&#160;31, 2021. The increase was mainly due to an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase of $0.6 million in clinical trial costs related to our Phase 2 trials evaluating ONA-XR, $0.6 million in preclinical costs associated with conducting research for the development of a CLDN6 BsMAb for gynecologic cancer therapy, and an increase in contract manufacturing costs of $0.5 million for ONA-XR. Additionally, consulting services increased by approximately $0.4 million as we increased the use of third-party contractors to focus on developing our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $2.7 million from $0.9 million for the year ended December&#160;31, 2020 to $3.6 million&#160; for the year ended December&#160;31, 2021. The increase was mainly due to an increase of $1.1 million in compensation and share-based compensation as a result of an increase in our general and administrative headcount and changes to compensation arrangements. Additionally, expenses increased by $1.6 million due to higher insurance costs of $0.3 million, professional fees and consulting services of $1.0 million, and other costs associated with operating as a public company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $0.6 million from $0.7 million for the year ended December&#160;31, 2020 to $0.1 million for the year ended December&#160;31, 2021 due to the conversion of all previously outstanding convertible promissory notes. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Convertible Promissory Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of convertible promissory notes was $9.9 million for the year ended December&#160;31, 2020 and $9,000 for the year ended December&#160;31, 2021. This change was attributable to a decrease in the fair value of our common stock as well as  the conversion of all previously outstanding convertible promissory notes.   </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income of $0.1 million for the year ended December&#160;31, 2021 is primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception through December&#160;31, 2021, we have funded our operations through the sale of convertible debt, convertible preferred stock and common stock. As of December&#160;31, 2021, we had $49.6 million in cash and cash equivalents and had an accumulated deficit of $29.3 million. In October 2021, we closed an initial public offering (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on the Nasdaq Stock Market and received gross proceeds of approximately $28.8 million as a result of the offering. Additionally, in December 2021, we sold 5,000,000 shares of our common stock together with warrants to purchase 5,000,000 shares of our common stock in a private placement and received gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into 2024. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and various general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing our product candidates for clinical trials and in preparation for regulatory approval and commercialization&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses needed to attract and retain skilled personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with being a public company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs required to scale up our clinical, regulatory and manufacturing capabilities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive regulatory approval&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive regulatory approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need additional funds to meet our operational needs and capital requirements for clinical trials, other research and development expenditures, and general and administrative expenses. We currently have no credit facility or committed sources of capital. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and&#47;or marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,799,487)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,034,620)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,394,036&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,344,549&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,434&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we used $8.8 million of cash in operating activities. Cash used in operating activities reflected our net loss of $10.5 million, a gain of $0.1 million from the extinguishment of debt and a net change in our operating assets and liabilities of $2.2 million. This was primarily offset by non-cash in-process research and development charges of $3.1 million, the non-cash fair value measurement of warrants for services of $0.4 million and share-based compensation of $0.5 million. The primary uses of cash were to fund our operations related to the development of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we used $1.0 million of cash in operating activities. Cash used in operating activities reflected the noncash change in fair value of convertible promissory notes of $9.9&#160;million, offset by our net income of $6.6&#160;million, noncash interest expense of $0.7&#160;million, share-based compensation of $0.2&#160;million and a $1.3&#160;million net change in our operating assets and liabilities. The primary use of cash was to fund our operations related to the development of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, cash used in investing activities was attributable to the initial upfront license fee of $0.3 million related to the Company&#8217;s acquired in-process research and development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have cash flows from investing activities during the year ended December&#160;31, 2020. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, financing activities provided $58.4 million, consisting of net proceeds of $5.0 million from the sale of Series A Stock and warrants for common stock, net proceeds of $24.4 million from the sale of common stock in connection with our IPO and net proceeds of $29.0 million from the sale of common stock and warrants in connection with our private placement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, financing activities provided $1.1&#160;million, consisting of $1.0&#160;million of proceeds from the sale of Series A Stock and warrants for common stock, $25,000 from the issuance of convertible bridge notes, $50,000 from the sale of Series Seed Stock and $0.1&#160;million of proceeds from the Paycheck Protection Program loan. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to prepaid&#47;accrued research and development expenses, share-based compensation and fair value of convertible promissory notes. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;3 to our audited consolidated financial statements included elsewhere in this prospectus, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an expense for preclinical studies and clinical trial activities performed by our vendors based upon estimates of the proportion of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our prepaid&#47;accrued expenses as of each balance sheet date in our consolidated financial statements based upon facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the prepaid&#47;accrual accordingly. Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed, or services are performed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date. We use the Black-Scholes option pricing model to value our share-based awards. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards for which vesting is subject to market or performance conditions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price volatility and the fair value of the underlying common stock on the date of grant. See Note&#160;8 to our audited consolidated financial statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our awards granted. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;3 to our audited consolidated financial statements found elsewhere in this prospectus for a description of recent accounting pronouncements applicable to our consolidated financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of December&#160;31, 2021, we had cash and cash equivalents of $49.6 million consisting of bank deposits and a commercial money market account. Due to the short-term duration of our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market value. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our labor and clinical trial costs. We do not believe inflation had a material effect on our business, financial condition or results of operations during the years ended December&#160;31, 2021 and 2020. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other exemptions and reduced reporting requirements under the JOBS Act include, without limitation, the requirements for providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We will remain an emerging growth company until the earlier to occur of (a)&#160;the last day of the fiscal year (i)&#160;following October 19, 2026, (ii)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means that we have been required to file annual and quarterly reports under the Exchange Act for a period of at least 12 months and have filed at least one annual report pursuant to the Exchange Act and either (a)&#160;the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We will continue to be a smaller reporting company until either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, our founders and management team have decades of experience identifying and characterizing the mechanisms that drive cancer initiation and subsequent relapse in women with cancer and who have been associated with the development of products such as Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus) to treat such cancers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers. Our first program and lead product candidate, onapristone extended release (&#8220;ONA-XR&#8221;), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers. ONA-XR is a selective and potentially potent antagonist of the progesterone receptor (PR), a receptor that is activated by the hormone progesterone and that has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, that are prescribed to treat female hormone-dependent cancers. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b&#47;2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4&#47;6 and&#47;or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L&#47;3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors. Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple cancers, including ovarian and endometrial tumors, and absent from healthy adult tissues. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022. Beyond these two product candidates, we continue to evaluate opportunities to expand our pipeline. We believe our team and capabilities uniquely position us to be a leader in developing novel therapies to address female cancers. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context retains worldwide development and commercialization rights for ONA-XR outside of Greater China and retains full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. Our product candidates are shown in the table below&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="a20220323_pipelineslide.jpg" src="a20220323_pipelineslide.jpg" style="height:351px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline and Development </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PR antagonist program&#58; ONA-XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in three Phase 2 trials, and one Phase 1b&#47;2 trial in women with primary or metastatic breast, ovarian, and endometrial cancers. These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help inform which patients may be most suitable for treatment with ONA-XR, we are evaluating multiple biomarker assays, including tools to monitor activated progesterone receptor as well as a PR gene activation signature that measures PR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. We expect to report preliminary data from two of our ongoing trials in mid-2022 and from the other two trials in the second half of 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLDN6xCD3 bispecific antibody program </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in ovarian and endometrial tumors and absent from healthy adult tissues. The structural complexity of CLDN6 and its similarity to proteins expressed on healthy tissue, particularly Claudin 9 (CLDN9), have limited its exploitation for targeted oncology therapies. Several pharmaceutical companies are developing anti-CLDN6 antibodies and&#47;or bispecific antibodies. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other preclinical programs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product candidates, we are leveraging our knowledge in female cancers to pursue discovery stage research programs. We continue to evaluate new opportunities to expand our pipeline in female cancers.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Management Team </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team to develop novel products to treat female cancers. Members of our management team have experience leading organizations that have advanced multiple oncology therapeutics from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization. Our team&#8217;s select accomplishments include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Executive Officer co-founded Context in 2015 and was previously a venture capitalist at Osage University Partners, where he led multiple oncology investments for the firm that resulted in successful public offerings or acquisitions. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Financial Officer previously served as Chief Financial Officer of Millendo Therapeutics, a publicly-traded biopharmaceutical company.  Prior to Millendo, our CFO served as Director of Technical Accounting at PAREXEL International and began her career as an auditor at Ernst &#38; Young.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Legal Officer previously severed as Vice President, Deputy General Counsel and Assistant Corporate Secretary of OptiNose, a publicly-traded specialty pharmaceutical company. Prior to OptiNose, he served as Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Medical Officer previously held the same position at H3 Biomedicine, where he led the early phase development for an oral selective estrogen receptor covalent antagonist (SERCA). During his career, he has either led or supported global drug development programs for several novel oncology drugs, including Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus), resulting in successful global registrations. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our management team has been involved in several multimillion-dollar strategic transactions, including as part of the leadership teams at Celgene and Novartis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supported by our advisors who are leading experts in female cancers. Our arrangements with these individuals do not entitle us to any of their existing or future intellectual property derived from their independent research or research with other third parties beyond what has previously been licensed to us. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop and commercialize innovative and differentiated oncology products that address significant unmet medical needs in the field of female cancer, with a primary focus on the hormone-dependent subcategory. The key components of our strategy to achieve this goal include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging the insights, experience, and networks of our management team and advisors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management team and advisors have extensive experience identifying, developing, and commercializing innovative cancer therapeutics aimed at novel targets, including Kisqali, Arimidex, and Afinitor. We are using this broad oncology experience together with our internal search and development capabilities to build a diverse pipeline of therapies targeting multiple cancer resistance mechanisms. For example, our first program and lead product candidate, ONA-XR, while acquired from Arno Therapeutics, builds on academic work originally conducted by the laboratory of our scientific advisor, Dr.&#160;Carol Lange. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Focusing on product candidates that can be first or second in market based on current competition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that being first or second in market provides a unique advantage that later competitors may not be able to overcome. Based on the current competitors that are developing similar product candidates, we believe that we have the opportunity to be the first anti-progestin approved for PR+&#160;cancer and one of the early market participants with our CLDN6xCD3 bsAb. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Completing clinical development and obtaining regulatory approval for ONA-XR for the treatment of breast, ovarian, and endometrial cancer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The PR signaling pathway has been implicated in resistance to anti-estrogen therapies in female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b&#47;2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4&#47;6 and&#47;or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L&#47;3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Advancing our second program, CLDN6xCD3 bsAb, as rapidly as reasonably possible through preclinical and clinical development.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a membrane protein target expressed in multiple female cancers, including ovarian and endometrial, and absent from healthy adult tissues. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Evaluating opportunities to accelerate development timelines and enhance the commercial potential of our programs in collaboration with third parties, including through the potential out-licensing of our product candidates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established collaborations and intend to continue evaluating opportunities to work with partners that meaningfully enhance our capabilities with respect to the development and commercialization of our product candidates, which may entail the potential out-licensing of the development and commercialization of our product candidates to larger pharmaceutical organizations, including our lead product candidate ONA-XR. For example, we entered into a manufacturing and development agreement with Tyligand Bioscience (Shanghai) Limited for ONA-XR that is intended to enhance our ability to meet drug manufacturing demands and expand our clinical trial footprint into Greater China. It is also possible that similar arrangements for ONA-XR could be sought for other geographic footprints. In addition, we intend to commercialize our product candidates in key markets either alone or with partners in order to maximize the worldwide commercial potential of our programs. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">In-licensing or acquiring additional drug candidates to build a fully integrated company focused on female cancers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that accessing external innovation and expertise is important to our success and plan to leverage our leadership team&#8217;s prior business development experience as we evaluate potential in-licensing and acquisition opportunities to further expand our portfolio. For example, CLDN6xCD3 bsAb was licensed from Integral Molecular, Inc. (&#8220;Integral&#8221;), a company where our management and advisors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have long-standing relationships. We aim to be the partner of choice for academic groups and companies in the field of female cancers. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our focus on female hormone-dependent cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 70% of women with breast, ovarian, and endometrial cancer have hormone-dependent cancer. The hormones estrogen and progesterone drive cancer progression in those patients, but anti-estrogens are the only antihormonal therapy that is FDA approved and available to clinicians. Therefore, treatment of those patients to date has consisted of anti-estrogens alone or in combination with drugs that enhance the antitumor activity of anti-estrogens, including inhibitors of CDK4&#47;6 or PI3K&#945;. Given the broad use of anti-estrogens, anti-estrogen resistance is now a major clinical challenge. Treatment options for anti-estrogen resistance are limited, provide modest therapeutic benefit, and are associated with side effects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estrogen and progesterone are master regulators of normal female sex organ development and function, acting via estrogen receptors (&#8220;ER&#8221;) and progesterone receptors (&#8220;PR&#8221;). Mechanistically, published data suggest that in hormone-dependent cancers, ER and PR are often hyperactive, constantly pushing breast, ovary, and endometrial tissues to grow, divide, and metastasize. One such strategy to block this hormone-mediated growth is to administer anti-estrogen therapy (fulvestrant, letrozole, anastrozole, or tamoxifen), which may be used in combination with inhibitors of CDK4&#47;6 or PI3K&#945; to enhance anti-estrogen mediated effects. However, the cancer cells respond to this selective pressure of ER inhibition by further activating progesterone signaling as a compensatory mechanism, along with other resistance mechanisms that can further activate PR, including ER ligand binding mutations (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), growth factor signaling, and enrichment of cancer stem cells. Over time, it is believed that all patients become resistant to anti-estrogens due to direct or indirect compensatory signaling mediated by the PR and other factors. These findings suggest that progesterone receptor and proteins that regulate PR could represent promising drug targets to address anti-estrogen resistance. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of antiestrogen resistance mechanisms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business4a.jpg" src="business4a.jpg" style="height:274px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a portfolio of novel agents targeting multiple anti-estrogen resistance mechanisms by leveraging our specialized expertise in hormone-dependent cancers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PR antagonist program&#58; ONA-XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Published data suggest that the PR signaling pathway is implicated in resistance to anti-estrogen therapies in female hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b&#47;2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4&#47;6 and&#47;or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L&#47;3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Progesterone receptor background </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone receptor (PR) is a member of the nuclear hormone receptor family of ligand-dependent transcription factors that is expressed primarily in female reproductive tissues. In response to the endogenous steroid hormone, progesterone, PR regulates the expression of gene networks to control development, differentiation, and proliferation of target tissues and the pathological processes in endocrine-based cancers. Anti-progestins are a class of nuclear receptor ligands that act to antagonize PR by binding to the progesterone binding site within the PR-ligand binding domain. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, the role of progesterone in carcinogenesis has gained further clarity. Mechanistically, published data suggest that progesterone promotes oncogenic progression and maintenance of stem cells, creating a reservoir of pre-malignant cells to seed metastasis. Initial evidence for this tumorigenic role is derived from longitudinal studies of the use of hormone replacement therapy in menopausal women. As shown in the figure below, these studies determined that supplemental estrogen was associated with a 23% decrease in cancer risk, whereas supplemental progesterone was associated with a 25% increase in cancer risk. The results demonstrated that women who were consistently exposed to progesterone had a higher risk of developing breast cancer than those who did not. This finding was confirmed by published data wherein mice treated with progesterone exhibited enhanced breast tumor growth whereas progesterone receptor inhibition via genetic knockdown conversely inhibited tumor growth. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Association of progesterone and breast cancer risk </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business3a.jpg" src="business3a.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from the Journal of the American Medical Association Oncology, Chlebowski et al, Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone&#58; Analyses of Data From 2 Women&#8217;s Health Initiative Randomized Clinical Trials, Copyright 2015. Reprinted with permission from American Medical Association. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; CEE&#58; synthetic estrogen&#59; E&#58; estrogen&#59; HRT&#58; hormone replacement therapy&#59; MPA&#58; synthetic progesterone&#59; P&#58; progesterone. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figure above, PR can be activated by ligand (progesterone) or ligand-independent (growth factor-mediated) mechanisms. Consistent with other steroid hormone receptor family members, PR is heavily post-translationally modified and thus acts as a molecular sensor for abnormally elevated or active signaling pathways. Little overlap exists between PR transcriptomes assayed in normal relative to neoplastic cells. In cancer cells, post-translational modifications (namely, phosphorylation and SUMOylation) via members of the growth factor signaling cascade create unique PR species whose altered behavior as ligand-dependent transcription factors is predicted to impact tumor initiation and progression. Due to the breadth of post-translational modifications of PR, there is limited selective mutational pressure to modify PR itself - thus, PR mutations are rare. However, when present, the PR mutations have a profound impact on PR activity and tumorigenesis. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illustrative mechanism of action </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business4a.jpg" src="business4a.jpg" style="height:274px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; ER&#58; estrogen receptor&#59; ESR1Y537S&#58; estrogen receptor mutation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The progesterone receptor as a mechanism of resistance </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, progesterone receptor has emerged as anti-estrogen resistance mechanism. Long term exposure of cancer cells to anti-estrogens results in a complex resistance profile that limits the utility of standard of care anti-estrogen and cyclin-dependent kinase 4&#47;6 (CDK4&#47;6) inhibitors. Mechanisms of resistance include mutations in the estrogen receptor (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) estrogen binding domain and ER pathway signaling (e.g., MAPK, PI3K&#945;&#47;mTOR proteins and associated signaling pathways). The prevalence of resistance mutations is associated with PR enrichment and activity. Based on our preclinical data and recent published data, we believe therapeutic inhibition of PR with either ONA-XR alone or in combination with anti-estrogens and&#47;or CDK4&#47;6 inhibitors may result in the impaired growth or death of resistant cells. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of other PR antagonists </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-progestins, the therapeutic inhibitors of PR, were first developed as oral contraceptives to block the maturation of the endometrium and subsequent ovulation. The first commercially available anti-progestin, Korlym (mifepristone), is a steroid derivative that acts both as a competitive progesterone receptor (PR) antagonist and as a partial PR agonist, depending on the physiological milieu. Mifepristone is approved for controlling hyperglycemia secondary to hypercortisolism in adult Cushing&#8217;s syndrome associated with Type 2 diabetes. Mifepristone was also clinically evaluated in breast and ovarian carcinomas, and while showing evidence of efficacy in clinical studies, mifepristone was also associated with off-target glucocorticoid receptor (GR) modulation leading to cortisolemia and rare cases of cholestasis. In order to optimize PR antagonism while minimizing off-target activities, additional anti-progestins&#8212;including ulipristal, telapristone, lonaprisan and onapristone&#8212;were developed and evaluated in gynecological cancer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unique Properties of Onapristone &#8211; Stereochemical Basis </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business5a.jpg" src="business5a.jpg" style="height:210px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; AR&#58; androgen receptor&#59; C-13&#58; carbon 13&#59; n.a.&#58; not applicable&#59;1L mBCa&#58; first-line metastatic breast cancer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ONA-XR differentiation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onapristone is a competitive PR antagonist that has no intrinsic activity for activating the receptor. As such, onapristone is also termed a &#8220;full&#8221; PR antagonist (inhibitor). Based on published data, all other anti-progestins that have reached the clinic demonstrate partial PR agonism. This differentiation may have a structural basis. It is well established that high energy, conformationally complex chemicals have improved selectivity and target affinity relative to low energy, flat counterparts. As shown above, all other anti-progestins have a roughly planar ring, low energy, A thru D conformation. In contrast, onapristone shows an inversion of stereochemistry at the C-13 methyl group that results in a high energy, chair conformation. This structural property is unique among clinically evaluated anti-progestins and may be important for onapristone&#8217;s full PR antagonist properties, as shown below. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onapristone PR binding properties vs. other anti-progestins and progesterone </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business6a.jpg" src="business6a.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:326px"></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from Steroids, Elger et al, Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity, Copyright 2000. Reprinted with permission from Elsevier. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; RU 486&#58; mifepristone&#59; J 867&#58; asoprisnil&#59; Ona&#58; onapristone. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classic </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models have provided limited benefit in determining PR agonist versus antagonist properties. As the cost of gene expression profiling has decreased considerably over the last decade, it is now feasible to run comparative studies to determine how compounds are affecting the expression, positively or negatively, of target genes. Afhuppe </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2009)&#160;conducted the first such study comparing anti-progestins in a gene array panel. T47D breast cancer cells (ER+, PR+) were grown in 2D, stimulated with estrogen (estradiol), and treated with anti-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progestins. An Affymetrix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene chip analysis of the cells was then conducted to determine transcriptional activity on the level of target genes. Onapristone demonstrated the purest PR antagonist activity as indicated downregulation (green blocks) of almost all PR target genes analyzed, whereas mifepristone had a transcriptional profile closer to R5020, which is pure progesterone. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modulation of PR signaling genes by different anti-progestins </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business7a.jpg" src="business7a.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from The Journal of Steroid Biochemistry and Molecular Biology, Afh&#252;ppe et al, Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system, Copyright 2009. Reprinted with permission from Elsevier. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-progestin clinical trial data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In subjects with breast cancer, clinical trials with mifepristone, lonapristone and onapristone demonstrated partial responses. Onapristone clinical efficacy in breast cancer was studied in two Phase 1-2 clinical studies treating hormone therapy-na&#239;ve and tamoxifen-resistant metastatic breast cancer, while the safety component of a third Phase 1-2 study has been reported by Cottu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2018). The earlier onapristone trials in breast cancer dosed orally with a simple solid dosage form (an &#8220;immediate release&#8221; or &#8220;IR&#8221; form&#59; onapristone IR&#59; ONA-IR), ONA-IR 100mg once per day (QD), for periods exceeding 12 months. The third breast cancer study used the extended release form, ONA-XR, dosed at 50mg twice per day (BID). Robertson </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1999)&#160;reported a 67% clinical benefit rate (CBR), defined as tumor shrinkage or tumor growth stabilization lasting for more than 6&#160;months, while Jonat </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2002)&#160;reported a 49% CBR. Both studies, therefore, indicated that onapristone could have a clinically meaningful impact on treatment of hormone-dependent breast cancer. Clinical development of ONA-IR for use in reproductive medicine and benign gynecological conditions was discontinued by the original sponsor (Schering AG), possibly due to concerns around drug-induced liver injury. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extensive use of anti-estrogens, together with efficacy limits with earlier anti-progestins, has led to renewed interest in anti-progestins as therapies for breast and gynecologic cancer, as well as for uterine fibroids and endometriosis. Compared to earlier anti-progestin clinical trials, we believe we have a better tolerated formulation of onapristone (ONA-XR) and we will be able to better identify those patients who are most likely to benefit from anti-progestin therapy through the incorporation of biomarkers in our trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current opportunities for ONA-XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the G7 (EU5, Japan, US) countries, it is estimated that there are over 362,000 patients living with metastatic breast, ovarian, or endometrial cancer. Up to 70% of these patients are expected to be progesterone receptor positive and would potentially be eligible for treatment with ONA-XR. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prevalence in G7 countries for metastatic breast, ovarian, and endometrial cancers </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business8a.jpg" src="business8a.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:569px"></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; secondary epidemiologic estimates, 2020 estimates. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; EU5&#58; France, Germany, Italy, Spain, United Kingdom. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resistance to anti-estrogen therapy in breast cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have chosen PR antagonism in breast cancer as our initial therapeutic focus due to the well-documented biology of PR signaling as a mechanism of resistance to anti-estrogen therapy in patients with hormone-dependent breast cancer. Hormone-dependent breast cancer cells express estrogen (ER) and&#47;or progesterone receptors (PR) that allow the cells to grow in the presence of the hormones estrogen and&#47;or progesterone. Published data suggests that PR signaling is predominantly required for breast cancer cell renewal (i.e., stemness) and metastatic spread, whereas ER is predominantly required for breast cancer cell proliferation. By combining anti-progestin and anti-estrogen therapy, we have shown preclinically that breast cancer cell growth, renewal, and spread can be mitigated. Based on these data, we believe that ONA-XR, in combination with current standard-of-care anti-estrogens, has the potential to significantly improve clinical outcomes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breast cancer overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer is the most frequent cancer among women, impacting 2.1&#160;million women globally each year, and causing the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer worldwide &#8212; that is approximately 15% of all cancer deaths among women according to the World Health Organization. According to the American Cancer Society, the prevalence of women in the United States living with adjuvant, first line metastatic, or second&#47;third line metastatic breast cancer are an estimated 250,000, 75,000, and 35,000 respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer treatment is primarily determined by the presence or absence of three proteins&#58; estrogen receptor (ER), progesterone receptor (PR), and HER2. The presentation of these proteins determines the subtype of breast cancer, which helps determine the optimal form of treatment for the patient. Patients who are ER+,PR+,HER2- are considered to be hormone receptor positive (i.e., hormone-dependent) and represent about 70% of breast cancers. HER2+ patients and triple negative patients (ER-,PR-,HER2-) represent the remaining 30% of breast cancers. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estrogen-deprivation (anti-estrogen) therapy is the core treatment modality in patients with hormone receptor positive metastatic breast cancer according to NCCN Guidelines&#174;. Anti-estrogen therapy options for postmenopausal women with ER+ advanced breast cancer include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective ER modulators (SERM)&#58; tamoxifen </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ER antagonists&#58; fulvestrant </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective nonsteroidal aromatase inhibitors&#58; anastrozole and letrozole </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Steroidal aromatase inhibitors&#58; exemestane </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, cyclin-dependent kinase 4 and 6 (CDK4&#47;6) inhibitors are rapidly transforming the care of patients with ER+, HER2- advanced breast cancer. There are currently three CDK4&#47;6 inhibitors that have been approved by the U.S. Food and Drug Administration&#58; Ibrance, Kisqali, and Verzenio. It is generally recommended to use the combination of a CDK4&#47;6 inhibitor along with an aromatase inhibitor (i.e., letrozole) for first line locally advanced or metastatic breast cancer treatment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Illustrative breast cancer treatment landscape </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business9a.jpg" src="business9a.jpg" style="height:235px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; ORR&#58; overall response rate&#59; PFS&#58; progression free survival. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon first line disease progression, second line therapy is most often fulvestrant (anti-estrogen) or fulvestrant plus alpelisib (Piqray), a PI3K&#945; inhibitor, if the patients have PIK3CA-mutated hormone receptor-positive breast cancer. Fulvestrant plus Piqray was FDA approved in 2019 based on a Phase III trial of 572 patients that demonstrated a progression free survival (PFS) of 11.0 months vs. 5.7 months in the Piqray plus fulvestrant arm compared with fulvestrant alone (HR, 0.65, 95% CI 0.50&#8211;0.85). However, a total of 25% of patients discontinued Piqray plus fulvestrant therapy due to toxicities, thus, emphasizing the need for novel agents. Upon progression on second line therapy, mammalian target of rapamycin (mTOR) inhibitors, including everolimus (Afinitor), plus anti-estrogen based regimen or chemotherapy is administered. One key limitation of both the Afinitor and Piqray studies is the lack of data for the role of these agents after prior CDK4&#47;6 inhibitor therapy. Most patients progress on these treatments and ultimately develop resistance. At that time, patients typically live for less than two years. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The female ovarian hormones estrogen and progesterone are master regulators of normal breast development and play a key role in breast cancer. Acting through ER and PR, estrogen and progesterone play complex, essential, and coordinated roles in the development of the lobular alveolar epithelial structures of the normal breast during puberty, the normal menstrual cycle, and pregnancy. It is likely that these actions become subverted in the development of breast cancer, implicating both estrogen and progesterone in the development and progression of this disease. Breast cancer is acknowledged to be a hormone-dependent disease and most breasts express ER and&#47;or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR. PR is expressed in humans as two major forms, progesterone receptor A (PR-A) and progesterone receptor B (PR-B), in normal cells and in certain malignant tissues. PR-A and PR-B mediate the effects of progesterone by association with a range of co-regulatory proteins and progesterone-regulated gene promoters. Over the past few decades, the estrogen receptor signaling pathway remains the most effective treatment for the management of ER+ breast cancer. Treatments include the selective estrogen receptor modulator (SERM) tamoxifen that binds to ER and prevents its activation, and aromatase inhibitors that block endogenous hormone synthesis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent published data suggests that progesterone receptor may function as an anti-estrogen resistance mechanism. Long term exposure of cancer cells to anti-estrogens results in a complex resistance profile that limits the utility of standard of care anti-estrogen and CDK4&#47;6 inhibitors. Mechanisms of resistance include mutations in estrogen receptor gene (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and ER pathway signaling (MAPK, PI3K&#945;, mTOR), as 20-35% of ER+,PR+,HER2-metastatic breast tumors are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutated. The prevalence of resistance mutations is correlated with PR enrichment and activity. We have presented data showing that therapeutic inhibition of PR with either onapristone alone or in combination with anti-estrogens and&#47;or CDK4&#47;6 inhibitors results in the impaired growth or death of resistant cells. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown below, estrogen receptor (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) mutational profiles of tumor biopsies were taken before and after prolonged treatment with anti-estrogen (fulvestrant) and CDK4&#47;6 inhibitor (palbociclib) therapy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations are enriched by the end of therapy and are associated with worse outcomes in patients. To determine the effect of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations, wild type (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and mutant (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) estrogen receptors were overexpressed in the T47D breast cancer cell line. The orange box denotes that both the PR-A and PR-B isoforms of progesterone receptor demonstrated increased expression upon exposure to the mutant form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increased expression of PR was found to be correlated with enhanced PR activity. To establish that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cells require PR for growth and dual ER-PR inhibition (i.e., complete hormone blockade) results in growth inhibition, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> organoid model was conducted using the rapidly proliferating, CDK4&#47;6 inhibitor resistant WHIM20 cell line. Organoid data demonstrates that dual blockade of ER and PR via treatment with fulvestrant and onapristone results in growth inhibition in a cell model that is intended to mimic human disease. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role of PR in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESR1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> mutations </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business10a.jpg" src="business10a.jpg" style="height:191px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from Cancer Cell, Razavi et al, The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers, Copyright 2018. Reprinted with permission from British Journal of Cancer, Lopez-Knowles et al, Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer&#58; the phenotypic effect of ESR1 mutations, Copyright 2018. Reprinted with permission from Nature Springer. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Addition of Onapristone to Standard of Care Enhances Tumor Regression </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hypothesis is that complete hormone blockade via downregulation of estrogen receptor (ER) and progesterone receptor (PR) signaling pathways, and their compensatory pathways, including CDK4&#47;6, will lead to enhanced therapeutic outcomes in patients. To test this hypothesis, we utilized a patient-derived xenograft (PDX) model to evaluate the efficacy of the antiprogestin onapristone in combination with fulvestrant (antiestrogen) and palbociclib (CDK4&#47;6 inhibitor) in PDX mouse models established from ER and PR positive bone metastasis of breast cancer. Two PDX models were tested, one with low level (data not shown) and one with high level of PR expression (data shown below). In the PDX model with high expression of PR, treatment by onapristone combined with palbociclib and fulvestrant resulted in enhanced tumor regressions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All treatment arms were well tolerated. Blood and tumor samples were taken at the end of the study from both experiments. Different biological analyses will be performed to analyze ER&#47;PR signaling by protein and RNAseq analyses. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business11a.jpg" src="business11a.jpg" style="height:166px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results from the experiment with the PR High Expression PDX are shown above. Treatment by onapristone alone resulted in a tumor growth inhibition (TGI) of 42%, while the combination onapristone (10 mg&#47;kg) + palbociclib (75 mg&#47;kg) resulted in a TGI of 67% and the triple combo onapristone + palbociclib + fulvestrant (5 mg&#47;mouse) in a TGI of 92% with 6&#47;7 xenografts showing tumor regression. The statistical analysis was performed with GraphPad software. Plasma and tumor samples were taken at the end of the study from 5 xenografts&#47;group for further analysis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resistance to hormone-dependent gynecologic cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gynecologic cancer overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ovarian and endometrial cancer represent the majority of gynecologic cancers. It is estimated that there are more than 22,000 new cases of ovarian cancer and 61,000 new cases of endometrial cancer annually, resulting in 14,000 ovarian and 12,000 endometrial deaths in the United States (US) every year. As of 2019, it is estimated that there are 235,000 patients living with ovarian cancer and over 770,000 patients living with endometrial cancer in the US. By applying PR positivity (PR+) rates to the 2019 prevalence count, it is estimated that there are 300,000 patients with recurrent gynecologic cancer in the US, 130,000 of whom are PR+. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximal surgical debulking and platinum chemotherapy are the cornerstone treatments for primary gynecologic cancer. The aim of surgery is to confirm diagnosis, define extent of disease spread (staging), and resect all visible tumor tissue. The goal of cytoreductive surgery is removal of the entire tumor burden to achieve either complete removal of the tumor upon visual inspection (complete cytoreductive surgery) or a residual tumor of &#60;&#160;1 cm (optimal cytoreductive surgery). Even centers experienced in ovarian tumor cytoreductive surgery achieve optimal resection in only 50% of patients. Patients with incomplete&#47;suboptimal cytoreductive surgery are at a significantly higher risk of recurrence and poor prognosis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following primary treatment for gynecologic cancer, the relapse rate is approximately 20-25% for early-stage disease and 70% for advanced (spread beyond primary site) disease. The survival curve after recurrence never plateaus, which means that the goal of treatment for recurrent gynecologic cancer is controlling the disease and disease-related symptoms, limiting treatment-related toxicity, and maintaining or improving quality of life. Primary or secondary resistance is the main cause for diminished effectiveness over time of platinum-based chemotherapy, contributing to the dismal outcome of advanced patients whose 5-year survival rate is less than 30%. Patients who are hormone receptor positive will often receive anti-estrogen therapy in the recurrent setting&#59; however, anti-estrogen efficacy is modest in this setting. In general, treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, maintaining or improving quality of life, delaying time to progression, and prolonging survival. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illustrative hormone-dependent gynecologic treatment landscape </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business12a.jpg" src="business12a.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reasons Why Such a Therapy is Needed </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytoreductive surgery followed by combination platinum and taxane chemotherapy is the first-line treatment for most gynecologic cancer patients regardless of type. Outside of DNA repair deficient high grade serous ovarian cancer, there are limited treatment options for all other forms of ovarian and endometrial cancer. Given the above-mentioned 5-year survival rate of less than 30%, there is a critical need to identify a targeted treatment in the recurrent setting. Ovarian and endometrial cancer remains a serious, life threatening, unmet medical need, resulting in more than 26,000 estimated deaths in the US every year. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PR in Endometrial Cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone receptor (PR)-targeted therapies are modestly active in patients with endometrial cancer, which may be attributed to an evolving understanding of the underlying molecular mechanisms of PR-targeted therapies for this disease. In the normal endometrium, estrogen drives proliferation of the endometrial glandular epithelium, whereas progesterone counteracts the effects of estrogen. Progesterone acts by binding to the PR and has a dual role through both genomic and nongenomic pathways. Anti-progestins such as onapristone have recently been shown to be efficacious in mouse models of uterine cancer, suggesting that PR blockade may be an effective approach for treating uterine cancer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role of PR in endometrial cancer </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business13a.jpg" src="business13a.jpg" style="height:187px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from Molecular Cancer Therapeutics, Huang et al, Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer, Copyright 2017. Reprinted with permission from Elsevier. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; In vivo&#160;effect of onapristone, trametinib, and the combination of both drugs on tumor weight, number of tumor nodules, and body weight. Error bars indicate the SEM&#59; *,&#160;P&#160;&#60; 0.05. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It has been reported that mitogen-activated protein kinases (MAPK) play a dual role in PR subcellular trafficking and aid in the rapid nuclear association of PR via Serine 294 (S294) phosphorylation in response to growth factors and in response to ligand (i.e., progesterone). In Huang </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2017, PR+ endometrial cancer cells were implanted in mice and upon tumor engraftment were treated with onapristone and&#47;or trametinib, a MEK inhibitor. If progesterone receptor does coordinate endometrial cancer response through MAPK via MEK signaling, then the MEK inhibitor, trametinib, should be anticipated to enhance onapristone sensitivity through blocking the nuclear translocation of phosphorylated PR. The study demonstrates that PR+ endometrial xenografts are sensitive to both onapristone and trametinib alone, and exhibit synergy when combined, indicating a rationale to develop onapristone alone or in combination with a MEK inhibitor for PR+ endometrial cancer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PR in Ovarian cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone and progesterone receptors (PR) are increasingly gaining attention for their emerging role as critical regulators of breast, ovarian, and endometrial cancer. Progesterone is a steroid hormone that is produced primarily by the corpus luteum in the ovaries during the second half of the menstrual cycle or luteal phase. Cyclical hormone exposure beginning at menarche and ending in menopause occurs monthly and regulates the growth and differentiation of specialized tissues within the reproductive tract and breast tissues. Until recently, little was known about the relative distribution of PR within the subtypes of ovarian tumors. In a cohort of 504 ovarian tumors, Diep </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013)&#160;reported that 35% of the tumors were progesterone receptor-positive (PR+) and that PR expression is associated with better outcomes, indicating a potential role for hormone therapy in PR+ ovarian cancer. Importantly, several subtypes were found to be highly enriched for PR. Retrospective studies evaluating the association of total PR expression and progression-free disease survival support the concept that subsets of PR+ ovarian tumors are highly sensitive to hormones and thus more likely to respond to endocrine therapy. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of extended release formulation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precedent Formulation &#8211; Onapristone IR (ONA-IR) </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onapristone was originally developed in an immediate release or &#8220;IR&#8221; form (onapristone IR&#59; ONA-IR). ONA-IR was first evaluated as an oral contraceptive and was dosed up to 400 mg&#47;day for periods of 7 days during single ovulatory cycles in healthy female subjects. Later, ONA-IR 100 mg&#47;day was administered for periods exceeding 12 months in breast cancer studies. Discontinuation of ONA-IR development by the original sponsor, Schering AG, is thought to have been due to the observation of liver test abnormalities and the perceived risk of drug-induced liver injury (DILI) during a Phase 2 study of ONA-IR as first line therapy in breast cancer subjects. Liver test elevations were considered a concern for the planned contraception and benign gynecological indications (e.g., uterine fibroids, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">endometriosis). However, renewed interest in anti-progestin therapy for PR-positive malignancies has led to the consideration of new strategies for reducing potential hepatotoxic effects of onapristone. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing new strategies for anti-progestin use, one consideration is that mifepristone, ulipristal, telapristone, and onapristone all contain a 17-carbon steroid ring structure that is typical of steroids. Anti-progestins with steroidal cores often display significant cross-reactivity with closely related steroid receptors, namely, androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). This functional overlap is partly responsible for the side effects linked with the steroidal drugs, which themselves carry a potential DILI risk. Because onapristone binds to GRs less efficiently than to PRs, one strategy to minimize liver test elevations was to seek a new onapristone formulation that yielded steady state pharmacokinetic (PK) parameters where&#58; (a)&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is lower than the C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated with ONA-IR 100mg QD (to target a reduced risk for LFT elevations)&#59; and (b)&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at least approximately equal to the C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated ONA-IR 100mg QD (to target at least equivalent, sustained suppression of PR activity). Various formulation strategies were evaluated and a 50mg, BID (twice-daily), extended release tablet (onapristone XR&#59; ONA-XR) was selected to be the second-generation dosage form for the clinical evaluation of onapristone in PR-positive cancers. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacokinetic Comparison of ONA-XR versus ONA-IR </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business14a.jpg" src="business14a.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Reprinted from Drug Safety, Lewis et al, Onapristone Extended Release&#58; Safety Evaluation from Phase I&#8211;II Studies with an Emphasis on Hepatotoxicity, Copyright 2020. Reprinted with permission from Nature Springer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel Formulation &#8211; Onapristone XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacokinetic (PK) parameters for ONA-IR 100mg QD and ONA-XR 50mg BID were previously evaluated within a dose escalation component of a Phase 1-2 clinical study in female subjects with endometrial carcinoma, breast cancer or ovarian cancer. This study (Cottu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2018) reported that ONA-XR showed &#8220;Clinical benefit with excellent tolerance&#8221;, while defining a recommended phase 2 dose level of ONA-XR of 50mg, BID. The PK dataset from this clinical study enabled a direct comparison between C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ONA-IR 100mg QD and ONA-XR 50mg BID. Steady-state pharmacokinetics of ONA were estimated using standard noncompartmental methods and the nonparametric superposition tool in Phoenix WinNonlin version 8.3 (Certara Inc., Princeton, NJ). These methods assume linear pharmacokinetics from the first dose to steady state. Dosing with ONA-XR 50mg BID resulted in a steady-state C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> almost 3 times lower than the C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ONA-IR 100mg QD, while the steady-state C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for both formulations were similar&#58; 829 ng&#47;mL versus 790 ng&#47;mL for ONA-IR versus ONA-XR, respectively. The findings of the Phase 1-2 PK and safety evaluation support that the recently developed, extended release form of onapristone appears to have achieved the PK goals of the formulation exercise. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed clinical trials </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial IR formulation (ONA-IR), developed by Schering AG at various strengths, was dosed up to 400 mg&#47;day in healthy volunteers and 100 mg&#47;day for periods exceeding six months in oncology studies. Arno Therapeutics (Cranbury, NJ) subsequently developed onapristone extended release (&#8220;ONA-XR&#8221;) formulation and administered it in doses of 10, 20, 30, 40 and 50 mg ONA-XR BID for up to 52 weeks. We acquired ONA-XR from Arno Therapeutics. There are no associated future payments due to Arno. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of clinical trials evaluating on a pristone with IR or XR formulation </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Antiprogestin</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stage </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(n) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Indication</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatments</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Range) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biomarker </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Data</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100mg QD)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast&#160;Cancer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Locally Advanced or Metastatic</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hormone<br>na&#239;ve</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56% ORR <br>17.5-month DoR 67% CBR <br>14.0 month PFS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Robertson 1999</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100mg QD)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast Cancer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 (1-2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10% ORR </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48% CBR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 month PFS</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jonat 2002</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50mg BID)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulosa Cell Tumor of Ovary Metastatic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 (2-17)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*57% DCR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*21% 6-month PFS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ongoing</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#177;Abiraterone</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase&#160;1b&#47;2</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Castrate Resistant Prostate Cancer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active progression on Abiraterone</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 (1-4)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONA-XR&#160;(10-50 mg)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 month PFS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONA-XR (50 mg) + Abiraterone</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4 month PFS</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jayaram&#160;2017</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast Cancer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 (2-14)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25% DCR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15% 6-month PFS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cottu 2018</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ovarian Cancer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 (2-10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8% ORR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31% 6-month PFS</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cottu 2018</font></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; BID&#58; twice per day&#59; DoR&#58; duration of response&#59; ORR&#58; overall response rate&#59; PFS&#58; progression free survival. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onapristone IR Clinical Data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across first and second line metastatic breast cancer, onapristone IR (ONA-IR) demonstrated clinical activity comparable to anti-estrogen standard of care. We believe that by selecting for PR+ status and combining ONA-XR, an improved form of ONA-IR, with anti-estrogen therapy to promote complete hormone blockade, we will potentially generate superior efficacy data compared to the current standard of care treatment options. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Line Locally Advanced or Metastatic Breast Cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2 study investigating onapristone (ONA-IR, 100 mg&#47;day as a single daily dose) as first-line endocrine therapy in patients with breast cancer was conducted as an investigator-initiated study, as shown below. Nineteen patients, either with locally advanced breast cancer (n &#61; 12) or who were elderly with primary breast cancer and considered unfit for standard of care (n &#61; 7) received ONA-IR. In 17 of the 19 patients, tumors expressed ER while 12 of 18 tumors tested expressed PR. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among 18 patients who were evaluable for response, 10 had a partial response and 2 had stable disease (&#8220;SD&#8221;) for six months or more. The median duration of objective response and SD was 70 weeks. Ten patients were ER-positive&#47;PR-positive, of whom 7 achieved partial response (PR&#59; tumor shrinkage of &#62;30%) and 1 had SD. Overall, the clinical benefit rate was considered comparable to the current standard of care of letrozole (anti-estrogen) and palbociclib (CDK4&#47;6 inhibitor). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of ONA-IR to standard of care in 1L locally advanced or metastatic breast cancer </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatment &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subtype &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients<br>(n)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CBR<br>(%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ORR<br>(%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grade 3,4 AE<br>(%) &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference &#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONA-IR</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PR+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#94;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GT (&#60;5%)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robertson (1999)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL + LET</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia (55%), Leukopenia&#160;(25%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-1 (2014)</font></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; CBR&#58; clinical benefit rate&#59; LET&#58; letrozole&#59; ONA&#58; onapristone, ORR&#58; overall response rate&#59; PAL&#58; palbociclib. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Line Metastatic Breast Cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-randomized, open label, multicenter Phase 2 study was conducted at 13 sites in Germany and the United Kingdom, as shown below. The study goal was to investigate the efficacy and safety of ONA-IR when given 100 mg&#47;day to post-menopausal women with advanced breast cancer who had progressed on tamoxifen, a selective estrogen receptor modulator therapy. The study was also designed to assess the influence of onapristone on the levels of relevant endocrine parameters (cortisol, androstenedione, estrone and estradiol). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 101 evaluable patients, 1 had a complete response (&#8220;CR&#8221;), 9 had a partial response, and 39 had SD for three months or more. The median duration of response was 11 months. Median time to progression was 4 months. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In second line metastatic breast cancer, ONA-IR exhibited monotherapy activity in patients who had progressed while on tamoxifen. In this trial, patients were not screened for progesterone receptor positive (PR+) status, meaning that only 60% of enrolled patients would have expected to be PR+ based upon historical prevalence in this setting and therefore derive clinical benefit from ONA-IR. Therefore, this trial potentially under-represents the likely true clinical benefit of ONA-IR had patients been stratified for the partial response biomarker. Despite administering a monotherapy without patient selection for PR+, ONA-IR demonstrated comparable clinical activity to standard of care anti-estrogens (FUL), CDK4&#47;6 inhibitors (PAL), and the combination of the two (FUL + PAL). </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of ONA-IR to standard of care in 2L metastatic breast cancer </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatment &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subtype &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients<br>(n)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CBR<br>(%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ORR<br>(%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grade 3,4 AE (%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONA</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Comers</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None reported</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonat (1996)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia&#160;(55%), Leukopenia&#160;(25%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TREnd (2017)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FUL</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fatigue (&#60;5%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-3 (2015)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL + FUL</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia&#160;(65%), Leukopenia&#160;(25%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-3 (2015)</font></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; CBR&#58; clinical benefit rate&#59; FUL&#58; fulvestrant&#59; LET&#58; letrozole&#59; ONA&#58; onapristone, ORR&#58; overall response rate&#59; PAL&#58; palbociclib. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onapristone XR Clinical Data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, over 140 subjects received at least a single dose of ONA-XR across both healthy volunteer and cancer trials through December&#160;31, 2021. Multiple drug product formulations of onapristone have been developed for evaluation throughout the clinical development program. Clinical development was initiated with a 10 mg immediate release (IR) capsule. An IR tablet formulation (10mg, 25 mg) and extended release (XR) tablet formulation (2.5 mg, 5 mg, 10 mg, and 20 mg) were also developed. The tablets have been administered as a single tablet or in multiples in order to obtain the desired dosage. The XR tablet has been used in ongoing safety and efficacy studies. ONA-XR 50 mg BID (twice-per-day) is the recommended dose for our ongoing investigational trials.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed clinical studies incorporating new formulation </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Study Protocol</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Status)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Study Design</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dosage<br>and Regimen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Endpoints</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-001</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single dose PK study of oral immediate release (IR) formulation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 Healthy female volunteers</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;mg single dose, fasting&#160;and&#160;2&#160;weeks later with food or vice-versa</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK profile, food effect, safety</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-101</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-center, open- label, randomized, two-stage study with a phase 2 expansion component in patients PR+ breast, ovarian, or endometrioid adenocarcinoma</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 post- menopausal females, recurrent or metastatic PR+ cancer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 mg XR BID 20 mg XR BID 30 mg XR BID 40 mg XR BID 50 mg XR BID 100 mg IR QD</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, RP2D, Efficacy, PK, Bioavailability</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-102</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open-label, randomized, two-stage phase 1 study and a phase 2 expansion in combination with abiraterone in males with castration-resistant prostate cancer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 males with adenocarcinoma of prostate</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 mg XR BID 20 mg XR BID 30 mg XR BID 40 mg XR BID 50 mg XR BID</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, RP2D PK</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONAWA </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-center, open-label, randomized, two-stage window of opportunity trial</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 females, primary PR+ cancer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 mg XR BID</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, Efficacy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Patient INDs (Closed)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single patient IND in patients with PR+ ovarian or endometrioid adenocarcinoma</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 females, recurrent or metastatic PR+ cancer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 mg XR BID</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, Efficacy</font></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; BID&#58; twice per day&#59; IR&#58; immediate release&#59; PK&#58; pharmacokinetic&#59; PR&#58; progesterone receptor&#59; QD&#58; once per day&#59; XR&#58; extended release. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 thirty-two subjects (22%) of the total onapristone safety set (n &#61; 144) experienced any treatment emergent adverse event (TEAE). Adverse events were generally consistent across all defined groups. Thirteen subjects experienced Grade 3 or Grade 4 TEAEs that were deemed related to ONA-XR with no correlation across dosing groups. The most common drug-related TEAEs included fatigue, abdominal pain, and an increase in gamma-glutamyltransferase. These events are generally consistent with disease progression and&#47;or prior anti-progestin experience, including onapristone. In addition, there were no clinically significant post-dose changes in electrocardiograms (ECGs), vital signs, or safety laboratory results. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Primary Breast Cancer</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a multicenter, open label, window of opportunity trial, Bellet </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2021) enrolled 10 adult patients with ER+, PR+, HER2- breast cancer and Ki-67 &#8805; 15%. Patients received ONA-XR tablets of 50 mg BID for a short course of endocrine therapy before surgery. Assessment of the treatment effects was possible for the 10 patients who successfully completed the protocol and the 10 paired samples (100%) were analyzed. Main patient characteristics were mean age 68, mean tumor size 20.2&#8197;mm, stage I (40%) and grade 2 (100%).  No patients achieved a CCCR (cell-cycle complete response). Tumor Ki-67 expression decreased, was stable and increased in 6, 1 and 3 patients, respectively. Mean percentage suppression of Ki-67 was 19.58%. Overall, no statistically significant change was observed in Ki-67 between paired samples (p&#61;0.234). Baseline IHC PgR (%) expression correlated with Ki-67 decrease (r &#61; -0.60). Mean percentage suppression of Ki-67 for tumors with IHC PgR expression &#8805;90% (N&#61;4) and &#60;90% (N&#61;6) was -62.0% and +8.7%, respectively. Six (60%) patients reported adverse events at any grade. Most </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common grade 1 or 2 adverse events were post procedural pain, dry mouth and GGT (gamma-glutamyl transferase) increased. Grade 3 reversible GGT and AST (aspartate aminotransferase) increase occurred in one patient.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Metastatic Breast Cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a multicenter, open label, Phase 1 trial, Cottu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2018)&#160;enrolled 52 adult patients with PR+ tumors, including 20 patients with breast cancer. Patients were randomized to five cohorts of ONA-XR tablets of 10, 20, 30, 40 or 50 mg BID, or immediate release 100 mg QD until progressive disease or intolerability. All patients were heavily pre-treated&#59; prior treatments included median (range)&#58; chemotherapy 4 (1&#8211;11), endocrine therapy 1 (1&#8211;7), biologic&#47;small molecule therapy 1 (1&#8211;2), and radiotherapy 1 (1&#8211;3). Among the 20 heavily pre-treated breast cancer patients, no CR or partial response were observed, 7 patients had SD, including 3 patients with SD lasting for at least 24 weeks (15% clinical benefit rate). The number of prior therapies was 3, 7 and 7, respectively, for these 3 patients and 2 of these 3 patients had liver metastases at baseline. The study authors concluded that the new XR formulation of onapristone was well tolerated and resulted in meaningful clinical benefit in heavily pretreated patients with breast cancer. The only treatment-related serious adverse events were G3 LFT elevations (n &#61; 4&#59; 8%), all associated with disease progression in the liver as reviewed. These occurred across dose cohorts&#58; 10 mg BID (AST increased, bilirubin increased), 20 mg BID (LFTs abnormal), and 40 mg BID (bilirubin increased). No relationship was found between adverse events and study drug exposure. No treatment-related deaths were reported. One patient died within 30 days of last dose (respiratory distress syndrome due to progressive lung metastases). No other significant adverse events attributable to the mechanism of action were recorded. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Metastatic Gynecologic Cancers </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase I dose escalation study of ONA-XR in breast, endometrial, and ovarian cancer patients found all doses tested to be safe and well tolerated, with 50mg BID administered orally recommended as the Phase 2 dose. The most common treatment-related adverse events reported by investigators (&#62;10%) were nausea, fatigue and constipation. In that Phase I study, 33% of ovarian and 25% of endometrial cancer patients were seen to have sustained disease control. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focusing on the ovarian cancer (n&#61;13) subpopulation, all PR+ ovarian patients were heavily pre-treated&#59; prior treatments included median (range)&#58; chemotherapy 4 (2&#8211;6), and treatment lines in metastatic setting 4 (2-10). All patients were platinum resistant. Clinical data is shown below. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1 ovarian cancer data </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business15a.jpg" src="business15a.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Granulosa Cell Tumor of the Ovary </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granulosa cell tumors (GCT) of the ovary is a rare form of ovarian cancer. These tumors account for 2-5% of all ovarian malignancies and it is estimated that there are approximately 5,000 patients with recurrent disease in the US and EU. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Almost all GCT tumors are progesterone receptor (PR) positive, whereas about 50% are estrogen receptor (ER) positive. These tumors often produce estrogen and progesterone, which can cause symptoms such as abnormal vaginal bleeding or breast tenderness. Further, PR expression is correlated with worse outcomes in GCT patients. GCT tumors have a low mitotic ratio and few actionable mutations, which limits the applicability of chemotherapeutic and precision medicine approaches. Platinum-based chemotherapy is recommended as the first line of treatment for patients in the metastatic setting. Following progression to metastatic disease, patients typically cycle through chemotherapy, antihormonal treatments, and cytoreductive surgeries. There are currently no FDA treatments for GCT tumors of the ovary, and few, if any, open clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that GCT tumors are hormone driven, it is plausible that complete hormone blockade via antiprogestin and antiestrogen therapy may provide a therapeutic benefit to patients. In 2019, Memorial Sloan Kettering Cancer Center initiated an Investigator-sponsored Trial to evaluate onapristone extended release (ONA-XR) in women with GCT of the ovary who had progressed on multiple prior therapies. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 data evaluating ONA-XR in late line GCT of the ovary </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fourteen patients with progesterone receptor positive (PR+) GCT of the ovary were enrolled in the stage I trial, with thirteen of those patients completing at least one full cycle of treatment. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business16a.jpg" src="business16a.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four of the 14 patients (29%) had clinical benefit lasting at least 24 weeks, and 5 additional patients (64%) experienced stable disease as best response. Importantly, two patients (14%) remain on treatment after 12 months. To date, no significant treatment-related adverse events have been identified. The most common treatment-related adverse events reported were nausea, fatigue, and constipation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Phase 2 monotherapy data presented above, a combination arm seeking to enroll 25 patients was activated to evaluate the combination of ONA-XR with Arimidex (anastrozole), a selective nonsteroidal aromatase inhibitor. Aromatase inhibitors are commonly used to treat recurrent granulosa cell tumors based on low response rates to chemotherapy and historically high rates of ER&#47;PR expression within these tumors. However, objective response rate for anastrozole remains low and was found to be 2.5% in a recent clinical trial (Banerjee, JCO, 2018). We seek to test the combination of ONA-XR and anastrozole to enhance the response rate in patients with PR+ GCT tumors of the ovary. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have FDA Fast Track designation for PR+ ovarian cancer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we received FDA Fast Track designation for ONA-XR in PR+ ovarian cancer. Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. If any of our product candidates receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical development plan for&#160;ONA-XR </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PR signaling pathway has been implicated in female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b&#47;2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4&#47;6 and&#47;or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L&#47;3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6xCD3 bispecific antibody program&#58; CLDN6xCD3 bsAb </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background CLDN6 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claudin 6 (CLDN6) is an oncofetal tight junction protein involved in the cell-to-cell adhesion of epithelial and endothelial cell sheets. Although silenced in healthy adult human tissues, CLDN6 expression has been found in ovarian, gastric, pediatric, and other cancer tissues and can lead to a poor prognosis. Monoclonal antibody (MAb) discovery against CLDN6 has been encumbered by the high homology of endogenously expressed claudin&#160;9 (CLDN9), which varies from CLDN6 by only 3 amino acids in the extracellular domain.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proposed mechanism of action </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business17a.jpg" src="business17a.jpg" style="height:214px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rationale for bispecific antibody </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytotoxic T cells are considered to be the most potent effector cells of the immune system. As a consequence, broad T cell activation can lead to significant and sometimes lethal side effects. Therefore, to harness the potential of cytotoxic T cells, therapeutic strategies seek to pair T cell activation with drug targets that are restricted to cancer tissue so as to avoid unwanted toxicity. CLDN6 expression is restricted to various cancer types (i.e., a tumor specific antigen or TSA), making it an ideal target to help T cells recognize and eliminate cancer cells. Recently, a class of bispecific antibodies (TSAxCD3) with a native immunoglobulin format has emerged that can efficiently trigger T cell&#8211;mediated killing of tumor cells by linking a T cell to a tumor cell and activating the CD3&#47;t cell receptor complex, as shown above. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6 expression in cancer versus normal tissue </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business18a.jpg" src="business18a.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:434px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source&#58; Cancer RNAseq data from The Cancer Genome Atlas (TCGA)&#59; normal tissue RNAseq data from the Genotype-Tissue Expression (GTEx) project. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. As shown below, preclinical studies demonstrate that CLDN6xCD3 bsAb exhibits selectivity for CLDN6 over CLDN9 and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that CLDN6xCD3 bsAb mediates strong T-cell activation and specific lysis of cells expressing CLDN6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies with a prototype bispecific of CLDN6xCD3 bsAb demonstrated dose-dependent tumor regressions in an established ovarian cancer xenograft model with an intact immune system. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6 x CD3 bispecific retains selectivity of parental mAb </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business19a.jpg" src="business19a.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure above illustrates the results of a binding assay showing that Context&#8217;s Claudin 6 monoclonal and bispecific antibodies bind to Claudin 6 preferentially over other Claudin proteins. Human embryonic kidney 293T (HEK-293T) cells were transiently transfected with DNA for the indicated Claudin protein along with GFP (pUC) for 22 hours. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context bispecifics activate T cells against CLDN6+ cells </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business20a.jpg" src="business20a.jpg" style="height:171px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure above illustrates the results of immune assays showing that Context&#8217;s CLDN6 x CD3 bispecific antibodies activate T cells and drive T-cell dependent cytotoxicity. All bispecific formats contain the same CD3 cassette. Activity was measured after 72 hours of treatment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of CLDN6 development programs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed head-to-head </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies comparing internally developed CLDN6 monoclonal antibodies and those from BioNTech and Xencor. Antibodies for BioNTech and comparative data for Xencor were derived from publicly available reports published independent of the Company and may differ in material ways from the actual antibody that is in development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results presented in the below table have been derived from publicly available reports of preclinical studies and clinical trials run independently of our trials or meta-analyses of such clinical results. We have not performed any head-to-head trials comparing any of these other therapies with CLDN6xCD3 bsAb. As such, the results of these other clinical trials may not be comparable to clinical results for CLDN6xCD3 bsAb. The design of these other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials vary in material ways from the design of the clinical trials for CLDN6xCD3 bsAb. For further information and to understand these material differences, you should read the relevant reports or meta-analyses. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the BioNTech and Xencor&#8217;s product candidates are not intended to compete with our CLDN6xCD3 bsAb, it is useful to compare the symptomatic results achieved by their devices and approaches a good proxy to understand the adoption of these therapies. </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Context &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xencor &#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BioNTech &#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6xCD3 bsAb</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6xCD3 bsAb</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BNT211 BNT142</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Antibody Format</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bispecific <br>CLDN6xCD3</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bispecific <br>CLDN6xCD3</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6 <br>CAR-T, and <br>CLDN6xCD3 (bi(sFc))</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1, Phase 1</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selectivity CLDN6&#58;9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100x</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10x</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7x</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other preclinical programs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product candidates, we are leveraging our knowledge in hormone-dependent cancer to pursue discovery stage research programs. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the Company entered into a patent license agreement, as amended, (the &#8220;Drexel License Agreement&#8221;) with Drexel University (&#8220;Drexel&#8221;) for license rights to patents for certain intellectual property and know-how related to certain Sigma1 technology.  As part of a strategic review of our pipeline, we have recently notified Drexel that we are terminating the Drexel License Agreement, effective as of April 27, 2022.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our collaboration and license agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into a manufacturing and development agreement with Tyligand Bioscience (Shanghai) Limited for ONA-XR (the &#8220;Tyligand Process Development Agreement&#8221;) that is intended to enhance our ability to meet manufacturing demands for commercial launch and expand our clinical trial footprint into Greater China. Under the terms of the agreement, Tyligand is responsible for ONA-XR manufacturing process optimization. As a part of the agreement, Tyligand is eligible to receive development milestone payments of $0.8 million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $2.0 million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $3.0 million upon our completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. We will also pay Tyligand a 1% royalty of net sales of finished product commercialized in any country (other than the People&#8217;s Republic of China, including Hong Kong and Macau) utilizing the compound substantially manufactured in accordance with the process and specifications outlined in this agreement. This agreement terminated in August of 2021, subject to certain surviving and ongoing obligations. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.2 and which is incorporated herein by reference.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August of 2021, Tyligand achieved &#8220;successful completion&#8221; under the Tyligand Process Development Agreement as a result of Tyligand&#8217;s successful optimization of the ONA-XR manufacturing process. Because of this achievement, Tyligand has entered into a license agreement with us (the &#8220;Tyligand License Agreement&#8221;) whereby we have granted Tyligand an exclusive license to develop and commercialize ONA-XR in the People&#8217;s Republic of China, including Hong Kong and Macau (the &#8220;Tyligand Territory&#8221;), subject to Tyligand paying Context a mid-single digit royalty of net sales of ONA-XR in such countries. The royalty term of such exclusive license shall be the from period beginning on the date of the first commercial sale of ONA-XR in the Tyligand Territory and ending on the latest of (i) the sale of a generic product containing the same active pharmaceutical ingredients as ONA-XR in the Tyligand Territory, and (ii) fifteen (15) years after the date of the first commercial sale of ONA-XR in the Tyligand Territory. We have retained our global exclusive rights for ONA-XR for the remainder of the world. As a result of the completion of this milestone, Tyligand  was granted a warrant to purchase 111,576 shares of our common stock at an exercise price of $7.17 per share (which was automatically exercised and cancelled in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with our initial public offering), we paid Tyligand $800,000, and Tyligand will be eligible to receive manufacturing and development milestone payments totaling up to $5.0 million upon the achievement of certain future milestones. The Tyligand License Agreement provides for termination in the event of (a) insolvency, (b) a material breach of the agreement, and (c) in the event that Tyligand does not meet certain regulatory milestones. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.5 and which is incorporated herein by reference.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a license agreement with Integral for the exclusive worldwide rights (the &#8220;Integral License Agreement&#8221;) to certain Claudin 6 antibody patents in the field of bispecific antibodies. Under the terms of the license and development agreement, we are responsible for all costs associated with CLDN6xCD3 bsAb development as well as certain success-based payments, including milestone and royalty payments, to Integral. We paid an upfront license fee of $0.3 million and granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8 million. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3 million, sales milestone payments totaling up to $130 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. We shall continue to pay royalties on a country-by-country and licensed-by-licensed product basis, until the later of&#58; (i) the expiration of the patent covering such product in such territory, (ii) the expiration of any regulatory exclusivity granted with respect to a product in such territory and (iii) ten years from the first commercial sale of such product in such country. The agreement shall continue in full force and effect, until either (a) royalty payments for all products in all territories have expired or (b)(i) we provide written notice of termination, (ii) during three successive quarters we do not use commercially reasonable efforts to develop a product, (iii) if the agreement is breached or (iv) if a party goes bankrupt. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.1 and which is incorporated herein by reference.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain worldwide development and commercialization rights for ONA-XR outside of Greater China and retain full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. We periodically evaluate out-license opportunities for our product candidates, including our lead product candidate ONA-XR, and seek to identify drug candidates for novel indications and&#47;or patient subpopulations with an oncology focus that we might in-license. Our commercial plans and strategy for each particular program may change as programs advance, markets change, and we receive more clinical data, and will depend on availability of current and future capital. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and marketing </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing, or commercial product distribution capabilities, and we may explore partnerships with larger pharmaceutical organizations to out-license our product candidates, including our lead product candidate ONA-XR. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have obtained active pharmaceutical ingredients (API) and drug product for our product candidates from several third party contract manufacturers. We are in the process of developing our supply chain for each of our product candidates and intend to put in place additional framework agreements under which third-party contract </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers will generally provide us with necessary quantities of API and drug product on a&#160;project-by-project&#160;basis based on our development needs. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product for each of our product candidates to protect against any potential supply disruptions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect to rely on third parties for the manufacture of any companion diagnostics we may develop. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For ONA-XR, our small molecule PR antagonist, we are aware of several companies developing PR antagonists, including Allergan, Evestra, and Gedeon Richter. To our knowledge, there are no PR antagonists approved for the treatment of cancer and the most advanced such PR antagonist is in a Phase 2 clinical trial. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CLDN6xCD3 bsAb, our CLDN6xCD3 bispecific antibody, we are aware of several companies developing antibodies against this target, including Abbvie, Amgen, Astellas, AstraZeneca, BioNTech, Chugai, I-Mab, NovaRock, and Xencor. These companies are developing CDLN6 products in naked antibody, bispecific, CAR-T, and mRNA vaccine formats. To our knowledge, BioNTech has the only CLDN6 product in clinical trials.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining and defending our patent rights. We own the issued patent and patent applications relating to our first program and lead product candidate ONA-XR, and retain full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States directed to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and&#160;know-how&#160;relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our product candidates, technology, inventions and improvements&#59; to preserve the confidentiality of our trade secrets&#59; to defend and enforce our proprietary rights, including any patents that we may own or license in the future&#59; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 14, 2022, our patent portfolio consisted of pending or issued patents that we own or license related to our ONA-XR product candidate and various other compounds and programs. Specifically, we owned four issued U.S. patents, three pending U.S. patent applications, one granted Canadian patent, two granted Chinese patents, one granted Japanese patent, three granted Australian patents, one granted Hong Kong patent, and 18 pending foreign patent applications, two of which are Australian applications, three of which are Canadian applications, two of which are Chinese applications, three of which are European regional patent applications, two of which are Hong Kong applications, one of which is a Mexican application, two of which are Japanese applications, two of which are Korean applications, and one international PCT application. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically with respect to ONA-XR,&#160;our issued U.S. patents in our owned portfolio described above have claims directed to our ONA-XR as pharmaceutical compositions, formulations, and related methods of use, and methods of making. These U.S. patents are expected to expire between 2034 and 2036, subject to any extensions or disclaimers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a&#160;product-by-product&#160;basis, from&#160;country-to-country&#160;and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our product candidates, technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents may not guarantee us the right to commercialize our product candidates, if approved. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing our product candidates and practicing our proprietary product candidates, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar products. Furthermore, our competitors may independently develop similar products that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Pathway </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that ONA-XR will be classified and regulated by the FDA as a drug. We expect that our CLDN6xCD3 bsAb will be classified and regulated by the FDA as a biologic. A new drug application (&#8220;NDA&#8221;) is required to introduce a drug into interstate commerce. A biologics license application (&#8220;BLA&#8221;) is required to introduce a biologic product into interstate commerce. The specific requirements of NDAs and BLAs include applicant information, product information, manufacturing information, pre-clinical data, clinical data, and labelling. The most important, time-consuming, and expensive aspect of preparing for a BLA or NDA is conducting clinical trials to demonstrate safety and effectiveness. The requirements of such clinical trials heavily influence the eventual allowable product label claims. The FDA has a performance goal as defined in the Prescription Drug User Fee Act of ten months for a standard submission and six months for priority review. It is not uncommon for NDAs and BLAs to require medical advisory board review prior to the FDA granting marketing approval. A facility inspection verifying the manufacturing systems is also usually performed prior to FDA approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past used and intend to continue to utilize the services of third-party experts to supplement internal regulatory planning and implementation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing FDA Regulation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA permits a product to enter commercial distribution, numerous and pervasive regulatory requirements continue to apply to our business operations, products and technologies. These include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s quality system regulation, or QSR, which requires manufacturers, including third party manufacturers, to follow stringent design, testing, production, control, supplier&#47;contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling and marketing regulations which require that promotion is truthful, not misleading, fairly balanced and provide adequate directions for use and that all claims are substantiated&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advertising and promotion requirements, including FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses and FDA guidance on off-label dissemination of information and responding to unsolicited requests for information&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on sale, distribution or use&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product establishment, registration and listing requirements and reporting requirements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall requirements, including a mandatory recall if there is a reasonable probability that a product would cause serious adverse health consequences or death&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an order of repair, replacement or refund&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance activities and regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad post-market and regulatory enforcement powers. Manufacturers of biologic products and drug products like our product candidates are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters, untitled letters, Form&#160;483s, fines, injunctions, consent decrees and civil penalties&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall or seizure of products&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions, partial suspension or total shutdown of production&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s refusal of requests for approval of new products or indications for existing products&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing approvals that have already been granted&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Laws </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information, including health information. Among others, the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, (collectively referred to as HIPAA), establish privacy and security standards that limit the use and disclosure of protected health information, or PHI, and require covered entities and business associates to implement administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form, among other requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of HIPAA may result in civil and criminal penalties. Companies subject to HIPAA must also comply with HIPAA&#8217;s breach notification rule which requires notification of affected patients and the U.S. Department of Health and Human Services, or HHS, and in certain cases of media outlets, in the case of a breach of unsecured PHI. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate. State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have laws that protect the privacy and security of sensitive and personal information, including health information, to which we are subject. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, California enacted the California Consumer Privacy Act, or CCPA, which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA went into effect on January&#160;1, 2020, and the California Attorney General may bring enforcement actions for violations as of July&#160;1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place specific requirements on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain types of activities, such as data security and texting, and laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Union member states, the United Kingdom, Switzerland and other jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EEA and the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR became effective on May&#160;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical and medical device companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products. By way of example, the Patient Protection and Affordable Care Act, or PPACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical, medical device and biologics industries, among others. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the PPACA, and we expect there will be additional challenges and amendments to the PPACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the PPACA are invalid as well. While the Texas District Court Judge, as well as then-president Trump&#8217;s Administration and CMS, have stated that the ruling will have no immediate effect, and on December&#160;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal. In December 2019, a U.S. District Court upheld a ruling that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In November 2020, the Supreme Court of the United States heard oral arguments in the appeal of this case.  While the Supreme Court issued its ruling in July 2021, in part finding that the plaintiff&#8217;s lacked standing, it is unclear how this and other efforts to challenge, repeal, or replace the ACA, or how future changes in the Presidency, Congress or Senate, will impact the ACA or our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge and&#47;or patients&#8217; willingness to pay for our products. While in general it is too early to predict what effect, if any, any future healthcare reform legislation or policies will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and prospects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third party payors. Third party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. These third-party payors are increasingly challenging the price and examining the cost-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products, and efforts are underway to reduce the cost of medical products and services overall. We may need to conduct expensive studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product or procedure using the product does not ensure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate revenue levels. Future legislation could limit payments for our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of less costly products. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products. The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on medical product and service pricing. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback and False Claims Laws </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the research, manufacturing, distribution, sale and promotion of pharmaceutical products and devices are subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &#38; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other federal, state and local government agencies. For example, sales, marketing and scientific&#47;educational grant programs must comply with the FFDCA, Anti-Kickback Statute, as amended, the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, in the United States, we are subject to complex laws and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the federal Anti-Kickback Statute, the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a biological product manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase or order of an item for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state anti-kickback laws and the potential for additional legal or regulatory change in this area, it is possible that our sales and marketing practices and&#47;or our relationships with physicians might be challenged under anti-kickback laws, which could harm us. Because we plan to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we plan to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the rules and program requirements to which we are subject. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including pharmaceutical products, that are false or fraudulent. Although we would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their off-label promotion of drugs. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,665 and $23,331 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, a provision of the Patient Protection and Affordable Care Act, referred to as the Sunshine Act, requires pharmaceutical product manufacturers to track and report to the federal government certain payments or other transfers of value made to physicians, registered nurses and teaching hospitals, among others, in the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Federal Healthcare Fraud and Abuse Laws </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to other federal healthcare fraud and abuse laws, including provisions of HIPAA, which prohibit knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payors, as well as knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government-sponsored programs. Similar to the federal Anti-Kickback Statute, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or FCPA, prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records, which in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the corporation, including international subsidiaries, if any, and to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we had seven full-time employees, no part-time employees and three consultants. None of these employees are represented by labor unions or covered by collective bargaining agreements. We believe that our employee relations are good.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Culture is a critical element in the management of our organization. Our talented employees are focused on driving our business with the foundation for all our efforts being the development of treatments to transform care for female cancers and improving the lives of women living with cancer. Our goal is that each colleague feels a deep connection to what they do, loves coming to work, and is aligned to our mission.     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Culture begins with our hiring process and continues throughout an employee&#8217;s time with Context. We support our colleagues with a comprehensive offering of competitive pay and benefits. During the ongoing COVID-19 pandemic began, we strive to ensure the safety of our colleagues and continue to adapt over time to the changing environment. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal office is located in Philadelphia, Pennsylvania, where we lease approximately 3,500 square feet of office space pursuant to a lease that expires in July 2023. We believe our facility is adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and results of operations. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers and Directors </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our executive officers and directors as of the date of this prospectus&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Officers&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Levit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer and Corporate Secretary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarek Sahmoud, MD, PhD</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-Employee Directors&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Berman</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Evans Stacey, Esq.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philip Kantoff, MD</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda West</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a brief biography of our current executive officers and directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Martin Lehr &#8211; Chief Executive Officer and Director </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr.&#160;Lehr is the Co-founder and Chief Executive Officer of Context Therapeutics and member of our board of directors since its founding in 2015. In addition, Mr.&#160;Lehr serves on the boards of Praesidia Biologics and CureDuchenne Ventures. Previously, Mr.&#160;Lehr was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. Prior to Osage University Partners, Mr.&#160;Lehr conducted research at the Sloan Kettering Institute in DNA repair and at the Children&#8217;s Hospital of Philadelphia in thrombosis and hemostasis.&#160;Mr.&#160;Lehr is a director of BioBreak, a biotech executive peer networking group with over 2,500 active members across the United States, and an advisory board member of Life Science Cares and Life Science Leader magazine. Mr.&#160;Lehr holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania. The Company has determined that Mr.&#160;Lehr&#8217;s business experience and management background make him a qualified member of our management group and board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jennifer Minai Azary &#8211; Chief Financial Officer</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Minai-Azary joined Context in November 2021 as Chief Financial Officer.  She brings more than 20 years of finance and accounting experience and has spent the past several years leading finance teams within the life sciences industry. Prior to joining the Company, Ms. Minai-Azary served as Chief Financial Officer of Millendo Therapeutics, a publicly-traded biopharmaceutical company.  She also served as Vice President, Finance, as well as in other finance roles, at Millendo where she was responsible for the financial reporting, accounting, treasury, tax, and risk management functions.  While at Millendo, she played a key role in several financing transactions and company mergers. Before that, she served as Director, Technical Accounting at PAREXEL International. Ms. Minai-Azary began her career at Ernst &#38; Young and held positions of increasing responsibility where she managed financial statement audits for publicly-traded and privately-held clients within a variety of industries. Ms. Minai-Azary holds a Master of Accounting and a B.B.A. from the University of Michigan and is a certified public accountant.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alex Levit &#8211; Chief Legal Officer and Corporate Secretary </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alex Levit joined Context in April 2021 as Chief Legal Officer and serves as Corporate Secretary. Prior to joining the Company, Mr. Levit served as Vice President, Deputy General Counsel and Assistant Corporate Secretary of OptiNose, a publicly-traded specialty pharmaceutical company. Prior to OptiNose, Mr. Levit served as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company, from 2010 until 2017. During his tenures at OptiNose and Teva, Mr. Levit negotiated various in-bound and out-bound licenses, collaborations, mergers and acquisitions, and supply agreements. While at OptiNose, Mr. Levit also handled various public and private financing transactions. Before joining Teva, Mr. Levit was a corporate and life sciences attorney at the law firm of Reed Smith LLP. Mr. Levit also serves as a member of the board of directors of Strados Labs, a medical device company. Mr. Levit holds a JD from Temple University Beasley School of Law and a Bachelor of Arts in Labor &#38; Industrial Relations from Pennsylvania State University, where he is a graduate of the Schreyer Honors College. &#160;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tarek Sahmoud, MD, PhD. &#8211; Chief Medical Officer </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Sahmoud is currently President of OncoStrategy, a boutique clinical development consultancy, and is acting as consulting Chief Medical Officer to Context Therapeutics. Dr.&#160;Sahmoud has more than 25 years of experience in oncology drug development and medical affairs, most recently as Chief Medical Officer of H3 Biomedicines. Dr.&#160;Sahmoud also held senior clinical development positions at Celgene, Novartis and AstraZeneca. During his career, Dr.&#160;Sahmoud has either led or supported global drug development programs for several novel oncology drugs in multiple indications, including adjuvant breast cancer (Arimidex) and hormone receptor positive breast cancer (Kisqali and Afinitor), resulting in successful global registrations. His experience also includes the development and leading of global and U.S. medical affairs teams, multi-disciplinary teams of physicians and clinical scientists, as well as serving on the protocol review committee of a number of companies. Dr.&#160;Sahmoud received his medical degree from Cairo University Medical School, Egypt and a Ph.D. in biostatistics from University Bordeaux II, France.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Richard Berman &#8211; Chairman of the Board, Director </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr.&#160;Berman has served as a member of our board of directors since March of 2021 and as Chairman of the board of directors since March of 2021. Mr.&#160;Berman&#8217;s business career spans over 35 years of venture capital, senior management and merger&#160;&#38; acquisitions experience. In the past five years, Mr.&#160;Berman has served as a director and&#47;or officer of over a dozen public and private companies. Currently, he is a director of four public companies&#58; Advaxis, Inc., Cryoport, Inc., COMSovereign Holding Corp., and BioVie Inc. Over the last decade he has served on the board of five companies that have reached over $1&#160;billion in market capitalization &#8211; Cryoport, Advaxis, EXIDE, Internet Commerce Corporation and Ontrak (Catasys). Previously, Mr.&#160;Berman worked at Goldman Sachs&#59; was Senior Vice President of Bankers Trust Company, where he started the M&#38;A and Leveraged Buyout Departments. In the 1980s, he created one of the largest battery companies in the world by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE). He also helped create SoHo, the lower Manhattan neighborhood in NYC, by developing five buildings and he has advised on over $4&#160;billion M&#38;A transactions, completing over 300 deals. Mr.&#160;Berman is a past director of the Stern School of Business of New York University where he obtained his B.S. and M.B.A. degrees. He also has U.S. and foreign law degrees from Boston College and the Hague Academy of International Law, respectively. The Company has determined that Mr.&#160;Berman&#8217;s background and success in the life sciences industry, as well as in investment and finance in general, make him a qualified member of our board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jennifer Evans Stacey, Esq. &#8211; Director </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms.&#160;Stacey has served as a member of our board of directors since March of 2021. Ms.&#160;Stacey is currently Chief Legal and Compliance Officer of Galera Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. Ms.&#160;Stacey has 25 years of global senior executive experience managing public, private and non-profit companies, ranging in size from 60 to 5,500 employees and primarily within the life sciences industry. Prior to Galera, Ms.&#160;Stacey served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, and before that as Senior Vice President, General Counsel, Human Resources and Secretary at Antares Pharma, Inc. Previously, Ms.&#160;Stacey served as Executive Vice President, General Counsel, Human Resources, and Secretary at Auxilium Pharmaceuticals, Inc., and as Senior Vice President, Corporate Communications, General Counsel and Secretary at Aventis Behring, LLC. She began her career in life sciences at Rhone-Poulenc Rorer, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including two years in their Paris office and prior to that began her legal career at King&#160;&#38; Spalding in Washington, DC. Ms.&#160;Stacey graduated magna cum laude with an A.B. from Princeton University and earned her J.D. from the University of Pennsylvania Law School. The Company has determined that Ms.&#160;Stacey&#8217;s business and legal background make her a qualified member of our board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Philip Kantoff, MD. &#8211; Director </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Kantoff has served as a member of our board of directors since December of 2018. Dr.&#160;Kantoff is the Co-Founder and Chief Executive Officer of Convergent Therapeutics, a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. Previously, Dr. Kantoff served as the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, which is the leading development and testing center for novel cancer therapies. He also served as Director of The Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is the Jerome and Nancy Kohlberg Professor Emeritus at Harvard Medical School. He is a member of numerous professional societies and editorial boards. Dr.&#160;Kantoff has published more than 500 research articles on a variety of topics and has been cited over 76,000 times, written nearly 100 reviews and monographs on cancer and has edited numerous books, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prostate Cancer, A Multi-Disciplinary Guide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> published by Blackwell, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prostate Cancer&#58; Principles and Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a definitive text on prostate cancer. The Company has determined that Dr.&#160;Kantoff&#8217;s medical and business background make him a qualified member of our board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Linda West &#8211; Director </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms.&#160;West has served as a member of our board of directors since March of 2021. Ms.&#160;West served in multiple leadership roles of increasing responsibility for E. I. du Pont de Nemours and Company from 1981 until her retirement in November 2019. Ms.&#160;West most recently served as Vice President, Corporate Planning and Analyses, where she led the execution of transformational transactions from October 2009 until her retirement including major divestitures, spins, acquisitions, and the merger with The Dow Company followed by simultaneous spins into three independent companies. Throughout her career with DuPont, Ms.&#160;West had P&#38;L accountabilities varying from late to early stage businesses including DuPont Imaging Technologies, DuPont Personal Protection, DuPont Microcircuit Materials, and DuPont Industrial Imaging. In addition, Ms.&#160;West was the Chief Financial Officer of multiple DuPont businesses and was the Vice President, General Auditor and Chief Ethics and Compliance Officer for five years during the initial implementation of the Sarbanes-Oxley Act of 2002. Ms.&#160;West serves on the board of directors of Galera Therapeutics, Inc. Ms.&#160;West holds a B.S. in Accounting with a minor in Business Administration from the University of Delaware. The Company has determined that Ms.&#160;West&#8217;s business and finance background make her a qualified member of our board of directors. &#160;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors currently have terms which will end at our next annual meeting of the stockholders or until their successors are elected and qualify, subject to their prior death, resignation or removal. Officers serve at the discretion of the board of directors. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of the directors or executive officers. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance Structure </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and affairs are organized under the direction of our board of directors, which currently consists of five members. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and on an ad hoc basis as required. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of our amended &#38; restated certificate of incorporation and amended &#38; restated bylaws, our board of directors will be elected annually to a&#160;three-year&#160;term. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized size of our board of directors is currently five members. The authorized number of directors may be changed only by resolution of our board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Independence </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that four current members qualify as &#8220;independent&#8221; in accordance with the Nasdaq listing standards. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of our directors or executive officers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committees of the Board of Directors </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board has established an audit committee, a compensation committee and a nominating &#38; corporate governance committee, each with its own charter approved by the board. Each committee&#8217;s charter is available on our website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ir.contexttherapeutics&#47;corporate-governance&#47;committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the committees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our audit committee are Richard Berman, Linda West and Jennifer Evans Stacey. Linda West serves as the chairperson of the committee. Each member of the audit committee satisfies the Nasdaq independence requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that Linda West is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of the Nasdaq. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. Our board of directors has determined that each of Richard Berman, Linda West and Jennifer Evans Stacey are independent under the applicable rules of the SEC and Nasdaq. &#160;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee&#8217;s primary responsibilities are to assist the board of directors in overseeing&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s accounting and financial reporting processes and internal controls as well as the audit and integrity of the Company&#8217;s financial statements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the qualifications, independence and performance of the Company&#8217;s independent registered public accounting firm&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s compliance with applicable law, including U.S. federal securities laws and other legal and regulatory requirements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of the Company&#8217;s internal audit function&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s overall risk exposure and management </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both our independent registered public accounting firm and management periodically meet privately with our audit committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the composition and functioning of our audit committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our compensation committee are Richard Berman, Jennifer Evans Stacey, Esq. and Linda West. Mr.&#160;Berman serves as the chairperson of the committee. Each member of the compensation committee is a&#160;non-employee&#160;director, as defined in Rule&#160;16b-3&#160;promulgated under the Exchange Act and satisfies the Nasdaq independence requirements. The compensation committee assists the board of directors in setting the compensation of our directors and executive officers and administering and implementing our incentive compensation plans and equity-based plans. The compensation committee&#8217;s duties and responsibilities include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing oversight of the compensation of our Chief Executive Officer and other executive officers&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">administering our equity compensation plans and granting equity awards pursuant to such plans or outside of such plans&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing oversight of the Company&#8217;s compensation policies and plans and benefits programs and overall compensation philosophy. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our compensation committee charter, the compensation committee has the authority to retain compensation consultants. The compensation committee also has the authority to obtain advice and assistance from our executives, internal or external legal, accounting or other advisors as it determines necessary to carry out its duties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee may delegate its authority to determine the amount and form of compensation paid to our&#160;non-executive&#160;employees and consultants to officers and other appropriate supervisory personnel. It may also delegate its authority (other than its authority to determine the compensation of our Chief Executive Officer) to a subcommittee of the compensation committee. Finally, to the extent permitted by applicable law, the compensation committee may delegate to one or more officers of the Company (or other appropriate personnel) the authority to recommend stock options and other stock awards for employees who are not executive officers or members of our board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nominating &#38; Corporate Governance Committee </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our nominating and corporate governance committee are Philip Kantoff, MD, Jennifer Evans Stacey, Esq. and Linda West. Ms.&#160;Stacey serves as the chairperson of the committee. Each of the members of our nominating and corporate governance committee is an independent director under the applicable rules and regulations of the Nasdaq relating to nominating and corporate governance committee independence. The nominating and corporate governance committee&#8217;s duties and responsibilities include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assisting the board of directors in identifying individuals who are qualified to become members of the board and selecting, or recommending to the board that the board select, specified individuals as director nominees&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining corporate governance policies applicable to the Company&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing evaluations of the board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nominating and corporate governance committee identifies director candidates based on input provided by a number of sources, including members of the committee, other directors, our stockholders, members of management and third parties. The nominating and corporate governance committee also has the authority to consult with or retain advisors or search firms to assist in the identification of qualified director candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the identification process, the nominating and corporate governance committee also takes into account each candidate&#8217;s business and professional skills, experience serving in management or on the board of directors of companies similar to the Company, financial literacy, independence, personal integrity and judgment. In conducting this assessment, the nominating and corporate governance committee, in connection with its assessment and recommendation of candidates for director, considers diversity (including, but not limited to, gender, race, ethnicity, age, experience and skills) and such other factors as it deems appropriate given the then-current and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipated future needs of the board and the Company, and to maintain a balance of perspectives, qualifications, qualities and skills on the board. The board of directors does not have a formal diversity policy for directors. However, the board of directors is committed to an inclusive membership. Although the nominating and corporate governance committee may seek candidates that have different qualities and experiences at different times in order to maximize the aggregate experience, qualities and strengths of the board members, nominees for each election or appointment of directors will be evaluated using a substantially similar process. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer. Such code of ethics addresses, among other things, honesty and ethical conduct, conflicts of interest, compliance with laws, regulations and policies, including disclosure requirements under the federal securities laws, and reporting of violations of the code. Our code of business conduct and ethics is available under the Corporate Governance section of our website. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose any amendment to, or waiver from, a provision of our code of ethics applicable to our principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. We intend to use our website as a method of disseminating this disclosure, as permitted by applicable SEC rules. Any such disclosure will be posted to our website within four business days following the date of any such amendment to, or waiver from, a provision of our code of ethics. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation of Liability and Indemnification </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation limits the liability of our directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any breach of their duty of loyalty to the corporation or its stockholders&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any transaction from which the director derived an improper personal benefit. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation and amended &#38; restated bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law (&#8220;DGCL&#8221;). In addition, the amended &#38; restated certificate of incorporation provides that our directors shall not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director and that if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by the DGCL, we have entered into or plan to enter into separate indemnification agreements with each of our directors and certain of our officers that require us, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain other employees. We maintain insurance policies under which our directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities that might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not we would have the power to indemnify such person against such liability under the provisions of the DGCL. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these provisions and agreements are necessary to attract and retain qualified persons as our officers and directors. At present, there is no pending litigation or proceeding involving our directors or officers for which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation of liability and indemnification provisions contained in our amended &#38; restated certificate of incorporation and our amended &#38; restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opted to comply with the executive compensation disclosure rules applicable to &#8220;smaller reporting companies,&#8221; as such term is defined in the rules promulgated under the Securities Act. In accordance with these rules, our &#8220;named executive officers&#8221; for fiscal year 2021 were&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Martin Lehr, Chief Executive Officer </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alex Levit, Chief Legal Officer </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jennifer Minai-Azary, Chief Financial Officer</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from the currently planned programs and arrangements summarized in this discussion, including the terms of the 2015 Option Plan and the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to the named persons for services rendered in all capacities during the noted periods.  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incentive&#160;Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($) </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,208&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064,083&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,791&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Levit</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,512&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,709&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Legal Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,833&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,009&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,333&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect discretionary bonuses for all named executive officers.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during the applicable year computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (&#34;ASC 718&#34;). Assumptions used in the calculation of these amounts are included in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. These amounts do not reflect the actual economic value that may be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See &#8220;&#8212;Employment and Consulting Arrangements&#8221; below for a description of the material terms of the programs pursuant to which this compensation to our named executive officers was awarded.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Mr. Levit&#8217;s employment as Chief Legal Officer commenced on April 7, 2021.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Ms. Minai-Azary&#8217;s employment as Chief Financial Officer commenced on November 1, 2021.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment and Consulting Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lehr Employment Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Company entered into an amended and restated employment agreement (the &#8220;Lehr Employment Agreement&#8221;) with Martin Lehr. The Lehr Employment Agreement provides that Mr. Lehr will&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive a base salary of $465,000 per year and is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 50% of his base salary (the &#8220;Lehr Target Bonus&#8221;). Mr. Lehr&#8217;s salary and target bonus will be reviewed periodically by the Company&#8217;s Compensation Committee or Board of Directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be eligible to participate in the Company&#8217;s incentive plans and be eligible to participate in all of the Company&#8217;s employee benefit plans available to the Company&#8217;s executive employees, subject to the terms and conditions applicable to such plans.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be entitled to receive the following severance benefits if Mr. Lehr&#8217;s employment is terminated by the Company without &#8220;cause&#8221; or by Mr. Lehr for &#8220;good reason&#8221; (each as defined in the Lehr Employment Agreement), subject to his execution and non-revocation of a release of claims and compliance with the restrictive covenants set forth in the Lehr Employment Agreement&#58; (i) twelve months of base salary continuation, (ii) up to twelve months of continued participation by Mr. Lehr and his eligible dependents in the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iii) all unvested options and any other unvested incentive equity awards granted to him by the Company that are scheduled to vest within eighteen months after such termination shall immediately vest&#59; and&#59; provided that if such termination of employment occurs within twelve months after a &#8220;change in control,&#8221; (as defined in the Lehr Employment Agreement), then Mr. Lehr shall be entitled to receive&#58; (i) an amount equal to 150% of his annual base salary at the rate in effect on his date of termination, payable ratably over an eighteen month period, (ii) an amount equal to 100% of his Lehr Target Bonus for the fiscal year in which the Termination Date (as defined in the Lehr Employment Agreement) occurs, payable ratably over a twelve month period, (ii) up to twelve months of continued participation by Mr. Lehr and his eligible dependents in the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iii) all of Mr. Lehr&#8217;s then-outstanding equity awards granted to him by the Company will become immediately vested.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to restrictive covenants relating to non-disclosure of confidential information, assignment of inventions, non-competition that runs during the term of the Lehr Employment Agreement and for twelve months following Mr. Lehr&#8217;s termination of employment for any reason, and non-solicitation of employees, customers and suppliers that runs during the term of the Employment Agreement and for the same period following Mr. Lehr&#8217;s termination of employment for any reason.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lehr Employment Agreement acknowledges that the non-qualified stock options granted to Mr. Lehr intended to represent four percent (4%) of the Company&#8217;s common stock on a fully diluted basis as of the date of grant, were granted, on April 30, 2021. The non-qualified stock options were granted pursuant to the Company&#8217;s 2021 Incentive Plan and will vest over three years, vesting in thirty-six equal monthly installments. The vesting of shares underlying the non-qualified stock option is subject to Mr. Lehr&#8217;s continuous service with the Company through each such vesting date and is subject to potential vesting acceleration under certain circumstances pursuant to the terms of the Lehr Employment Agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Levit Employment Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, Mr. Levit entered into an employment agreement (the &#8220;Levit Employment Agreement&#8221;) detailing the terms of his employment. The Levit Employment Agreement provides that Mr. Levit will&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive a base salary of $350,000 per year and is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 40% of his base salary (the &#8220;Levit Target Bonus&#8221;). Mr. Levit&#8217;s salary and target bonus will be reviewed periodically by the Company&#8217;s Compensation Committee or Board of Directors.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be eligible to participate in the Company's incentive plans and be eligible to participate in all of the Company&#8217;s employee benefit plans available to the Company's executive employees, subject to the terms and conditions applicable to such plans.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be entitled to receive the following severance benefits if Mr. Levit&#8217;s employment is terminated by the Company without &#8220;cause&#8221; or by Mr. Levit for &#8220;good reason&#8221; (each as defined in the Levit Employment Agreement), subject to his execution and non-revocation of a release of claims and compliance with the restrictive covenants set forth in the Levit Employment Agreement&#58; (i) nine months of base salary continuation, (ii) up to twelve months of continued participation by Mr. Levit and his eligible dependents in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iii) all unvested options and any other unvested incentive equity awards granted to him by the Company that are scheduled to vest within twelve months after such termination shall immediately vest&#59; and&#59; provided that if such termination of employment occurs within twelve months after a &#8220;change in control,&#8221; (as defined in the Levit Employment Agreement), then Mr. Levit shall be entitled to receive&#58; (i) an amount equal to 100% of his annual base salary at the rate in effect on his date of termination, payable ratably over an twelve month period, (ii) an amount equal to 100% of his Levit Target Bonus for the fiscal year in which the Termination Date (as defined in the Levit Employment Agreement) occurs, payable ratably over a twelve month period, (iii) up to twelve months of continued participation by Mr. Levit and his eligible dependents in the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iv) all of Mr. Levit&#8217;s then-outstanding equity awards granted to him by the Company will become immediately vested.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to restrictive covenants relating to non-disclosure of confidential information, assignment of inventions, non-competition that runs during the term of the Levit Employment Agreement and for six months following Mr. Levit&#8217;s termination of employment for any reason, and non-solicitation of employees, customers and suppliers that runs during the term of the Levit Employment Agreement and for the same period following Mr. Levit&#8217;s termination of employment for any reason.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minai-Azary Employment Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, Ms. Minai-Azary entered into an employment agreement (the &#8220;Minai-Azary Employment Agreement&#8221;) detailing the terms of her employment. The Minai-Azary Employment Agreement provides that Ms. Minai-Azary will&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive a base salary of $365,000 per year and is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 40% of her base salary (the &#8220;Minai-Azary Target Bonus&#8221;), which target bonus shall be prorated on a per diem basis for 2021. Ms. Minai-Azary&#8217;s salary and target bonus will be reviewed periodically by the Company&#8217;s Compensation Committee or Board of Directors.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive a non-qualified stock option grant to purchase up to 52,753 shares of the Company&#8217;s common stock at a per share purchase price equal to the last sale price of a share of the Company&#8217;s common stock on the Nasdaq Capital Market on November 1, 2021 (the date of grant). The non-qualified stock options were granted pursuant to the Company&#8217;s. 2021 Incentive Plan and will vest over three years, vesting in thirty-six equal monthly installments. The vesting of shares underlying the non-qualified stock option is subject to Ms. Minai-Azary&#8217;s continuous service with the Company through each such vesting date and is subject to potential vesting acceleration under certain circumstances.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be eligible to participate in the Company's incentive plans and be eligible to participate in all of the Company&#8217;s employee benefit plans available to the Company's executive employees, subject to the terms and conditions applicable to such plans.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be entitled to receive the following severance benefits if Ms. Minai-Azary&#8217;s employment is terminated by the Company without &#8220;cause&#8221; or by Ms. Minai-Azary for &#8220;good reason&#8221; (each as defined in the Minai-Azary Employment Agreement), subject to her execution and non-revocation of a release of claims and compliance with the restrictive covenants set forth in the Minai-Azary Employment Agreement&#58; (i) nine months of base salary continuation, (ii) up to twelve months of continued participation by Ms. Minai-Azary and her eligible dependents in the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iii) all unvested options and any other unvested incentive equity awards granted to her by the Company that are scheduled to vest within twelve months after such termination shall immediately vest&#59; and&#59; provided that if such termination of employment occurs within twelve months after a &#8220;change in control,&#8221; (as defined in the Minai-Azary Employment Agreement), then Ms. Minai-Azary shall be entitled to receive&#58; (i) an amount </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to 100% of her annual base salary at the rate in effect on her date of termination, payable ratably over an twelve month period, (ii) an amount equal to 100% of her Minai-Azary Target Bonus for the fiscal year in which the Termination Date (as defined in the Minai-Azary Employment Agreement) occurs, payable ratably over a twelve month period, (iii) up to twelve months of continued participation by Ms. Minai-Azary and her eligible dependents in the Company&#8217;s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, and (iv) all of Ms. Minai-Azary&#8217;s then-outstanding equity awards granted to her by the Company will become immediately vested.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to restrictive covenants relating to non-disclosure of confidential information, assignment of inventions, non-competition that runs during the term of the Minai-Azary Employment Agreement and for six months following Ms. Minai-Azary&#8217;s termination of employment for any reason, and non-solicitation of employees, customers and suppliers that runs during the term of the Minai-Azary Employment Agreement and for the same period following Ms. Minai-Azary&#8217;s termination of employment for any reason.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sahmoud Consulting Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the Company entered into a consulting agreement with OncoStrategy, LLC, a Pennsylvania limited liability company, of which Tarek Sahmoud, MD, PhD, our consulting Chief Medical Officer, is the sole member, regarding Dr. Sahmoud&#8217;s provision of consultative services to the Company (the &#8220;Sahmoud Consulting Agreement&#8221;). Pursuant to the Sahmoud Consulting Agreement, Dr. Sahmoud is entitled to a monthly retainer of $10,000 for his consulting services.  On March 21, 2022, we entered into an amendment to the Sahmoud Consulting Agreement, which was effective as of February 1, 2022, pursuant to which Dr. Sahmoud&#8217;s monthly time commitment to the Company and retainer fee doubled. For the months of February through June 2022, Dr. Sahmoud&#8217;s retainer fee is $20,000 per month.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information for each of our named executive officers regarding the number of shares of common stock underlying outstanding equity awards as of December 31, 2021. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and<br>Principal Position</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Underlying</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unexercised</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options (#)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Underlying</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unexercised</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options (#)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unexercisable </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option&#160;Exercise</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;($) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date </font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#47;30&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) (3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,338&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#47;30&#47;2031</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Levit</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Legal Officer </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#47;2&#47;2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#47;2&#47;2030</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#47;30&#47;2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) (3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,566&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#47;30&#47;2031</font></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#47;1&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) (4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,823&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#47;1&#47;2031</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Previously granted under the Context Therapeutics LLC 2015 Stock Option Plan&#59; now governed by the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Granted under the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of common stock underlying this option vest and become exercisable in equal monthly installments over 36 months from the date of grant on April 30, 2021, subject to the recipient&#8217;s continued service through each vesting date.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of common stock underlying this option vest and become exercisable in equal monthly installments over 36 months from the date of grant on November 1, 2021, subject to the recipient&#8217;s continued service through each vesting date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had entered into Board of Director Services Agreements (the &#8220;Director Agreements&#8221;) with each of its independent directors that granted each director the right to cash compensation in the amount of $35,000 annually. In addition, the Director Agreements grant each director an option to purchase 15,000 shares of common stock of the Company pursuant to the Company&#8217;s 2021 Incentive Plan. The Chair of our Board of Directors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is entitled to an additional annual cash retainer of $15,000 and is granted an option to purchase an additional 15,000 shares of common stock of the Company. The Chairs of the Audit, Compensation and Nominating and Corporate Governance Committees are entitled to receive additional annual cash retainers of $15,000, $10,000 and $7,500, respectively. The other members of our Audit, Compensation, and Nominating and Corporate Governance Committees receive additional annual cash retainers of $7,500, $5,000 and $3,500, respectively. The annual cash compensation amounts set forth above are payable in equal quarterly installments, payable in arrears following the end of each calendar quarter in which the board service occurs, prorated for any partial years of service. We also reimburse all reasonable out-of-pocket travel expenses incurred by non-employee directors in attending meetings of our Board or any committee thereof.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 the Board of Directors approved an amended director compensation plan and agreed to terminate the Board of Directors Services Agreements (the &#8220;Director Agreements&#8221;) effective as of March 21, 2022. Under the new plan, effective as of June 1, 2022, each non-employee director&#8217;s cash compensation will be increased from $35,000 to $40,000 annually and at each Annual Meeting, starting as of the June 2, 2022 meeting, each non-employee director will be granted 25,000 options to purchase the Company&#8217;s common stock pursuant to the Company&#8217;s 2021 Long-Term Performance Incentive Plan, with the Chairperson of our Board of Directors granted an option to purchase an additional 25,000 shares of common stock of the Company. Such options shall vest annually on the earlier of the one-year anniversary of the grant date or the next Annual Meeting.  The remainder of the Board of Directors&#8217; compensation is unchanged from the terms of the Director Agreements.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Option Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of certain significant features of the Context Therapeutics LLC 2015 Option Plan (the &#8220;2015 Option Plan&#8221;). The information that follows is subject to, and qualified in its entirety by reference to, the 2015 Option Plan document itself, which is filed as an exhibit to the registration statement of which this prospectus forms a part. The 2015 Option Plan provides for grants of options to purchase &#8220;units&#8221; of Context Therapeutics LLC as such term is defined in the Operating Agreement of Context Therapeutics LLC dated May&#160;4, 2015. One million units were made available for issuance under the 2015 Option Plan. Of these, options have been granted for 24,830 Units. To the extent that an option expired or was cancelled for any reason the shares underlying such option were added back to the 2015 Option Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding options under the 2015 Option Plan are fully vested with the exception of an option granted to Bill Rencher to purchase 12,333 shares of common stock which would have become fully vested on April 2, 2022. Effective April&#160;23, 2021, following its merger with Context Therapeutics Merger Sub, LLC, Context Therapeutics LLC became a wholly owned subsidiary of Context Therapeutics Inc. All units of Context Therapeutics LLC under the 2015 Option Plan that remain unused are cancelled and each outstanding option to purchase units of Context Therapeutics LLC, in accordance with Section 409A of the Internal Revenue Code of 1986, as amended, were converted into options to purchase shares of common stock of Context Therapeutics Inc., subject to the terms of the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purposes of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The 2015 Option Plan is intended to enable the Company to (i)&#160;recruit and retain highly qualified employees, managers, consultants and other service providers, (ii)&#160;provide those employees, managers, and consultants with an incentive for productivity, and (iii)&#160;provide those employees, managers, consultants and other service providers with an opportunity to share in the growth and value of the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administration of the Plan&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Management Committee of the Company has the authority to administer the 2015 Option Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Recipients&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible recipients include employees, managers and consultants of the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All options granted under the 2015 Option Plan are nonqualified stock options. Upon exercise, the spread on the option at the time of exercise is taxable as ordinary income to the optionee. Upon disposition, the difference between the sale price and the fair market value of the underlying stock on the exercise date is taxable as a capital gain (or loss) to the participant. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The exercise price per Unit purchasable under an option will be determined by the Management Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise of Options&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Management Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The term of each option will be fixed by the Management Committee&#59; provided that no such option shall have a term of more than ten years. No Option may be exercised by any person after expiration of the term of the option. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Long-Term Performance Incentive Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of certain significant features of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan (the &#8220;2021 Incentive Plan&#8221;). The information that follows is subject to, and qualified in its entirety by reference to, the Plan document itself, which is filed as an exhibit to the registration statement of which this prospectus forms a part. Awards that may be granted include stock options, stock appreciation rights, restricted stock, restricted stock units and stock grants. These awards are described in more detail below. The Company has reserved 1,266,092 shares of common stock (the &#8220;Share Limit&#8221;) for issuance under the 2021 Incentive Plan. The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year&#59; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. The Share Limit is subject to adjustment for certain changes in the Company&#8217;s capitalization such as stock dividends, stock splits, combinations or similar events. If an award expires, terminates, is forfeited or cancelled, or is settled in cash rather than common stock, the common stock not issued under that award will again become available for grant under the 2021 Incentive Plan. If common stock is surrendered to the Company or withheld to pay any exercise price or tax withholding requirements, only the shares issued net of the shares withheld or surrendered will be counted against the number of shares of common stock available under the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purpose of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Plan is intended to enable the Company to (i)&#160;provide incentives and awards to employees, nonemployee directors and consultants of the Company, (ii)&#160;enable the Company to attract and retain employees, nonemployee directors and consultants, and (iii)&#160;encourage employees, nonemployee directors and consultants to acquire a proprietary interest in the performance of the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administration of the Plan&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Compensation Committee of the Company has the authority to administer the 2021 Incentive Plan. The Compensation Committee has considerable discretion in setting the terms of awards granted under the Plan. The Compensation Committee may also establish another committee of the Board of Directors (such as a committee of which the Chairman of the Board is the sole member) to make awards to employees who are not subject to Section 16(b) of the Securities Exchange Act of 1934, as amended. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Recipients&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible recipients include employees, nonemployee directors and consultants of the Company. Nonemployee directors and consultants are not eligible to receive incentive stock options. The Compensation Committee selects the employees, non-employee directors and consultants who will receive awards under the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A stock option under the 2021 Incentive Plan may be granted as an incentive stock option or as a nonqualified stock option in the discretion of the Compensation Committee. Incentive stock options offer employees certain tax advantages that are not available for nonqualified stock options. The Compensation Committee determines the terms and conditions of the options, including the number of shares of common stock subject to the option. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The exercise price per share of the Company&#8217;s common stock purchasable under a stock option shall not be less than one hundred percent of the fair market value of such stock on the date the stock option is granted. With </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to an incentive stock option granted to a more than 10% stockholder of the Company, the per share exercise price may not be less than 110% of the fair market value of a share of Common Stock on the date the stock option is granted. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Compensation Committee. An optionee may pay the exercise price of an option in cash or its equivalent. The Compensation Committee may also permit an optionee to pay the exercise price by surrendering previously acquired shares of common stock, withholding shares issuable upon exercise of the option, through a so-called &#8220;broker-financed transaction,&#8221; or in any combination of such methods. The 2021 Incentive Plan permits an employee to pay the tax withholding obligation with shares of common stock issuable upon the exercise of the option or previously acquired shares. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The term of each stock option will be fixed by the Compensation Committee&#59; provided that no option shall have a term of more than ten years (five years for an incentive stock option granted to a more than 10% stockholder). No stock option may be exercised by any person after expiration of the term of the stock option. When an optionee terminates service with the Company, his or her stock option may expire before the end of the otherwise applicable option term. For example, upon a termination of service due to the optionee&#8217;s disability, options generally remain exercisable for the full option term, and upon a termination service due to the optionee&#8217;s death, options generally remain exercisable for up to three years. If an optionee has a termination of service for cause, his or her stock options will be terminated. The Compensation Committee has the discretion to determine the exercise period after termination of service for other reasons. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Rights&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A stock appreciation right may be granted to eligible participants under the 2021 Incentive Plan at the discretion of the Compensation Committee, which may at the time of such grant approve. The Compensation Committee determines the terms and conditions of stock appreciation rights. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A stock appreciation right entitles a recipient to receive, with respect to each share of the Company&#8217;s common stock to which the stock appreciation right is exercised, the excess, if any, of the fair market value of the share on the date of exercise over the fair market value of the share on the date the stock appreciation right is granted. Such excess may be paid in cash, shares of the Company&#8217;s common stock, or a combination thereof, as determined by the Compensation Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock appreciation rights will be exercisable at such time or times and subject to such terms and conditions as determined by the Compensation Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expiration or Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The term of each stock appreciation right will be fixed by the Compensation Committee&#59; provided that no stock appreciation right shall have a term of more than ten years. No stock appreciation right may be exercised by any person after expiration of the term of the stock option. When an employee, non-employee director or consultant terminates service, his or her stock appreciation rights may expire before the end of the otherwise applicable stock appreciation right term. The period during which the stock appreciation right may be exercised is the same as the period for stock options, discussed above. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may be granted by the Compensation Committee to eligible participants for no consideration in the form of an award of common stock subject to restrictions. At the time restricted stock is granted, the Compensation Committee shall determine whether the restricted stock is performance stock (where the lapse of restrictions is based on performance targets), or restricted stock that is not performance stock (where the lapse of restrictions is based on times and&#47;or conditions determined by the Compensation Committee). The Company holds the common stock during the restriction period and the participant cannot transfer the shares before the end of that period. The participant is, however, generally entitled to vote the common stock and receive any cash dividends declared and paid on common stock of the Company during the restriction period. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance stock awards, the restrictions lapse only to the extent performance goals established by the Compensation Committee are met. The Compensation Committee may select one or more performance criteria for each performance stock award from the following list&#58; profit before taxes, earnings before or after taxes, interest, depreciation and&#47;or amortization, stock price, market share, gross revenue, net revenue, pre-tax income, operating income, cash flow, earnings per share, return on equity, return on invested capital or assets, cost reductions and savings, return on revenues or productivity, or any variations of the preceding business criteria. The criteria may be applied to the individual, a division, a regional business unit, the Company or a subsidiary of the Company. Additional business criteria on which an individual&#8217;s performance may be measured are implementing policies and plans, negotiating transactions and sales, developing long-term business goals and exercising managerial responsibility. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restrictions lapse for restricted stock awards that are not performance stock awards on the earliest of the date or event determined by the Compensation Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock unit entitles a recipient to receive one share of the Company&#8217;s common stock, cash equal to the fair market value of a share of the Company&#8217;s common stock on the date of vesting, or a combination thereof, with respect to each restricted stock unit that vests in accordance with the award of such restricted stock unit. A bookkeeping account is established for each recipient of a restricted stock unit award that shows the number of restricted stock units granted, and may include full and fractional restricted stock units representing any cash dividends prior to the date the restricted stock unit vests. Performance stock units vest only to the extent performance goals established by the Compensation Committee are met. The Compensation Committee may select one or more performance criteria for each award of performance stock units from the above list for performance stock awards. Restricted stock units that are not performance stock units vest on the date or event determined by the Compensation Committee. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Grants&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee may make grants of unrestricted common stock to eligible recipients. Such stock grants shall be fully vested on the date granted. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Miscellaneous </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Awards generally are not transferable, except by will or under the laws of descent and distribution. The Compensation Committee has the authority to the extent permitted under the Code, however, to permit an employee, non-employee director or consultant to transfer non-qualified stock options, restricted stock, restricted stock units and stock appreciation rights to certain permitted transferees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acceleration of Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All awards (other than performance-based awards) vest on a pro-rata basis (based on active service during the applicable vesting period) upon a termination due to death or disability. The Compensation Committee may, in its discretion, provide for the acceleration or continuation of the vesting of all awards (other than performance-based awards) following termination of service, if it determines that to do so would be in the best interests of the Company. Upon a change in control of the Company (as defined in the 2021 Incentive Plan), to the extent that the Awards are not assumed by the acquiring or succeeding corporation, all outstanding options and stock appreciation rights become exercisable, all outstanding restricted stock becomes vested, and all outstanding restricted stock units become vested. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Capitalization&#47;Certain Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If there is a change in the capitalization of the Company that affects its outstanding common stock, the Compensation Committee will adjust the kind and aggregate number of shares of common stock subject to awards, together with the option exercise price and amount over which appreciation of stock appreciation rights is measured. The 2021 Incentive Plan also provides that, in the event of a merger, consolidation or other specified corporate transaction, with respect to awards that will not be assumed or substituted, the Compensation Committee may (i)&#160;terminate outstanding awards after providing notice to holders specifying a period of time by which they may exercise their options or (ii)&#160;terminate outstanding awards and pay to the holders the value of such awards based upon the price per share of stock received or to be received by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other stockholders of the Company in the event (except that underwater options and stock appreciation rights would receive no payment) or replace the award with rights or property selected by the Compensation Committee in its sole discretion. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment&#47;Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Compensation Committee may amend outstanding awards, and the Board of Directors may amend or suspend the 2021 Incentive Plan. However, stockholder approval is required for (1)&#160;any material amendment to the 2021 Incentive Plan (as defined under applicable NASDAQ Listing Standards), (2)&#160;an amendment to &#8220;reprice&#8221; an outstanding option or stock appreciation right, and (3)&#160;certain amendments of which the 2021 Incentive Plan requires stockholder approval, such as an increase in the number of shares of common stock authorized for issuance of incentive stock options and a change in the class of employees who may receive incentive stock options under the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may terminate the 2021 Incentive Plan at any time and for any reason. No awards will be granted under the 2021 Incentive Plan after the close of business on the day immediately preceding the tenth anniversary of the effective date of the 2021 Incentive Plan or any earlier termination date determined by the Board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A participant&#8217;s right to receive an award, to retain amounts payable under the award, and to retain any profit or gain associated with a non-cash award are all subject to any recoupment or &#8220;clawback&#8221; policy adopted by the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration under the Securities Act of 1933.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company filed with the Securities and Exchange Commission a Registration Statement on Form S-8 to register the shares of the Company&#8217;s common stock subject to the 2021 Incentive Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have entered into or plan to enter into indemnification agreements with each of our directors and executive officers. The indemnification agreements and our amended &#38; restated certificate of incorporation and amended &#38; restated bylaws will require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Income Tax Consequences &#8211; Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have been advised that the Federal income tax consequences of granting and exercising options under the 2021 Incentive Plan are as follows (based on Federal tax laws and regulations, as of January&#160;1, 2021). The grant of an option does not result in Federal income tax consequences for the optionee or a deduction for the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an option is exercised, the Federal income tax consequences depend on whether the option is an incentive stock option or a non-qualified stock option. An optionee exercising a non-qualified stock option will recognize ordinary income equal to the difference between the fair market value of the stock exercised (on the date of exercise) and the exercise price. An employee will generally not recognize taxable income as a result of acquiring stock by exercising an incentive stock option. If the employee holds the stock he receives on exercise of an incentive stock option for a required period of time, the employee will have capital gain (or loss) when the stock is later disposed of. If the employee does not hold the stock for the required period of time, the employee will generally have ordinary income when the stock is disposed of. When an optionee recognizes ordinary income on the exercise of a non-qualified stock option or the sale of stock acquired on exercise of an incentive stock option, the Company is generally entitled to a deduction in the same amount. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL STOCKHOLDERS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 1, 2022, by&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our named executive officers and directors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our named executive officers and directors as a group&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each other stockholder known by us to be the beneficial owner of more than 5% of the outstanding shares of our voting stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares that they beneficially own, subject to applicable community property laws. Unless otherwise indicated in the footnotes below, based on the information provided to us by or on behalf of the selling stockholders, no selling stockholder is a broker-dealer or an affiliate of a broker-dealer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Percentage ownership of our common stock is based on 15,966,053 shares of common stock outstanding as of March 1, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options or other convertible securities held by that person or entity that are currently exercisable or releasable or that will become exercisable or releasable only by such person within 60 days of March 1, 2022, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To calculate a stockholder&#8217;s percentage of beneficial ownership of common stock, we must include in the numerator and denominator those shares of common stock, as well as those shares of common stock underlying options or other convertible securities, that such stockholder is considered to beneficially own. Shares of common stock, and common stock underlying options and other convertible securities, held by other stockholders, however, are disregarded in this calculation. Therefore, the denominator used in calculating beneficial ownership of each of the stockholders may be different.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c&#47;o the Company, 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103. To our knowledge, there is no arrangement, including any pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in control of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beneficial Ownership</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officers and Directors</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,792&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Levit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,883&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarek Sahmoud, MD, PhD</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Berman </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jenifer Evans Stacey, Esq. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philip Kantoff </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,948&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda West </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All executive officers and directors as a group (8&#160;persons)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073,663&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 5% Holders</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altium Growth Fund, L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hudson Bay Master Fund Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kepos Alpha Master Fund L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabby Volatility Warrant Master Fund, Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230,830&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.71&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empery Asset Management, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Represents beneficial ownership of less than 1%.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 909,773 shares of common stock&#59; and (ii) 101,600 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 8,792 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 3,000 shares of common stock&#59; and (ii) 19,833 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of  March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 10,833 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 5,417 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 3,531 shares of common stock&#59; and (ii) 5,417 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 5,417 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of March 1, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 1,000,000 shares of common stock purchased in the Private Placement. The principal address of Altium Capital Management, LP is 152 West 57th Street, 20th Floor, New York, NY 10019.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Based solely on the information reported in a Schedule 13G filed by Hudson Bay Master Fund Ltd. on February 2, 2022 with the SEC. As reported in the filing, Hudson Bay Master Fund Ltd. has sole voting power with respect to no shares of common stock, shared voting power with respect to 1,000,000 shares of common stock issuable upon the exercise of warrants purchased in the Private Placement that are exercisable within 60 days of March 1, 2022, sole dispositive power with respect to no shares of common stock and shared dispositive power with respect to 1,000,000 shares of common stock issuable upon the exercise of warrants purchased in the Private Placement that are exercisable within 60 days of March 1, 2022.  The principal address for Hudson Bay Master Fund Ltd. is c&#47;o Hudson Bay Capital Management LP, 28 Havemeyer Pl. 2nd Floor, Greenwich, CT 06830.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of 1,000,000 shares of common stock purchased in the Private Placement. The principal address of Kepos Alpha Master Fund L.P. is c&#47;o Kepos Capital LP, 11 Times Square, 35th Flr., New York, NY 10036.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Based solely on the information reported in a Schedule 13G filed by Sabby Volatility Warrant Master Fund, Ltd. on January 5, 2022 with the SEC. As reported in the filing, Sabby Volatility Warrant Master Fund, Ltd.. has sole voting power with respect to no shares of common stock, shared voting power with respect to 1,230,830 shares of common stock, sole dispositive power with respect to no shares of common stock and shared dispositive power with respect to 1,230,830 shares of common stock. Sabby Management, LLC serves as the investment manager of Sabby Volatility Warrant Master Fund, Ltd. Hal Mintz is the manager of Sabby Management, LLC and has voting and investment control of the securities held by Sabby Volatility Warrant Master Fund, Ltd. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities beneficially owned by Sabby Volatility Warrant Master Fund, Ltd., except to the extent of their respective pecuniary interest therein. The address of Sabby Volatility Warrant Master Fund, Ltd. is c&#47;o Sabby Mgt. LLC, 10 Mountainview Rd. Suite 205, Upper Saddle River, NJ 07458.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 589,311 shares of common stock directly held by Empery Asset Master, LTD purchased in the Private Placement&#59; and (ii) 410,689 shares of common stock directly held by Empery Tax Efficient, LP. purchased in the Private Placement. The business address is c&#47;o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, New York 10020.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLING STOCKHOLDERS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock being offered by the selling stockholders are those previously issued to the selling stockholders and those that may be acquired by them upon exercise of the warrants issued in the Private Placement. For additional information regarding the issuances of those shares of common stock, see &#8220;Recent Developments&#8221; in &#8220;Prospectus Summary&#8221; above. We are registering the shares of common stock to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock, the Selling Stockholders have not had any material relationship with us within the past three years.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below lists the selling stockholders and other information regarding the beneficial ownership of common stock by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of shares of common stock, as of the date of this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third column lists the shares of common stock being offered pursuant to this prospectus by the selling stockholders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of a registration rights agreement with the selling stockholders, this prospectus generally covers the resale of the sum of (i) the number of shares of common stock issued to the selling stockholders in the Private Placement and (ii) the maximum number of shares of common stock issuable upon exercise of the related warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants.  The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the warrants, a selling stockholder may not exercise the warrants to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock that would exceed 4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants that have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation.  The selling stockholders may sell all, some or none of their shares in this offering.  See &#8220;Plan of Distribution.&#8221; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Selling Stockholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares of Common Stock Owned Prior to this Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares of Common Stock Owned After Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altium Growth Fund, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empery Asset Master, LTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empery Tax Efficient, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hudson Bay Master Fund Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kepos Alpha Master Fund L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabby Volatility Warrant Master Fund, Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Under applicable SEC rules, a person is deemed to beneficially own securities which the person has the right to acquire within 60 days through the exercise of any option or warrant or through the conversion of a convertible security. Also under applicable SEC rules, a person is deemed to be the &#8220;beneficial owner&#8221; of a security with regard to which the person directly or indirectly, has or shares (a) voting power, which includes the power to vote or direct the voting of the security, or (b) investment power, which includes the power to dispose, or direct the disposition, of the security, in each case, irrespective of the person&#8217;s economic interest in the security. To our knowledge, subject to community property laws where applicable, each person named in the table has sole voting and investment power with respect to the common shares shown as beneficially owned by such selling shareholder, except as otherwise indicated in the footnotes to the table.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">This table and the information in the notes below are based upon information supplied by the selling shareholders. Except as expressly noted in the footnotes below, beneficial ownership has been determined in accordance with Rule 13d-3 under the Securities and Exchange Act of 1934, as amended. Represents the amount of shares that will be held by the selling shareholder after completion of this offering based on the assumptions that (a) all common shares registered for sale by the registration statement of which this prospectus is part will be sold and (b) no other common shares are acquired or sold by the selling shareholder prior to completion of this offering. However, each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">selling shareholder may sell all, some or none of the such shares offered pursuant to this prospectus and may sell other common shares that they may own pursuant to another registration statement under the Securities Act or sell some or all of their shares pursuant to an exemption from the registration provisions of the Securities Act, including under Rule 144.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents (i) 1,000,000 shares of common stock and (ii) 1,000,000 shares of common stock issuable upon exercise of warrants. Altium Capital Management, LP, the investment manager of Altium Growth Fund, LP, has voting and investment power over these securities. Jacob Gottlieb is the managing member of Altium Capital Growth GP, LLC, which is the general partner of Altium Growth Fund, LP. Each of Altium Growth Fund, LP and Jacob Gottlieb disclaims beneficial ownership over these securities. The principal address of Altium Capital Management, LP is 152 West 57th Street, 20th Floor, New York, NY 10019.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents (i) 589,311 shares of common stock and (ii) 589,311 shares of common stock issuable upon exercise of warrants. The business address is c&#47;o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, New York 10020. Empery Asset Management LP, the authorized agent of Empery Asset Master Ltd (&#8220;EAM&#8221;) has discretionary authority to vote and dispose of the shares held by EAM and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM and Messrs. Hoe and Lane each disclaim any beneficial ownership of these shares. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents (i) 410,689 shares of common stock and (ii) 410,689 shares of common stock issuable upon exercise of warrants. The business address is c&#47;o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, New York 10020. Empery Asset Management LP, the authorized agent of Empery Tax Efficient, LP (&#8220;ETE&#8221;) has discretionary authority to vote and dispose of the shares held by ETE and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by ETE. ETE and Messrs. Hoe and Lane each disclaim any beneficial ownership of these shares.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents 1,000,000 shares of common stock issuable upon exercise of warrants. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial ownership over these securities.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents (i) 1,000,000 shares of common stock and (ii) 1,000,000 shares of common stock issuable upon exercise of warrants. Kepos Capital LP is the investment manager of the selling securityholder and Kepos Partners LLC is the General Partner of the selling securityholder and each may be deemed to have voting and dispositive power with respect to the shares. The general partner of Kepos Capital LP is Kepos Capital GP LLC (the &#8220;Kepos GP&#8221;) and the Managing Member of Kepos Partners LLC is Kepos Partners MM LLC (&#8220;Kepos MM&#8221;). Mark Carhart controls Kepos GP and Kepos MM and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by this selling securityholder. Mr. Carhart disclaims beneficial ownership of the shares held by the selling securityholder. The address of Kepos Capital LP and Mr. Carhart is 11 Times Square, 35th Floor, New York, New York 10036.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents (i) 1,000,000 shares of common stock and (ii) 1,000,000 shares of common stock issuable upon exercise of warrants. Sabby Management, LLC serves as the investment manager of Sabby Volatility Warrant Master Fund, Ltd. Hal Mintz is the manager of Sabby Management, LLC and has voting and investment control of the securities held by Sabby Volatility Warrant Master Fund, Ltd. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities beneficially owned by Sabby Volatility Warrant Master Fund, Ltd., except to the extent of their respective pecuniary interest therein. The address of Sabby Volatility Warrant Master Fund, Ltd. is c&#47;o Sabby Mgt. LLC, 10 Mountainview Rd. Suite 205, Upper Saddle River, NJ 07458. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_61"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSACTIONS WITH RELATED PERSONS </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Related Persons </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Junior Convertible Note </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 2018, the Company issued Junior Convertible Notes that had a fair value of $15.8&#160;million and bore interest at rates ranging from 3.00% to 7.73% per year. From January 2019 to April 2019, the Company issued Junior Convertible Notes in the aggregate principal amount of $1.5&#160;million that bore interest at rates ranging between 6.00% and 15.00% per year. From April 2015 through December 2017, the Company issued demand notes to the Company&#8217;s Chief Executive Officer and an immediate family member (the &#8220;Related Party&#8221;) with an aggregate principal balance of $1.8&#160;million that bore interest at rates ranging from 3.00% to 6.00% per year. During April 2019, $1.9&#160;million of principal and interest was converted from demand notes to a Junior Convertible Note bearing interest at a rate of 15.00%. Additionally, in July 2019, the Company issued $1.2&#160;million of Junior Convertible Notes in lieu of severance payments to former executives, of which $0.9&#160;million and $0.3&#160;million were expensed to general and administrative and research and development expense, respectively, during the year ended December&#160;31, 2019. On December&#160;31, 2019, $5.7&#160;million of Junior Convertible Notes outstanding were held by the Related Party. The Junior Convertible Notes outstanding principal amount of $10.2&#160;million and accrued but unpaid interest of $1.5&#160;million converted into 2,615,553 Series Seed Convertible Preferred Units (the &#8220;Series Seed Units&#8221;) in May 2020, of which 840,363 were issued to the Related Party. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bridge Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 2019 to March 2020, the Company issued convertible bridge notes (the &#8220;Convertible Bridge Notes&#8221;) to the Related Party in the amount of $0.5&#160;million. The Convertible Bridge Notes bore interest at a rate of 6.0% per annum and on December&#160;22, 2020, the outstanding principal and accrued interest of $35,000 converted into 78,178 Series A Units that were issued to the Related Party. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Convertible Note </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, $5.1&#160;million of principal and $0.6&#160;million of accrued interest related to certain Junior Convertible Notes were converted into Senior Convertible Notes. Of the Senior Convertible Notes issued in April 2020, $2.5&#160;million of principal and $0.4&#160;million of accrued interest were issued to the Related Party. On February&#160;18, 2021, the outstanding principal and interest of the Senior Convertible Notes was automatically converted into 844,824 Series A Units, of which 430,467 Series A Units were issued to the Related Party, at a price per share of $7.168 pursuant to the terms of a Qualified Financing as described below. Prior to such conversion, however, the Senior Convertible Notes accrued interest at a rate of 6.0% per year and had an anticipated maturity date of December&#160;31, 2021. Under the terms of the Senior Convertible Notes, in the event of a qualified financing, whereby the Company issued and sold its Series A Preferred Units (&#8220;Series A Units&#8221;) and raised capital of at least $2.5&#160;million of total gross proceeds in cash (a &#8220;Qualified Financing&#8221;), the outstanding principal and interest of the Senior Convertible Notes would automatically convert into Series A Units at a price equal to the issue price per share of the units issued in the Qualified Financing and on the same terms and conditions of such Qualified Financing. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Units and Series Seed Preferred Units </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company converted $11.7&#160;million of principal and interest related to certain Junior Convertible Notes into 2,615,553 Series Seed Units at prices ranging from $4.28 to $4.56 per unit. In May 2020, the Related Party purchased 8,771 Series Seed Units at a price of $5.70 per unit for $50,000. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020 the Company sold 132,537 Series A Units to the Related Party for $7.168 per unit for proceeds of $1.0&#160;million. The Company also issued 52,673 warrants to purchase common member units (the &#8220;Common Member Units&#8221;) at an exercise price of $7.168 to the holders of Series A Units as part of the Series A financing. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of certain terms of the Series A Units and Series Seed Units (collectively, &#8220;Convertible Preferred Units&#8221;)&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Units received a non-cumulative distribution of 6% per year of the original capital contribution, which was payable upon the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (&#8220;Dissolution Event&#8221;), or the redemption or repurchase of any Series A Units. Series Seed Units did not receive a distribution right. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a Dissolution Event, the holders of Series A Units would have received the greater of 1.5 times the original issuance price plus any accrued distributions or the amount that such holders of Series A Units would receive if the Series A Units were converted to Common Member Units, prior to any distribution with respect to Series Seed Units or Common Member Units. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After amounts paid out to the Series A Units upon a Dissolution Event, the Series Seed Units then outstanding would have been entitled to be paid out in accordance with the positive balance in their capital accounts with respect to their Series Seed Units, after giving effect to all contributions, distributions and allocations with respect to such Series Seed Units for all periods, before any payment shall be made to the holders of Common Member Units. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion rights </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Convertible Preferred Unit was convertible, at the option of the holder thereof, at any time, and without the payment of additional consideration, into a number of fully paid and nonassessable common member units as determined by dividing the original issue price for the Convertible Preferred Unit by the conversion price for the Convertible Preferred Unit in effect at the time of conversion, except as otherwise defined in the Operating Agreement (the &#8220;Operating Agreement&#8221;). Notwithstanding the foregoing, in the event of a liquidation, dissolution, or winding up of the Company or acquisition of the majority of the Company&#8217;s assets, the Series Seed Unit conversion right would have terminated at the close of business on the last full day preceding the date fixed for the first payment of any funds and assets distributable on such event to the Members holding Series Seed Units. No fractional Common Member Units would have been issued upon conversion of the Convertible Preferred Unit. In lieu of any fractional units, the Company would have paid cash equal to such fraction multiplied by the fair market value of a Common Member Unit as determined in good faith by the Management Committee of the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants for Common Member Units </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has granted warrants to the Related Party to purchase Common Member Units at various dates. At December&#160;31, 2020, the Company had the following warrants outstanding to acquire Common Member Units&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;Price </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;Dates </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,680&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2025</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,281&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2039</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information regarding the Senior Convertible Notes, Junior Convertible Notes, Convertible Bridge Notes, Series A Units and Series Seed Units, see Notes 5 and 6 to our consolidated financial statements included elsewhere in this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Integral Transaction </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of CLDN6xCD3 bsAb. Under the terms of the agreement, we will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6xCD3 bsAb candidates. We paid an upfront license fee of $0.3 million and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted Integral 418,559 Series A Units with a fair market value of approximately $2.8 million. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3 million, sales milestone payments totaling up to $130 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. Prior to our public offering, Integral held, but currently does not hold, more than 5% of our equity. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series Seed Units Sales </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, Laura Spain was granted 29,125 Series Seed Units at a per unit price of $4.28 and 23,858 Series Seed Units at a per unit price of $4.56, in exchange for her Junior Convertible Notes. Ms. Spain is the spouse of our Chief Legal Officer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on May 1, 2020, PCL Investments was granted 57,781 Series Seed Units at a per unit price of $4.28 and 72,094 Series Seed Units at a per unit price of $4.56, in exchange for its Junior Convertible Notes. PCL Investments is jointly owned by Ms. Spain, who is the spouse of our Chief Legal Officer, and Peter Spain and Craig Spain, who are the brothers-in-law of our Chief Legal Officer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our capital stock and certain provisions of our amended &#38; restated certificate of incorporation and amended &#38; restated bylaws are summaries. Copies of these documents are filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 100,000,000&#160;shares of common stock, par value $0.001 per share and 10,000,000&#160;shares of preferred stock, par value $0.001 per share. As of March 18, 2022, 15,966,053&#160;shares of our common stock were outstanding, and no&#160;shares of our preferred stock were outstanding.  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue one class of common stock. Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote of stockholders. A majority vote of the holders of common stock will generally required to take action under our amended &#38; restated certificate of incorporation and amended &#38; restated bylaws. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000&#160;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors will make any determination to issue shares of preferred stock based on its judgment as to the best interests of the Company and the best interests of our stockholders. We have no shares of preferred stock currently outstanding and we have no current plans to issue any shares of preferred stock. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Provisions of Our Amended &#38; Restated Certificate of Incorporation, Amended &#38; Restated Bylaws and Delaware Law </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of Delaware law and our amended &#38; restated certificate of incorporation and our amended &#38; restated bylaws contain provisions that could make the following transactions more difficult&#58; acquisition of us by means of a tender offer&#59; acquisition of us by means of a proxy contest or otherwise&#59; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware Takeover Statute </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least&#160;two-thirds&#160;of the outstanding voting stock which is not owned by the interested stockholder. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;203 defines a business combination to include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No Written Consent of Stockholders </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Meetings of Stockholders </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated bylaws provides that a special meeting of stockholders may be called only by our chairman of the board of directors, Chief Executive Officer or by a resolution adopted by a majority of our board of directors, and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated bylaws also limits the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advance Notice Requirements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated bylaws establishes advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our amended and restated bylaws specifies the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Our Certificate of Incorporation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undesignated Preferred Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Choice of Forum </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &#38; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware) will be the sole and exclusive forum for&#58; (1)&#160;any derivative action or proceeding brought on our behalf&#59; (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders&#59; (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended &#38; restated certificate of incorporation or amended &#38; restated bylaws&#59; (4)&#160;any action to interpret, apply, enforce or determine the validity of our amended &#38; restated certificate of incorporation or amended &#38; restated bylaws&#59; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. In addition, our amended &#38; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision shall not apply to claims seeking to enforce any liability or duty created by the Exchange Act. Our amended &#38; restated certificate of incorporation also </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could rule that the choice of forum provisions contained in our amended &#38; restated certificate of incorporation are inapplicable or unenforceable if they are challenged in a proceeding or otherwise. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law and the Securities Act for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants for Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, in addition to the warrants issued in connection with the Private Placement, the Company has granted warrants to purchase shares of common stock at various dates. At March 18, 2022, the Company had the following warrants outstanding to acquire shares of common stock&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;dates </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in 2021 to the underwriters of the Company&#8217;s IPO</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2026</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in 2021 to the placement agents of the Company&#8217;s Private Placement</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2027</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in 2022 to consultant of the Company in a private placement for services provided</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,000&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 18, 2022, there are options to purchase 1,180,222 of our shares of common stock outstanding under the 2021 Incentive Plan with a weighted average exercise price of $3.48 per share. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is American Stock Transfer&#160;&#38; Trust Company, LLC. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHARES ELIGIBLE FOR FUTURE SALE </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 18, 2022 we have 15,966,053 shares of common stock outstanding, all of which will be freely transferable without restriction under the Securities Act unless purchased by one of our affiliates as that term is defined in Rule 144 under the Securities Act, which generally includes directors, executive officers and 10% stockholders, or are subject to lock-up agreements. Sales of substantial amounts of our shares in the public market could adversely affect prevailing market prices of our shares. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the lock-up agreements referred to below and the provisions of Rule 144 and Rule 701 under the Securities Act, based on the number of shares of our common stock outstanding as of March 18, 2022, the remaining shares of our common stock will generally become available for sale in the public market as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Number of Shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Date Available for Sale on the Public Markets</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,216,053 shares</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 days after October 19, 2021, in the case of our officers and directors, and 181 days after October 19, 2021, in the case of our pre-IPO stockholders, upon expiration of the lock-up agreements referred to below, subject in some cases to applicable volume, manner of sale and other limitations under Rule 144 and Rule 701.</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue shares of common stock from time to time as consideration for future acquisitions, investments or other corporate purposes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may in turn be significant. We may also grant registration rights covering those shares of common stock issued in connection with any such acquisition and investment. In addition, the shares of common stock reserved for future issuance under our 2021 Incentive Plan will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements, a registration statement under the Securities Act or an exemption from registration, including Rule 144 and Rule 701. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 144 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Rule 144 of the Securities Act, a person or entity that has beneficially owned our common stock for at least six months and is not our &#8220;affiliate&#8221; will be entitled to sell our common stock, subject only to the availability of current public information about us, and will be entitled to sell shares held for at least one year without any restriction. A person or entity that is our &#8220;affiliate&#8221; and has beneficially owned our common stock for at least six months will be able to sell, within a rolling three month period, the number of shares that does not exceed the greater of the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">1% of the then outstanding common stock, which immediately after this offering will equal approximately 159,660 shares of common stock&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by affiliates under Rule 144 must be made through unsolicited brokers&#8217; transactions. They are also subject to manner of sale provisions, notice requirements and the availability of current public information about us. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 701 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, directors or consultants who purchases our common stock from us pursuant to a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such common stock 90 days after we become a reporting company under the Exchange Act in reliance on Rule 144, but without compliance with some of the restrictions, such as the holding period, contained in Rule 144. However, the Rule 701 shares would remain subject to lock-up arrangements and would only become eligible for sale when the lock-up period expires. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lock-Up Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our initial public offering, we, along with our directors, executive officers and substantially all of our other stockholders, have agreed with the underwriter that for the period from the date of the lock-up agreement continuing through 365 days from October 19, 2021, in the case of our executive officers and directors, and 180 days from October 19, 2021, in the case of our stockholders who held stock in the Company prior to our initial public offering and us, will not sell, offer to sell, contract to sell or lend, effect any short sale or establish or increase any put equivalent position or liquidate or decrease any call equivalent position, pledge, hypothecate, grant any security interest in or in any other way transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After our initial public offering, certain of our employees, including our executive officers and&#47;or directors may enter into written trading plans that are intended to comply with Rule 10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the Private Placement, our officers and directors have agreed, subject to certain exceptions, with the placement agent in such Private Placement not to directly or indirectly offer, sell, contract to sell, pledge or otherwise dispose of any shares of our common stock or any securities convertible into or exchangeable for shares of common stock during the 60-day period starting on December 1, 2021, except with the prior written consent of the placement agent.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2021, we filed with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock reserved for issuance under our 2021 Incentive Plan. Accordingly, shares registered under the registration statement became available for sale in the open market following its effective date, subject to vesting restrictions, Rule 144 volume limitations and the lock-up agreements described above, if applicable. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_70"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY&#8217;S COMMON STOCK </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the purchase, ownership and disposition of the Company&#8217;s common stock included in this offering, but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, Treasury regulations promulgated thereunder, published administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed or be subject to differing interpretations, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, local or other tax considerations relevant to the Company&#8217;s operations or to the purchase, ownership or disposition of its shares, has been requested from the U.S. Internal Revenue Service, or the IRS, or other tax authority. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax consequences described below. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary also does not address the tax considerations arising under any U.S. federal tax laws other than income tax laws, the laws of any non-U.S., state or local jurisdiction, or under U.S. federal gift and estate tax laws. In addition, this summary does not address U.S. federal income tax considerations applicable to a non-U.S. holder&#8217;s particular circumstances or to non-U.S. holders that may be subject to special tax rules, including, without limitation&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">banks, insurance companies or other financial institutions, regulated investment companies or real estate investment trusts&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons subject to the alternative minimum tax or Medicare contribution tax on net investment income&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax-exempt organizations or governmental organizations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax-qualified retirement plans&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brokers or dealers in securities or currencies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that own, or are deemed to own, more than five percent of the Company&#8217;s capital stock (except to the extent specifically set forth below)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. expatriates and former citizens or long-term residents of the United States&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partnerships or entities classified as partnerships for U.S. federal income tax purposes or other pass-through entities (and investors therein)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who hold the Company&#8217;s common stock as a position in a hedging transaction, &#8220;straddle,&#8221; &#8220;conversion transaction&#8221; or other risk reduction transaction or integrated investment&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Internal Revenue Code and entities all of the interests of which are held by qualified foreign pension funds&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to common stock being taken into account in an applicable financial statement&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who hold or receive the Company&#8217;s common stock pursuant to the exercise of any employee stock option or otherwise as compensation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who do not hold the Company&#8217;s common stock as a capital asset within the meaning of Section&#160;1221 of the Internal Revenue Code&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons deemed to sell the Company&#8217;s common stock under the constructive sale provisions of the Internal Revenue Code. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a partnership or entity classified as a partnership for U.S. federal income tax purposes holds the Company&#8217;s common stock, the tax treatment of a partner generally will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships that hold the Company&#8217;s common stock, and partners in such partnerships, should consult their tax advisors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This discussion is for informational purposes only and is not tax advice. You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of the Company&#8217;s common stock arising under the U.S. federal estate or gift tax rules or under the laws of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Holder Defined For purposes of this discussion, you are a non-U.S. holder (other than a partnership) if you are a beneficial owner of the Company&#8217;s common stock other than&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual citizen or resident of the United States (for U.S. federal income tax purposes)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States, any state thereof, or the District of Columbia, or other entity treated as such for U.S. federal income tax purposes&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income tax regardless of its source&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust (x)&#160;whose administration is subject to the primary supervision of a U.S. court and which has one or more &#8220;U.S. persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Internal Revenue Code) who have the authority to control all substantial decisions of the trust or (y)&#160;which has made a valid election to be treated as a U.S. person for U.S. federal income tax purposes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the section entitled &#8220;Dividend Policy,&#8221; the Company has never declared or paid cash dividends on its common stock and does not anticipate paying any dividends on its common stock in the foreseeable future. However, if the Company does make distributions of cash or property on its common stock, those payments will constitute dividends for U.S. tax purposes to the extent paid from the Company&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both the Company&#8217;s current and its accumulated earnings and profits, they will constitute a return of capital and will first reduce your basis in the Company&#8217;s common stock, but not below zero, and then will be treated as gain from the sale of stock as described below under &#8220;&#8212;Gain on the Sale or Other Taxable Disposition of Common Stock.&#8221; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the discussion below on effectively connected income, backup withholding and foreign accounts, any dividend paid to you generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, you must timely provide us or the applicable withholding agent with a valid IRS Form W-8BEN, IRS Form W-8BEN-E, or other appropriate version of IRS Form W-8 or applicable certifying qualification for the reduced rate. A non-U.S. holder of shares of the Company&#8217;s common stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the non-U.S. holder&#8217;s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to the Company or its paying agent, either directly or through other intermediaries. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends received by you that are effectively connected with your conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, attributable to a permanent establishment maintained by you in the United States) are generally exempt from the withholding tax described above. In order to obtain this exemption, you must provide us or the applicable withholding agent with a valid IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal income withholding tax, are taxed for U.S. federal income tax purposes at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, if you are a corporate non-U.S. holder, dividends you receive that are effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor regarding any applicable tax treaties that may provide for different rules. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on the Sale or other Taxable Disposition of Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the discussion below regarding information reporting, backup withholding and foreign accounts, you generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other taxable disposition of the Company&#8217;s common stock unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the gain is effectively connected with your conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment maintained by you in the United States)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">you are a non-resident alien individual who is present in the United States for a period or periods aggregating 183 days or more during the taxable year in which the sale or disposition occurs and certain other conditions are met&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company&#8217;s common stock constitutes a United States real property interest, or USRPI, by reason of its status as a &#8220;United States real property holding corporation,&#8221; or USRPHC, for U.S. federal income tax purposes at any time within the shorter of (i)&#160;the five-year period preceding your sale or other taxable disposition of the Company&#8217;s common stock, or (ii)&#160;your holding period for its common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination whether the Company is a USRPHC depends on the fair market value of its USRPIs relative to the fair market value of its other business assets, there can be no assurance that the Company will not become a USRPHC in the future. Even if the Company becomes a USRPHC, however, as long as its common stock is regularly traded on an established securities market, the common stock you own will be treated as a USRPI only if you actually or constructively hold more than five percent of the Company&#8217;s outstanding common stock at any time during the shorter of (i)&#160;the five-year period preceding your disposition of the Company&#8217;s common stock, or (ii)&#160;your holding period for the stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a non-U.S. holder described in the first bullet above, you will generally be required to pay tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and a corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are an individual non-U.S. holder described in the second bullet above, you will be required to pay a flat 30% tax (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale or other taxable disposition, which gain may be offset by U.S. source capital losses for the year (provided you have timely filed U.S. federal income tax returns with respect to such losses). You should consult any applicable income tax or other treaties that may provide for different rules. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Backup Withholding and Information Reporting </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the Company or an applicable withholding agent must report annually to the IRS, regardless of whether any tax was withheld, the amount of dividends paid to you, your name and address and the amount of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of dividends or of proceeds on the sale or disposition of stock made to you may be subject to information reporting and backup withholding at a current rate of 24% unless you establish an exemption, for example, by properly certifying your non-U.S. status on a timely provided and valid IRS Form W-8BEN, IRS Form W-8BEN-E, or another appropriate version of IRS Form W-8 or applicable documentation. Proceeds of a sale or other disposition of the Company&#8217;s common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Backup withholding is not an additional tax&#59; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Account Tax Compliance </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sections 1471 through 1474 of the Internal Revenue Code, known as the Foreign Account Tax Compliance Act, or FATCA, impose withholding tax at a rate of 30% on, dividends on and (subject to the proposed Treasury regulations discussed below) gross proceeds from the sale or other disposition of, the Company&#8217;s common stock paid to a &#8220;foreign financial institution&#8221; (as specially defined under these rules), unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds from the sale or other disposition of the Company&#8217;s common stock paid to a &#8220;non-financial foreign entity&#8221; (as specially defined for purposes of these rules) unless such entity (i)&#160;provides the withholding agent with a certification identifying certain substantial direct and indirect U.S. owners of the entity, (ii)&#160;certifies that there is none or (iii)&#160;otherwise establishes an exemption. The withholding provisions under FATCA generally apply to dividends on our common stock. Although potential withholding under FATCA would also have applied also to of gross proceeds from the sale or other disposition of stock on or after January&#160;1, 2019, recently proposed Treasury regulations eliminate FATCA withholding on payments of gross proceeds entirely. Withholding agents may rely on these proposed Treasury regulations until final Treasury regulations are issued. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their own tax advisors regarding the possible implications of this legislation on their investment in the Company&#8217;s common stock. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_73"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Selling Stockholder (the &#8220;Selling Stockholders&#8221;) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exchange distribution in accordance with the rules of the applicable exchange&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">privately negotiated transactions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">settlement of short sales&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a combination of any such methods of sale&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other method permitted pursuant to applicable law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), if available, rather than under this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121&#59; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2121. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The Company shall not be responsible for any of the Selling Stockholders&#8217; selling costs incurred pursuant to any available method provided hereunder for selling securities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_76"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the shares of our common stock offered hereby will be passed upon for us by Faegre Drinker Biddle&#160;&#38; Reath LLP.  </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_79"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements included in this prospectus have been audited by CohnReznick LLP, an independent registered public accounting firm, as stated in their report, appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_82"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed with the SEC a registration statement on Form&#160;S-1&#160;under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available over the internet at the website of the SEC referred to above. We also maintain a website at&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.contexttherapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTEXT THERAPEUTICS INC.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Report of Independent Registered Public Accounting Firm </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID 596)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Balance Sheets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Statements of Operations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; </a><a href="#i47e1006ae0674fccb030b14d141d1ccd_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equity (</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Deficit</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Statements of Cash Flows</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notes to Consolidated Financial Statements </a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i47e1006ae0674fccb030b14d141d1ccd_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i47e1006ae0674fccb030b14d141d1ccd_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_88"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders of </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context Therapeutics Inc.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Context Therapeutics Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; CohnReznick LLP</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since January 2021.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holmdel, New Jersey </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_91"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,635,197&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,255,361&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,342&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,631&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,305,750&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,340&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit)</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory notes</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable&#8212;current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,014&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826,294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,707,861&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033,415&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,548,156&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable&#8212;noncurrent</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033,415&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,617,196&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit)&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021)&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A preferred stock&#8212;$0.001 par value&#59; no shares and 210,715 issued and outstanding at  December 31, 2021 and 2020, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400,935&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Seed preferred stock&#8212;$0.001 par value&#59; no shares and 2,624,324 issued and outstanding at December 31, 2021 and 2020, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,341,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable common stock&#8212;$0.001 par value&#59; no shares and 16,666 issued and outstanding at December 31, 2021 and 2020, respectively </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred stock and redeemable common stock</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771,223&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit)&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#8212;$0.001 par value&#59; 10,000,000 shares authorized&#59; no shares issued or outstanding</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;$0.001 par value&#59; 100,000,000 shares authorized&#59; 15,966,053 and 331,789 shares issued and outstanding at December 31, 2021 and 2020, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,966&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,510,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,254,440)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,797,570)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,272,335&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,921,079)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit)</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,305,750&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,340&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,087,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805,067&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641,501&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,525,819)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,572,168)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,240)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,224)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,877,857&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share, basic</font></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, diluted</font></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.96)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054,875&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_100"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit) </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Series A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Preferred Stock </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Series Seed</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Preferred Stock</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Redeemable</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;stock </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Paid-in</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Capital</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deficit </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Stockholders&#8217;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity (Deficit)</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2020</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,666&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324,145&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,480,955&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,442,035)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,960,756)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Series A preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,537&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of bridge notes, including accrued interest, to Series A preferred stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529,902&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of warrants issued in conjunction with the Series A preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,967)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,967&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,967&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Series Seed preferred stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of Junior Convertible Notes to Series Seed preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,615,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,291,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,644&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,237&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,245&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of redeemable common stock to redemption value</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,715&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,400,935&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,624,324&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,341,288&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,666&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,000&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331,789&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876,159&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,797,570)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,921,079)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Series A preferred shares, net of offering costs of $310,021</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">738,445&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,982,835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">844,824&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,728,793&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">418,559&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,837,832&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of warrants issued in conjunction with the Series A preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(265,593)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">265,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">265,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of warrants issued as placement agent fees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43,797)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of warrants issued for services</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">371,895&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">371,895&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of redeemable common stock to redemption value</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(53,330)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(53,330)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,212,543)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,641,005)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,624,324)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,341,288)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16,666)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(82,330)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,853,533&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,853&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,059,770&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,064,623&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cashless exercise of warrants upon initial public offering</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock in initial public offering, net of issuance costs of $4,321,374</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,750,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,422,876&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,428,626&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock in private placement, net of issuance costs of $2,369,496</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,875,504&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,880,504&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,915&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">511,058&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">511,079&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10,456,870)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10,456,870)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,966,053&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,966&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">77,510,809&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29,254,440)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48,272,335&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_103"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from operating activities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (loss) income</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash used in operating activities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development charge</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,087,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fair value of warrants for services provided</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">371,895&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Share-based compensation expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">511,079&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">219,245&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash interest expense</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46,315&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">661,224&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,317)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,877,857)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(125,577)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,611,492)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,332&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(866,007)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,270&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">252,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">757,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash used in operating activities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(8,799,487)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,034,620)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from investing activities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(250,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash used in investing activities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(250,000)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from financing activities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible bridge notes</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of note payable</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">124,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the sale of Series A preferred stock, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,982,835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">950,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the sale of Series Seed preferred stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the sale of common stock in initial public offering, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,428,626&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from the sale of common stock in private placement, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28,982,575&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">58,394,036&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,149,054&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,344,549&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">114,434&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">341,037&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">226,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,685,586&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">341,037&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash financing activities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock and warrants</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,866,290&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Conversion of bridge notes, including accrued interest, to Series A preferred stock</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">529,902&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Conversion of convertible promissory notes, including accrued interest, to Series Seed preferred stock</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,291,288&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">309,390&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">78,967&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A preferred stock issued for acquired in-process research and development</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,837,832&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unpaid offering costs in accounts payable</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,071&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">117,631&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in fair value of redeemable common stock to redemption value</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,330&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97,000&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Conversion of preferred stock and redeemable common stock upon initial public offering</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,064,623&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_106"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTEXT THERAPEUTICS INC. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_109"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) Nature of Business </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context Therapeutics Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_112"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Risks and Liquidity </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $29.3 million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company&#8217;s primary source of liquidity to date has been the issuance of convertible promissory notes, convertible preferred stock and common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2021, the Company raised $5.0 million in net proceeds related to the sale of its Series A convertible preferred stock (&#8220;Series A Stock&#8221;) and warrants for common stock (see Note 7 for further discussion). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2021, the Company closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which it issued and sold 5,750,000 shares at a public offering price of $5.00 per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $6.25 per share and a term of five years from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and 480,415 warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of its initial public offering. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold 5,000,000 shares of its common stock together with warrants to purchase 5,000,000 shares of its common stock in a private placement and received net proceeds of $28.9 million.  Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $6.25 per share and a term of 5.5 years from the date of issuance.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its cash and cash equivalents at December&#160;31, 2021 are sufficient to fund its projected operations into fiscal year 2024. However, substantial additional capital will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to secure additional capital in the future through equity and&#47;or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s product candidates, length of time and cost of developing and commercializing these </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates and&#47;or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and&#47;or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_115"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Summary of Significant Accounting Policies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company&#8217;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis (see Note 4 for further discussion). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains approximately $50,000 as collateral for the Company&#8217;s credit card program. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its consolidated balance sheets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,635,197&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,670&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,685,586&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,037&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.  As of December&#160;31, 2020, the Company had deferred offering costs of $0.1 million related to the Company&#8217;s IPO and the Company&#8217;s Series A Stock financing.  All deferred offering costs related to the Company&#8217;s Series A Stock financing were recorded against Series A Stock upon completion of the financing in April 2021 and all deferred offering costs related to the Company&#8217;s IPO were recorded against additional paid-in capital upon completion of the IPO financing in October 2021. There were no deferred offering costs recorded as of December&#160;31, 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock and Redeemable Common Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. The Company&#8217;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Costs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development (&#8220;IPR&#38;D&#8221;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s acquired IPR&#38;D expense of $3.1&#160;million for the year ended December 31, 2021 reflects the fair value of consideration ascribed to the collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. See Note 9 for further discussion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of prepaid&#47;accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid&#47;accrual accordingly. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 740&#8221;).  Context BioPharma, Inc. has always been subject to corporate income taxes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statements of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Per Share </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in a net loss position for the year ended December 31, 2021 and therefore basic and diluted net loss per share was the same. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006,691&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,983&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company was in a net income position and therefore, used the two-class method to compute basic net income per common share. Under this method, undistributed earnings are allocated to common stock, the Series Seed Preferred Stock and the Series A Preferred Stock to the extent that the preferred stockholders may share in earnings. In periods of net loss, losses are not allocated to participating securities as the holders of such securities have no obligation to fund losses. The total earnings allocated to common stock is then divided by the weighted average common shares outstanding to determine the basic earnings per share. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants and share-based awards using the treasury stock method. In addition, the Company considers the potential dilutive impact of its preferred stock and convertible debt using the treasury stock and if-converted methods, if either is more dilutive than the two-class method. The two-class method was more dilutive for the year ended December 31, 2020. </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) income per common share calculation&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; undistributed earnings to participating securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders - basic</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,907&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) income per common share calculation&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; undistributed earnings to participating securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; change in fair value of convertible promissory notes and interest expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,216,633)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders &#8211; diluted</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,145,726)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706,507&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054,875&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - diluted</font></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.96)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470-20) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#58; Simplifying the Accounting for Income Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)&#58; Targeted Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.  </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_118"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) Fair Value Measurements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3 &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents and restricted cash (Money Market Accounts)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (Money Market Account)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Promissory Notes</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 6, the Company issued convertible promissory notes from inception through April 2019 (the &#8220;Junior Convertible Notes&#8221;) to various investors and from October 2019 through March 2020, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company issued convertible bridge notes to the Co-Founder and Chief Executive Officer (the &#8220;Convertible Bridge Notes&#8221;). During April 2020, certain of the Junior Convertible Notes were converted into Senior Convertible Notes (the &#8220;Senior Convertible Notes&#8221;) (collectively, the &#8220;Convertible Promissory Notes&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the number of embedded provisions contained in the Convertible Promissory Notes and Convertible Bridge Notes, the fair value option, as prescribed by ASC 815, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was elected and applied to all Convertible Promissory Note and Convertible Bridge Note issuances since the Company&#8217;s inception in 2015, in connection with the preparation of these financial statements. The fair value of the Convertible Promissory Notes and Convertible Bridge Notes was determined using a scenario-based analysis that estimates the fair value based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adjusted the carrying value of its Convertible Promissory Notes and Convertible Bridge Notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of convertible promissory notes in the consolidated statement of operations. The change in fair value of convertible promissory notes within the years ended December 31, 2021 and 2020 consolidated statement of operations also includes reversals of gains and losses previously recognized by the Company upon conversion of the notes (Note 6).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Convertible Notes at  December 31, 2020 was calculated using an option pricing model (&#8220;OPM&#8221;) framework and utilized the back-solve method for inferring and allocating the equity value predicated on the concurrent sale of Series A Stock. This method was selected as it was concluded that the sale of the Series A Stock was an arm&#8217;s-length transaction. Application of the OPM back-solve method involves making assumptions for the expected time to liquidity and volatility, and then solving for the value of equity such that value for the most recent financing equals the amount paid.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,842,931&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Convertible Bridge Notes</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,317)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,877,857)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,315&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,408&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Junior Convertible Notes into Series Seed Stock</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291,288)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Senior and Convertible Bridge Notes into Series A Stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866,290)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,902)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i47e1006ae0674fccb030b14d141d1ccd_990"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) Accrued Expenses and Other Current Liabilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,990&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,072&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,173&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,530&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,529&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,121&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,989&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_121"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) Convertible Promissory Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Junior Convertible Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 2018, the Company issued Junior Convertible Notes and demand notes that converted into Junior Convertible Notes which, due to certain embedded features within the Junior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. All of the outstanding principal and accrued but unpaid interest associated with the Junior Convertible Notes converted into 2,615,553 shares of Series Seed Stock in May 2020, of which 840,363 shares were issued to the Company&#8217;s Chief Executive Officer and an immediate family member (&#8220;Related Party&#8221;). At the time of conversion, the estimated fair value of the Junior Convertible Notes was $6.3 million and was reclassified to Series Seed convertible preferred equity. In connection with the conversion in 2020, the Company recorded a non-cash credit of $7.7 million related to the final decrease in fair value of the Junior Convertible Notes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Bridge Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 2019 through March 2020, the Company issued convertible bridge notes to the Related Party in the amount of $0.5 million. On December&#160;22, 2020, the outstanding principal and accrued but unpaid interest associated with the Convertible Bridge Notes converted into 78,178 Series A Stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain embedded features within the Convertible Bridge Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Convertible Bridge Notes was $0.5 million and was reclassified to Series A convertible preferred equity.  In connection with the conversion in December 2020, the Company recorded a non-cash credit of $0.1 million related to the final decrease in fair value of the Convertible Bridge Notes. For the year ended December 31, 2020, the Company recognized approximately $30,000 of interest expense in connection with the Convertible Bridge Notes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, $5.1 million of principal and $0.6 million of accrued interest related to certain Junior Convertible Notes were converted into Senior Convertible Notes. Of the Senior Convertible Notes issued in 2020, $2.5 million of principal and $0.4 million of accrued interest were issued to the Related Party. During the year ended December 31, 2021, the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into 844,824 shares of Series A Stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company recognized a credit of $2.1 million in the consolidated statement of operations related to decreases in the fair value of the Senior Convertible Notes. For the year ended December 31, 2020, the Company recognized $0.3 million of interest expense in connection with the Senior Convertible Notes, including $0.1 million payable to the Related Party. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender (&#8220;Lender&#8221;) for a loan in an aggregate principal amount of $0.1 million (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act and implemented by the U.S. Small Business Administration. In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#8217;s loan forgiveness covered period. The Loan was set to mature in two years and bore interest at a rate of 1.0% per year, with all payments deferred through September&#160;5, 2021. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding principal balance of the Loan of $0.1 million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the consolidated statement of operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_124"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) Convertible Preferred Stock, Redeemable Common Stock and Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company converted $11.7 million of principal and interest related to certain Junior Convertible Notes into 2,615,553 shares of Series Seed Stock at prices ranging from $4.28 to $4.56 per share. In May 2020, the Related Party purchased 8,771 shares of Series Seed Stock at a price of $5.70 per share for $50,000. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020, the Company sold 132,537 shares of Series A Stock to the Related Party for $7.168 per share for proceeds of $1.0 million. The Company also issued 33,129 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A Stock holder as part of the Series A Stock financing. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, $0.6 million in principal and accrued interest related to the Convertible Bridge Notes were converted into 78,178 shares of Series A Stock. The Company also issued 19,544 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A stockholders as part of the conversion from Convertible Bridge Notes to Series A Stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February, March and April 2021, the Company sold 738,445 shares of Series A Stock for $7.168 per share for net proceeds of $5.0 million. The Company also issued 184,597 warrants to purchase common stock at an exercise price of $7.168 to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued 24,134 warrants to purchase common stock at an exercise price of $7.168 to placement agents as a part of the Series A Stock financing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company converted $6.1&#160;million of principal and interest related to Senior Convertible Notes into 844,824 shares of Series A Stock at a price of $7.168 per share. In addition, warrants with a fair value of $0.1&#160;million associated with the Senior Convertible Notes were reclassified into additional paid-in capital.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed its IPO in which the Company sold 5,750,000 shares at a public offering price of $5.00 per share. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and all of the outstanding warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of the offering. The Company issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per shares and a term of 5.0 years.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock and received net proceeds of $28.9 million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. The Company also issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.5 years. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants for Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:47.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;dates</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in connection with IPO</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2026</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued as part of December 2021 private placement</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2027</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During its evaluation of equity classification for the Company's common stock warrants issued in 2021, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The conditions within ASC 815-40 are not subject to a probability assessment. The warrants do not fall under the liability criteria within ASC 480, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company effected a one-for-6 reverse stock split of its common stock and convertible preferred stock. No fractional shares were issued in connection with the reverse stock split. Any fractional share resulting from the reverse stock split was rounded down to the nearest whole share, and in lieu of any fractional shares, the Company paid in cash to the holders of such fractional shares an amount equal to the fair value, as determined by the board of directors, of such fractional shares. All common stock, convertible preferred stock, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.</font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_130"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) Share-based Compensation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Context Therapeutics Inc. adopted the 2021 Long-Term Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#8220;Share Limit&#8221;). The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year&#59; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of December&#160;31, 2021, 742,706 shares remained available for future grants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Grants</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company issued 7,512 shares of common stock to members of the board of managers as compensation for their services. The Company recorded share-based compensation expense of $0.1 million in general and administrative expense during the year ended December 31, 2020.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options generally vest over a period of one to four years, and stock options that lapse or are forfeited are available to be granted again. The contractual life of all stock options is 10 years. The expiration dates of the outstanding stock options range from January 2028 to November 2031. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Stock option compensation expense is allocated to employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock option compensation expense of $74,000 and $404,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2021.  The Company recorded stock option compensation expense of $75,000 and $29,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2020.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.06%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.86%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.78</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for the periods presented&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Term</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(years) </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.79&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.84&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,861&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,059&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of share-based awards granted during the years ended December 31, 2021 and 2020 was $3.84 and $9.34, respectively. The aggregate intrinsic value of the options outstanding and exercisable as of December 31, 2021 was $0.  As of December&#160;31, 2021, the unrecognized compensation cost related to outstanding stock options was $1.5 million and is expected to be recognized as expense over a weighted-average period of approximately 1.73 years. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues restricted stock units (&#8220;RSU&#8221;) to employees and consultants that generally vest monthly over one to three-year periods. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to RSU share-based payment awards&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Grant</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date&#160;Fair&#160;value </font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at January&#160;1, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Granted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Vested</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,096&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Vested</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,915)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cancelled</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,226)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded share-based compensation expense of $33,000 in research and development expense for the year ended December&#160;31, 2021 related to RSUs. The Company recorded share-based compensation expense of $2,000 in general and administrative expense for the year ended December&#160;31, 2020 related to RSUs. As of December&#160;31, 2021, there was no remaining unrecognized expense related to RSUs.</font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_133"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) Commitments and Contingencies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent License Agreement with Drexel University </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the Company entered into a patent license agreement, as amended, (the &#8220;Drexel License Agreement&#8221;) with Drexel for license rights to patents for certain intellectual property and know-how related to certain technology. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Drexel License Agreement, the Company issued Drexel 16,666 shares of common stock. In partial consideration of the Drexel License Agreement, the Company is required to pay to Drexel certain milestone payments, ranging from $10,000 to $0.2 million on the achievement of certain milestone events for each licensed product. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to pay Drexel a royalty in the low single digits of net sales for each licensed product on a country-by-country, licensed product-by-licensed product basis on issued or pending valid claims. The Company may credit against amounts payable to Drexel, on a country-by-country, licensed product-by-licensed product basis up to 50% of any third-party payments which the Company must make on account of third-party license agreements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration of the Drexel License Agreement, the Company will pay to Drexel a de-escalating sublicense fee on a quarterly basis of a high single-digit percentage that decreases to a mid-single digit percentage as time passes. In addition, the Company will make payments of the fair market value of all other consideration received by the Company from sublicensees during the quarter, other than&#58; (a)&#160;royalties paid to the Company by a sublicensee based upon sales or net sales by the sublicensee&#59; (b)&#160;equity investments in the Company by a sublicensee up to the amount of fair market value of the equity purchased on the date of the investment&#59; (c)&#160;loan proceeds paid to the Company by a sublicensee in an arm&#8217;s length, full recourse debt financing to the extent that such loan is not forgiven&#59; and (d)&#160;sponsored research funding, paid to the Company by a sublicensee in a bona fide transaction for future research to be performed by the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a strategic review of its pipeline, the Company recently notified Drexel that it is terminating the Drexel License Agreement, effective as of April 27, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement with Tyligand Bioscience </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a license (the &#8220;Tyligand License Agreement&#8221;) and process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) (collectively, the &#8220;Tyligand Agreements&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#8220;ONA-XR&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Tyligand Agreements, Tyligand will be solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand will be granted the exclusive right to ONA-XR and will be solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company will retain rest of world rights to commercialize ONA-XR. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tyligand Process Development Agreement, the Company is obligated to pay Tyligand $0.8 million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $2.0 million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $3.0 million upon the Company&#8217;s completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i)&#160;the sale of a generic product in the territory and (ii) 15 years after the date of the first commercial sale of product in the territory. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, upon successful completion of the process development plan with Tyligand, the Company issued Tyligand warrants to purchase 111,576 shares of common stock at an exercise price of $7.17 per share all of which were cancelled in connection with the IPO. The Company recognized an expense and liability of $0.4&#160;million to account for the fair value of the warrants upon completion of the manufacturing development plan in June 2021. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the warrants in August 2021, the Company reclassified the $0.4&#160;million liability into equity. The Company has expensed $0.8&#160;million related to the process development plan as of December 31, 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, while the Company&#8217;s license agreement with Tyligand was signed in March 2020, the parties acknowledged that such signature was premature since the &#8216;successful completion&#8217; under the process development agreement had not yet occurred, and as such, the parties properly executed the license agreement upon such successful completion in August 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and Licensing Agreement with Integral Molecular</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $0.3&#160;million and granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8&#160;million, and these costs were expensed to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3&#160;million, sales milestone payments totaling up to $130&#160;million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company leased its corporate offices in Philadelphia, Pennsylvania under a month-to-month lease arrangement. The Company recorded rent expense of approximately $10,000 for the years ended December&#160;31, 2021 and 2020.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. The minimum lease payments under the sublease is $0.1&#160;million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company believes no matters existed at either December&#160;31, 2021 or 2020 that will have a material impact to the Company&#8217;s financial position, results of operations or cash flows. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_136"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) Income Taxes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2021 and 2020. The Company had also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199,412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,874&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,526&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,659&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,802,828&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527,181)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,647&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; valuation allowance</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,275,647)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,569,489)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased by $1.7 million and $0.2 million during the years ended December&#160;31, 2021 and 2020, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense&#47;(benefit) at statutory rate</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable partnership income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes carryforwards of federal, state and local net operating losses (&#8220;NOL&#8221;) and research tax credits&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Federal</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;State</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Local</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,926,879&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399,777&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits&#8212;Federal</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes&#59; however, all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. Local NOL carryforwards expire after three years with the 2019 NOL set to expire in 2022. As of December&#160;31, 2021 and 2020, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company had federal research and development tax credit carryforwards of $0.4 million and  $0.3 million, respectively, that will begin to expire in 2037, unless previously utilized. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. State and local NOLs may also be limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statement of operations. Due to NOLs and tax credit carry forwards that remain unutilized, income tax returns for tax years from all years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_139"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11) Related Party Transactions </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception through December&#160;31, 2021, the Company entered into various convertible note agreements with the Related Party. The terms of the convertible notes and their subsequent conversions are further described in more detail in Note 6 and Note 7. </font></div><div id="i47e1006ae0674fccb030b14d141d1ccd_142"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12) Subsequent Events </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense on the consolidated statement of operations for the year ended December 31, 2021. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</font></div></div></div><div id="i47e1006ae0674fccb030b14d141d1ccd_190"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:100pt;text-align:center"><font><br></font></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">10,000,000 Shares of Common Stock </font></div><div style="margin-bottom:30pt;text-align:center"><img alt="image_26.jpg" src="image_26.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:272px"></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </font></div><div style="margin-bottom:20pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS </font></div><div style="margin-bottom:20pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:40pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:80pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 12, 2022 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a20220323_pipelineslide.jpg
<TEXT>
begin 644 a20220323_pipelineslide.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" C*#Z # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#COBC\4=*^$OA^WUC6+>\N;:>Z6T5+%$=PY1V!(9E&,(>
M_I7E_P#PVQX'_P"@5X@_\!X/_CU'[;'_ "2O2O\ L-1?^B)Z^** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZNP^%W[0_ASXM>(+C1]'LM4MKF"U:[9[Z*-$*!T4@%9&.<N.WK7Y
M\5] _L3_ /)5-5_[ LO_ */@H ^UZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /G[]MC_ ))7I7_8:B_]$3U\45]K_ML?\DKT
MK_L-1?\ HB>OBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^@?V)_^2J:K_V!9?\ T?!7S]7T#^Q/_P E4U7_
M + LO_H^"@#[7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^?OVV/^25Z5_V&HO\ T1/7Q17VO^VQ_P DKTK_ +#47_HB>OBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^@?V)_\ DJFJ_P#8%E_]'P5\_5] _L3_ /)5-5_[ LO_ */@H ^U
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G[
M]MC_ ))7I7_8:B_]$3U\45]K_ML?\DKTK_L-1?\ HB>OBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?0/[$_\ R535?^P++_Z/@KY^KZ!_8G_Y*IJO_8%E_P#1\% 'VO1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_?ML?\DKTK_L
M-1?^B)Z^**^U_P!MC_DE>E?]AJ+_ -$3U\44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.JSP2J4DBDO965U(P006P01VK#HHH **** "BBB@ HHHH **** "OH']B?\
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M_A;2YHVV&U(@0QG_ &A_#_P+% 'YUT5^@_C'X!^ OB5I9GATZTLYYTWPZII
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ML+Q9IGPJ7X:ZR]I:>#AJ0TB8Q-#':><)?).TK@9W;L8QSF@#X8HHHH ****
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M?Q%?:;X9T?3[V+[/Y=S:V$44B9N8@<,J@C()'T)KX>H **^EOV,O"6A^*?\
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M]/TJS"F[OKB.UA#G"[W8*N3V&2* *5%?2'C_ /9FT[X7?!G6-;U"\;5/$2&
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M!M6742)3[A1CK]*\^^,/[(ECH'AR_P!<\*7MRQLHFN)M/O&#[HU&6\MP 00
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MX]>WGX5F#$ D*,D@=!T_K24 ?>_[)O\ R1#1_P#KM<_^CFKXX^,?_)6?&/\
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MG:1D\X). ?G_ ,:>,=2\<^)[W6]2N))KFXE+J&8D1+DE47T51P!7K6B_M?\
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MQFMHT 5YM/MP3ZDNXS_*OK?Q%=Q_#?X9:A/81KY>BZ4YMHV'RGRHCL!]L@4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY%M,JGB2-N"I'<=#]0#VH U_V@?@(_P?O+.[L;N2_P!"OG:.*291YL+CG8Y
M .1R" ,X;@8Y\@K[I_;"A23X-RLR@M'?P,I/8_,,_D3^=?"U !1110 4444
M%%%% !1110 4444 %?IQXL_Y$#6?^P9-_P"BC7YCU^ICI;R:.R78C-HT&)A+
MC9LV_-NSQC&<T ?EG7V'^Q&=9_X1CQ +KSO[$\^+[#YF=GF8?SMGM_J\XXS[
MYKT.#P[\&;=]R6O@PG&/G-JX_(DU-XB^/'P[\ Z25CUJPN1 NV+3]'9)FX_@
M 3Y5_$@4 > _MO"'_A.?#Y7'VC^S3O\ ]WS6V_KNKZ;^%R&3X1^$5499M#M
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M&'CE2V,L1Z@@?7K6IK_['W@?Q!IKR^'K^ZTRX(/E2QSBY@SZ,#R?P8=:Z/\
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M"SZJTI:X-XT'FE^^\,<Y^M 'RQ^R*^LK\7K0:<)CIS02C4=F?+$?EMLW]O\
M6;,>_P"->^?MBB'_ (4ZWFD;_P"T(/*_WL-_[+NKL%\?_#'X?6$BVFL>'-)M
MS\[6^FO$"WOY<7)_*ODS]HKX[+\6M2M;'2XY(/#]@Q>/S1A[B0C'F$?P@#(
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MM7Z*>*M/U*U\#7]AX62*WU)+,V]@I;8D1V[5(/;:.1]!0!Y=<?LF?#2\1[&
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M7]S9741ANK:5H98VZHZDA@?H0: (**** "BBB@ HHHH **** "BBB@ HHHH
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MOGZOH']B?_DJFJ_]@67_ -'P4 ?:]%%% !1110 4444 %%%% !1110 4444
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M2(>*O^N,?_HY*^ _#VHIH^OZ9?RJSQVMU%.RIU(5PQ ]^*^C_BO^U9X>\?\
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M,9('5A0!]3_MKDCX5:6 2,ZS$#[_ +B>OE/X2_\ )5/!G_8:LO\ T>E>J?M
M?M%:+\7/!MGH^FZ;?V<\%^EVTET$VE5CD7 VL3G+C\C7C/@K7(O#/C+0=8GC
M>6#3[^WNY(X\;F6.16(&>,D"@#[>_:R_Y(AK'_7:V_\ 1RUY3^PU_P A7Q=_
MUQMO_0I*H_&K]I_0?B9\/;[0+#2M1M;FXDB=9;@1[ %<,<X8GM7%_L[_ !GT
MOX.WNN3:G8W=ZM_'$B"TVY4H6)SN(_O"@#I_VVO^2E:-_P!@A/\ T=+7TK\"
M_$<'BKX2>&;J)E<QV26DJ]</$/+8'_OG/T(KXS_:"^*VG?%WQ98:KIMI<V<-
MO9+:LEUMW%A([9&TGC#"H_@Q\=-7^#U],L,0U'1KE@UQI\C[06Z;T;!VMCCH
M00!GH" #'\??"O7_  +XKO-(GTN[D19F6UGCA9DN(R3L92,YR,<=0>#S7NW@
MW]C2TUKP/IU[K6I:AHVO3QF6>WVHT<().P%2 0=N,@MUR.,5V-M^VEX'DM1)
M-8:U#-C)A$$;<^@/F8/XXKR[XO\ [6]WXRTBZT7PU8RZ187*^7->7#C[0Z'J
MH"DA >AY)(/:@!/V2O">C7WQ<UJ;S5U*/2(7?3Y9$"[_ -X$$VW)P=ON<%O8
M&O2_VK?BOXL^'G]C6GA^0Z=:WJ.TNH+$'8N"/W:E@0O'/KSQC!KY6^&?Q&U/
MX6^*[?7-,VR,JF*:WD)"3Q'&4./< @]B :^IHOVQ_ >KZ8$U71=4$A ,EJ]O
M%/'N_P!DEQGZD"@"A^R)<^+?$E]K_B'7[[4;^QEBCM[::^F=U=MQ+>7N.,#
MSCCGZUQ7[;H/_"?:"<<?V9U_[:O6VO[:JCQ;;%-">U\*PQ.C01E6N9&Q\C=E
M4#&-H/<\G@5Y]^T/\9/#_P 83HUSIFG7]C?6/F1NUT$VR1M@@?*QY!!_[Z-
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M&ZMI7@N(762.6-MK(P.00>Q!%?5?P_\ VU+:/3H;7Q?I=R]W&H4W^G!6$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR(]F%.2.&)KYSH **** "BBB@ HHHH **** "BBB@ K]./%G_(@:S_V#)O\
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MSH5:4;MSL >=N0H![\^E<G^VOXBAU#QQHVD1.'?3;-GFQ_"\K [3[[44_P#
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M:]I^./[3&A?%'P%+H6GZ7J-I</<1RB2Y$>S"G)'#$T >$>$O^1KT7_K]A_\
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M444 %%%% !7T#^Q/_P E4U7_ + LO_H^"OGZOH']B?\ Y*IJO_8%E_\ 1\%
M'VO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\_?ML?\ )*]*_P"PU%_Z(GKXHK[7_;8_Y)7I7_8:B_\ 1$]?%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'V!^S)\6/"'A#X60:=K.OVFG7JW4SF"9B&"DC!Z5\W_&#5K/7?B?XEU#3
M[A+JRN;UY(IH_NNIZ$5Q]% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Z=^S_\ %M/A)XR:[NXFGTF^C%O=B,9=!G*NH[D'MZ$]
MZ^M]<\0?";XQZ1!%JVKZ+J=O&?-C2XO/LTT1/7'S*ZYXSTSQ7Y]44 ??FB:E
M\'?@Q:7-QI6I:-IIF7,A@O#=3R*.P^9W(SV'%?*?[0/Q@'Q=\717%I%)!HUA
M&8;-)1AVR<O(P[%L#CT4=\UY?10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5] _L3_\E4U7_L"R_P#H^"OGZOH']B?_ )*IJO\ V!9?_1\%
M 'VO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\_?ML?\DKTK_L-1?^B)Z^**^U_VV/\ DE>E?]AJ+_T1/7Q10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >N?#S]F3Q
M1\2O"UMK^F7^D06=PSHJ7<TJR JQ4Y"QL.H]:Z7_ (8G\<?]!7P__P"!$_\
M\9KFOAY^TWXH^&OA:VT#3+#2)[.W9W5[N&5I"68L<E9%'4^E>\_L[_M">(OB
MWXNU#2M8LM+MK>WL6N5:QBD1RPD1<$M(PQACV]* /*_^&)_''_05\/\ _@1/
M_P#&:R_%/[)/B_PEX<U+6KS4M$DM;"![B5()YBY51DA08@,_4BOH/]I'XTZW
M\'H/#[Z-:Z?<G4&G$OVZ-WV[!'C;M=?[YSG/:OGSQ3^UMXO\6^'-2T6\TW1(
M[6_@>WE>""8.%88)4F4C/U!H \2HKJM-^%/C'6--AU"Q\,ZG=V4R;X[B*V9D
M=?4''2G>%OA/XO\ &M@]]HGA^\O[-<C[0B!48C@A2Q 8CT&: .3HJYJVC7^@
MZC+8:E9SV-[$=LEO<1E'4]L@\UUNC? [Q[K]M'<67A;4'@D&4>6,1!AZC>1Q
M[T <-174^)?A9XO\(6QN=8\.ZA8VH^]</"3$O..7&0/Q-<M0 45;TK1[_7;Z
M.RTVRN-0O)/N06L32.WT4 FNV;]G[XB+:_:#X3O_ "_0!2_3/W<[OTH \^KN
M/A7\(-9^+VH7UGHUS8VTMG$LLAOI'0$$X&-J-S7(:EI=YHU[+9W]I-97<1VR
M07$91U/NIY%?1O[#W_(U>)O^O*/_ -#H \?^*GPDUCX1:I96&L7-C<S7<)G1
MK&1W4*&*\[D7G(KB:^D?VW_^1T\._P#8/;_T8U>'^'OAWXG\66;W>C:!J&IV
MJN8VFM;=G0, "1D#KR/SH YZBM;Q'X1UKPA<10:WIESI<\J[TCNHRC,N<9 /
M;/>LF@ HHHH **** "BBB@ KZ!_8G_Y*IJO_ &!9?_1\%?/U?0/[$_\ R535
M?^P++_Z/@H ^UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G[]MC_DE>E?\ 8:B_]$3U\45]K_ML?\DKTK_L-1?^B)Z^** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KZ&_8E_Y*5K/_8(?_T=%7SS7T-^Q+_R4K6?^P0__HZ*@#J_VZ/^/3P9_OW?
M\H:^3J^L?VZ/^/3P9_OW?\H:^3J /T6^ :"3X+>%$/1K$ _F:XGQ!^TUX+^%
MFOKX0M=+NY++2PMK))9*OEP%1@HH)!;;T)]<]:[?X ?\D9\)?]>2_P S7Y_^
M,;EKSQ=KEPS;FEOIY"Q[DR,: /:OAA\0O!FL?&GQ!XV\:WRVSO-YFE0SP22*
MISA&.U2 415 SW.>H%>E?$W]L/3O#.L1V/ABRM_$,8C5Y;UIRL63SL4 9) Q
MD]CQCBO$/V?_ ($O\8=2NY[VZDL="L2JS2P@>9*YY"(3D#CDD@XR..>/=->T
MCX%_ Z=;/4M-M[W5E0.;:>-[V8@]"0V43/7!V^M 'I'P=^*%K\9_!<NJ'3A9
M,DSV=S:2.)4W!5)P<#*E7'4>HYKX<^,OA>W\)?%3Q'H]C%Y=K#=DP0J/N*X#
MJH]@& 'TK[F^#GQ)T?XF>';N]T+3)=*TVSNC:1PRHB$X16R%0D*/GZ9[5\D_
M&>6-OVGKYYL+"NIV8?<>-H2$'^5 'U-\*/AUH_P0^'AGN4CBODM?M>K7S#+$
MJNYES_<7D >V>I->5I^W#8MKZQ-X7F31C)M-S]J!G"9^_P"7MQG'\.[\:]D^
M/,<LGP<\7"$D.+!R<#^$8+?H#7YR4 ?;G[2UOX&\:^ [B>;7-(B\06D)N-.<
MW2":3'S&+;G)##@ ]"0:\Y_8>_Y&KQ-_UY1_^AU\_7OA/7--M(KJ[T;4+6UE
M02QSS6KHCH1D,&(P000<U] _L/?\C5XF_P"O*/\ ]#H [OX\?"'4/BY\7/#=
ME!NM]+M[ O?7N.(D\UOE'J[8( ^IZ UVWC_QWX;_ &=?A_:VMI;1JZ1F'3=,
M0X:9AU9CUP"<LQZY]378>,_'^A> +2TN==OX[*.ZG2WB#<EF8@$X_NKG)/8?
MA7D_[6?PL_X3+P:OB*PBWZKHJ,[A1S+;=7'_  '[P]MWK0!\;^+/%>I^-M?N
M]9UBY:ZOKEMS,>BCLJCLH' %9%%% !1110 4444 %%%% !7T#^Q/_P E4U7_
M + LO_H^"OGZOH']B?\ Y*IJO_8%E_\ 1\% 'VO1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\_?ML?\ )*]*_P"PU%_Z(GKX
MHK[7_;8_Y)7I7_8:B_\ 1$]?%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5]#?L2_\E*UG_L$/_Z.BKYYJYI6M:CH
M<[3:;?W.GS,NQI+69HF*Y!P2I'&0./:@#ZE_;H_X]/!G^_=_RAKY.K0U;Q'J
MVO"(:GJE[J(BSY8N[AY=F<9QN)QG _*L^@#]%_@!_P D9\)?]>2_S-?GQXB_
MY&#4_P#KZE_]#-6K/QOXBTZUCMK77]4MK>,;4AAO)$11Z !L"L9W:1V=V+.Q
MR68Y)/K0!]8?L4>-M.@T[6?"T\R0ZA)<_;K=7('G*456"GN5V X]#GL:Z3XR
M?LKO\2_'$OB*QUU-.:[6,74,\!DP44(&3!'\*C@]QUYX^+89I+>5)8G:*5&#
M*Z'#*1T(/8UU4OQ<\;S61M)/%VM/ 1@JU_*21Z$[LXH ^[/A#X:\-_#[2+GP
MAH>I)J%[IS+/J!W R>;)G#.!PI(3 7J HSZGY!_:ITJ;2OC=K<CH4CO$@N86
M_O*8E4G_ +Z1A^%>9Z9X@U31)99=.U*\L)9>)'M9WC9^_)4C-,U76]1UV=)M
M2O[K4)D78LEU,TK!<YP"Q/&2>/>@#[Y^"OQ7TGXP^"([6ZEBDUA+;[/J5A*?
MF?Y=K.!W1NO'3.#7$G]BGPO_ ,)"+L:O?C2O,WG3B%SC.=GF]=O;IG'?/-?&
MUG>W&G7,=S:3RVMQ&<I+"Y1U/J".1752_&+QU-;B%O&&MF/&.+^0$CW(.30!
M]A_M$_%C2_AOX$N]%LYXQKE];FTMK2!ANMXRNTR,!]T!3\OJ<8Z''D7[#W_(
MU>)O^O*/_P!#KYMN+B6[GDGGE>::1BSR2,69B>I)/4U:TK7M3T*2233=1N].
M>0;7:TG:(L/0E2,T ?0G[;Y/_"9^'1DX&GL<?]M#7K?[+GQ/7X@^ 1I5_()=
M7T=5MI@YR9H<8C?GKP-I]UR>M?#^JZYJ6NRI+J6H76H2(NU7NIFE*CT!8G I
M-*UK4=#G:;3;^YT^9EV-):S-$Q7(."5(XR!Q[4 >A?M"_"UOA=X_N(+:,KHU
M_FZL& X52?FC^J$X^A4]Z\QK1U;Q)J^O+&NIZI>ZBL9)07=P\H4GKC<3BLZ@
M HHHH **** "BBB@ KZ!_8G_ .2J:K_V!9?_ $?!7S]7T#^Q/_R535?^P++_
M .CX* /M>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y^_;8_Y)7I7_8:B_\ 1$]?%%?:_P"VQ_R2O2O^PU%_Z(GKXHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OH']B?_DJFJ_\ 8%E_]'P5\_5] _L3_P#)5-5_[ LO_H^"@#[7HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?OVV/^25Z5
M_P!AJ+_T1/7Q17VO^VQ_R2O2O^PU%_Z(GKXHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OH']B?\ Y*IJO_8%
ME_\ 1\%?/U?0/[$__)5-5_[ LO\ Z/@H ^UZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
M7_R:@_\ BZ/95/Y7]P>TAW1PM%=U_P */\;?] 7_ ,FH/_BZ/^%'^-O^@+_Y
M-0?_ !='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_ )-0?_%T?\*/\;?] 7_R:@_^
M+H]E4_E?W![2'='"T5W7_"C_ !M_T!?_ ":@_P#BZ/\ A1_C;_H"_P#DU!_\
M71[*I_*_N#VD.Z.%HKNO^%'^-O\ H"_^34'_ ,71_P */\;?] 7_ ,FH/_BZ
M/95/Y7]P>TAW1PM%=U_PH_QM_P! 7_R:@_\ BZ/^%'^-O^@+_P"34'_Q='LJ
MG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\ &W_0%_\ )J#_ .+H]E4_
ME?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\ H"_^34'_ ,71[*I_*_N#
MVD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P! 7_R:@_\ BZ/95/Y7]P>T
MAW1PM%=U_P */\;?] 7_ ,FH/_BZ/^%'^-O^@+_Y-0?_ !='LJG\K^X/:0[H
MX6BNZ_X4?XV_Z O_ )-0?_%T?\*/\;?] 7_R:@_^+H]E4_E?W![2'='"T5W7
M_"C_ !M_T!?_ ":@_P#BZ/\ A1_C;_H"_P#DU!_\71[*I_*_N#VD.Z.%HKNO
M^%'^-O\ H"_^34'_ ,71_P */\;?] 7_ ,FH/_BZ/95/Y7]P>TAW1PM%=U_P
MH_QM_P! 7_R:@_\ BZ/^%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?X
MV_Z O_DU!_\ %T?\*/\ &W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W
M_0%_\FH/_BZ/^%'^-O\ H"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"
M_P#DU!_\71_PH_QM_P! 7_R:@_\ BZ/95/Y7]P>TAW1PM%=U_P */\;?] 7_
M ,FH/_BZ/^%'^-O^@+_Y-0?_ !='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_ )-0
M?_%T?\*/\;?] 7_R:@_^+H]E4_E?W![2'='"T5W7_"C_ !M_T!?_ ":@_P#B
MZ/\ A1_C;_H"_P#DU!_\71[*I_*_N#VD.Z.%HKNO^%'^-O\ H"_^34'_ ,71
M_P */\;?] 7_ ,FH/_BZ/95/Y7]P>TAW1PM%=U_PH_QM_P! 7_R:@_\ BZ/^
M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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MH_QM_P! 7_R:@_\ BZ/^%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6OH']B?\
MY*IJO_8%E_\ 1\%><?\ "C_&W_0%_P#)J#_XNO:_V2_ASXB\(?$;4;S5M/\
MLEL^E20J_GQOES-"0,*Q/13^5)TYI7<6-3B]$SZSHHHK,L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7XC?\@2#_ *^%_P#06KSF
MO1OB-_R!(/\ KX7_ -!:O.:]O"?PCR\1_$"BBBNTY@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOAS_ ,AN?_KW;_T)
M:Y6NJ^'/_(;G_P"O=O\ T):Y\1_"D:TOC1Z-1117SY[ 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!ROQ&_P"0)!_U\+_Z"U><UZ-\
M1O\ D"0?]?"_^@M7G->WA/X1Y>(_B!1117:<P4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5U7PY_Y#<__ %[M_P"A+7*U
MU7PY_P"0W/\ ]>[?^A+7/B/X4C6E\:/1J***^?/8"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"QESLG@;<I(ZCV([@\BN-^*?QOT+X17&G0ZQ::C<M?*[QFQCC< *0#NW.O\
M>'3-:N48KF;T(46W9;GH=%>!?\-H^"?^@7K_ /X#P?\ QZIH/VRO LJY:TUJ
M$YQM>VC)^O$AK+V]+^8OV4^Q[O17#^!/C3X0^(TYMM&U97O@-WV.X0Q2D=R
MWWO?;G'>NXK524E=,S:<79A1115""BBB@ HHHH **** "BBLK6?%.D>'[FPM
M]1U""UN+^9;>UA=OWDTC$* JCD\D9/0=\4F[;A:YJT444P"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HKQ.\_:T\(6/B.?19-.ULW4-VUFSK!#L+A]A
M(/FYQD>GX5[941G&?PLJ491W044459(445%=7<%C;2W%S-';V\2EY)96"HBC
MJ23P!0!+16?H.OZ?XGTJ'4M+NDO;"8L(YX\[7VL5.,]1E3SW[<5YKXZ_:(TW
MX=^/H/#>L:5=0Q2^4ZZB'7RO+?C?CKA2&!_W342G&*NWH4HN3LD>M44BL'4,
MI#*1D$'((K,\2>*-*\(:5+J6LW\.GV<8YEF;&3Z =6/L,DU3:6K)W-2BOF#P
M%^T?KWQ!^.=CI5I(MMX6NYI4CM'@3S"BPN06;D@DJ#@'C.*^GZSIU(U$W$N<
M'!V84445J0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?^0W/_P!>[?\
MH2URM=5\.?\ D-S_ /7NW_H2USXC^%(UI?&CT:BBBOGSV HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_R!(/^OA?_ $%J\YKT
M;XC?\@2#_KX7_P!!:O.:]O"?PCR\1_$"BBBNTYC,\3>(+7PIX>U'6+TD6MC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS0@B-KZUCF* ]=NX'&<#IZ5K44FD]PO;8S]%\/:7X;M7MM(TVSTJV=S(T-E
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M"M<7=C%+(0. "S*3Q6]13:3W$FUL065C;:;:0VMI;Q6MK"H2*"! B(HZ!5'
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M2DY-R844459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?^0W/_
M ->[?^A+7*UU7PY_Y#<__7NW_H2USXC^%(UI?&CT:BBBOGSV HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_R!(/\ KX7_ -!:
MO.:]&^(W_($@_P"OA?\ T%J\YKV\)_"/+Q'\0****[3F"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\
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M31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B:/\
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M #WM/^^V_P#B:/\ A7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\
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M175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\ Q-'MZ7\P>RGV.5HKJO\
MA7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^)H]O2_F#V4^QRM%=5_PKG4O^>]I_
MWVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?S![*?8Y6BNJ_X5SJ7_/>T_[[;_XF
MC_A7.I?\][3_ +[;_P")H]O2_F#V4^QRM%=5_P *YU+_ )[VG_?;?_$T?\*Y
MU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7.I?\][3_ +[;_P")H_X5SJ7_ #WM
M/^^V_P#B:/;TOY@]E/L<K175?\*YU+_GO:?]]M_\31_PKG4O^>]I_P!]M_\
M$T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B:/\ A7.I?\][3_OMO_B:/;TO
MY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\ Q-'MZ7\P>RGV
M.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^)H]O2_F#V4^QRM%=5_PK
MG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?S![*?8Y6BNJ_X5SJ7_/>
MT_[[;_XFC_A7.I?\][3_ +[;_P")H]O2_F#V4^QRM%=5_P *YU+_ )[VG_?;
M?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7.I?\][3_ +[;_P")H_X5
MSJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175?\*YU+_GO:?]]M_\31_PKG4O^>]I
M_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B:/\ A7.I?\][3_OM
MO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\ Q-'M
MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^)H]O2_F#V4^Q
MRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?S![*?8Y6BNJ_
MX5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")H]O2_F#V4^QRM%=5_P *YU+_
M )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7.I?\][3_ +[;
M_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175?\*YU+_GO:?]]M_\31_P
MKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B:/\ A7.I
M?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?
M;?\ Q-'MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^)H]O
M2_F#V4^QRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?S![*
M?8Y6BNJ_X5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")H]O2_F#V4^QRM%=5
M_P *YU+_ )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7.I?\
M][3_ +[;_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175?\*YU+_GO:?]
M]M_\31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B
M:/\ A7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=
M2_Y[VG_?;?\ Q-'MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_SWM/^
M^V_^)H]O2_F#V4^QRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;?_$T
M>WI?S![*?8Y6BNJ_X5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")H]O2_F#V
M4^QRM%=5_P *YU+_ )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]CE:*Z
MK_A7.I?\][3_ +[;_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175?\*Y
MU+_GO:?]]M_\31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM
M/^^V_P#B:/\ A7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_
M !-'_"N=2_Y[VG_?;?\ Q-'MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<
MZE_SWM/^^V_^)H]O2_F#V4^QRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[V
MG_?;?_$T>WI?S![*?8Y6BNJ_X5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")
MH]O2_F#V4^QRM%=5_P *YU+_ )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'
MLI]CE:*ZK_A7.I?\][3_ +[;_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<
MK175?\*YU+_GO:?]]M_\31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BN_LOA
MS:_9D^USS?:.=_DN-G7C&5STQ4__  KG3?\ GO=_]]K_ /$UD\7274OZO,\Y
MHKT;_A7.F_\ />[_ .^U_P#B:/\ A7.F_P#/>[_[[7_XFCZW2']7F><T5Z-_
MPKG3?^>]W_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W
M_P!]K_\ $T?\*YTW_GO=_P#?:_\ Q-'UND'U>9YS17HW_"N=-_Y[W?\ WVO_
M ,31_P *YTW_ )[W?_?:_P#Q-'UND'U>9YS17HW_  KG3?\ GO=_]]K_ /$T
M?\*YTW_GO=_]]K_\31];I!]7F><T5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y[W?_
M 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\
MQ-'UND'U>9YS17HW_"N=-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UN
MD'U>9YS17HW_  KG3?\ GO=_]]K_ /$T?\*YTW_GO=_]]K_\31];I!]7F><T
M5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?
M^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\ Q-'UND'U>9YS17HW_"N=-_Y[W?\
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M-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UND'U>9YS17HW_  KG3?\
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MW_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\
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M %\@]FCZJ_X7;X+_ .@U_P"2L_\ \11_PNWP7_T&O_)6?_XBOE6BCZE3[O\
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M4?\ "[?!?_0:_P#)6?\ ^(KY5HH^I4^[_KY![-'U5_PNWP7_ -!K_P E9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !"_X53\.-;\5_V?_:G]FQI)]D\[R?,W2*F-^UL?>ST/2OE'_AY?_P!4X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .&^-O\
MR3#6O^V/_H^.OE6OJKXV_P#),-:_[8_^CXZ^5:]O!?PWZ_Y'13V"BBBO0-0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"YH^L7F@ZE!?V$[6]U
M"VY'7^1]0>XKZD^&WQ)L_'VF_P -OJD*C[1;9_\ 'U]5/Z=#V)^3ZN:/K%YH
M.I07]A.UO=0MN1U_D?4'N*Y:]!5EYD2CS'VO17&?#;XDV?C[3?X;?5(5'VBV
MS_X^OJI_3H>Q/9UX$HN#Y9;G,U;1A1114B"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6IV&EVBE8+9+)&" L6(RT9/4D\GO6M_PU!\<O^AFU7_P B_^-4 ?J=17S/\
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MGK4TMWK-YX:NWN))$"N[F*0<J .>G05\#_LP:/?P?'_P/)+97,<:Z@I+/$P
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M\E2\,_\ 8&'_ */DKH_V1OC=\3O'?QCMM*\5:U?7VDM9SR-#<6J1J74#:<A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGF;</$3T#CICMD?D.*\^K>$XU%S192:>J"BBOI.+]GOPN\2,9-0R0#_KU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KB@"Q1110 444QIHTE2-I%61\[4) +8ZX'?% #Z*** "BD9@BEF(50,DDX
M%,AGCN8EDAD66-NCHP(/XB@"2BBB@ HIC31I*D;2*LCYVH2 6QUP.^*?0 44
M44 %%,AFCN(EDBD66-NCH00?QI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,E=HXG94,K*I(12 6/H,\?G7Q]X)\/^+?VD/VCM,^(NN>'+GPMX3\
M,CRK."^!66>2-G*@9 W'S&W,P&T!0N2>:^Q** "BBB@ HHHH **** "BBB@
MHHHH **** &2NT<3LJ&5E4D(I +'T&>/SKX^\$^'_%O[2'[1VF?$77/#ESX6
M\)^&1Y5G!? K+/)&SE0,@;CYC;F8#: H7)/-?8E% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <-\;?^28:U_VQ_\ 1\=?*M?57QM_Y)AK7_;'_P!'
MQU\JU[>"_AOU_P CHI[!1117H&I;TG_D*V7_ %V3_P!"%?7?CN:2V\%:[+%(
MT4J64S*Z'#*0AP01T-?(FD_\A6R_Z[)_Z$*^S-9TN+6])O-/G9TANH6A=HR
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MCSX_ATW27\/6<H>^N@/M.T_ZJ+K@^[>GIGU%?/-1@XN,&WU"FK(*U1XLUL#
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M,!8XKXHH'8"3 KZ@^*G_ "3S7?\ KV/\Q5XEWG3?]=!SW1\CT445Z9J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %S1]8O-!U*"_L)VM[J%MR.O\
MCZ@]Q7U)\-OB39^/M-_AM]4A4?:+;/\ X^OJI_3H>Q/R?70^ K+6[[Q19KH!
M=-11MRRCA8U[E_\ 9]<]<XYS7)B*,:L;O1KJ1**:/L*BHX!(L$8F97F"C>R#
M"EL<D#)P,^]25\^<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>)_M)_M6>&?V
M;M/L4U&VFUG7K]2]KI-JX1C&#@R2.<[%SD X))! '!(XO]G7]O+PS\=?%,?A
MF^T:;PGKUP&-G%+="Y@N2 2463:A#X!(!7!P<'. 0#Z@HHHH **** "L/QU_
MR)'B'_L'7'_HIJW*P_'7_(D>(?\ L'7'_HIJ /QO\.>'=0\6Z]8:+I-O]KU.
M_F6WMH-ZIOD8X4;F( Y[D@5ZY)^Q9\9HHV<^#"0HR0NI6;'\ )LFN7_9R_Y+
MSX!_[#-M_P"C!7ZZRRI!&TDCK&BC)9C@ >YH _(70/&WQ"^ 'BQK>VO-3\.:
MG9N//TVYW+&XZ@21'Y64YSG'0Y![U^HGP4^*%K\8?AMH_BBW18)+J,I<VZG(
MAG4[9$^F1D9Z@@]Z^$?V\_'GASQM\5=/CT"Y@U"73+'[+>WEL0R-)YC,(PPX
M;:#R1D L1U!KZ1_X)]V-U:? 226X5A#<ZO<RVQ8<&,+&A(]MZ/\ B#0!\+6'
M_)>K?_L95_\ 2JOU_K\<K[5HM ^+]QJ<R/)#9:ZURZ1XW,J7&X@9[X%>^>+_
M (P_M#_%RWG\2>'-*U[1O"I):UAT2V8#8#][S /,E/J1\N0< <B@#]$:*_.?
M]GC]L[QAH7C/2]'\8ZLVN^';Z=+>6>^P9[0N<"02 ;F )!(;/&<8-?>?Q)\?
M:;\+_ ^K^*-5W&RTZ'S#&F-TC$A41<]V8JH^M '2T5^9UU^TK\</CAXIFM/"
MMQ?VY*LZ:7X?AVB&//WFDQN[@;F8#)XQG%9^M_%_]H'X-:G:-X@UGQ!ILD^7
MA36$$\4P'W@/,#*<9&0#D9'3(H _4&BO)/V9/C@WQW^' UF[M8[+5[.X:SOH
M82?+,@56#H"20K!AP>A!&3C->#?M5?MB^(?"WC2\\$>!"EG<696&\U-H1+,9
MB 3'"K94  @$D$DYQC&2 ?:E%?G//IW[5T5@=;DD\5"%4WE%N8]^,?\ /N&W
M9QVV9_&NO_9A_;1\1ZGXTT[PCX]N(]1M]0D6UM=3:-8IH9B<(LF,!E8X7.,@
MD9)YH ^Z:*Q?&GB_3/ /A74_$.LS_9],T^$S3.!DXZ!0.[$D #N2*_._Q?\
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MWQ?\:?V9X&:\TJUFE9;'3-)@#W4BC.&D?!). 2<$*.?3- 'Z245^8/B3Q_\
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M;3QQX2T;Q!8AEM-3M(KN-7^\H=0VT^XS@^XH V:^<_V]_P#DWN[_ .PC:_\
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MR#7P99_'?X[?&+Q1*N@:SK=W>8\S[#H2&**%,\95!@*"0-SD^Y- 'UI^W_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&_.O ;:)9KB*-W$2NX4NW103U-;X?5SJ/JRH=6>M?!7X5IKCIKVK1!["-O\
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M*>J6NL^/=6O+*=+FUE:,I*G1L1J#^H->;1BUB)MHRBGSLY2OJ/X%?\DVT_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%:GAKPU?^+-6AT[3H3+/)R2>%1>[,>P'^>:3:2NP#PUX:O_%FK0Z=
MIT)EGDY)/"HO=F/8#_/-?5/@/P'8> ])%K:@2W,F#<73##2M_0#L/ZY-'@/P
M'8> ])%K:@2W,F#<73##2M_0#L/ZY-=-7A8C$.J^6.QS3GS:(****XC,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /SB_P""FWPK\0'QSI'CV"UFO?#KZ='I\\\:
MEA9RI)(P#X^ZK"08/3=N'IGQ?]BKX5^(/B%\>/"^HZ7:S+I6@W\.HW^H!2(H
MEC;>(RW3<Y&T+U()/0$C]A&4.I5@&4C!!Z&H[>VAM(A%!$D,2]$C4*H_ 4 2
MT444 %%%% !6'XZ_Y$CQ#_V#KC_T4U;E8?CK_D2/$/\ V#KC_P!%-0!^-N@:
M#?\ BC6K+2-+MVN]1O95@MX%(!D=C@*"2!R?4UZM;_L=?&*YD")X*G#'O)>6
MR#\VD KG_P!G+_DO/@'_ +#-M_Z,%?KQ0!^<WPX_X)_>.M>U: ^+9+;PQI*L
M#,$G2XN77NJ!"4![9+<=<-TK] _"?A;3?!'AO3M!T>V%IIFGPK!!$.<*.Y/<
MDY)/<DGO6M10!^.5_I<>N?%^XTV7/E7FNM;M@X.'N-I_G7[#65E!IMG!:6L*
M6]M!&L4448PJ(HPJ@=@  *_(>P_Y+U;_ /8RK_Z55^O] 'Y ?'ZSATWXX>.X
M+9!#$FM715%X"YE8X'H.:_6+Q##H=WX3FD\41:?<:-' )[K^U41[=549+.'&
MW ZY-?E)^T;_ ,EY\??]AFY_]&&OM3]ON_U&S^ &EQ6;LEG=:I;17NP_>C$4
MCJI_V=ZH?J%H YJY_:]^"_PAO]3'P^\'M=W-V5$\^FVR6-M-MSM&6^; W'HF
M.:\%_:'_ &F]?^/WA^QAN/#%OHN@V=YYL4\9DF<R[&&PS$*IX).T*#\OM76?
ML)I\-W\0:\?&0THZVJPG3/[9*>3M^;S/+W_+YF=GOCI_%73?MZ?&?PIXJT/0
M?!OAK4+759+.\^VW,M@P>"#;&R)&&7Y23O8D#IM&>M '7?\ !-PG_A!_&(R<
M#48CC_ME7A?[8'P;\1?#KXL:QXH2">;0M8O&U"VU. ,5AE=MS1NP^XP8G;ZC
M&.00/</^";4ZMX1\:0@_.E] Y'L8V _]!-5?B)^WGJWA/QQJ/AC4/ -K;PV%
MZ;2^6XO3<-)$'PQ4;%'S)R,Y'(ZB@#RSP5_P4 ^(WAQ(H-8ATWQ/ H +W,/D
MSD#_ &X\+^)4U[U\ _VH_A5XV\21:>/"5EX'\3ZC.65Q;1&.YG9LX$ZJI+L3
M_&HR3@$D@5H:[X,_9D^)VA_VU)<>%].CF3S#<65^FGS1DCG?$K+A^>CJ3D]*
M^ O$.C6(^(][I7@RYN=5L#J1M])GP1-.IDQ$> /F/'.!GT'2@#[M_P""B6O7
M&G_"#1]-A8K%J&K()B/XD2-V"G_@6T_\!KYB_99_:!T'X 7FOWVI>'[G6-0U
M".*&">W=$,,:EBZY;^\2A/\ N"OKW]M[P%?^,O@!)<0[9[[0;B+4YA&O,B*C
M)+CT $A?Z(:^6?V-/B/X#\)>(-8T?Q]8:9)9:FL3VFHZG:)-';RIN!1BRG:K
MAAST!09ZYH W/VC/VO/#7QS^',GA^+PM>V-_'<Q7-K=W$L;B)E.&Z<\H6'XB
MNC_X)MZ]-'XC\9Z*7)MYK2"\"$\!D<H2![B09^@KO/CK\>/@]\,]-L!X7\-^
M#/&FK7$PWV]E!;R0Q0@'<S2QJP#9V@+UY)[<]Y^RM\2]&^+>E:MK>D?#NR\%
M);.MHUS:"(BY8C<R*RQH2%^0G(_B6@#WFBBB@ K\H_VO?^3C_&W_ %\1?^B(
MZ_5RORC_ &O?^3C_ !M_U\1?^B(Z /TY^&__ "3OPM_V"K7_ -$K7RC_ ,%*
M?^0)X#_Z^+S_ -!BKZN^&_\ R3OPM_V"K7_T2M?*/_!2G_D"> _^OB\_]!BH
M M_\$W_#5G'X.\5^(/*0W\U^MAYIY98TC5]H] 3)D^NT>@KUC]LSPO9^)?V>
MO$LES"KSZ:L=_;2'K'(K@$CZHSK_ ,"KY4_8E_:)T/X2WFL>'?%%P;'2-4D2
MY@O]I9()E4JP<#)PP"C('!7G@Y'J7[8G[47A'5_AC=^$?"FKP:[J&KM&EQ-:
M$M%;P*P<Y?H68J%P,X!;..,@'D/_  3[U6:Q^.TMJC'R;W2;B*1>QVLC@_4%
M?U-?I+7Y_?\ !.GP+<W_ (\U[Q;)$PT_3K(V,<A& T\K*Q /?:B'([;U]:_0
M&@#F/BCK$WA[X9^+M5MFV7%CI%W=1L.S)"[ _F*_+S]EWPS9^,/C]X-TS4(D
MGM&NVG>*3[K^5&\H!]03&.._2OU6\5:%'XH\,:QHTK;8M1LYK-V]!(A0G]:_
M)/P3KFI? ;XS:=?ZA9N+[P]J)2[M>C,H)255SZJ6P?<&@#]?V4.I5@&4C!!&
M017X\_&_PU;>#OB_XPT:R0165IJDZ01KT2,N2J_@"!^%?H]=_MA_"BV\*/KB
M>*(;C$6]=.C1OMC-C/E^60"#GC)^7WQS7YB^-_%5QXX\8ZWXANT6*XU2\EO'
MC0Y5"[EMH]AG'X4 ?L9:6EG?^%+:WU"&"XLI+1!-%<H&C9=@R&!X(^M?+.N_
MM-_ ;X/>)[N\\&^%[?4=<\MK9[OP_91V]N5R"R^9\H()4?,BL#CK7I/[4U_J
M.G?LK^()=,=HYFL;6*5T.&$+RQ)*!]49@?8FOBS]C=/ ,GQ79?'PL#;?8V-A
M_:I7[+]H#+]_=\N=N[&[C/OB@#H?CK^V#KWQQ\#ZAH5MX0@TOP^9(I+BZ+R7
M,L960%#Y@"JF3@<J>N!76?\ !-PG_A-O&(R<'3X3C_MH:[G]M;XS^"K?X2S^
M!/#^H:??ZC?3P[K;2V1X[6*.02$L4^522J@+UY)Q7 _\$WIU7Q_XNA)^=],C
M<#V$H!_]"% &S_P4L_X_OA]_USO_ .=O7IO_  3X_P"2#7'_ &&;C_T7%7FO
M_!2R)A<?#R7'R%;]<^X-O_C5[]B/XY>"/ OPHN="\0:_!I>JG5W>.VE1RTJR
M+$J%=JG/S CVQDX% 'TC\:+OX;:)X=&K?$BTT:>PB)BA;4[1+B0L>=D2E2Q8
MXSA?3/09KYLE_;T\"_#W1X]$^'_@2Y.FVY;R8YY4LX068LS!5$A.22><'GM7
M$_\ !1F_U&3XK>'[.9V_LN+1UEMH\_+YC32"1O\ >(2,'V5:]6_8VU'X2:'\
M(['4IKK0+#Q1 TC:G<ZI+$EU&P<[2&<Y";=F-O'XYH ^/?CO\4-<^+_C:/Q%
MKVD0Z+<26B10P012(KPJS;7RY)8Y)&X8!V].*_2;]ELEOV?/ I))_P")<HY_
MWFKX!_; ^*6D?%GXR7&I:#+]ITNRM(M/BNMI GV,[,Z@\XW.0#W SWK[Y_93
MG6X_9X\#,AR!8[/Q61@?U!H ]8KYS_;W_P"3>[O_ +"-K_Z$:^C*^<_V]_\
MDWN[_P"PC:_^A&@#Y_\ V(/"2>//!7QD\/. 3J6F6UNA/\+D7.QOP;:?PK@?
MV/OB5#\*?C$]SJ;_ &?3[G3KNWN_,.T+L0S#.>^Z$+_P*O9/^":?_']\0?\
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M1@<!?X03GDX7H?\ @H7"TOP)LF4<1ZW;LWT\J8?S(J3_ (>#_"__ )]]?_\
M */_ ..5WG[3G@N;XH_ 'Q#9:="\][]G34+2)5R[M&PDV@>K*&4#U- 'S9_P
M37D \0^.H^=S6MJP_!Y/\:]-_P""B<JQ_ _2E/5]?@ _[\7!_I7R_P#L:_&/
M2O@_\49I=?N/LFB:K:&SFN=I987W*T;L!DXR"IXXW9Z"N\_;G_: \-_$RW\/
M^&_"NHIJ]G9RM?7=W""(O,*[8T4D#) 9R<<?,!G.< &__P $U+=FU+Q_/@[%
MALDSCC),Y_I7W!J&H6NDV-Q>WMQ%:6=O&TLT\SA4C0#)9B>  .]?,_\ P3^\
M W'A?X1WNN7D3PS:_>>="KC!-O&-B-CW8R$>H(/>O'OV[OV@+O7?$L_PZT>X
M,6C:<RG4GB;_ (^KC ;RR1_"F1D?W\Y^Z* .9_:J_:QO/B_>S>&/#,DMKX.B
MDPSJ"LFI,#PS#J(\\JG?@MS@+[3^QA^RO<>"F@\>^+K;RM:EB/\ 9NFRK\UH
MC#!ED!Z2,#@+_""<\G"_./[,?C3X7?#?6I/$?CFVU+4]9MI!_9MM;6JR00$<
M^<V7&Y\_=&,+C/)QM^L_^'@_PO\ ^??7_P#P"C_^.4 ?3->+?M)_M*Z3\!M
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MN ;JN<#D8/O78?LTNTGP$\"N[%W;2XB68Y)..IH Z+7/BKX*\,:G+IVL>,-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W@OX;
M]?\ (Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%:GAKPU?\ BS5H=.TZ$RSR<DGA47NS'L!_GFDVDKL \->&K_Q9JT.G:="9
M9Y.23PJ+W9CV _SS7U3X#\!V'@/21:VH$MS)@W%TPPTK?T [#^N31X#\!V'@
M/21:VH$MS)@W%TPPTK?T [#^N3735X6(Q#JOECL<TY\VB"BBBN(S"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAM?V>[W7+BW\03:V=4CBC*RVHA\O86.1AFSG?^E>WT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^W;\)M#O/":?%))M4AUJZ:TM/L<Y5(4C*L?FC*;U<=P6X.>*[/]D/\ 9O\
M#/AC0O"OQ(M;[5I-<O\ 3-TMO--$;8>8/FVJ(PW;C+'\:N_M[7,5Y^SRL\$J
M3PR:G:LDD;!E8$/@@C@BO2?V9O\ D@/@/_L%1?RH ^6/'7_*1C3O^OVQ_P#2
M-*^]*^"_'7_*1C3O^OVQ_P#2-*^]* &R1K*C(ZAT8$,K#((]#7P)^Q@&\'_M
M2^-?#5N2EB(KZU\K.1^YN5"'\ &'XFOO34M1MM(TZZOKR9;>TM8GGFF<X5$4
M$LQ]@ 37PC^PM:3>-?C[XX\9F)EMA!/(21]V6YN ZC/^ZDE &C^V)_R=C\+?
M^N>G_P#I?)1^UU\,M4^"_P 2-,^,G@I3:H]VKWZQK\L-R>-[ ?\ +.895O\
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M3[?NY!) Q[ 4>(_A]X>\7:UH6KZOID=[J.ARM/IT[NX-N[%26 ! /*)U!Z4
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MD'@.P].:Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .&^-O_ "3#6O\ MC_Z/CKY5KZJ^-O_ "3#6O\
MMC_Z/CKY5KV\%_#?K_D=%/8****] U"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***U/#7AJ_\6:M#IVG0F6>3DD\*B]V8]@/\\TFTE=@'AKPU?^+-
M6AT[3H3+/)R2>%1>[,>P'^>:^J? ?@.P\!Z2+6U EN9,&XNF&&E;^@'8?UR:
M/ ?@.P\!Z2+6U EN9,&XNF&&E;^@'8?UR:Z:O"Q&(=5\L=CFG/FT04445Q&8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W
M@OX;]?\ (Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116IX:
M\-7_ (LU:'3M.A,L\G))X5%[LQ[ ?YYI-I*[ /#7AJ_\6:M#IVG0F6>3DD\*
MB]V8]@/\\U]4^ _ =AX#TD6MJ!+<R8-Q=,,-*W] .P_KDT> _ =AX#TD6MJ!
M+<R8-Q=,,-*W] .P_KDUTU>%B,0ZKY8['-.?-H@HHHKB,PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6W3<"@.01@YXXH ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  "B_P#B:/\ A!/#7_0O:5_X!1?_ !-;M%'/+N%V87_"">&O^A>TK_P"B_\
MB:/^$$\-?]"]I7_@%%_\36[11SR[A=F%_P ()X:_Z%[2O_ *+_XFC_A!/#7_
M $+VE?\ @%%_\36[11SR[A=F%_P@GAK_ *%[2O\ P"B_^)H_X03PU_T+VE?^
M 47_ ,36[11SR[A=F%_P@GAK_H7M*_\  *+_ .)H_P"$$\-?]"]I7_@%%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!*D\J?IBL+P9\!_A]\/=134/#_A/3M/OXP1'=B,R31Y!!VNY++D$C@C@XZ4
M=[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<U?1%% 'SO\ :_&7_/;7?^^YJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\
MON:C[7XR_P">VN_]]S5]$44 ?._VOQE_SVUW_ON:C[7XR_Y[:[_WW-7T110!
M\[_:_&7_ #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,
MO^>VN_\ ?<U?1%% 'SO]K\9?\]M=_P"^YJ/M?C+_ )[:[_WW-7T110!\[_:_
M&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\ /;7?^^YJ/M?C+_GMKO\
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MJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\ ON:C[7XR_P">VN_]]S5]$44
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M:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\ ?<U?1%%
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M^,O^>VN_]]S5]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% 'SO\
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M &OQE_SVUW_ON:C[7XR_Y[:[_P!]S5]$44 ?._VOQE_SVUW_ +[FH^U^,O\
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M )[:[_WW-7T110!\[_:_&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\
M/;7?^^YJ/M?C+_GMKO\ WW-7T110!\[_ &OQE_SVUW_ON:C[7XR_Y[:[_P!]
MS5]$44 ?._VOQE_SVUW_ +[FH^U^,O\ GMKO_?<U?1%% 'SO]K\9?\]M=_[[
MFH^U^,O^>VN_]]S5]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% '
MSO\ :_&7_/;7?^^YJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\ ON:C[7XR
M_P">VN_]]S5]$44 ?._VOQE_SVUW_ON:C[7XR_Y[:[_WW-7T110!\[_:_&7_
M #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\
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M[G;&6=CPJ*.[$X %?#GC/_@HQXKO=1<>%_#^F:7IZM\AU /<3N/4[655SUP
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M)(Z!/+1<$NB'.5/:O<:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8O\ XJOCFBCZC'^8/9H^QO\ A._#7_0PZ5_X&Q?_ !5'_"=^&O\ H8=*_P#
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M_@;%_P#%4?\ "=^&O^AATK_P-B_^*KXYHH^HQ_F#V:/L;_A._#7_ $,.E?\
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MB_\ BJ^.:*/J,?Y@]FC[&_X3OPU_T,.E?^!L7_Q5'_"=^&O^AATK_P #8O\
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MU_T,.E?^!L7_ ,51_P )WX:_Z&'2O_ V+_XJOCFBCZC'^8/9H^QO^$[\-?\
M0PZ5_P"!L7_Q5'_"=^&O^AATK_P-B_\ BJ^.:*/J,?Y@]FC[&_X3OPU_T,.E
M?^!L7_Q5'_"=^&O^AATK_P #8O\ XJOCFBCZC'^8/9H^QO\ A._#7_0PZ5_X
M&Q?_ !57],US3=:$AT_4+6_$>-YMIEDVYZ9VDXKXJK7\*^*M0\'ZO%J&GR[)
M5X=#]R1>ZL.XJ98%6]UZB]F?9E%<[X(\;Z?XZTA;RS;9*N%GMF/SQ-Z'U'H>
M_P"8KHJ\N47%V9BU8****D04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\F5AP?+C0J2OHQ89].Y]?\ _"K4D_9,TOP7IEZFBZKJ&B!7N70MY+W'[R4$
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MLQ_&+4_CA\-Y?$6JV5I872W\MH(K/=LVJJ$'YB3GYCWKY?\ ^"D?_([^#O\
ML'2_^C:]B_X)\?\ )!KC_L,W'_HN*@#Z9HHHH *X+X[>/=0^&'PF\1>*-*AM
MKC4-.B22*.\5FB8F5$.X*RD\,>A%=[7CO[7O_)N'C;_KWB_]'QT ?)7_  \8
M^)/_ $!/"O\ X"7/_P D4?\ #QCXD_\ 0$\*_P#@)<__ "17)?L3^&](\5_'
M.UL-;TNRUBQ:PN'-K?VZ3Q%@HP=K@C(]:_0S_A1?PV_Z)]X5_P#!+;?_ !%
M'Q!_P\8^)/\ T!/"O_@)<_\ R17W'_PFE]_PIG_A+O*M_P"TO[ _M7RMK>3Y
MOV?S=N,YV[N,9SCOWJ/_ (47\-O^B?>%?_!+;?\ Q%6?B9:06'PC\5VUM#';
M6T.AW<<4,2A4C06[@*H'     % 'PO\ \/&/B3_T!/"O_@)<_P#R11_P\8^)
M/_0$\*_^ ES_ /)%>0_LWZ38Z[\<_!EAJ5G;ZA8W%^J36MU$LL4B[3PRL""/
M8U^GO_"B_AM_T3[PK_X);;_XB@#X[\._\%(/$\%S%_;OA/2;RWS^\_LZ26W?
M&>HWM(.G;V[9X^S/A5\5-!^,7A"W\1>'IVDM9&,<L,H"RV\HQNCD4$X89!ZX
M(((R#7R+^WA\$O!/@7PGHOB3P[I5KH.I7&H"SEM;)?+BFC,;ON$8^52I0#(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_/B?#<Q2-<:!M5PQQ>OV/_7.@#](**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XV_P#)
M,-:_[8_^CXZ^5:^JOC;_ ,DPUK_MC_Z/CKY5KV\%_#?K_D=%/8****] U"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7Z!T4 ?E1IOPV^/>C645G8:1XXL;.(8CM[8W,<:#.>%! ')-6?\ A"?VA_\
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M:]BHH _,W]G3X&_$'PY\;_!VI:IX-UFPT^VOEDFN;BS=(XUVGDDC@5^F5%%
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M[:W[.4_Q/T*#Q7X;L6N?%.FJ(I;:!<O>V^>@'=T))'J"PY^45Y+^Q]IGQ/\
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M@M]<2&VO(C'(%+#!P>QKW:B@#/U_0;#Q1HE]I&J6R7FG7L+07$$G1T88(_\
MK]J_,3XD_LG_ !"\">/M0L?#_A_5]<TRWF$MAJEA;L^Z,\H2R]'7H>G(R.,5
M^I=% 'ROX]\8?$OQK^R=)9'PEK<'CB]=-'U"V%BXD>+!,DZC'W9$7:3T#.P]
M#7QC'^SO\4X9%DC\">(4=2&5EL9 01T(.*_7:B@#\H_^%6?'3_H!>-/^^;C_
M !KZ(_8B\&?$?PY\2]:N/&.F^(+/3GTAXXGU82^69?.B( W\;L!OPS7VI10
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MQN7/U%3>$O'/A[QY937GAW6;+6K6&3RI)K*82*CX!VDCO@@_C7Q[_P %+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XV_P#),-:_
M[8_^CXZ^5:^JOC;_ ,DPUK_MC_Z/CKY5KV\%_#?K_D=%/8****] U+>D_P#(
M5LO^NR?^A"OL#QC?SZ5X3UB]M9/*N;>TEEC? .U@I(.#P>?6OC_2?^0K9?\
M79/_ $(5]D>(=)_M[0M0TWS?(^UP/!YNW=LW*1G&1GKZUY6,MS0N8U-T?,R_
M&[QHK G6 P'8VL.#_P".5[A\)/'MQX\T&:6\B2.]M9/*D:,85P1D-CL>N1[>
M^*X=?V90&&[Q&2N>0+'!_P#1E>G^#_!^F_#_ $-K2U8B,$RSW,S %SCEB>@
M Z=OS-9XB="4;4UKZ"DXM:'@GQ[TF'2_'\DD*!!>6Z7+ =-Q+*3^.S->\_\
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M6>!^!^I-/8****](U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH U_"OBK4/!^KQ:AI\NR5>'0_<D7NK#N*^JO!'C?3_
M !UI"WEFVR5<+/;,?GB;T/J/0]_S%?'U=%X"U;6M(\3VCZ"KRWTC>6+<<K,O
M=6'IWSVQGC%<>(H*JK[-$2CS'V#14<#2/!&TR+'*5!=%;<%;'(!P,_7%25X!
MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!\U?M=_MAP?LXG3M%TK3(M9\5ZA#]J
M6*Y9E@MH-Q4.^W!8L5<!01]TDD< ^??LP?\ !06Z^*WCJS\(>-=&L-+O]28Q
MV%_I7F+"TN"1$Z.S$;L8#!NN!CG(P?\ @H?^S3XM\;^*--\>^%-+N=?B2Q2P
MO["QC,MQ$4=BDJQC+.I$F"%!*[<]"2/(?V./V5/'6O\ Q?\ #WB76M U#P[X
M>T&\CU"2YU.W>W:>2-MT<<2. SY=1E@-H .3G (!^J5%%% !1110 5A^.O\
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ML-W%X>FMWCF0HZB-'C4$'GHHH ^!/V3O^3B? _\ U^M_Z*>ON3]N#6]1\/\
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M58EU/7:N 1C<"#@ ^9M;_9)^-FCZ%=:Y<PO,8(C<S01:J)+@ #<W ;YF R<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0.=WD12*5'LI*DX_.BI[)S?M8\K\@?+?56.C\7> -"^(.DM*(H/M,L>^WU&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^"/C/XBM];\2P7LM];VJV:&VNC$OEJ[N. .N9&YH S?V-?\ DVKP7_USN?\
MTJFKX\_;_P#^2_-_V"K;^;U^A?@#P+I7PT\(:?X:T1)4TNQ#K"LTF]P&=G.6
M[\L:X+XH?LL^!/B]XG.O^(;>^DU$P);[K>Z,:[%SC@#W- %K]EK_ )-[\"_]
M@Y?_ $)J^$_VY_\ DX_7_P#KWM/_ $0E?I-X+\(Z=X"\+:;X>TE9$T[3XA#
MLK[V"Y)Y/?K7FOQ(_9-\ ?%7Q;=>(]>M[^34[E$21H+LQIA%"KA<>@% %GX<
M_P#)JN@?]BC%_P"D@K\]_P!D[_DXGP/_ -?K?^BGK]1M)\&Z;HO@JU\*VRR#
M2;:Q&G1JSY?R0FP MZ[>]>6^"/V.OAS\/?%>F^(M(MM134M/D,L#37A=0V".
M1CG@F@#"_;W_ .3>[O\ ["-K_P"A&O%_^";/_(T^-O\ KRMO_0WK[(^)OPRT
M3XM^%I/#_B".>33GE28K;RF-MRG(Y%<]\(_V>/!_P2O=1NO#$-W%+?QI%,;F
MX,H*J21C(XZF@#*_:]_Y-P\;?]>\7_H^.OD/_@GA_P ESU'_ + 5Q_Z.@K[_
M /'?@G3/B-X2U'PYK*ROIE^BI,L+['(#!AANW*BN$^%7[,/@?X-^))M<\-P7
ML5_+;-:,;FZ,B^6S*QX(ZY1>: /A3]M^RU&U_:-\127WF&&XBM9+-G!"F'R$
M7Y<]@ZN#CN&KZA^$/[6OPC\(_!W0;62_&BWFGV,<,^D0V<AE:95 <KM7:V]L
MMN)YSEB#FO9OBS\#O"'QJTV&U\3:<9I;?/V>]MW\NX@SC(5_0XY4@COC.#7D
M&A?\$]_AII.IBZN[O7=8@5@5L[NZC6,CT8QQJQ_ CK0!\(?&'X@-\4_B;XA\
M5& VJ:E<[XH6^\D2J$C!]]JKG'?-?I]>7J:C^S//=Q$-'/X1:52.A#661_.L
M;QU^R)\-/']_8W5[I$MB;*T2RAATR;[/$L2EBHVJ,9^8\UWVB?#C2- ^':^"
MK<W+Z(MG)8 32[I1"X8%=_L&('H * /S3_8U_P"3E?!?_72Y_P#26:OU5KQ3
MP!^R%\//AIXOT_Q+HMMJ":I8EVA::\+H"R,ARN.>&->UT >9_M'_  W'Q4^#
M?B+1(XO-OQ ;NQ '/VB+YT _WL%/HYK\I+'Q5J>F>&]5T&WN#'INIRP37<(_
MY:-#O\O\BY/X"OV"\1_$GPMX2TR^O]6\0:=9VUD&\\O<IN5EZIM!R6SQM SD
M@8K\E;BR/Q3^*\]MH%C]D&OZPXLK11D0K+,2JGV4,,]@ : /N[_@G_\ #K_A
M%_A-=>)+B+9>>(KDNA(Y^SQ$HGYL93[@BOJ&LOPOX=M/"/AO2]$L$V66G6L=
MI".^Q%"C/OQS6I0 5\U?MX_#&[\=?"6#6-.@:YOO#MPUV\:+EC;,N)B![81C
M[(:^E:0@$$$9!H _,S]D3]IFR^!=_JNF:_;W%QX>U-DE,EJ SVTR@C<%)&X,
M, \Y&U<9YKO_ -JO]KK1OBGX+?P9X&BO+V"\83ZA>RP&,>3%^\V(I^;J@9F.
M  G?)Q[9X_\ V%?AMXWU6;4K9+_PU<S-ODCTF5%@9CU/ENC!?HNT>U=)X&_9
M*^'?@'PYK&E6.GW%U+JUI+8W6IWLH>[,,BE656"@("#_  J,\9SB@#X__P""
M?'_)>;C_ + UQ_Z,BK8_X*,V6HQ_%?P_=S>8=,ET=8[9L$()%FD,@';=AHR?
M8K[5]8_"W]EWP+\'O$S:]X<@OH]0:W>V+7%T9%V,5)X(ZY45V/Q(^%_AKXL^
M'FT;Q/IJ:A:;M\;9*R0/C >-QRIY^AZ$$<4 ?,'[*?[2OPM^'_P9L='U>_B\
M/:S9M*;Q#:2.UVQ=F60,BG<=I"X/(QCIBOF+]IOXP6WQM^*MWK]A!+!I4,$=
ME9B<8D:-,G<P!."6=CCL"*^Q+7_@GA\-H-3%Q)J7B&YM0<BTDNH@I]BRQ!L?
M0@^]>@>+?V2?AGXOT;1-+FT,Z=9:0LBVR:=,820^TL7;DN25!RQ)Z\\T 3_L
MF7J7_P"SKX(DC(95LVB./5)70_JIK\W/C+'-H7QV\:&:,K)!XANY0K#&Y?M#
M,I^A!!'L:_5+X8?##1?A'X7'A_0/M(TU9GG1+J8RLA;&X GMD9QZDUY_\7_V
M0_ ?QDUV;7-16_TO6ID"RWFFS*OG%0%4NKJRD@ #( ) Z]* -'X2?M+^$_CE
MJ5]I?AC[?%?VUD+N1KVW5$3)"XX8Y()&>WO7YF>%;Z'P;\5=,N_%NGR7T.FZ
MLCZI97"[G?9+^]5E;[QX.0>O0]:_2[X(_LN>$O@/JEWJ>AW6J7NHW5O]EEFU
M"=&&PLK$*J(H'* \Y(]:@^+?[)'P_P#C#J[ZOJ5K=Z5K$@_?7VDRK$\V,8+J
MRLK' QG&<=^!@ Y/XE?MN?#C0_ MXWAG53K6LSVS1V5G!:R(L;E<*TA=5"JI
M(R <\8 KXA_9IO$T_P"/O@.20A5.K0Q<^KG8/U85]Y_#C]B/X;?#W5(=3>WO
M/$=]"P>)M8D62*-AT(C554X_VMW\JLW_ .Q?\-;_ ,57'B$6NI6NI37C7^ZW
MO614E+[\J,< -T':@#W:BBB@#\VOVX?CA=^/?B+<^$;&Y(\.^'YC"T<9XGNP
M,2.WKL.4 [88_P 5<E^S?\<?"_P+OKS6+_PA-XB\0R'R[>\-VL:VL6,$(I1O
MF;G+>G QDY^S]2_88^%^KZC=7UU;ZM+=74KSRR&_;YG8DL>GJ35;_A@CX3_\
M^FJ_^![?X4 >=?\ #RG3?^A#N_\ P9K_ /&Z]]_:+N1>_LZ>-+@+L$VC22;<
MYQE0<5P__#!'PG_Y]-5_\#V_PKV_Q/X-TWQ=X/OO#.H+(VEWEM]DE6-]KF/&
M.&['CK0!^;G[#'_)Q^@?]>]W_P"B'K]0*\;^&_[)O@#X5>+;7Q'H-O?QZG;(
MZ1M/=F1,.I5LKCT)KV2@#X@_X*7_ /-./^XE_P"VM=5_P3B_Y);XF_[#)_\
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MN8(HP,GN<4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+2-%L_"^N!&-K>Z='Y,:OU DC7Y64G@\9 Z$5[U10!\A?L*>,O&%C)KOP_\
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M(7[*'[+&E?$_P99^,?B ;K6+-PUKI.EM</'$D$;$;R58-@N'PH('4G.[B/\
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M_P"28:U_VQ_]'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!\+?%_P#81\;>-?B=XB\0
M:-JN@1:=JU]+=HEU/,DD>\ECN"Q,.I/0GK7JW[-O[&]A\%]8'B/6]1CUWQ&B
M%+;R8RL%IN!#%<\LQ!(W$# )&.]?2=% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XM^V5
M_P FU>-/^N=M_P"E4->TUY/^U5X>U/Q5\ O%FE:/8SZGJ5Q';B&UMD+R28N(
MF. .N "?PH \2_8V^!W@/Q[\%+;5O$/A>QU746OKB,W-PI+%5(P.#VKWJR_9
MI^%FGR;XO >B,<@XGM1*./9\BN4_8O\ ">L^"_@A:Z;KVF76D:@M]<2&VO(C
M'(%+#!P>QKW:@"MIVFVFD6<5I86L%E:1#$<%O&(XT'H%  %?#W[>!&F?'#X;
MZI>+_P 2U(8RQ8X4^7<[I/\ QUEK[JKQS]I[X Q?'OP/%9VT\=GK^G.T^G7,
MWW"2 'C? )"L .1T*J><$$ ]A1UD165@RL,A@<@BOE[_ (*(7]O;_!/3+:3:
MUQ<:U#Y2D\C;%,68#V''_ A7#>#OCM\;?@AHUOX4\3_#'4/$XL(_L]I>PI)G
MRU&$!EB21) O'(P<8R<\U6'PI^*G[7'C[3-8^(>E2^#O!NGL?+L)4,,NPD;T
MC1OGWOM&9'   XZ;: /H3X*6>DV7[,O@^S\4M9II5SHT2W":FRI"\<BEMK;^
M,;37B?BS_@G[H>N.NN?#OQBVG03_ +^VBG_TF#!Y!CG0A@OH<.?<U]$?&CX.
MV/Q7^%%]X.C9-.'EQFPE"Y6WDCQY?']W VG_ &6..:^8/AS\4/C5^S;HJ^#]
M<^&.H>*M*L&(M+JS64A$8D[1/&DB,N>0" PS@]@ #GK_ ,=?'3]D'6M+'BN_
M/BCPS<.8T2>[-S#.!U5)7'FQ,!R 0![$ U].?M)ZQ;^(_P!EKQ/JMF2UI?Z5
M#=0EA@E':-ES^!%?/OB[1OB[^V3X@T2QU7PC-X#\&V,WG/)>QNC#( 9\R!6E
M;;D*%4+R<GN/J_XE_#@>)_@SK7@K1REKYNEFQLA(3L4J@$88^GRJ"?2@#S;]
MA#_DW;2O^OVZ_P#1IKSCXB?LL_&WQ+X]\1:MH_Q!MK#2;[4)[BTM6UJ^C,43
M.612JQ%5P"!@$@=JQ/V8_$_QA^$>JZ5\/[_X<Z@?#LVK 7.HRZ;.?LRR, ["
M9?W90?>SSWY/&/N>@#Y<_9\_9Z^+'PX^(T.L^+_&D&N:,EM+$UI'JMW<$NP&
MT[)(U7CUS7D?B*Y3X#?MYC5M2;[/HVK71N#<2#:OE7495W)]$E+9/HE??]>-
M?M,?LZV/Q]\*PQQS)I_B/3M[Z?>N,H<XW128YV-@<CE2,C/((![)UH9@BEF(
M50,DDX %?"WAGXC_ +1?[/\ :)X>U?P5=>+]*M$V6]Q]FDN_+0?= N(<_+SP
M'R0,#C&*C\5_$?\ :&_:%L3X:TSP3=>$](O08KF?[++;++&>&5YYL?+P<A "
M>1SG! /8_@Y^U?<?%[XR:UX/T_P[#-HMFUQ+%K<-T1^XC;8CF,J0V]BN,,.&
MSCBO%OVX?^3EOA]_UY6?_I9+7TA^S3^SM8? /PI+%)+'?^)-0VMJ%_&#LXSM
MBCSR$7)Y/+$DG' 'A'[;/P[\:^(_C+X7UWPOX8U#7(;#383YMK:O+&)4N)7V
M,5^JG&>AH ^VZ9--';0R332+%%&I=Y'("J!R22>@KXP/[17[3)! ^$]J/<:+
M><?^1ZP=9TW]IW]H6W_L74['_A%-#FRMR)$%A"Z]")!EI77K\H!!SR.E %#X
M!2'XS_ML:UXRM%:32;&:ZOEE(P#%L-O!GW(96Q_LGT-=!_P4O_YIQ_W$O_;6
MOHS]GOX":5\!/![Z;:3?;]5O&674-1*[?.< A54=D7)P/<GO7BW[?_PY\4?$
M#_A _P#A&] U#7/LGV_[1]A@:7RMWV?;NQTSM;'T- 'O7P:^%OAOX>?#/3M%
MTG3HQ:7=JDEXTRAWNW=!O:4X^;.2,= . ,5\7^/=!UG]B3X]VOB+08I+CP?J
MC,8X"3ME@)!EM6/]Y."I/^R>?F%?H!X:@DMO#FE0RH8Y8[2)'1A@J0@!!KF_
MC%\*M+^,G@+4/#6J ()AYEM=!<M;3@'9(OT)P1W!([T ;WA#Q9I?CKPSIVOZ
M+=+>:9?PB:&5>X/4$=F!R".H(([5^>>A:M\8/"_QGUOX@W/PMUGQ)KMQ)(L$
MU_HMX8[=2=H,04#&$ 0<G"Y]<UZA^R/:?$[X*>,[WP7XD\*:O+X4N[ED6^BM
MGDM[6X' E5P,&)\ $_[K<?-G[4H ^ OBQ^T5\9_%7PYU_2=?^%=SHNC7=L8[
MJ_?2;V(0)D?,6?Y1VY-1_LB_%_XC^'M,\->%M&\"S:IX1NM92.YUQ;"YD6%)
M)565O,7]V-@).3TQS7UU^T7HM_XC^"'C'3-+LYK_ %"YL6CAMK="\DC;AP .
MIKD/V+_">L^"_@A:Z;KVF76D:@M]<2&VO(C'(%+#!P>QH Y/]O;7[B?P1X7\
M$:<=VH^)]6CB6('[Z1D<?]_)(?RKZ/\ #&@6_A7PWI6BV8Q:Z=:16D0QCY(T
M"C]!7S=XM\.:M\2?VV_#K7&EWJ^&?"5B)Q=R6[BWDGVF0%'(VEM\D0X/_+,^
MAKZDH _/S]E[PW;:#^VCXHTW4U5;NP;4A9[U W2>: &7ZQ,Y&.U?H'7RG^TO
M^SMXIE\?V?Q6^&+X\46I1[NQ1@KS,B[1(FXX8E $9#]X#C))!Q)OVM?C)?:6
M=(M/@SJ,'B9E,1O3;7+0H_3<(3'P!UYD(]>* .=\*1I8?\%'=2BTE%%I+-<&
MY"+@ M8EY"<?]-?S)]Z^Z:^:OV3OV=-9^'E]JWCGQQ)Y_C360X:)I!(UNCMO
MD+L.#([ $XR !C/)Q]*T ?/7[=__ ";MJO\ U^VO_HT5>_9M_P"31]"_[!5W
M_P"C)JG_ &R?"NL>,O@7J6F:%IMSJVHO=VSK:VD9DD($@)( ]!5SX">&M5T#
M]F31M%U+3[BRU:+3;J-[*>,K*K,\I4%3SD@C\Z /$?\ @FLBC1O'K8&XW%F"
M?8+-_B:^FOCI_P D2^(7_8O:A_Z325X/^P+\/?$W@'2/&4?B30K_ $1[F>U:
M%;Z!HC(%63<5SUQD?G7T#\8M-NM8^$?C>PL;>2[O;K0[Z""WB7<\LC6[JJJ.
MY)( 'O0!X/\ \$Y_^2):W_V,,_\ Z36U>?\ @M0?^"C.L$@$B6Z(SV_T.O6O
MV$_!6O>!/A'J]AXBTB\T6]DUR:=+>]B,;M&;>W4, >V589]C7%>$OAMXIM/V
M[-5\3S>']0B\.R27!34WMV$#9M=HP_3EN/K0!]A5\,_LQ_\ )\'Q3_ZZ:Q_Z
M7I7W-7Q[^SY\-_%/A[]KWXC:_J?A_4+'1+V35#;7\]NRPS;[U'3:QX.Y02/4
M4 <W_P %"?\ DHOPX_ZYR?\ HZ.O8?V[_P#DW;5?^OVU_P#1HK@OVW_AMXI\
M<>.O =UX?\/ZAK%O:1R"XEL[=I%BS*A&XCIP#^5>I?MD^%=8\9? O4M,T+3;
MG5M1>[MG6UM(S)(0) 20!Z"@#5_9/N[>\_9W\$/;%2BV1C;:<X=9'5_QW UD
M?MKW]O9?LV>*TGVEKAK6&)&.-S_:8FX]P%+?\!KP?X7ZA\9?V6/"UBC>"KOQ
MAX4U*-+S[#$CI<Z=.P'F1L%5VCY]5*G@@@EA4?B+1_B]^V9XBTNQUCP[/X$\
M$64WFO\ :HG0!N07'F!6FDP2HP HR<XR30![%^R;:W-K^R+9?:-P62WU"2)6
M[(99<8]B<G\:\Z_X)K?\@3QY_P!?%G_Z#+7U8OA:T\,_#I_#VC6Y2TL],:SM
M8%Y8A8RJCW)]>Y-?.G[ OP]\3> =(\91^)-"O]$>YGM6A6^@:(R!5DW%<]<9
M'YT <AX^_P"4B7AS_MV_])FKTW]OZTGN/@ \D0)C@U2VDEQV7YU&?^!,M<#^
MU;\-O'^@?'7P_P#%#P7H<_B(6\</[BUMGN6BFB)&UXT^8HRD<C_:Y'!/L_@2
M76?VC?@IK>F_$?PO/X6N;^66R>T>VD@<( C1S(LO.0QR">,I0!?_ &4+^VU#
M]GGP0]J5*1V7DN$.<.CLKY]]P)_&NF^-5_;Z9\'O&]S=;3 FBWFY7. V87 7
M\20/QKY$\'P_&K]CN]U#1[?PM)XY\'3SF:)K&-Y$W' WJ4#/$2  5=2,],]3
M9\=>)?C?^U?;Q^%['P-<>"?"\TJM=S:@KQI( P(WRR(I=5(!VQKDD<^P!UG_
M  3@LI8_AOXINV#"&;55C3(X)6%2V/\ OL5RW[%$"-^T?\49BH,B+<HK>@-X
M"1_XZ/RKZO\ @]\+M.^#OP_TSPOISF=;92\]RPPT\S<O(1VR>@[  <XKYW_9
M)^'/BCPC\<_B/J>M:!J&EZ?>^?\ 9KFZ@9(YLW6X;2>N1S]* /KRBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XV_\DPUK_MC_ .CX
MZ^5:^JOC;_R3#6O^V/\ Z/CKY5KV\%_#?K_D=%/8****] U"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***M:7I=UK5_!964#7%U,VU(T')/\ A[]J
M6VK -+TNZUJ_@LK*!KBZF;:D:#DG_#W[5]0_#+X96O@.P\R3;<:O,O[ZX X4
M?W$]O?O^0!\,OAE:^ [#S)-MQJ\R_OK@#A1_<3V]^_Y =Q7B8G$^T]V&WYG/
M.=]$%%%%<!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <-\;?^28:U_VQ_P#1\=?*M?57QM_Y)AK7_;'_ -'Q
MU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.MZ
M)9>(]+FT[48?M%G-M\R/>RYPP8<J0>H'>N4_X4EX+_Z O_DU/_\ %UW-%7&<
MXJT6T--K8X;_ (4EX+_Z O\ Y-3_ /Q='_"DO!?_ $!?_)J?_P"+KN:*KVU3
M^9_>/F?<X;_A27@O_H"_^34__P 71_PI+P7_ - 7_P FI_\ XNNYHH]M4_F?
MWAS/N<-_PI+P7_T!?_)J?_XNC_A27@O_ * O_DU/_P#%UW-%'MJG\S^\.9]S
MAO\ A27@O_H"_P#DU/\ _%T?\*2\%_\ 0%_\FI__ (NNYHH]M4_F?WAS/N<-
M_P *2\%_] 7_ ,FI_P#XNC_A27@O_H"_^34__P 77<T4>VJ?S/[PYGW.&_X4
MEX+_ .@+_P"34_\ \71_PI+P7_T!?_)J?_XNNYHH]M4_F?WAS/N<-_PI+P7_
M - 7_P FI_\ XNC_ (4EX+_Z O\ Y-3_ /Q==S11[:I_,_O#F?<X;_A27@O_
M * O_DU/_P#%T?\ "DO!?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\
M0%_\FI__ (NC_A27@O\ Z O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_
M^34__P 71_PI+P7_ - 7_P FI_\ XNNYHH]M4_F?WAS/N<-_PI+P7_T!?_)J
M?_XNC_A27@O_ * O_DU/_P#%UW-%'MJG\S^\.9]SAO\ A27@O_H"_P#DU/\
M_%T?\*2\%_\ 0%_\FI__ (NNYHH]M4_F?WAS/N<-_P *2\%_] 7_ ,FI_P#X
MNC_A27@O_H"_^34__P 77<T4>VJ?S/[PYGW.&_X4EX+_ .@+_P"34_\ \71_
MPI+P7_T!?_)J?_XNNYHH]M4_F?WAS/N<-_PI+P7_ - 7_P FI_\ XNC_ (4E
MX+_Z O\ Y-3_ /Q==S11[:I_,_O#F?<X;_A27@O_ * O_DU/_P#%T?\ "DO!
M?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\ 0%_\FI__ (NC_A27@O\
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M * O_DU/_P#%T?\ "DO!?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\
M0%_\FI__ (NC_A27@O\ Z O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_
M^34__P 71_PI+P7_ - 7_P FI_\ XNNYHH]M4_F?WAS/N<-_PI+P7_T!?_)J
M?_XNC_A27@O_ * O_DU/_P#%UW-%'MJG\S^\.9]SAO\ A27@O_H"_P#DU/\
M_%T?\*2\%_\ 0%_\FI__ (NNYHH]M4_F?WAS/N<-_P *2\%_] 7_ ,FI_P#X
MNC_A27@O_H"_^34__P 77<T4>VJ?S/[PYGW.&_X4EX+_ .@+_P"34_\ \71_
MPI+P7_T!?_)J?_XNNYHH]M4_F?WAS/N<-_PI+P7_ - 7_P FI_\ XNC_ (4E
MX+_Z O\ Y-3_ /Q==S11[:I_,_O#F?<X;_A27@O_ * O_DU/_P#%T?\ "DO!
M?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\ 0%_\FI__ (NC_A27@O\
MZ O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_^34__P 76QX;\ >'_"-Q
M+/I.G):S2+M:0R/(V/0%B<?AUXKH:*3J3DK.3%=]PHHHK,04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45QWQ3T2]U[PY%;V%N;F87*N4
M4@?*%89Y/N*\H_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&NX^%'A/5O#^LWDVH6;6T;V^Q69E.3N!Q
MP?:@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
MJ6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_
M +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNC_ (::_P"I;_\ )[_[77AU
M%'U6C_+^8<D>Q[C_ ,--?]2W_P"3W_VNC_AIK_J6_P#R>_\ M=>'44?5:/\
M+^8<D>Q[C_PTU_U+?_D]_P#:Z/\ AIK_ *EO_P GO_M=>'44?5:/\OYAR1['
MN/\ PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37
M_4M_^3W_ -KH_P"&FO\ J6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\
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M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
MJ6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_
M +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNC_ (::_P"I;_\ )[_[77AU
M%'U6C_+^8<D>Q[C_ ,--?]2W_P"3W_VNC_AIK_J6_P#R>_\ M=>'44?5:/\
M+^8<D>Q[C_PTU_U+?_D]_P#:Z/\ AIK_ *EO_P GO_M=>'44?5:/\OYAR1['
MN/\ PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37
M_4M_^3W_ -KH_P"&FO\ J6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\
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M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45AZKXY\-Z#.8=3\0:5ITP.#'=WL<3 _1F%7]
M*UO3M=@,^FW]KJ$(QF2TF65>1D<J2* +M%%% !1110 4444 %%%% !1110 4
M4A( ))P!52+6+">18X[ZVD=C@*LJDD^PS0!<HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .&^-O_ "3#6O\ MC_Z/CKY5KZJ^-O_ "3#
M6O\ MC_Z/CKY5KV\%_#?K_D=%/8****] U"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 D8SUP #]"J*_,7Q%J/[2?@'2VU[6=0\96.GIM>2XGNGDCCYP-Z[B$&>/F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <-\;?^28:U_VQ_P#1\=?*M?57QM_Y)AK7
M_;'_ -'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7NOP>^,/F^1H.O3_O.$M;V0_>]$<^OH>_0^_A5%8U:4
M:L>60I)25F?<=%>(_![XP^;Y&@Z]/^\X2UO9#][T1SZ^A[]#[^W5\_4IRI2Y
M9'*TXNS"BBBLB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>X4'AI52/RL_@TM<S^PA=_"ZTT'6I?$CZ+!XOBO-\4VLF-2MML0(83)P#O\
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MCWKT&@ HHHH ***Y3XE?$_P]\)/#JZYXFNY+/3FG6V$D<+RG>P) PH)Z*>:
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M* "BBB@ HI54LP !)/  [U],^ _A+HOA+1HKW5[>"ZU$1^;/-=8:.'C) !X
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MG_><):WLA^]Z(Y]?0]^A]_"J*QJTHU8\LA22DK,^XZ*\1^#WQA\WR-!UZ?\
M><):WLA^]Z(Y]?0]^A]_;J^?J4Y4I<LCE:<79A11161(4444 %%%% !1110
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M?M3?#OXH>*+;P]X>U:XN]4N%=XXI+*6,$(I9OF90.@->M4 %%<!\5?CGX/\
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MJP_W2: /:Z*X[X??&#P9\5(IG\*^(+35VA ,D,>Y)4!Q@F-P& YZXQGBNQH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)MX(490$7:#D\\U[5X!\(P^ O!6B>'+>X>Z@TNTCM$GD #.$7 ) XSQ6_10
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M5_:3_;3M?B_X%E\)^'M$NM.L;R2-[RYOW7S&5'#JBJA(QN5223VQCO0!J?\
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M+?:3?@QZ=)=.6>TF4$B,,>=C %0O9MN,9->R?\%!_P#D@UO_ -AFW_\ 1<M
M'F7_  33_P"/[X@_]<[#^=Q7.?\ !1W_ )*EX9_[ P_]'R5T?_!-/_C^^(/_
M %SL/YW%<Y_P4=_Y*EX9_P"P,/\ T?)0!])?L0_\FU>%_P#KI>?^E4M>[UX1
M^Q#_ ,FU>%_^NEY_Z52U[O0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '#?&W_ ))AK7_;'_T?'7RK
M7U5\;?\ DF&M?]L?_1\=?*M>W@OX;]?\CHI[!1117H&I;TG_ )"ME_UV3_T(
M5]<?$'_D1/$'_7A-_P"@&OD?2?\ D*V7_79/_0A7VAJ%Q;6EA<37C(EI'&S2
MM(,J$ YS[8KRL8[2@S&INCXDKZ1_9\TO4=/\)7,EXCQ6UQ/YELDF02NT98#T
M/'Y5MIXZ\!1.'2_TM&'(98P"/TK.\1_'CPWI-HYL)FU:[Q\D42,J9_VF8#CZ
M9J:M6I7CR*#"3<E:QYG^T/)$_CR)8R-Z64:R8_O;G/\ (K7N]E:/?^!H+:/
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MT]Z].\>>"O'?A[2VDEUBXU31[= I^SSN B 8!:/TQWY]S47[.VG1W?C2YN9
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MXD^)ND^$?B!=0:W9ZU.MI;Z@EK';S6\[<1@B,*K*S$*?ER,@YX((!^B%%%%
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MPY]RC(3[Y/>O@S]JKX\VWQX\>VU]IEG)9Z-IMN;6U,^/-FRQ9I& ^[G@!<G
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MQHS,P55&2Q. !7Y$1WWC#]F?XLW5M;WILM<T:Y$<ZVTI,%RG#!6'&^-U(."
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M0!T7[/\ ^Q-)\8OAVOBG4_$,FAI>/(EA#%:"7<J-M,CY8<%@PVC'3.>:\O\
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M>H5"N/=V]J?\%OV#%^(?P\TWQ+KOB2?29M4A%S:VEK;*^R)ON,[%N2PPV!C
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MKG.QB5\PC_MK/)^5?M+7XI_" GQK_P %)[*YN/G,WCR_NSGUBDG=?R\M?RH
M_9OPYH-GX5\/:9HNG1"&PTZUBL[>,?PQQH$4?@ *T:** "BBB@ HHHH ****
M "OE3]LW]NK0?V;-.E\/Z%]GU_XBW,68M/W9AT]6'RS7)'3U6,?,WL.:\[_;
M@_X*)6?PL&H>!?AI=P:AXQ4-%J&M#$EOI'JJ]I)QZ?=3^+)^6O"/V-/V M9^
M.>IQ?$CXL_;H_"]W+]MBL;V1Q>ZZ['=YLS'YEA8\Y^\XZ87!(!R/[-G[*7C[
M]N'Q]=_$#Q]JNH1>%9[C??Z_<<7&I,IQY%H",*@^[N V(.%!(P/UT\!^ ?#_
M ,,?"FG^&O"^E6^C:)81^7!:6RX51W)/5F)Y+$DDDDDFM;2M*LM#TVUT[3K2
M"PL+6-88+6VC$<<2*,*JJ.  . !5J@ HHHH _'O_ (*K> 3X*_:4LO$VG@VY
M\2:7%>^8@QMN[=O*9A[[1 ?K7ZI?!GQROQ,^$O@[Q6K!FUG2;6]?'0.\2EQ^
M#$C\*^%?^"QVF1G0OA9J04><EY?VI;N5:.)\?G'7T;_P3NU)M2_8Y^'1<DM!
M!<VV3Z1W4RC] * /H^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"/KG\J\G^"/QZ^.'Q<^*T6FZ/KTO]GW=X;F^1K.&:"QMB^6PS(2H4'"C<,G
MKZ]_:7^%,OQB^$.KZ%9JK:K&5O+#>0 9X^0N3TW*73/;=0!\Y?\ !--(=WQ#
M;_EX L ,]E_TCI^/]*^V+Z"VN;9H[R.*6W)!99U!3(((R#QU (]\5^4?P.^,
MNN_LU?$*\N9-+DF5E-EJ>D71:%SM;/<?+(I!P2#U88YKTK]HC]M=_C#X&?PK
MHNA2Z+97;H]]/<7 D>158,(U  P-P4DYYQC YH _1E5"*%4 *!@ =J_+G]M[
M_DY7Q1_USL__ $EBKZ'_ ."?GPY\0Z5H6I^+M9FO8=-OXDMM*LYIGV-&#EYO
M+)P 2%53C. V.",^/?\ !0'P9>Z+\:%UYH'_ +.UJRB:.X"_(98U\MTSZA50
M_1A0!]W?!9UE^#G@1U.5;0; @^WV=*^#/^"@S _'F$ @D:/;@X[?/+7:_!?]
MO32_ GPUTOP[X@\/7UY?:3;+:6UQ8.GES1H,1APQ!4A< D;LXSCFOG?XZ>,]
M?^)WC1O&FN::=+BUN,2:?!G*BVC)C7:3@L,JV6P,G<0!TH _1?\ 9=_Y-H\'
M_P#8.D_]#>OS8^"6GQ:M\9/ UG.H>";7+))%(R&7STR/Q'%?I/\ LN_\FT>#
M_P#L'2?^AO7YT?LZH'^._@$,,C^VK4_B) 10!^O-?G#_ ,%#_P#DN>G?]@*W
M_P#1T]?H]7YP_P#!0_\ Y+GIW_8"M_\ T=/0!]6?L4:?%8?LV>%&C4![EKJ>
M1@,;F-S*,_\ ?*J/PKRO_@I(]P/!O@Q%S]E-_.9.>-XC&WCZ%Z]C_8_0)^S?
MX)"C ^SS'\3<2DU!^UQ\(;GXP?"&[L],B:;6],E74+&%>LS*"K1_5D9L?[06
M@#XI_9N\4_&+PUH6L?\ "LM#&IV,UROVR7[*LQ60+\JY)&.#G\:[3XG/^TE\
M7?"[^'_$7@N:;3VF2?$%BD;AUS@@AO<_G7!?LS?M&W7[.GB#5K74M+GO]'OR
MJ7EFA$<\$L>0&4-W&2I4X[<\5Z+\=_V\]0\61Z=:?#H:EX:A@E\^XOKM8A/,
M<8$>P%U"<DG).2!TQR >B?L'?#'QK\--5\81^)M!N]%L[Z&V:(W2@"1T:3I@
M]@Y_2OGC]M[_ ).5\4?]<[/_ -)8J^W_ -E75OB-XE^'1UOXBW;37=]*'L(9
M;2.WD6W X=@BK]\DX!'10?XJ^(/VWO\ DY7Q1_USL_\ TEBH _0;]GNT6R^!
M?@"-$"!M#LY,#U>%6)_$MG\:^)_^"BD2Q_&_2&'5_#\#-]?M%P/Y 5]P_ O_
M )(E\/?^Q>T__P!)HZ^(/^"C'_);=$_[%Z#_ -*;F@#ZU_9"_P"3</!/_7O+
M_P"CY*_.&Q('QYMR3@#Q*O\ Z55^CW[(7_)N'@G_ *]Y?_1\E?F_\1HKKP1\
M;_$1G@_TG3M>FF$3C:'"SEU_!A@@^AH _8*BO#/V=_VI+/\ :"UC6K&VT&71
M?[-MX9]TUR)3*7+!@ %& I YSSGH*]SH Y7XK_\ )+?&/_8&O/\ T0]?DK\+
M? W_  LOXA:%X7^V_P!G?VI<"W^U>5YOE9!.=FY<].F17ZU?%?\ Y);XQ_[
MUY_Z(>OR_P#V6O\ DX3P+_V$5_\ 06H ^B_^':'_ %4?_P H?_W37H/PS_8%
M\$>"M6@U+7+ZZ\6W,#!X[>YC6&UW#D%HP26^A;;Z@U]/44 (JA%"J % P .U
M?C':V$6J_$&&RN 3!<ZH(9 IP=K2X.#]#7[.U^->A_\ )4M/_P"PS'_Z/% '
MVM\1?^">'ABZT"ZE\&:GJ%CK: O#!J$RRV\O_3,D*&7/0-DX[@U\>_#?Q7%\
M'_B&9?$GA*PU^.TF:VOM)U>W#M&5;#;=V0LBD'J"/;N/V KXE_;V_9_,\?\
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MBD%RO0G<N"".<5YU;:U^U7\:+<26:7OA_2K@962..+3%53T96;$Q'NI-?/\
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MM/\ [6G@'XO> I]"T7PS=W.JRO&8]5U.WBC-H%<,3&59F)(!4CY1ACUZ5O\
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M1_\ Q5?/?Q+\#Z_^S%\:D:W22)=/O1?:/>RKE+F%7RAST/'RL/7/J*^F+_\
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M/5O$DNMB7=+'#+-(Q0#@,58D#.2.#V-<!6AKVO7WB75)M0U"<SW,IR6/0#L
M.P'I6?7I4TXQ2EN:K1#D1I75$4L[' 4#))]*^K_AC\/K?P+H:*RJ^J7"AKJ;
MOG^X/]D?J>:^8/#>K1Z#KUAJ,MM]K6UF6;R=^S<5.1S@XYQVKU__ (::_P"I
M;_\ )[_[77)BH5:B48+0B:;T1>^*GAKQQXWOVM;2S2'1(6_=Q_:4!F(_C<9_
M(=OK7F6M_"/Q-X>TJXU&^LXX[6 !I&6=&(!('0'U(KO_ /AIK_J6_P#R>_\
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M5I5I>1S2ES!1117,0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M74IUBL=#2&*X2- ,?,70]@69N .>0 ,??>OV][:_"_4X=2NEOM1CT>5;FY1
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M\F]^!?\ L'+_ .A-7PG^W/\ \G'Z_P#]>]I_Z(2@#[E^'/\ R:KH'_8HQ?\
MI(*_/?\ 9._Y.)\#_P#7ZW_HIZ_0CX<_\FJZ!_V*,7_I(*_/?]D[_DXGP/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LSQ)X;TSQ?HEUH^LV46H:9=*%FMIAE) "& /X@'\*TZ* .%\(_ WP'X"UE=
M6\/^%['2M15&C%S;J0P5NHY/>NZHHH PO&/@?0/B!I TOQ'I5MK%@)%F$%RF
MY0XSAAZ'!(R/4USWA?X"_#_P3K=OK&A>%K'2]3@W".YMPRNH8%2.O0@D5WU%
M &?KWA_3/%&ESZ;K&GVVJ:?.,26UW$LD;?52,5Y%-^QA\')[W[2?!RJV2QC2
M_NEC)R/X1+@8]!@<]*]MHH P?!O@/P[\/=*&F^&]&M-&L\Y:.UB"ESZNW5C[
ML2:WJ** .#\?_ KP%\49Q<>)O#%GJ5T %^U#=#.0.@,D95B!Z$US_AG]D[X3
M^$KV&\L?!MI+<Q-O1[Z66Z /8[979>.W'ZUZY10 BJ$4*H 4#  [5D>*_!^B
M>.M&ETGQ!I=MJ^G2D%K>ZC#+D=&'<$=B,$5L44 >-:-^Q]\(="U);ZW\&V\L
MR-N1+RZGN(A_VSDD93Z\@UV'C#X+^!_']U:W/B'PU8ZI-:PBW@:9#^[C!)"
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M^&_7_(Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^U<ZIX<\,V.D:@8FA-Q;J0Q0D$KR>A('Y5VLD:31M'(H=&!5E89!!Z@BG44
M>.:[^R!\(O$6I-?77@VWBG=MSK9W,]M&W7C9&ZJ.N> .E=]X&^&_ACX:::UA
MX8T2TT:V<AI!;I\\A'0NYRS'W8FNEHH P_&'@G0_'^C_ -E>(=-AU;3C(LIM
MY\[2PS@\'MDUP_\ PRU\)_\ H1=*_P"^&_QKU2B@#RO_ (9:^$__ $(NE?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P! 7_R:@_\ BZ/;4_YE]X<R[G#45W/_  I+QI_T!?\ R:@_^+H_X4EXT_Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEV*FRL ?1B"9)!_P)1[5]O\ A'P;H7@'0;;1/#>CV6A:3;#$5EI\"PQ+[[5
MY..3U/>MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
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M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%9/BGQ);>$="NM6O$EDMK?;O6  N=S!1@$@
M=6'>N _X:.\-?\^.J_\ ?F+_ ..5K"E.:O%7*46]CU6BO*O^&CO#7_/CJO\
MWYB_^.4?\-'>&O\ GQU7_OS%_P#'*OZO5_E'RR['JM%>5?\ #1WAK_GQU7_O
MS%_\<H_X:.\-?\^.J_\ ?F+_ ..4?5ZO\H<LNQZK17E7_#1WAK_GQU7_ +\Q
M?_'*/^&CO#7_ #XZK_WYB_\ CE'U>K_*'++L>JT5Y5_PT=X:_P"?'5?^_,7_
M ,<H_P"&CO#7_/CJO_?F+_XY1]7J_P H<LNQZK17E7_#1WAK_GQU7_OS%_\
M'*/^&CO#7_/CJO\ WYB_^.4?5ZO\H<LNQZK17E7_  T=X:_Y\=5_[\Q?_'*/
M^&CO#7_/CJO_ 'YB_P#CE'U>K_*'++L>JT5Y5_PT=X:_Y\=5_P"_,7_QRC_A
MH[PU_P ^.J_]^8O_ (Y1]7J_RARR['JM%>5?\-'>&O\ GQU7_OS%_P#'*/\
MAH[PU_SXZK_WYB_^.4?5ZO\ *'++L>JT5Y5_PT=X:_Y\=5_[\Q?_ !RC_AH[
MPU_SXZK_ -^8O_CE'U>K_*'++L>JT5Y5_P -'>&O^?'5?^_,7_QRC_AH[PU_
MSXZK_P!^8O\ XY1]7J_RARR['JM%>5?\-'>&O^?'5?\ OS%_\<H_X:.\-?\
M/CJO_?F+_P".4?5ZO\H<LNQZK17E7_#1WAK_ )\=5_[\Q?\ QRC_ (:.\-?\
M^.J_]^8O_CE'U>K_ "ARR['JM%>5?\-'>&O^?'5?^_,7_P <H_X:.\-?\^.J
M_P#?F+_XY1]7J_RARR['JM%>5?\ #1WAK_GQU7_OS%_\<H_X:.\-?\^.J_\
M?F+_ ..4?5ZO\H<LNQZK17E7_#1WAK_GQU7_ +\Q?_'*/^&CO#7_ #XZK_WY
MB_\ CE'U>K_*'++L>JT5Y5_PT=X:_P"?'5?^_,7_ ,<H_P"&CO#7_/CJO_?F
M+_XY1]7J_P H<LNQZK17E7_#1WAK_GQU7_OS%_\ '*/^&CO#7_/CJO\ WYB_
M^.4?5ZO\H<LNQZK17E7_  T=X:_Y\=5_[\Q?_'*/^&CO#7_/CJO_ 'YB_P#C
ME'U>K_*'++L>JT5Y5_PT=X:_Y\=5_P"_,7_QRC_AH[PU_P ^.J_]^8O_ (Y1
M]7J_RARR['JM%>5?\-'>&O\ GQU7_OS%_P#'*/\ AH[PU_SXZK_WYB_^.4?5
MZO\ *'++L>JT5Y5_PT=X:_Y\=5_[\Q?_ !RC_AH[PU_SXZK_ -^8O_CE'U>K
M_*'++L>JT5Y5_P -'>&O^?'5?^_,7_QRC_AH[PU_SXZK_P!^8O\ XY1]7J_R
MARR['JM%>5?\-'>&O^?'5?\ OS%_\<H_X:.\-?\ /CJO_?F+_P".4?5ZO\H<
MLNQZK17E7_#1WAK_ )\=5_[\Q?\ QRC_ (:.\-?\^.J_]^8O_CE'U>K_ "AR
MR['JM%>5?\-'>&O^?'5?^_,7_P <H_X:.\-?\^.J_P#?F+_XY1]7J_RARR['
MJM%>5?\ #1WAK_GQU7_OS%_\<H_X:.\-?\^.J_\ ?F+_ ..4?5ZO\H<LNQZK
M17E7_#1WAK_GQU7_ +\Q?_'*/^&CO#7_ #XZK_WYB_\ CE'U>K_*'++L>JT5
MY5_PT=X:_P"?'5?^_,7_ ,<H_P"&CO#7_/CJO_?F+_XY1]7J_P H<LNQZK17
ME7_#1WAK_GQU7_OS%_\ '*/^&CO#7_/CJO\ WYB_^.4?5ZO\H<LNQZK17E7_
M  T=X:_Y\=5_[\Q?_'*/^&CO#7_/CJO_ 'YB_P#CE'U>K_*'++L>JT5Y5_PT
M=X:_Y\=5_P"_,7_QRC_AH[PU_P ^.J_]^8O_ (Y1]7J_RARR['JM%>5?\-'>
M&O\ GQU7_OS%_P#'*/\ AH[PU_SXZK_WYB_^.4?5ZO\ *'++L>JT5Y5_PT=X
M:_Y\=5_[\Q?_ !RC_AH[PU_SXZK_ -^8O_CE'U>K_*'++L>JT5Y5_P -'>&O
M^?'5?^_,7_QRC_AH[PU_SXZK_P!^8O\ XY1]7J_RARR['JM%>5?\-'>&O^?'
M5?\ OS%_\<H_X:.\-?\ /CJO_?F+_P".4?5ZO\H<LNQZK17E7_#1WAK_ )\=
M5_[\Q?\ QRC_ (:.\-?\^.J_]^8O_CE'U>K_ "ARR['JM%>5?\-'>&O^?'5?
M^_,7_P <H_X:.\-?\^.J_P#?F+_XY1]7J_RARR['JM%>5?\ #1WAK_GQU7_O
MS%_\<H_X:.\-?\^.J_\ ?F+_ ..4?5ZO\H<LNQZK17E7_#1WAK_GQU7_ +\Q
M?_'*/^&CO#7_ #XZK_WYB_\ CE'U>K_*'++L>JT5Y5_PT=X:_P"?'5?^_,7_
M ,<H_P"&CO#7_/CJO_?F+_XY1]7J_P H<LNQZK17E7_#1WAK_GQU7_OS%_\
M'*/^&CO#7_/CJO\ WYB_^.4?5ZO\H<LNQZK17E7_  T=X:_Y\=5_[\Q?_'*W
M/"/QCT#QCJ?]GVWVFTNF&8UO$51)ZA2&//M2="I%7<1<K70[FBBBL"0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .&^-O\ R3#6O^V/_H^.OE6OJKXV_P#),-:_[8_^CXZ^5:]O
M!?PWZ_Y'13V"BBBO0-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%*\,B2
M1NT<B$,KJ<%2.A!IM% 'T?\ "/XN)XGCCTC5Y%CU=!B.4\"Y _\ 9_;OU%>J
M5\/12O#(DD;M'(A#*ZG!4CH0:^C?A'\7$\3QQZ1J\BQZN@Q'*>!<@?\ L_MW
MZBO&Q.&Y??AL83A;5'JE%%%>:8A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#AOC;_ ,DP
MUK_MC_Z/CKY5KZJ^-O\ R3#6O^V/_H^.OE6O;P7\-^O^1T4]@HHHKT#4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IT4KPR))&[1R(0RNIP5(Z$&FT
M4 ?1_P (_BXGB>./2-7D6/5T&(Y3P+D#_P!G]N_45ZI7P]%*\,B21NT<B$,K
MJ<%2.A!KZ-^$?Q<3Q/''I&KR+'JZ#$<IX%R!_P"S^W?J*\;$X;E]^&QA.%M4
M>J4445YIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ'*>!<@?^S^W?J*\;$X;E]^&QA.%M4>J4445YIB%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)WPTO/ </A%-"^R:7'<K>&6WE9;B29590SRG+-P[<'CG@"@#@/\ @GE=Q3_
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M@F3[LD; ,K#V((-<CXQ^-G@7X?:N-+\1^)K'2-0,2S"WN&(8H20&X'0D'\J
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MJ0"/2MNOSM_X)Y^-K_2OBIJ'AH2NVEZK8O,T!)*K-%@JX]/E+@^N1Z"OT2H
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M4\"Y _\ 9_;OU%>-B<-R^_#8PG"VJ/5****\TQ"BBB@ HHHH **** "BBB@
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MP]\#M93P[:WESJ>HLE@&L86D>*-\F5\*"0-BNN[L6%?&'[*/[,T?QC\5ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM"3><0&SVPW.:^JO^%*_M4?]#E=_^#YJ /(O@9\2->_9H^-KZ/J<S0Z:+_\
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M6UE)'Y$D\4"2),",'<_(!/X&J/P T6+5/')N)E#+8V[3H#_?)"C\MQ/U KZ
MLI[/QIX7BFGMF^Q:A;AF@G&#M8=#_C^->#_ #48=.\?7-H9@4NK:2*(GC>RL
MK#_QT-1"IS4II1LUV!.\7H>E_&6T\3ZIIEG8>';>:2.5F:[D@D"-@8VKDD<'
M)S]!7,_!W0?&?A?Q +?4K.XCT:=&$@EE5EC<#*L &."2,<>M='\9_$OB/PG8
M6.H:+*$M-S1W),*OM)QL/(.!]X?EZUP/A#X@_$3QO?36NF7=NSQ1^8[RP(J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%=;\.? >H^-]91;5GM;6W8/->CCRNXV_[7H/QIGP^^'U]X]U7R8<PV41!N+H
MCA!Z#U8]A7U1X?\ #]CX8TJ'3M.A$-M$.G=CW9CW)]:X<1B%27+'<SG.VB+L
M$7D01QEWE**%WR'+-@=3[U)117A',%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?$\DH'RK);VZ*3[D3G'Y&OACX3^$[3QW\2_#'AV_DGALM3U"&UFDMF"R*CL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#TW1(7.6CTZTCMU8^X0#-;% '*_%?_DEOC'_ + UY_Z(>OR__9:_Y.$\"_\
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MQ1);Q)%$BQQHH5408"@= !V%9VO^%]&\5V8M-;TBPUFU!R(-0MDG3/KM<$4
M? 7B+]L#XD_'W25\!^&_#=M9ZAK"&UN7T[?))+&V0X7=Q$A4_,QS@9^85XO\
M)=*FT+]H;P9IMP4:XL_%-E;R&,Y4LEVBG'MD5^K_ (;\$^'?!R2IH&@:7H:2
MG,BZ;9QVX?Z[%&:>GA'0H[M;I=%TY;I7\T3BTC#A\YW;L9SGG- '/_&?X8VO
MQ@^&^L^%KF46[7<8:WN=N?)F0AHW^F0 <=02.]?F;IUW\0_V3?B9Y[6KZ/K$
M2F)DN(_,MKV D$C(X="0.5(((Z@CC]::HZOH>G>(+-K35-/M=2M&.3!>0K+&
M3Z[6!% 'YN_%#]N7QO\ $GPG<^'XK'3] M;V,PWDMD':69""&0%B=JL#@X&>
MV>37HO[$W[,.J1>(+7XA>*["2PM;0%])LKE"LDTA!'GLIY"J"=N>22&' !/V
M!I'PF\#^'[U+S2_!OA_3;M/NW%GI<$4B_1E0$5U= 'R5_P %'?\ DEOAG_L,
MC_T1)65_P39_Y%;QM_U^VW_H#U]?:EH]AK,2Q:A96U]&C;E2YB60 ^H!!YI-
M,T73M%1UT^PM;!9""ZVT*QACVSM S0!\A?\ !2;_ )%;P3_U^W/_ * E:O\
MP3B_Y);XF_[#)_\ 1$=?5&IZ+IVM(BZA86M^L9)1;F%9 I[XW XI=-T>PT:)
MHM/LK:QC=MS);1+&"?4@ <T ?%G_  4O_P":<?\ <2_]M:[[_@GDH?X%:FK
M,IUVX!!&01Y,%?2>IZ%INM>7_:.GVE_Y6?+^U0+)LSC.-P.,X'Y"I-.TJRT>
M P6%G;V4);>8[:)8U)]< #G@?E0!^7W[0/P5\1?L[?$YM7TF"XM]!^VB\T;5
M( 66 AMR1LW9T/&#]X#//->C7W_!1?Q3=^#I=/C\-6-MK\D)B_M>.X;RT)&-
MZP%>&[C+D9[$<5]_W5I!?6\EO<PQW$$@VO%*H96'H0>#7)P_!?X>V]QY\7@3
MPS%/DGS$T>W#9[\A,T ?&7[%/A7XF>,?%UGKMUXAU^S\#Z>_F2I-?3"&^D&=
ML2(3AANP6.,8!&<M7TI^V/X5O?%O[/GB6WT^)I[FU\F]$2#)9(Y%9\ >B;C^
M%>TQQI#&L<:A$4!551@ #H *=0!^1_P'^/>L? /7=2U+2;"SU$W]M]GDAO-V
MT8;<K J0>#V[@GZU]D?'WQK<?$;]AM_$MVD,5WJ5O833I;@B-9/M408*"20,
M@]2?K7O=]\(O NJ7QO;WP7X>N[PG<;B?2H'D)SG.XIG.:Z&71K"?3A82V-M)
M8 !1:O"IB !R!MQC@B@#X"_X)Q ?\+2\3''/]C'G_MO%7Z$UG:;X<TG1I6ET
M_2[.QD==K/;6Z1DCT) '%:- 'Y#_ +1O_)>?'W_89N?_ $8:_5GQ%X6LO''@
M:^\/ZBI:QU.Q:UEVXW*'3&Y<]",Y!]0*GN?!V@7EQ)/<:'IL\\C%GDDM(V9B
M>I)(R36N    , 4 ?DYXP\!^/?V5/B5;7RB:QN;.9FTW68H]UO=)R.,Y'*DA
MD/(!Y'0GTCQ-_P %!O'^N^&I=-M-.TK1KZ:,QR:E:+(9%SU,:LQ"GKR=V,\8
M-?HI?Z?:ZK:2VM[;0WEK*-LD$\8=''H5/!KE[7X.> ;&\6[MO _ANWNU;<L\
M6DVZN#ZA@F<T ?!O[(G[,>K?$3Q9I_BWQ#8RVOA.PE6YC-RA4ZA*IRJH#UCS
M@LW0XVC.3C[ _:]_Y-P\;?\ 7O%_Z/CKV$ *    . !45Y96^HVSV]U!%<V\
M@P\4R!T;OR#P: /SG_X)X?\ )<]1_P"P%<?^CH*]_P#VX?@)J'Q1\+V'B3P]
M:M>:YHBNLMI$,R7-LW)"#NR$$A1R0S8R< _1NG>&M(T><SV&E65E,5V&2VMT
MC8KZ9 '' _*M*@#\KO@1^U/XJ^ ,%WI-O9P:MHTLWFOIUZ61H9.C%&'*DX (
M((XZ YS)\9?'OQ _:+T6Y\<ZOIZ:?X3T(K;6Z0JRP+)*RJ51CS(YP"QZ *.F
M0#^DNM?"SP7XDOVOM7\(:#JEZW6YO=,AFD/U9E)K:DT+39=-33GT^U?3T "V
MC0*8E Z83&!CZ4 ?%W_!-#_FH_\ W#?_ &ZK[?JCIFA:;HOF?V=I]I8>;CS/
MLL"Q[\9QG:!G&3^9J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <-\;?\ DF&M?]L?
M_1\=?*M?57QM_P"28:U_VQ_]'QU\JU[>"_AOU_R.BGL%%%%>@:D]A,MM?6\S
MYV1R*YQUP#FO>?%?QS\.:UX9U6PMTOA/=6LD,>^$!=S*0,G=[U\_T5A4HQJ-
M.703BGN%%%%;C"O?O^%X^'/^$1_LW9>_:/L/V?/DC;N\O;UW=,UX#16-2E&K
M;FZ"<4]PKW[PA\<?#FA^%]*T^Y2],]M;I$^R$%<@8.#NKP&BBK2C55I XJ6Y
MO^#_ !?<>#?$L6JVJB0*2LD+' DC/5<]NW/J!7NA^-/@?Q!IPCU5#M.&:UO+
M0S#=^ 8'ZU\V45%2A"JTWN)Q3/>4^/\ HVG:M9V>FZ4UKH,>X2LD2H_W3MV1
M@X SCJ?RKEOC%\0-"\>6NFOIPNEN[5W!$T852C 9Y!/(*C\S7E]%*.'A"2DM
MT)02=SU?X:_&Y_"UC%I6KP27=A'Q#/$1YD2_W<'[P_'(]^,=S-\4OAQ>3&]N
M(();P<[Y=.W2G_@6WV]:^;Z*4L+3E+FV] <$]3VKQ_\ 'R/4=.GTWP]#+"LR
M['O9?E8*>H11ZCC)Z>G>O'=/OY]+OH+RUD,-S XDCD7JK Y!JO16M.E"FN6*
M*22V/H7PY^T%HVH6"PZ];R6=SMVR,D?F0R?AU&?0@_6KEQ\;_!F@VD@TJ)YV
M/S"&UM?)5F]R0/SP:^;J*P>$I-W(Y$;WC3QE?>.-;?4+W"#&R&%?NQ)GA1Z]
M>3WK!HHKK2459&FQJ>&+JRL?$6G7.HJSV,,ZRRHBABRJ<XP>N<8KZ!_X:&\+
M?\\]0_[\+_\ %5\U45C5H0JM.1+BI;GTK_PT-X6_YYZA_P!^%_\ BJY_Q_\
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M7%S"40R1 +G(ZG=7@U%%52I1I*T1J*CL%%%%;#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOA]\/K[Q[JODPYALHB#<71
M'"#T'JQ["CX??#Z^\>ZKY,.8;*(@W%T1P@]!ZL>PKZH\/^'['PQI4.G:="(;
M:(=.['NS'N3ZUPXC$*DN6.YG.?+H@\/^'['PQI4.G:="(;:(=.['NS'N3ZUH
MT45X;;;NSF"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8?CK_D2/$/_8.N/_135N4V2-949'4.C AE89!'H: /R)_9R_Y+SX!_[#-M
M_P"C!7Z\5CVW@[0+.XCGM]#TV">-@R21VD:LI'0@@9!K8H **** /R ^&_\
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MV5^M];^"?#L%ZK;EN8M)@60'U#!,YKH-3T/3M:$8U#3[6_$>2@N85DVYZXW
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M?^T'XS^#FG7EEX5N[2PCO)1+.[V44LDA PH+LI.!S@=!D^IKMO\ AN?XO_\
M0?M/_!;!_P#$5^DG_""^&O\ H7M*_P# *+_XFC_A!?#7_0O:5_X!1?\ Q- &
MEI4[W6EV<TAS))"CL<8R2H)JU2*H10J@!0, #M2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S[^W9-)%^SIK"
MH"5DN[19,'HOFJ?Y@5\S?\$[(8Y?CAJK. 6CT"=D)['S[<?R)K[3_:+\!3?$
MKX+>*M!M8O.OI;7S[6,=6FB82HH]V*;?^!5^</[,'Q/MOA#\9M'UG4G:'29
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M!)9>>N?N?X0? /PK\#WUH^&8KF-=5DC>474OF% @(5%;&=OS,>23DGFO"O\
M@F_'CX=>*Y-N-VJJN[UQ"O'Z_K7UY0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W@OX;]?\
M(Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\
M/OA]?>/=5\F',-E$0;BZ(X0>@]6/84?#[X?7WCW5?)AS#91$&XNB.$'H/5CV
M%?5'A_P_8^&-*AT[3H1#;1#IW8]V8]R?6N'$8A4ERQW,YSY=$'A_P_8^&-*A
MT[3H1#;1#IW8]V8]R?6M&BBO#;;=V<P4444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GKQY^P]
M\/\ XA>,=1\2:A?:];7NH3FXN(K2YB6)F/7 :)B ?K7HOPF^!7@[X+6,T'AC
M3/(N+@ 7%]<.9;B8#H&8]!_LJ .^,UZ!10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHG606@88:1V&07()4!20 3R2?EO_ +=_PT\4?$CP]X3@\,:+=:S+:W4[S);
M$QJ44 G)[X-?4E% 'S9^PO\ #SQ)\.?A[K]EXET>YT:[GU0S117( +)Y,8W#
M!Z9!'X5])T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PWQM_P"28:U_
MVQ_]'QU\JU]5?&W_ ))AK7_;'_T?'7RK7MX+^&_7_(Z*>P4445Z!J%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5U7P^^'U]X]U7R8<PV41!N+HCA!Z
M#U8]A1\/OA]?>/=5\F',-E$0;BZ(X0>@]6/85]4>'_#]CX8TJ'3M.A$-M$.G
M=CW9CW)]:X<1B%27+'<SG/ET0>'_  _8^&-*AT[3H1#;1#IW8]V8]R?6M&BB
MO#;;=V<P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .-^+]A<ZG\.M6MK.WEN[E_)V0P(7=L3(3@#D\ G
M\*^:O^$$\2_]"]JO_@%+_P#$U]CT5V4<2Z,>5(TC/E5CXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*W^O2_E*]HSXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*/KTOY0]HSXX_X03Q+_ -"]JO\
MX!2__$T?\()XE_Z%[5?_  "E_P#B:^QZ*/KTOY0]HSXX_P"$$\2_]"]JO_@%
M+_\ $T?\()XE_P"A>U7_ , I?_B:^QZ*/KTOY0]HSXX_X03Q+_T+VJ_^ 4O_
M ,31_P ()XE_Z%[5?_ *7_XFOL>BCZ]+^4/:,^./^$$\2_\ 0O:K_P" 4O\
M\31_P@GB7_H7M5_\ I?_ (FOL>BCZ]+^4/:,^./^$$\2_P#0O:K_ . 4O_Q-
M'_"">)?^A>U7_P  I?\ XFOL>BCZ]+^4/:,^./\ A!/$O_0O:K_X!2__ !-'
M_"">)?\ H7M5_P# *7_XFOL>BCZ]+^4/:,^./^$$\2_]"]JO_@%+_P#$T?\
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M (FOL>BCZ]+^4/:,^./^$$\2_P#0O:K_ . 4O_Q-'_"">)?^A>U7_P  I?\
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M$$\2_P#0O:K_ . 4O_Q-'_"">)?^A>U7_P  I?\ XFOL>BCZ]+^4/:,^./\
MA!/$O_0O:K_X!2__ !-'_"">)?\ H7M5_P# *7_XFOL>BCZ]+^4/:,^./^$$
M\2_]"]JO_@%+_P#$T?\ "">)?^A>U7_P"E_^)K['HH^O2_E#VC/CC_A!/$O_
M $+VJ_\ @%+_ /$T?\()XE_Z%[5?_ *7_P")K['HH^O2_E#VC/CC_A!/$O\
MT+VJ_P#@%+_\31_P@GB7_H7M5_\  *7_ .)K['HH^O2_E#VC/CC_ (03Q+_T
M+VJ_^ 4O_P 31_P@GB7_ *%[5?\ P"E_^)K['HH^O2_E#VC/CC_A!/$O_0O:
MK_X!2_\ Q-'_  @GB7_H7M5_\ I?_B:^QZ*/KTOY0]HSXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*/KTOY0]HSXX_X03Q+_ -"]JO\
MX!2__$T?\()XE_Z%[5?_  "E_P#B:^QZ*/KTOY0]HSXX_P"$$\2_]"]JO_@%
M+_\ $T?\()XE_P"A>U7_ , I?_B:^QZ*/KTOY0]HSXX_X03Q+_T+VJ_^ 4O_
M ,31_P ()XE_Z%[5?_ *7_XFOL>BCZ]+^4/:,^./^$$\2_\ 0O:K_P" 4O\
M\36WX1^$>O\ B36([:ZT^[TJT'S37-U T8"^BA@-S>U?5E%2\;-K1"]HS.\/
M^'['PQI4.G:="(;:(=.['NS'N3ZUHT45Y[;;NS(****0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
M?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_
MZ"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\
M:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=C
MV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_
MZ"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\
M:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W
M_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4
MNX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO
M'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W
M_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=
MU+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_
MV_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6
MEV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=
MU+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_
MV_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H
M(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH
M^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8
MJ*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H
M(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH
M_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_
M '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[
MA]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=
M_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_
M '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4
MO^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;
M_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:7
M8]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4
MO^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;
M_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A
M=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZ
ME+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BH
MKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A
M=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'UI=CV*BO'?[=U+_H(7?_ '_;_&C^
MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MI/ .I7=YK$R7%U/.@@8A9)"P!W+SR:SGA)0BY-[%1Q"DTK'?4445PG6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K\1O^0)!_P!?
M"_\ H+5YS7HWQ&_Y D'_ %\+_P"@M7G->WA/X1Y>(_B!1117:<P4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U7PY_P"0
MW/\ ]>[?^A+7*UU7PY_Y#<__ %[M_P"A+7/B/X4C6E\:/1J***^?/8"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5^(W_ "!(/^OA
M?_06KSFO1OB-_P @2#_KX7_T%J\YKV\)_"/+Q'\0****[3F"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NJ^'/_(;G_Z]
MV_\ 0EKE:ZKX<_\ (;G_ .O=O_0EKGQ'\*1K2^-'HU%%%?/GL!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/RK)@$,O?:PY&>G(YQFOF3X\?%+Q?H/Q:\16&G>)-2LK*&5!'!!<LJ(#$A.
M#QR37U[X3\!>'O T4T>@Z3;Z8LP42F%?FDVYV[F.2<9/7UKX9_:._P"2U^*/
M^NT?_HE*O$N<:4;O4F@HRJ.RT/I+XRW'C6[^%7A*?PE)JLNJR^0]S)IQ8RLI
M@))8KS@MC\:^,T_M'^W5V>?_ &M]IXQGS?.W?GNW?K7Z2^"?^1,T#_L'V_\
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MMTP1ZX/? ])\3^&--\8Z'<Z/J]L+O3[D*)82Q7=A@PY!!'('(-9?A'X7>%?
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M%92@Z=:"O=&D9*=*3M8ZW]I_Q'XS\ _$%9--\2:I9Z1J4"S0117+*D;K\LB
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MHUJ/W%C;I IQ][:,%C[DY)^M%)NI6E.^B"HE"FH]6:M%%%>@<@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !75?#G_D-S_]>[?^A+7*UU7PY_Y#<_\
MU[M_Z$M<^(_A2-:7QH]&HHHKY\]@**** "BBB@ HHHH **** "BBB@ HHHH
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MD?PY%XE36AK&J&X6[%YY9,>W=OWX^[G&:JO2E44>7H*E4C!N_4]UK\X/$/\
MR5S4O^PY+_Z4&OT?KPJ]_9(\.7WB6XUI]8U1;B:[:\,8,>T,7WX^[G&33Q-*
M52W+T"C.,+\QV'[0'@V?QS\*M9L+.,S7T*K=V\:C)=HSN*@=R5W #U(KY&_9
M]^*=O\*?&[W6HI(VEWD)MKGRURT?S JX'?!'(]">^*^_J\<^(W[+OA3Q[J,^
MIP//H6ISDM+): &*1CU9HSW_ -TC/).2<TJU*4I*I3W04JD5%PGLS!^+7[4?
MANW\%W4/A+5WO=;NT\N&2&&2/[.#U<EU'(&<#KG%4/V7/B%X\^(6KZB^MZFU
M]H-E#MWR6T:EIF(VJ'503@;B>3U'K1I?[$^A6]RCZAXBOKR%6!,4,*0[AZ9)
M:O>O"_A;2O!FBP:3HUFEC80YVQ)DY)ZDD\DGU/-$(UI3YJFB[!*5.,>6&IK5
MXA^V ]XGPBQ:LPA;4(1=!>ABPY /MO$?Z5[?5'6]%L?$>DW>F:E;I=V-U&8I
MH7Z,I_4?4<@\BNFI'G@X]S"$N629\:_LI:SX+T?Q#JS>*'L;>^:.,V%UJ.T1
M1X+>8 S<*QRF">P.#UST7[6'Q?\ #_B[2--\-Z%>1ZHT%V+R>ZMSNB4JCHJ*
MW1B=Y)QP,#GTZ75?V*-$N;R233_$5[96[,2L,L"S%!Z!LKG\:ZG3_P!E#P78
M>%+_ $@BYGN[P*'U64J9X]K!OW?&U1D8/&2#R37!&E6]FZ=D=CG3Y^>YQ'[$
M$JG3_%\8/SK+:L1[$2X_D:\^_:__ .2O'_L'P?S:OI'X4? 72_A'JU[>Z9JN
MH78NX1#)!=%-APP(;Y5!R.1_P(U3^)W[-^A_%+Q,=;U#4]0M+CR4@\NV*;,+
MG!Y4G/-6Z,W05.VI*J155SZ&Y\ _^2.>%/\ KS'\S7S[^VQ_R.?A[_L'M_Z,
M:OJ?P;X7M_!7A?3=#M99)[>QB$2238WL,DY. !WKBOBQ\!-'^+FJV5_J6H7U
MG):PF!5M=F""Q;)W*>>:UJTY2H\BWT,Z<U&IS/8H?LI_\D4TC_KM<?\ HYJ^
M0/C!"UI\6/%PP8V_M:YD&>O,K,#^N:^]_ASX#L_AKX3MM L;B>ZMH'=UEN,;
MSN8L<X '>N"^*?[,F@?$S79=:%]=:1JDP43/"JR1R;0%#%3CG  X(Z=*RJT9
M3I1BMT73JQC4;>S.N\#_ !B\)_$:_>RT#4FO+J.W^TR1&"2,QKD#DLH!.6'3
M-?%_[1W_ "6OQ1_UVC_]$I7U1\'OV=K#X1ZW<ZM#K-UJ5W-;M:E7C6.,(65C
MQR2<H.<^O%4O'7[+'A_Q[XLU#7[S5M2M[F]=7>* Q[%PH7C*D_PTZM.K5II-
M:W"G.%.;:>AVW_-&?^X!_P"V]?G[X/\ $=QX0\4:7K=J@DFL+A+@(>C 'E3Z
M C(_&OTA_P"$>A_X1;^PO,D^S_8OL7F<;]NS9GTSBO*O!7[*GACP9KJZB+V]
MU1?)E@>TO1&T4B2(48, H/0T5J,ZCCR]!4JD8*5R]!^U-\/I?#W]I/JLD<X3
M<VG&!S.'QG8.-I],YV^]?'5RVH_%_P")DK6\)^WZW?DI&HR(PS=_95ZGT4FO
MI?7_ -BWP_?ZA)/I6MWFE6[DG[-)$LX3V5B5./KD^]>B?"OX$^&_A1YEQ8)+
M>ZI*NQ[^[(+A>ZH  %'TY/<FIE3K5FE4LDBHSITTW#<9\:OAV_BWX0WN@Z9$
M9+JTBCDLX@>6:+&%^I4$#W(KY'^ _P 4U^$7C:2ZOX)9--NHS:WD:+^\3Y@0
MP![J1T]">]?H#7E'Q'_9L\(_$6]EU!XYM(U23E[FQ(42GU="""?<8)[DUK6H
MRE)5*>Z(IU$DX3V9F>+OVKO!&D^'Y[C1M0;6=39#]GM4MY$&[L7+J  #U[^@
MKYB^"_@N^^*/Q2LMZM)!'<B_U"?;\JH&W$'T+'Y1]?8U[E9?L2:1'<JUWXGO
M9[<'YHX;9(W/_ B6 _*O<_!'@#0OAWHXTW0K%;2 G=(^=TDK?WG8\D_H.V*S
M]E5K23JZ)%\].G%JGJV>7_M=^#KCQ'\-X=1M(S++H]Q]HD51D^2RE7(^AVD^
MP->+?LQ?&C3/AG?ZEIFO.\&E:@4D6Z5"X@E4$?,J@DA@0,C."HXY)'VS)&DT
M;1R*'1@596&00>H(KP+Q?^QUX9UW4Y+S2=1N=!65BSVJ1B:%3_L D%1[9(],
M"JJTI^T56GN33J1Y'">Q@_M%?M">']<\%S^&_#%[_:ESJ!5;B>*-@D40(8@%
M@,L< <9P,]#BO-OV1O\ DL=M_P!><_\ (5] >"OV6O"WA#3]062:XU/4KRUE
MM?MTX4&!9$*,8DQA3ANIR?P)JS\-/V;-#^&'BB/7+#5-0NKA(GB$=R8]F&&"
M>%!J/959U(U)%>TIQ@X1/5[VSAU"SGM;B,2V\\;121MT96&"#]0:_.Z\.J_!
M'XI7T=I(4O\ 29Y8HI&_B1E*JWXHX/XU^B]?"G[5FNZ1KOQ8G.E%)7MK:.WN
MYXV#+),N2<8[JI53[KCM58Q+E4NJ%AGJX]"]^R1X,/B7XF-J\Z;[71H3.21D
M&9\K&#_X^WU2OMVO&_V5/!9\*_"RVO)H]EYK$AO7R.1']V,?3:-P_P!^O9*U
MPT.2FO,SK2YIL****ZC **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MJOAS_P AN?\ Z]V_]"6N5KJOAS_R&Y_^O=O_ $):Y\1_"D:TOC1Z-1117SY[
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROQ&_Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?\ D-S_ /7N
MW_H2URM=5\.?^0W/_P!>[?\ H2USXC^%(UI?&CT:BBBOGSV HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_P @2#_KX7_T%J\Y
MKT;XC?\ ($@_Z^%_]!:O.:]O"?PCR\1_$"BBBNTY@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOAS_R&Y_^O=O_ $):
MY6NJ^'/_ "&Y_P#KW;_T):Y\1_"D:TOC1Z-1117SY[ 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!S7CZTGO-'A2WADG<3J2L:EB!M
M;GBN"_L+4O\ H'W?_?AO\*]BHKLI8ETH\J1S5*"J2YFSQW^PM2_Z!]W_ -^&
M_P */["U+_H'W?\ WX;_  KV*BMOKLNQG]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
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MGD'U:!YE_P (#JW]R+_OY1_P@.K?W(O^_E>FT4?7*GD'U:!YE_P@.K?W(O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PWQM_P"28:U_VQ_]
M'QU\JU]5?&W_ ))AK7_;'_T?'7RK7MX+^&_7_(Z*>P4445Z!J%%%% !1110
M4444 %%%% !1110 4444 %==\.OB+>^ =3WINN-.F(^T6N>&_P!I?1A^O0^W
M(T5,HJ:Y9; U?1GVIH>N67B/3(-0T^=;BUF&58=1Z@CL1W%7Z^2OAU\1;WP#
MJ>]-UQITQ'VBUSPW^TOHP_7H?;ZFT/7++Q'ID&H:?.MQ:S#*L.H]01V([BO
MKT'1?D<LH\I?HHHKE("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!PWQM_Y)AK7_;'_ -'QU\JU]5?&W_DF&M?]L?\ T?'7RK7MX+^&_7_(
MZ*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UWPZ^
M(M[X!U/>FZXTZ8C[1:YX;_:7T8?KT/MR-%3**FN66P-7T9]J:'KEEXCTR#4-
M/G6XM9AE6'4>H([$=Q5^ODKX=?$6]\ ZGO3=<:=,1]HM<\-_M+Z,/UZ'V^IM
M#URR\1Z9!J&GSK<6LPRK#J/4$=B.XKP*]!T7Y'+*/*7Z***Y2 HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM\K 'J#7GOB[]KOX9>!O$NH:#J^LW-OJ=A*89XDL9G"MC.-P7!Z]JQ_V&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#XK_ /)+?&/_ &!KS_T0] 'YJ?L:_P#)RO@O_KI<_P#I+-7W=^U9X@\=:/\
M#.2U^'^DZAJ&L:A)Y$MSIL1DEM(-IWLH7YMYX4$ D98C! KX1_8U_P"3E?!?
M_72Y_P#26:OT#_:"^/ND? +PI#J5];MJ.I7KM%8:=&^PS,!EF9L':BY&3@GY
M@,<T ?#GPB_8P\;_ !<M[W5-6N&\*P1W#0L=7MY3=328!8B,X..1\Q(R<XS@
MUQ/QI^#/B+]F[QMI]I-JB2S21"\L=3TYWB;AB/8HX([$]1S7M&G?M+_M!_'.
M[N(O NDI9VJ-L9]+LD*1YZ*\\Y*AL>Z^H KQS]H3P7\1_"6MZ5+\2M3EU'5;
M^!I85FOC<M"@;!7^ZHSV4XH _1?]FCX@7WQ.^"7AG7]3D\[4Y8G@N9> 9)(I
M&C+G'=@@8_6OS:^-6I2:/^T1XSOXE5Y;7Q)=3HK_ '25N&8 X[<5][?L,?\
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MVSBOVCK\9=/LX=0^(UM:W""6WGU58I$)QN5I@"/R- 'U;_P\IU+_ *$.T_\
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M_P#HPU^JGBO6-2T#P#J&H:-ILFL:M;V)>TL8ADS3;?D7J.,XS[9K\J_VC?\
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M !@5\@_MSW_Q-U^ZM?#GACP_K<WA..$37MUIEM)(+J4Y^1BF3L48X. 6)SG
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M<;(' EN),'U6UE8'\",_A0!Z+XP_8%\<:9X2O_$4OB&QUG6XHGN[JP02,\A
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MR-%3**FN66P-7T9]J:'KEEXCTR#4-/G6XM9AE6'4>H([$=Q5^ODKX=?$6]\
MZGO3=<:=,1]HM<\-_M+Z,/UZ'V^IM#URR\1Z9!J&GSK<6LPRK#J/4$=B.XKP
M*]!T7Y'+*/*7Z***Y2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPW\3=)\7?$"U@T2ST6=;NWT]+J.XFN)UYC),99556 8_-DX QR2 #]$****
M"BBB@ KG/B1_R3OQ3_V"KK_T2U='7.?$C_DG?BG_ +!5U_Z):@#\L?V9O^2_
M> _^PK%_.OK7_@I!_P D[\)_]A5O_1+5\E?LS?\ )?O ?_85B_G7UK_P4@_Y
M)WX3_P"PJW_HEJ /D?P_\';OQ5\$==\<:;OFGT+41#>VX&<VS1J?, _V&//^
MRQ/&VO>OV!?CK_86M2_#K6+C;8:BYGTJ20\17&/GB]@X&0/[P/=Z[C_@G5:0
M7_PP\96MS$EQ;3ZD(Y8I%#*ZF!05(/4$'&*^8?VBOA#??L__ !8DMK!YH=-D
MD%_HUXK$,J;LA=W]^-ACUX4]Q0!T_P"W?_R<3JO_ %Y6O_HH5^@/P+_Y(E\/
M?^Q>T_\ ])HZ_+7XS_%"7XO^+H/$=U#Y-_)86\%V  %::--CNOH&(W8[9QVK
M]2O@7_R1+X>_]B]I_P#Z31T ?E'KG_)4M0_[#,G_ */-?LI7XUZY_P E2U#_
M +#,G_H\U^RE 'G7[16B0^(/@3X\M)T#JNCW-RH(S\\2&5/_ !Y%K\Z_V/=8
MET;]HSP<\;;5N)I;60=F5X77'YD'\*_0[]I3Q!!X:^ OCJ[G<(LNE3V:$G&7
MF7R5Q[YD%?GG^QWHDVN?M%^$5C7*6LLMW(W952)SG\]H_$4 ?JO1110!\9_M
MU?M%:MX5O(/ 'AJ]?3YY[<7&J7MNY64(^=D*L.5R!N8CDAE'0G/C_P (?V'O
M%7Q5\&6_B:XU>TT"UO4,EE%<Q/)+,N>'8#&U6Z@\DCG&"*Y#]K]YY/VC_&IN
M22XN(0N?[@@CV?\ CN*]9\)^-_VI+#PMHUKHFBW!T:&RACL2FF6S*8 @$>"1
MR-H'- 'F'A7QCXY_8^^+=QI=U(XCMID&HZ8DA:UOH2 =Z9&,E>5? (/!_B6O
MTH\0:Q:>(?A?J6JV$HGL;[1Y;F"4='C> LI_$$5^=/Q*^%/QX^+?B)=<\2^#
MM0N]26!;;S8K6*(%%)(R%P,_,>:^W/A?I&KZ!^RW9:9KMI-8ZK9Z%<036TXP
M\>U9 H/_  $+^% 'YG_"_P 4^(/"'C6PO?"H)\0RB2RLMJ;G$DZ-""@_O?/Q
MGC.*^A_$?[ GC^3PS>>(;KQ#9ZMXD:-KJXTXF2265\;BHF;[\AZ<C!/?O7D7
M[+-JEY^T)X%C< J-063D9Y568?J!7ZTT ?E=^R)\5-3^'7QET"SANI/['UN[
MCTZ\LRY\M_-8(CXZ;E8J<]<9'0FOOC]IOQ'XU\/_  ONE\ :5?:EX@O)!;B6
MPA,DEK$02\J@<[N HP,@MGM7YK?#&)8/CMX3C081/$EHH'L+I*_3CX\?'/1_
M@-X/76=2A>^N[B3R++3XF"M<28R<L<[5 Y+8.,C@D@4 ?"?PB_8Z\<?&275M
M0UN>?PJEO,8I)=:M93<SS8!;"-M) !&6)ZG SSCD/CI\"/$'[.'BC2HKC5(K
MI;I3<6.HV):)PR, >.J,I*G@GJ,'KCV*S_:C^/GQQOKFV\!:-'901D*YTNS6
M3R@>@DGGRBD\\_+T..E>2_M$>!_B?X5N=#OOB;JLNH7VI+,;6*:^^TM $V;Q
M@91 =Z\(<'!H ^__ -E+XB:C\3?@AH6KZQ,;G58S+:7-PW65HW*JY]RNW)[G
M)K\Y?VC?^2\^/O\ L,W/_HPU]V?L$?\ )O=I_P!A&Z_]"%?"?[1O_)>?'W_8
M9N?_ $8: /:O"W[)7Q&_:*TI/'?BCQ/!8SZI&)K-+U7FD>(\H=JX$49!^4#/
M&.!FO&KZ#QQ^RW\5I+=+IM+UW3G5M\#EH+J(\KD<!XV'8CU!P1Q^L7AR.WB\
M/:6EH +5;6(1 =-FP;?TQ7P7_P %'XH%^)7A:5<?:6T@J_\ NB9]OZEJ /MG
MX5>/[7XI?#O0?%-HGE1ZE;"1XLY\J4$K(F>^UU89[XS7Y66'_)>K?_L95_\
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M$6CV*6O%JL$8B_W-HV_IBO@+_@H[%;K\4O#4B$?:GT<"08_A$TFT_F7_ "H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9TJ1K>[L+D$+-$PPRDC^%A@JPR/NL,U^MNGV%OI-A;65I$MO:6T2PPQ)T1%
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M:A4C10JJ!T  Z"@#Y._X*._\DM\,_P#89'_HB2LK_@FS_P BMXV_Z_;;_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#AOC;_R3#6O^V/_ */CKY5KZJ^-O_),-:_[8_\ H^.OE6O;P7\-^O\
MD=%/8****] U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBK^AZ'>^(]3@T_3X&N+J8X51T [DGL!W-)M+5@&AZ'>^(]3@T_3X&N+J8X
M51T [DGL!W-?57PZ\!P> =#^R)*UQ<S$27$N3M9\8^4=@.GJ>_M%\.OAU9>
M=,V)MN-1F ^T76.6/]U?11^O4^W7UX>)Q'M7RQV.:<[Z(****X3,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/B1_P D[\4_]@JZ_P#1
M+5T=07UE!J5E<6EU$LUM<1M%+&W1T88(/U!- 'Y*_LS?\E^\!_\ 85B_G7UK
M_P %(/\ DG?A/_L*M_Z):O=M"_9V^&WAG6+35=+\'Z=9:C:2"6"XB5MT;CH1
MS71>-OASX:^(]E;VGB;1[;6;:WD\V*.Y!(1\8R,'T- 'S/\ \$W_ /DG?BS_
M +"J_P#HE:]?_:=^"<7QN^&EUI\$:#7[#-UI<S<?O0.8R?[KCY3VSM/\-=SX
M)^'/AKX<65Q:>&='MM&MKB3S98[8$!WQC)R?05TE 'XC7-M+9W,MO/$\,\3F
M.2.089&!P01V(-?L#\"_^2)?#W_L7M/_ /2:.J.N?LZ_#7Q+K%WJNI^#=,N]
M0NY#+/.\9#2.>K'!ZGJ3WKN])TJTT+2K/3;"!+6QLX4M[>"/[L<:*%51[  #
M\* /QN\6W)LOB%K-PJAFBU2:0*>^)B:^H3_P4C\2XX\':5G_ *^):^K+O]F3
MX6WUU-<W'@G3)9YG:221D;+,3DD\]R:B_P"&6OA/_P!"+I7_ 'PW^- 'YZ_&
M#]I3QU\?WMM+U$Q0:;YJM#H^EPL$>7H"<EG=N> 3CG@"OK_]BG]G.^^%&B7G
MB?Q);FV\2:M$(H[.0#?9V^=VUO1W(4D=@J@\Y ]V\*?"SP=X&F\[P_X7TG1[
M@C:9[.SC24CT+@;B/QKJ: "BBB@#X'_X* _!:^LO%,7Q$TVVDN--OHH[?4W0
M;OL\R )&[>BL@5<] 4Y/S"E^!G[>=IX$\ Z=X;\5Z'?:C)I< MK6]T]T)DB4
M81'5BN-HPN03D <9Z_>=Q;Q7<$D$\230R*4>.10RNI&""#P0?2O(M7_9#^$&
MMWINKCP3:1RDYVVEQ/;1_P#?$4BK^E 'QNW[4OQ@^*GQ;D3P+?7>G-J<RQ6.
MB0K'<10H !EO,4KT!9F( ')X%??VNVU]9_"[4H-3O!J&HQZ/*MS=+&$$THA.
M]@H  !.2!VH\#?"OPC\-()(O#'A^QT?S/]9)!'^]<>C2'+$>Q-=+=VL-]:S6
MUQ&)8)D:.2-NC*1@@_4&@#\HOV3O^3B? _\ U^M_Z*>OUCKSSP]^SW\.?">M
M6FKZ1X1TZPU*U;?!<Q*P:-L$9'/H37H= 'Y ?#?_ )+WX6_[&:U_]*EKZU_X
M*/\ A#4M1\/>$?$5M%)-INF2W%O=E1E83-Y7EL?0$QE<],[1W&?H*Q_9Q^&>
MFZO;ZI:^#=-AU"WG6YBN%1MR2JVX,.>H(!KT&]L;;4K.:TO+>*ZM9D,<L$Z!
MTD4\%64\$'T- 'YZ?LG_ +6OA[X)^#-0\-^(]*OI8GNWO8+K38T=F+(JE'5F
M7^X,')ZX.,9KS[]IGXVZE\?]=M-?BT:XTSPMIVZQL3*I;,C?.Y=Q\N]@ =H/
M 4=>I^\)_P!C_P"#]QJ O'\$VPF#;ML=U<)'G.?]6) F/;%=KK'PD\&:_P"%
M[3PY?>&M.FT&TD$UOIZP!(8G (#*JXP<,WYF@#Q/_@GSJL-]\"Y[1'4S66K3
MQR)W 94<'Z'<?R/I7Q-^T#:RWW[0?C>V@7?--KEQ&BY RQD( R?<U^I?@?X8
M^%OAK'>1^&-$MM%CNRK3K; @2%<[2<D]-Q_.L34OV>_ASK&O3ZW>^$=.N-5G
MG-S)=.K;VESG<>>N>: /DKX8_MQ:O\)/#B>#/&WA6YOM1T-?L44J3"&95C&U
M8Y493RN,;P>1C@G)/@GQ*\>^)?VEOBN+]-.:74[\I9Z?I=IE_*C&=J GKU9F
M;@9+'@=/TX^(/P,\!_%25)O%'AFSU.Z4!1= M#/M'13+&5<@>A.*D^'WP3\#
M?"QWD\+^&[/2IW78UR-TLY7^[YCEGQ[9H 7X+?#Q?A5\+?#OA?<LDUA; 7$B
M?=>9R7E(]M[-CVQ7Y;6'_)>K?_L95_\ 2JOU_KS=/V<?AG'JZZHO@W31J"S_
M &D7&QMPEW;MW7KGF@"G^U+_ ,F]^.O^P<W_ *$M?$_[ '_)?E_[!5S_ #2O
MT<U_0-.\4Z-=Z3JUI'?:==IY<]M*,K(OH:Y;P?\ !#P)X UC^U?#OABQTG4?
M+:+[1;J0VPXR.3WP* /G7_@I'_R)/@[_ +",W_HJI_\ @F__ ,D[\6?]A5?_
M $2M?2_C?X;^&?B1:VUMXFT:VUF"V<R0QW()",1@D8/I2^"?ASX:^'%E<6GA
MG1[;1K:XD\V6.V! =\8R<GT% 'A7_!0?_D@UO_V&;?\ ]%RUYE_P33_X_OB#
M_P!<[#^=Q7V3XQ\#:#\0=(&E^(]+@U?3Q*LPM[@$J' (#<=P"?SJCX'^%7A+
MX:O>-X8T&TT5KP(+@VRD>8%SMSDGIN;\Z /A[]O/X(W^@>.I?'NFV<DVA:LJ
M?;98ER+:Y V_-C[JN I!_O;AW&<OX4_MW^)OAQX(M?#E[H=KX@2PB$%E=2W#
M0O'&  JN #O"C@8VG&.>*]K_ &@?VOM;^#OQ.U7PG?>$-.UO1&@BE@::5XVG
MB>,;@V0RD;]Z].U1_"CXA_LY>+M)A\1ZEX=\*>$-?5G:?3+V-&$+!CM9"R*C
MY&&!5<@G':@#XZ^,NN>,?&_B"W\9>,8&MY]>B\ZR79Y:?9T.Q?+0\A.#@GKR
M<G.3^@'[#'_)N&@?]?%W_P"CWKY"_;2^+_A_XM?$C3W\,SF]TS2K$6GVP(52
M9R[,VP$ [1D#..2#CC!/VU^R/X7N?"7[/7A&SO(FANIH9+QD88($TKR)D?[C
M+0![#7!_'"P\87_PTU8> ]0?3_%$*K-:E$C8S;3EHOWBD LN<'CD#D#-=Y10
M!^:_P=_;)\8_#;QS?-X\N=6\2:=,/L]U97$F)[21&^]&C84,.0RG;GN1BNN_
M:-_;)\$?%OX<7OA[2/"NH37]SM"7NL0PQ_9,.K;X]CN2QP1U7KWZ'[!\<_ [
MP%\2;I;KQ)X7L-2NP,?:BACF(]#(A#$>Q/%<UHW[)'PBT&X6:U\$V<CJVX?;
M)IKE<\?PRNP/3IC^= 'S9_P3P^%^JCQ+JWCJZMY+?2%LWT^TD?*_:)&=&8J/
MXE4)@GIEAC)!QM_\%*-$N9=.\":ND9:S@EN[663LKN(F0?B(Y/\ OFOM*WMX
MK2".""-(88U")'&H554<  #H!6?XE\+Z1XQT:?2=<TZVU739P/,MKJ,.C8Y!
MP>A!Y!'([4 ?GC^S)^US%\%?"+>%+GPZVJ"YU(W$=XMV(A$)!&C!EV'.-I;K
MSG''6OH'_@H+X)O?$GPCT_5[&![@Z)?":Y5!DI Z%6?Z!MF?8D]!7H%A^R)\
M(=.U(7T/@FT:<-N"S7$\L6?^N;R%/TKU^6))HWCD19(W!5D89# ]010!^8?[
M+/[42_ %M7L-2TJ75=%U%TF(MG"S0RJ,;ANX8$<$$CH.>M7_ -I3]H#6?VC]
M*\[2- N--\%^'I%FFFF(9FGD.Q#(1\H."0J DX+DDCI]GZE^R+\(=6U1M0G\
M$VBW#'<5MYYX(L_]<DD"#_OFNSN/A+X-NO!X\*OX;TY?#H<2?V;%"(X2X.0Q
M"XR<C.>IH ^3?^":'_-1_P#N&_\ MU7!_MW?!J_\)_$B?QI:VSR:#KI5I)D&
M5@N@H5D;TW!0P)ZDMZ5]X^!OA9X3^&GVW_A%]"M=%^V[/M'V8$>;LW;,Y)Z;
MV_,UOZKI-CKNG7&GZE9P7]C<+LFMKF,21R+Z,IX(H ^"_A!^W]<>"? ]CH'B
M3P[+K<^G0K;VU];7(C:2-0 BR*5/( QO!YXR,Y)\&^-OC;Q-\6/$:^/->L6L
MK+5F>VTY1GREC@V@I&3RP4N,MT+,WN!^B\?[(?P@BU0:@/!-H9]V[8UQ.T.?
M^N1DV8]MN*Z_Q7\'/!/CBVTVWUSPUI^H6^FHT5E"\6U+=#MRJ*N !\J\>PH
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MTK%W=E8EF)R2>?6@#\Y_@I^T7K?P'BU ^']"T"[O+TCS;_4K>:2<(.D:E95
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M%IHLEVJK.ULI'F!<[0<GMD_G76T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <-\;?^28:U_VQ_\ 1\=?
M*M?57QM_Y)AK7_;'_P!'QU\JU[>"_AOU_P CHI[!1117H&H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !115_0]#O?$>IP:?I\#7%U,<*HZ =R3
MV [FDVEJP#0]#O?$>IP:?I\#7%U,<*HZ =R3V [FOJ7X=?#JR\ Z9L3;<:C,
M!]HNL<L?[J^BC]>I]CX=?#JR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]NOKP\1B'
M4]V.WYG/.=]$%%%%<)D%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><?&?X!>$_CII
M=O:^(;>:.ZM<_9=0LW"7$.>H!((*G R&!'I@\U\WWW_!-2UDN"UG\09H(.R3
MZ0)6'_ A,H_2OM>B@#Y@^'/[ 7@?P?JMOJ.MW]YXJG@<.EM<(L-J2#D;HQDM
MVX+8/<&OIX *    . !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#?&W_DF&M?]
ML?\ T?'7RK7U5\;?^28:U_VQ_P#1\=?*M>W@OX;]?\CHI[!1117H&H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%7]#T.]\1ZG!I^GP-<74QPJCH!W
M)/8#N:3:6K -#T.]\1ZG!I^GP-<74QPJCH!W)/8#N:^I?AU\.K+P#IFQ-MQJ
M,P'VBZQRQ_NKZ*/UZGV/AU\.K+P#IFQ-MQJ,P'VBZQRQ_NKZ*/UZGVZ^O#Q&
M(=3W8[?F<\YWT04445PF04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <-\;?^28:U_P!L?_1\=?*M?57QM_Y)
MAK7_ &Q_]'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 444
M4 %%%% !115_0]#O?$>IP:?I\#7%U,<*HZ =R3V [FDVEJP#0]#O?$>IP:?I
M\#7%U,<*HZ =R3V [FOJ7X=?#JR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]CX=?#
MJR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]NOKP\1B'4]V.WYG/.=]$%%%%<)D%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX5V.E:C:ZQX,2-[R]N!']GGW[<>7ABW\0Z@4 >R4444 %%%% !1110 4444
M%%%% !1110 45XW\+_VG=!^*GQK^(WPTT_2M1M-6\$/&E[=W(C\B?>2!Y>UB
MW;^("O9* "BBB@ HKQN7]IW08OVH(?@>=*U$^()=(_M@:B!']D$>"=OWMV[C
M^[CWKV2@ HHKQOXH?M.Z#\*_C7\.?AIJ&E:C=ZMXW>1+*[MA'Y$&P@'S-S!N
M_P#"#0![)116!X\\>>'_ (8>$-3\4>*=5@T70--C\V[OKDG9$I(4< $DEF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?+W_!23XV7/P0_91\37FFSFWUK7F30+&56PR-.&\QEQSN$*3$$="
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MA_M]ML_\>Q7H/['D5S#^RC\'TNC^]_X1/3"/9#;1E!_WSMH ]@KX _X+5_\
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M<$,#B@#8UC]L'X^?L[>,?"\/Q^^'7A=?!FOWZ::GB+P5<2LMK,XR-\<LCL<
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M%Y[9QZCS/,_6@#ZL\>>*H? G@;Q%XEN4\RWT;3KG49$SC<L,32$9^BU\)?\
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M[)/PE_:"^ _BK5_B!X.@\1:G;^(I;&*Z>[N('2$6MNX0&*1<?,['/7GK5O\
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M&<U5O?\ E,58?]B,?_07JO\ LJ6,,G_!37]IJ]9<W$-I!"C>BN8"P_.-?RH
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M&W2V^J:9%*9(7!9TW1YR1M9"I&6'*$,0W&O_ ,$][**P_8P^%,4*A$;2C*0
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MC=ZKLAA3(W.V#[  DD $CNO^"1%E;Z;/\?;.TA2WM;?Q2L44,8PJ(IG"J!V
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M.NL_''XO2$S:'X7U[3O 6@.?F0^5YCW;*>GWUW CJ+@_C^BWQA_:CT_]E?\
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MU-^VC;_'7_A(81:1:"=&_L7[*?,)PP\SS=V,?-TV_C6M^V%^SQ<?M1?!#4?
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M &=]>\+_ ! ^"W_":_%'4OBM\6/%'B>VM(5DMX[*WM;)9$!6"V0E8P99%R_
M;'W1AL_>?QI_9<NOBQ^T9\)/B=%XAATV#P,\KR::]J9&O-Y!X<, F,=P:SO@
MC^P9X!^#?CY?'EWJWB3X@^.HXS'#K_C#4/MLUN""I\H;0 =I(R=Q )P1DU])
MT <#\?/AC+\:/@SXP\#0Z@FE2Z]ITEBM[)$95A+#[Q4$9QZ9%>;:3^R/;_\
M#%Z? /5]>-PG]DOIS:S:V^S$GFF6.41ECPK[<KNY (R,Y'T/10!\<_![]B/Q
MEI_P8\7_  C^+GQ$B\??#^_TZVT[1;2UM/L\VE+"S,DB.03E2(2 2P!C Z<'
MGO"/[)_[4WPQ\-VW@;PC^T)H\/@BRC:UL;B^T!)+^TM\81$RK?=&0,R?+QC
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M[(QR6R><)(_-<.0Y  !("YY/'2NX_8W_ &1[C]F./QWJ>N^)8_&/B[QAJO\
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M ^*=>@^!'QIM?"7@36[MKN71M9TE+Q[-F7&8]RLK,,  _)E0H;=MYZWX'_\
M!/V7X,_M':=\5Y/'UWXHU%](FMM;DU2 FYU+4)F8R7(?>1&F"BK$ <!!\Q.3
M7V)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>business10a.jpg
<TEXT>
begin 644 business10a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H64&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?J^9E X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R1(,0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              CL   <S          $
M                 0             ',P   CL
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   CL     4F=H=&QO;F<   <S
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ([     %)G:'1L;VYG   ',P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      /E
M  $   "@    ,@   >   %W    />  8  '_V/_M  Q!9&]B95]#30 "_^X
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     /_A04YH
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB
M[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR
M-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I$
M.#0W.#=$0S-%03E%0C$Q.#$P-$1#0T,X-T,T.#9$0SPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I$,4(Y
M1$%%.3-&03E%0C$Q.#$P-$1#0T,X-T,T.#9$0SPO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#XW1$%%-S8Y
M-4(S1#4R03(V,S=#.#8U-40Y-S!&-4$R-SPO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z1#<T-S@W1$,S14$Y14(Q,3@Q,#1$0T-#
M.#=#-#@V1$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#0M,S!4,#0Z,SDZ,#,K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0X-#<X-T1#
M,T5!.45",3$X,3 T1$-#0S@W0S0X-D1#/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,Y
M.C S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z1#DT-S@W1$,S14$Y14(Q,3@Q,#1$0T-#
M.#=#-#@V1$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#0M,S!4,#0Z,SDZ,3,K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0Q0CE$044Y
M,T9!.45",3$X,3 T1$-#0S@W0S0X-D1#/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,Y
M.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D0Y-#<X-T1#,T5!.45",3$X,3 T1$-#0S@W0S0X
M-D1#/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.D0X-#<X-T1#,T5!.45",3$X,3 T1$-#0S@W0S0X
M-D1#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/C=$044W-CDU0C-$-3)!,C8S-T,X-C4U1#DW,$8U
M03(W/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP
M:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A
M=&4^,C R,2TP-"TR.50Q.3HS,SHR."LP-3HS,#PO>&UP.D-R96%T941A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3,P5# T.C,Y.C$S
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,2TP-"TS,%0P-#HS.3HQ,RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ ET# 1$  A$! Q$!_\0
M'P   00" P$!              8'" D!!0($"@,+_\0 ?!   00"  ,# P@.
M$@L)#0,-!0(#! 8!!P ($0DA,1(3%!46&3A!45?7%R(V.5AA<7=X@9BQM_ *
M&!HR-W5VD966EZ&UML'1U=8C)B<H9W*3L[2XX20E,T)#1D=4\35$14A24U56
M8V:&A]-SHJ0I-&1E=(6(E*6FI[+%_\0 '0$!  (# 0$! 0            $&
M @,%! <("?_$ &H1  $"! (#!@X*#P4$!P<$ P$" P $!1$&(1(Q01,646%Q
M\!0B-395=8&1E*&QM,'4!Q<T5'22E;71TQ4C)3(S1%-6<G-VLK/A\21"4F23
M)D.$U3=%8F6%MM((1F.&HJ2E1U=F@I;#Q/_:  P# 0 "$0,1 #\ E/VM/.]S
M=ZA[0+?FN-9<Q.U*%1:TC5B -5JMHFB HS!C3&N["35'B1%M(\Y.,%R,^0ZO
MRG5O2E]5X;2A"?TI['V%<.U#"5*GIZC2$W-3!GRZ^^P''%[E4YUIL%14;:+;
M;8L !TNTYGXYBJN5:4KT]+2\_-,,-="Z#33I;2G3DI=:OO<R2M:E$D\ &0SK
ME]DFY]\XZ?EN=Z]WACU^%_J8_P"7Z_C]+BZ#!.$@;[W:3W)1([IS_EQ17AB2
MN#_K2>[LPOO\\N*,>R3<^_=_?<;V]WIUOAC'3ZO]G]WW>OVNN.&\G"7YO4D<
M/]D3Q6.O9LAODKG92>V_C*_3&<]I-S[_ $7&]?=_Y^%_O^?]WW?JY\?=;R<)
M?F]2?!$Z]FHVRY-7?AODKG92>[LROCY(/9)N??Z+C>W[>R__ -?P^EX<-Y.$
M]N'J3E_E$Z^'[[EU6UPWR5SLI/:K>Z5\M_IXLA:,>R3<^_?C\MQO;]OICO\
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M9UC";\.UL4<MY)PJ4A@FM>ZX+,BVYCZ5/JB-$2Q&4TVXM?FW);N$9PC.$X^
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M<Y%)*'C>(.V:C8<B1T(O"$AW13QHQ"B$[:.N+><#K";A,OUS%*+S76ZRY>2
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M>4XCR,*QC.<6; 5!Q/A!BI-35%3-&>=EG&]QJ<DWH!A#J#I;HLWT@XDI*?\
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MX-NT0N7=W[HD%21U_;VT'C9@.W72QEZ_6QTL3K[3C[S8(D1<,*F3@Z'9<IQ
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M*,=>F%9Z]^>[.>_&<].(T&;DZ#6DK)2M!%R+BZ>0C(#8!KX9#JAH@.*"4WL
MZ+7)VYYWUV[^<9RXYW8\O.<8Z=/*ZYSCR>G3IGKW=,)3C'O8QT\,8QPW-D9!
MIH#4>E3F+9$CCOSO$[HO:XO4#^%'</WQRV"U\QP$1CRE>.%9QGIG'7KG/DIR
MK*O)3USW)\K/E93TZ=>O=WYSQ)0T=*Z4'2-R"A/("<S?*ULLKF,0M0 &D0$Y
M AQ(L#QZ5[9\%\^00>6OIG'EY^6QT5CPQG'7KC'3KWX\K.5=,_\ &SE7CW\
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M)[XJ?^O*^IP?F<_D?^$KFF_;OJKN_P#\*</;FQ3[PH'@E3_YG#VO:)[XJ?\
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M![$EV<_T+%'_ &8O']:N'M@8R[/3?Q);ZB&]3#W8MCXSWUL'L279S_0L4?\
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MW^J.2QB[)52PXA*\N"P8$R(A5D88C3$RAC"5:U()6A1S2DZ*T$7"DJ(TN,+
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M;K%'<;'A[*:&06W'J[$6\MN)"FL,(6ZO.5N*2WA2UYRI6<JSG/"$1SY2-B;
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MQF-ZGMQE2_2,99\SYS&4\9.TRI,H6X]3YYI#8*EK=E)AM"$C6I:E-@) VDD
M;8A$]).*2AN<E5K60$H1,-*4HG4$I2LDD[  ;Q+KCPQZHTEF^9RP?I(5_P!
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M?H+_ '%=[F-L0U[+KYWQRF?6A!^/_P!O-\<<67'/7=7OAZ_W41R,.=0*6?\
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MD_RP0:MJ_,,;':LDH::K=$KNR3$HL58<?C)N&Q;A#C19DEIN,PM$+,-"/;H
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MIYCTB.I6'6?/,NM><0GSC3B.J%(0U'+@1H4N#=(5'YHW^9K->*U^KV:;+O\
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MZI5Z41E%:T3L@QYA]$9@ABN'@S1:# APYK;C:'\R$(9\1R/:_ 7'6%L#WK9
MV-JTL,-"JC#GUN+43! 35QM3B/'1<>LMN25>@#L2%N1941U$V3(<B.16GY+,
MA")DD1\0L/G"R#.)$ E#DP)L=2E)2_$F,KCR65*0I*TX=9<6C*D*2O&%=4JP
MK&,X0BOW9>F]3 ;/KZJ[1ONW+[:;0.F@J%.DA:?-S6:I6!LVGY1)D@*8&&PV
M0ZMM)G2K,9:EGYDGT:1)GO0!K\?"(SY_UY=O!"HUKH/0LR'O/52KX>W8.V_$
M$W>Y,6@P$LL(8%L<8H(KT:O%P0F#$B,,QARYHN,I^5*'MI'$(7HT"3!;X1,3
M9&C8 <= $"H<<>,%PHHX= B-)9BPH,)A$:)$C,HQA#3$>.TVRRVG&$H;0E.,
M8QC'"$=S/A]M/W\<0=:>7T&(.KNI\HBMWL_/F][1;[/O8WX+M0<6[%'N;"7[
M*2'GD_'!H?X>O=NYCS>5B%V^B T7:NU^FE) \>RUN;L]$Q#!)X,ABO%WJ#HI
MD)9FXMEL52JIB=6B[D(Z-KMLLP2J6,B/C [)/:#$)N%*[UMX'SSZ"K.5@?\
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M:[QIK?5JK]M*AQ?C;VR,Z;U.D/@4K_ ;B-6J?GF'.#]CERJ_PUNOCL3UMY-
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M*LU*._$=>:+\[R\_92:@_P Z<X0Y\^??B4G"$([80B<?H=V!C&DOD3-0LHF
MRIQ#27IQ$+.AQ&U.NY2VTE<AYM.7'%80C"LJ5G"<9SCT2CB69R5>62$-3##B
MR!>R6W4J4; $DZ()  S(MMC1,MJ=EIAI(NIUEUM.8&:VU)&9RUD#/EB/5(VI
MM2N4ZIU^?RI[P=F@JR #2W(]@Y?U1URA@J)"D+94YNYM:V5.L+RTI;:%*1E.
M5(2KKC'7F*?(/3,P\FO4U*77WG$A354OHK=<4F]J=P$'.QS M<&.:Q.3;3++
M1I$\2VRRDD+I]BI+:0H6,\#D1HZ^#9"HSNW9'7/7E/WIX>.3O+W\>'7[WAQJ
M-+DK'[OTO_2JGIIUN_&X3\UV(G_]2G^O&(_ZJL-OLIF20K 'UQ5Y\_3^90$%
M<2-K=P&C-TQMT"3%:L#\VS$ZS.)5TL&CJ9E"9D=AV+)?:3Z:J,W)>HM:D:E3
MJDN2:8;GW*55TSZTRSC;)=:F6ZHPO1<FBVV=%2FR,T+(-R !G<\4/2]:PM@3
M$E/E)M,TT9FA3TF\_+:#B:!39#<9J6R9#*G4UP!]EUQT!QE2FW5(4$B:5)N,
MFUH/LSZ[/K!.MG, R(XA-&3UX?<#B3C+S<L3+EQ'&G(1F+GN>RM#F'$+3A2>
M/;3I]<Z)A+LH[)/2CXEGF'G675!:F&IA)TY=QQLZ3;S:KZ5\R#G<"J2DRJ9#
MX6PN7<8>W%;:UMK5?<FG@H*96M!!0\C4HV-P<P87>%8SX9Z_K_C]3W\=^.[C
MIQZ[QGA"#A"#A"/DZPR^A3;[+3S:\=%MNMH<0O'=W*2O&4JQW8[LXSCNQPA#
M8JKMGJ$Z:3JDI1BORIZ9CU%?]'8S#3+5(65=KI)__@'5RWD$&1<AV..4KTEA
MMV+AQK*$/)SXO3&W@7(K+ALRGM?W&&IUO"\QWL5_+K:LYZ>0I.#R5XST^6ZN
M-MYZ>.,*^5X1/= Y;^@&-A'LTU^0RRNGVF,AUUMI4A]L+YAA*U83EY[S1MUW
MS3>,^6YEMMQ>$X5Y*%*QA.4+<8\?T1 &W>T:[0+_ !NT _TS9OX]W':PWUQT
M#MU2^7W=+\SW(YU7ZE5/M?.^;.Q*SE0]JWRV?6#T]^#VN\::WU:J]M7V4J%O
M"W8SIO4Z0^!2O\!N(U:I^>8<X7V.7*K_  WNOCL3W630.WV(/-J9PQSI;KCJ
MO:VE?Q9^+$^*DG4.0>2.]$;=J6T549A@J>.0P0J+B.IZ:2G-P83"<Q6,Y4X^
M\XVTWCKGQ4I.,YSX]>N>!X,^46V6Y\>< =MAK(\9$1=<YN=!^E>B?)QUQB3E
MQ#>6<7<'AW"UYZ(3AO)'K\MG/3&.G7/T\]<\0-GWW!8]S6>YP[2.*'<'/O\
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M\U-RXY&2.SE;3"8R*A+T\)775 3J5=&[I+JZ+F@I?W-D@%(.ZW79QM2;*N
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M">T7(#I).N!(EB?KLAF;.?A%$(=CEWU\>U9IRG46RJ%H+!4GG%C04^:5 UN
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M,L1,&MY$GA.S.&PL.G.S%+ !M05<S1:L[A.[&O27JC>+V5!'7KGA=TLQXQ+
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M/K0@_P#/S>++CGKNKWP]?[J(Y&'.H-+^!HV<NST6C1WSYZ)RZ>'M0>8GN_\
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MK-!$MN!PP.P9UW@ME-G(0V52':TEQ"$$SKOM0IEE$7DV:()LL*/28UM:$FM
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M5LA@:_#M8"IT1B#C,]PV//MW7)<<Q/8&#T1?GSXH[&I=M\^LN4;-[1U()=K
MW6E^F@Z^.I2:G=+/? <F=*J'G\.;4N(P W9XK,0*S6UKG^0^M1Z38H;,ML-
M0]/=MXM7&8:JDRNTC$:AVX%V*R4SMFD5?28>L66K8KMW#7TDYNC8)[8YZG9E
M"J6Y/G_(:.T:K'<S@(-4<S7):P<&0\VW*FHGG;A@";,[5>!9*[12NLM:$Z]%
MK5$;*[93526214I+V&+C72<JHN[ 9%0Y0BA/2(;,"3:V<S"F5VYEV3#9F5V
MAP<^?=XMMH:43SE]I6(8-3;[H*NC9U2KM9+%*J]2" M!]^V["N (",#VY_8C
MS:;H>@#ZH#"TMJMRV\2RD\[/L"(\9$/*$2FVG>N>>!LRS@=20:R22&QKR(04
M<HLX[79 (B-UM#G66NQFK]4W8<F58+3N@G+6[-*+5$U6#".QHZ<KEE4/1#.V
M7;?:L6*F[+R$U%5J0:AU?87K<9BTR.2.N6><X.$TP54R$_:4P,3:K$(D[;D7
M V'C0[>0B. 9-1K30N=F:A'4)[6[22K#)X6QTSU0JJ*[MHS"V&.J#8VZ0BT6
MD>NO40<A&:MQH=*?7?D1* 389#8D6-HG'AQ02FL$Y@Q#CYF+FV,N*994\C"'
ME--Y=1C/E80YE&,K1A7_ !L)5UQC/NXQUX0CZ\(1&KG-]J!S6?8V;S_!C9^.
MUAOKBH';JE^?2\<^K=2JGVOG?-G8V_*A[5OEL^L'I[\'M=XTUSJU6.VE0\[>
MC.F]3I#X%*_P&XB/6< ,]H'SU8M;^8E6_*H<N'KEE8ES(&8P#,G>F#$C$X<Z
MP0A>:'YD+]+@O,S(WD^>BNMO(;6GL3W63A_M]7]6?XM3.6.=+=<55[6TO^+/
MPR-*HG9,U.KI'UG8<<8-]?=%+0R,J^;*'%Q=^C1MW#:/81<V7F%.#S*\NU;8
ML:#41,875'($:UE7Q@\('FLU(7L+Z[9\L=Z%:_8N1&VVG6NHE;&MS%)TC4=Q
MP84:3;[1%K.Q1H]K7.V;K$L%D58FKCLVMQ =:Q:2C$^ <HUR#XF3"1(C'=KJ
M#<Q%]7/DY\-N&%AJG4?9WWJR3]::XLDZW6R-&LK$H7.O>SB9? NKU$;J></C
M%+-+5Y\74Z4:#4T+&A376(P\<A<+TF>',3F43'9KVUN1J:T($'"UHIR^7D[?
MM<4R)?WK5&GK'Z\WM3CDM81,:26F%1#^T>786Q1!)_T6WGJUK>R+$5V14HQ>
M8Z@.?/R>+*&\K&D>0LUL[8_*X.K^SPKVO]:5RRG9)39Q\551%( :^,QFQD.!
M)ORK?6Q;(+FUL5C,N66F@*I;K7:+0]$*V0YKVSCJHB.>OC_ER\D:W6U;[,86
M)&5RL&[)51H.YV]%6)%K)M .N>5A5[2NQ;-/&G5R<2H4)^O:9ICL>,=?#$2(
MNFW=8D=(&-GYSJ'/QY\.W7#VC.7CD.WWJ,KR2UZ6_;*'IL^4*6*F@;;=!TP&
M;M>;=@NP0LD-V B6LA'O)R7@5"GNMBH!ZOG1D4:Q(JA+*%N7CX\A_+5],-6@
M[R$8N),^_%V76KQKG<)<7"".V&WUZ;L$]JS:XAIPA%$1[*P)L=*3M34!*?6Q
M5R4+E6E>GKX<K0 I5PAJ?-0SN>>>>1\1]-HV)V;V8?,',L.WKU8 *C&RJ6TN
MX)L]IM 'R0M_UQ&UE+&RFH1/%;00A &9%3)NUN?-: 7>O6%C$]BUULRN$AS^
MCGW[QH;+7.RM!U-8.>>!FH^EBU=VO%"B;!:R=@<+-4?$>/)"1XJVTGXY.F.M
ME+5"$J<# !<R#;[ JLP&QQJ,AW;=X<7!WNYKA9^H7+._SFVJZ[ V?9X]GLH'
M61JF:M/-'Q5&B&]FHUF/9)#I48X6KA:TV.1JBEMS!30RM2VH,&PD""+.*C$C
M(-$\]<=\WI'LZ:V/U^2M]APMF0*"7*E&+?LS8I6?8:\H4(VC5GU3RYB3,/B(
M&O\ E0>'!X4Y<KS.M*Y=*@XTX(OUF@V5#AY\_)XXZ[MO[-^#2(]5&WX>?"TV
MPVN^C0-;-W0\<<,Z$T$+UG8"4-H>AZ<0%B]1R0(N!.6[FN6@H9"/A)Q4^:@*
MDHCNY_UV<7?RSC8V#9'9\&]?U^OSMLD*T&U5#D5='K8MNTZE<P@"\UHO=+;3
M+%/J:H=GEU>=7M>GR6Q(,M]\769>N2KMBD@CU%?=$(GT\]7=C5W9OD>%D*U:
MR-VVO%7NJ!L,Y0[F$V7MD<S7L4.XP*M<==A77C\.5KMDY=MOR:PJDF( VM.6
M"6JJRTA2HZHBL(C._%SVW]$23U3S1<M,I&H]2:P//NK+^I6NZ?51P<[.Q5V@
M6NK?:( HX5RS,'Q80P)J^X5=1K)<D.<NE2L%0R3?L8,W$@H9^/Q7] YF)(WW
MYA;I^I.Q_P #S.-TO[H8_7-?OIC6]^"<XD.?N*B&O9=?.^.4SZT(/_/S>+-C
MGKNK_;!S]U$<C#G4&E_ T>GD\HC1WSN[4/ETQW=W*#S$?O;)T]]/P^W]OA(]
M8];_ &@H?F-4C5,]<M/[45'SB3A6<UM\Y8 -LIH3=E'G7BS3 <^OHF#:G;36
M:!0=@$6IQ,Z3L-='2(]746*:H1+K*D3X-M*&J:\BDJ65AO(<J<6&(]%=M]ET
M<UVWL$Q''&*L*A'R^",RK;1)6&)"GK'\KEEMKZE0W[$IGT[5PK6A*]/NN(BE
MZW!)*.M3G6S,A"UHG71N7O080W6MGT6C0!1MH"&:$'Q\VQ0GB02/5X=>KWJ]
M">(MM6)8FMMHC!'+5#(SP;DXM,@+A$S)F3-0CXW3E8T?L8R8,WZG(MV#=E;N
M$H.7)$U5_%F35:W37"V0\25$B3'70E.J:FXY5)""-,UX;9 T4;8D/%'T([4[
ME>T*1.C;)*UP)R7%FI5@;>8F&8D8D6EW<SLK$FR#(A)@7;6X&P+$=N0.):81
MB%7;(6GEP$<;,DN.Y0AQJ_KFDU5-117J]!%)H5+5KNGIC>=Q@!2E>MWRJ[!\
MXZOI SZTZYC^R^=>Z"8N//?\)Y:!SY\_'" E<MVGBP>H!['5&;.FE6DU=A)
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M.GO6(/8IN1_X.MC?=,<T'QR<1OVQ)[\EODJD^HPWM4C\C,>'SWK$'L4W(_\
M!UL;[ICF@^.3B=^^)/?LO\E4GU&,=[=)R^TS&8!/]OGN$#+^TY:S![%-R/\
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MZV-]TQS0?')PW[XD]^R_R52=NO\ $8G>U2 ;;E,:B<Y^>.JW#,<<'L4W(_\
M!UL;[ICF@^.3AOWQ)[]E_DJD[=?XC$'#=)_(S&?^?GN$#9,<<2:T#RRZ5Y7Z
MR?J&DJG,J0*T6J7=K S/MUTND\M:)PP4'E%I9N]V&RFW'G1H07&RSZHXC(3%
MPMMA+KCRW.)5:M4*V^U,5*8W=UEE,NT4M,LI0RA2E);2VPVVVE*2M1%D#7'3
CD:?*TUM;4HV6T..%U>DM;JE.%*4E16ZI:R2$I&:CJ%H__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>business11a.jpg
<TEXT>
begin 644 business11a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *""^$"<CA"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@P.2LP,# P.$))300E       0^J?1#3F_36!^($EZOG
M#>6#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           ?\   =D          $                          0
M         '9    ?\                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   ?\     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '_
M   %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !#A"24T$#      ,Y@    $   "@    *P   >   %
M"@   ,R@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
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MP?Z57N==>ZO]$RL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ I )= P$1  (1 0,1 ?_$ !\
M 0 " @(# 0$            ("08'!0H! P0""__$ &(0  $$ @(  P0""PH(
M!PL- 04" P0& 0< " D1$A,4%2$6,1<X.4%1<7=XL;:W(C(U-V%V@9&U\!@C
M,S1YH;3!"B0V<W6R\24F)RE'4E979VC1&2A%2$E866)C9H:7IN'_Q  = 0$
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M@QG&<\4KSQ2G%*<4KQG.,8\\YQC'X<Y\L?@_3Q2O&%HSGRPI.<_@PK&<_?\
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M+>.Z:.U2.30^&2_.M@I69B+R;!+#'J]L9JZWG>=<)4XI6F^Q?VOF]OR-[/\
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MZD'B-:L8YK7=_(-0C J0N+.C-SH%<DPI:&GFU)3(B/O,.8QZFW%)SC/,'O\
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M ,DX&T,2>F <]\]L8.?<"1T!-1P<@=R2!@8/4@$=O;N7\9 [UE-<[-]?+<7
M *SN+7QLY:)$R("$#[(.?(SY<&7/@NQ<0TO>WC27I@HI''L2T1W2CHV>D8B7
M[H_[.;!R!@]5W#IW + D>W!1@1W!5O\ );$H(.3Y X/N. >ORAE(]S*?,5O/
MBHTXI3BE.*4XI7P%9PL6+)$C<R ."CH$R<7(%9$>(+@BXD=R00F$I4M;<2-
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MX=<D'%<D<7\;>.%CQ1KUGH6F:U)H]MJEW#ILD'"'ID+V4<K+ T=U\&R^D(R
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M/EC&<D]L8P<GRQ[J8Z]NN=OOR#U'MR"#T]M<0>V5KBJA@]BL]^I-;K]B>&L
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M"^?SQ\O.L[T\OO\ R\_GY>?^OG<^EC_?3AT'S\-IOVC1!G\60?R>1K6-T/\
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M<R&,97C+K?JX7\8\GA2# S_OS:?FMKW^W\7XZ^CW^#S('CKJA) '^+S7ADX
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MD0=U#2.1DLI&0PJ3-;OM+MX$99ZU9PI< 8$J.C"D2>QF+,#(SE+A1I:UH5F
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M_'?Q?'L'SX X8 SCN+/BI2 #[VP??TJPKP]]E5^NZ0,OWVY1(#Y[>)FN '+
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MA/FT][)SV:U>A7E&E4J:5V+J[L)X@M?W-J7M7HUP3,>MV9NC&.U5VL6[[1\
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M:*UY)E,?H\<H$L<&WEI( ZJ& (POM#.OFT-7[-TQUW,S(6X209H?%NPPZ0K
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MW=WQ1INM:K+?ZC##OU*SVSEK5UU*.&TU2X9&6>0+'&HV9TGZ8:(ZUS]BVW5
M(R)-&[+<J(1?)64N::=KM6NI%H/'1'(27FFGV40V<.RD)P](SA675*\\^=_P
MIPGHO#\E]<Z9!+#+-/<VDA>YFF!@M[IQ$NV1F7(VY+#UCYDUB_CKX[^(_BM;
M<,Z+QGJ=E?6.FZ;HVOVL=KI-AI[KJ6JZ);F\E:6TAC=T<R/MA8F./(V*,"K
M^9I7.5>%8\\9QC/EYXSCSSCS^O\ D^7G_7R!&1CY_/YC%*I>W-X*^HMT;8V)
MMDON79(<IL6W'+>0%#1=8<@#Y9R<].>B0W),1<A<9A;RD-*?6IW*,8RM2E>>
M<[+TOQ,U+2].LM.BTZQECLK:*V220S!W6)0H9@K!0S8R0H ![ #I6P-/\0+R
MPL;2R73[:1;2"*W61IIE9UB4(K,J] 2 ,XZ9[5./I?T^JW2W6MAUG4;=8+D-
ML-WGWA\E9(PZ+.8G$ 5= N0VD"VF6,Q4,5R.^A2TY=R](>QE7HPC&,6XEXBN
M>)K^*_N8(;9XK1+18X-Y0JDLTH<F0L=Q,Q! PN%7IG)..<0:[-Q!>17<T$5N
MT5NMN$C9W!"R22!B7R<DR$8& ,9\^FB]E^'%!OS-O$P-PD*K6K\W8U6P/$H8
M:>_-F$=F=D=DU]Z"268B*'1PDKLQ:AQ)CW65(/)K-4DLS@C39F 7QT 9C)P1
M'U08Q@F!K<GI[4;ITZ$9[Y->)O;:ZCH)!M;S]431S =>WK1@9&,CW#%2(HG4
MJ@U2N;OJ!Z7*N]9W5;3)9\25B1X351I,]UT@$U@!7"7C.:I4#I.S&:XAU*%0
MGK)-CI9Q':;3D1E A[ ^0QV"(H]VV..) 1U/+#'J34,G>7SDGKUR>Y9F)R3D
ML[NYSYM@8 &-7[BZ61[31]#:>U02!:]UOK&%L"KF'BM>@7(DS3KQJJUZZ)-@
MAQ;#,7%F(HM$UY!Y4EA V8^Y*E#3@ATC6R<22TC.Q^/&ZG QU:6"3 /4J,1'
M!ZG.,DGO+@!54#JLBN#[A',I! P""74D'H>O2H^2_">BS+%8+-)["62=/(V*
MAG@R#=.59H8I.N[%N*R!8LL59+L5!/-3IFX2"#8NLB*939& [$@93@\HH5>D
M3*Y4 $*Q"A22, XEM9<X]YM5&,X7<2N,*%$=\9 +.V,G(WQ7$6"W=L"X;J3E
MMHWEB6)D-J3HS%U?L<'?G=F/V!F!M6[=@"P9ND!P;Q+=>PZ#;-:V8@/-1B,R
M2"U<FM7(L\#U<U&FN"S[4 L]<2+;4F#+E7U=W0'(P,YZ=$!/L)]3H3U .!@(
MFT1D@^PY_.Y[]_ZYSUZX\MS[I\<5&G%*<4IQ2G%*Q:\5L+<:5<*A9 *;57;5
M5K!6SU84^F,FR!3@F6,* 525RH*(Z3$&4^/R^J;#2UB1EQ4J/A.7D*53SX9M
M[ZQVK=NW0&FNMK.C]DT&I$ZAM'!SM]K?L1=P*P6QI02'0YM.I6\MSF:7%1)%
MR"I>398])Q&-Q\ A<:RM,OE8RE8WUJJX:R>*EV3-%(&D[3.&R-BS3!T-2M/3
MYB"-:L6LX6J8U>/U_2X79P;8VN12[4%W/*O^W[8DA:W0ZZY 2S!CQ:<H/GGY
M_P"SW5\8ZW5TMXSUUI=LQ5[K/7+K]=KDF,/L:%TD0-ZV@]K!M=VQ7^ [*I!V
MPLW2L63;-?20[N0S8]B6$)0*KF758U9<5#W8]OR=?+^WVU>_Q4:BYV2Z?Z;[
M5(KV-I,6UM^O KU3T3*;<CU,FF*!M"&&@;)UZ?D@Y4=PG3[Q$KH)HX/7[.7A
M0F%(&3QTIKVRI BB0R%0VZ-(I$8!HY8X[B*ZC21#\94N(8Y ,C)4HVZ-W1IM
M[A @8J!)SE(Z,DO(GM]Z'R8PW$R=0PP^X .L;)"SQ6.M/72/T<[7[*:T'I=.
MQX>LWB,787V+J0J],$H4P+#AD6K>H&JPH(18C+,:/.P1]Z98:;:0]A"$XQ5=
MFD9G<EG=F9V/4LS$EB?:222?EJFB+&BQHH5$5410,!54!54#R    ]@JTI-*
MITF,I,BIUE],V1!)S$O 1;N)9*%A*X9"3AR*K#\Z(K&%19;OK?CJQC+3B,XQ
MRHMS<*5*W$ZE$:-")I!MC;XT:X;U4.!E!A3[*%5.<JIR<G('4CL3[_?7O=I=
M/?S.4_5*V\HF0CEB2G@8QS) K$2E$4G.RN*K,LC&0A"(\V1[22RA"4M.I2G&
M,!<7"E"L\RF-#'&1*X*1GO&F&]1#URBX4Y/3K3:O7U5ZG)Z#J?:?:??7J<HM
M)>7[5VG59QSX@\6RXY7Q*UY*R&YC3Y+*E1,JR0?:(3VWIF<^\.-SIB%N*3)?
MPN GG&W$\PV#:F)9!L&,83#>J,=,#'3/M-1VKU]4=>_0=<=L^W'OKVP*73Q4
MMB>,JE;'3HJYKD69!!C(DJ.LDI:R*V)$>*VZRN>MUQ4U3:TYE*<6I_+F5JSF
M#32LNQI9&3.=C.S+GKUVDD9ZGKC/4^TTP,YP,^W S[/T 5YS3:AF,/AYJM<]
MT$#7 PJ+\#&>[C [WNOMA(]CW7V<(:[[E"]I C);BK]TB^IK/N[7HHLB.,.J
MN/8P##MCL01V)'R$CS-5H9YK=^9;S2P28V[X9'B?;D'&Y"K8R <9QD ]Q7J5
M1J4MF3'74*PMB8.9#S&%@12F90F-A28XN2TJ+E#XZ/A2L,0G4JC-85G#;2?/
M/)3%$<YC0EL;B54EMIR-Q(RV#VSFJJ7M['RA'=W2"#/)"7$JB'<,-R@K@1[A
MT;9C(P#D"O:_3JC)S.5)J]>D**,0HI)3X8<ZHA&&N8>'1YV7(ZLRV(#R4NPF
MG\N(BNI2XPEM:<9Q'E1]?I:=0 ?47J!C /3J!@8![8'L%!?7J\O;>72\EWDB
MQ<2CE22%B[QX?U'<NY=EPS%FR3N.:6:D,&O>.#LT6Z/@NC6.O@.>R/=BQW(+
M,X4#UG(%SFHBVU,-S!S\6,] E);2_$=C,.1UMK9;4G4UEE?%_5(QD1KP_"50
M$A >5IZY"]NBG';H/97>&NHC_P"#\X2N757N9/%2ZYEPRAIWSJ?%&=\I&]LX
M!.6.>A/6KL\5X ESVN 8?#OQ=5@]I@9"PY\>7&5"6;]>&/5\77#6N(HEY^^J
MC*4QE[+2LHSMRN!:^#Z%4[VR)/T3K7O#4V>1;?\ @8SVS9 JN4X4GMN^Z^T1
M-).39KD^4E6'YBY<I4AQS,AW*Z9AA8L6BC)? <F-27 ((#$CUL$ C.<$ ^0J
MD8(26)AB)< .3&A+@8(#G'K $ @-D @$=0*Q>1I33LN42FRM5:ZD3# CX 6E
M/4NNN2"8+UL.?!I[RQV7)8OVD6,YF ^IR+E<=A66O4TC*;*32-*EDEEETVPD
MEGB6">22TMW>:!=FV&5FC+/$O+CQ&Q*C8G3U5QYL_#^A7,UQ<7.BZ5//=6PL
M[F:;3[266XLUV!;6:1XF>6W411 0N6C C0!?47%&/;D&&K7<S88"NB1H($+Z
M3;"@#0P>#%&BH$+[&UX<]SA#X;;,2-%PYGVGL&64->O/JPCU8QGFD^*8HK7B
M_4+>VC2WMXN%+Y8H(5$44:C2KG"I&@5$ ))PJ@9)/<FN6?$&"&P\3M8M+*&*
MSM(/"G6D@MK5$@MXE72=8*K'!$$CC53UPJ@9P>]:CZKP817L+X?8\I#BDH!/
M3E_BDH)".S,B$(R;YV82F-.C24.,RHZ4^:<,OH<:QC/EZ?GSS.%V;X?\/O6;
M#:=J!;UCAL:AKN,]>N !C/E7@>'<DAXS\',NYSPQK6<L2#C5..0"03@D   G
MK@#V"NS!+KM?()G(G@P\Y!-T>^23,&0I*2#XEQEX4].P\PO$MT:['8=@.2/:
M+AN,M+CY;4VC..D49E*NK,K@=&4E6&00<$8(R"0<=P2.U=NJS(0RL58=F!((
M^0@Y_/7&YHM(4MUS-/JV7'I3$YYS( 5E;LV*Q'BQICJO=/4Y*CQHD2.Q(7G+
MS3$:.TVM+;+:4S<R3MS),;MV-[8W9SNQGXV>H/<'M4_-E_\ &2?&W_';X_\
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M#05GC""%MKR0@P&_0M=EHISI&EGVZ=9G_P!GCK)_$7)X_P"-\_\ .SB#W_\
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MHGE*JM>[BE.*4XI3BE.*4XI5(=.^[G[2_-QA?J[KK^G^^.:BM/LPZK][T/\
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MKT9;C;<X.9@SQ1.&I6'QY.',@RFVI3#S2'0#W8]OET']@S^(4KY:]5Z]5!F
MM=%Q10M$\P33"C87EE)"PEIYTS*QAU;BL.D2Y2?.?_=>G+TIS"$H1Z4)AM4
M>P*%'7IM50H7WJ% P#GM3^))/RDDG\YKF\89RK*,>SRM&$K4G]SE:<*PI"%J
MQ^^QZL(6E*L_7Z%)QG/ISC$< >[N3_$FH$#SQGI\O?I^>O/H;QY9]"<>GR\O
M)./EC&,XQY>6/O8SG&,?>QG.,?7Q@=_S_/\ )\G3M4:PZC;$H6RA3IO7ENKM
MS"QWH,9XG62L(O :?)  UH',+DP77F4N3*U80)R,C*L9=%%QTQ&,L2F5J#J
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MP<X! -4H[S1KH[=,XBX=UJ10&FAT76++4YK9&R US';2.T +*4', .X8([5
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M@$YV,PSNV*SG Z[5=8\ 9ZON<>J.I 8_U340-P!'FZQC/0;F5V!)\DPARQZ
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MJ=K)INO7&K21FXM;6,V,T4VDZ>,1"T,OI:OF1FY9MT"AVM_A4^IC4LI'5D!
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M,!Y;62,F0H-Q7!*[F6K'#)(\"*O](%X5;!VJMBEO)<%B!V2*Y23U=QV@Y .
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MF9G8N[,69F.69F)+,Q[DDDDD]23D]:E55151%"HBA450 JJH 55 Z     =
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MKC-5Z*T]I'%F1J>A@*.FX%LFK"@*V^A,V6E3ZX[#29$B1@<''JES,B:^,Q#
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M/@#HH:66:9PH :6665@7D=C\UQZY:5V1M"D[OM57>+;)H0AX-3;5#M]R$I'
M)Y%@S.%9%@K&/KY<28G1H<@O"+#"$,RB' 8)-2XL*(TS!5Y;SD##3(()PPR)
M(U#@12(^5*KS9"%*^J7+ !NM0+F6*)-VZ*.3TB$J<;9'"9E1TPP9EC0;@WQ
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MULKRVC<'&R>)E"L'Q7NG2X:U8H6"2:<;M)6#1W%O86NJVS6B@(&6"Y-];RS
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M6(EAK=TK5[TK.%71R%7JE=(S *\TVXNYAQRPV&^?LI4^>OX;5U4TIJZB:6M
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>business12a.jpg
<TEXT>
begin 644 business12a.jpg
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M4W9WD[:W)3(W5'*UT0HS0D-A<7-XHKCA-#92D2:"H?_$ !T! 0 !!0$! 0
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MN)0%"-J<4I2EJK17*^7&->+[">VL1:&[7&MIAMNVZ!),UYVVMO2,!;&^)4^
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MK;9G%LKD^I[';.0+CLE+NAV:8VBNC>T!@):D7IZS(;@]KX[Y4'1-B,+4AY>
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ME L>5(B^\3TVI1R8("A1KC$:4Z0MW:9LO=HD06JSN6"\&;N76DS5R;.]"<2
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M[#;:,ZT'T]F#JK4=K@*,@S1QJZ6ZJS3-@G $.V)NH5V.1+X!M.SUX1AMUMO
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MR2,E*D04PI>VD;;PIKNV@F6E]47:TV]Y+;,Y+;T*1:U*<C:G%1E)?:4\H*=
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ML!+2NQ+W:0BK[M%R#KZOC0I #F(!-V\3?R;X$4]7:]5I!JP*/!I SS#I/6>
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M^AR]$5*6L36NO6D-BA*4BV66JOZ6>.%;1>KY*GF$U1;QD?2R8^NQ!"LI4-G
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MX.?1_K!..GGSU='5D8])J?M[VZ38=;=2;\U?[#K\19=S:.-G"JH *H*F#K2
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M5 U%3]>!#H4>T0/JM=@7:[<8M\WY0F+38E# P-DH7>DM(A^:""KE>!C(0^#
M&"Q(,9"'P8S45.,CQICY:DE4:.OU/.PROUFT-.^9I"O5:;RO+;3GBG/G;;RX
MYE"%>*4Y<7E.,94KQ4K&ZU30=5EVL@+9>R2NUF?MEF(RWLR)A(LX-& XF7',
MX2EN()KP,( %16D(;C"Q,1"_6E9DRI"E9 B#!;4^IN'%;5)RZJ2I$=E*I"G_
M "^OE_*48R[E[RI]7+F59<\J?/X^&/!2N,P(.93,W,*)F;&87&CR\QF<RH\9
MS.,N1V9&4>JTPO*4Y6TA:6U93C*DY\,<4KAP</>Q%2]!ANI@O(DP4N16',0Y
M#:5)0_%PI&<1WD)6M*'6?(M*5*QA6,*SXJ5B(;7%2 VZTW@<,2BPV[X#\4E.
MYPZVSBN!U AJ1;*T>48GX8K+$E,3+>)6/#+OCC&,<?HI^FNJC:WK] ?M\X4^
M9)%[W:'[99S=B*R#)8@05 @!Q\1,J1Y<10P(&*&A@8F(VS#@PH?JY0Z0ED)L
MQ^BGK^BLRDC1TQ&6YD"%+;S):F9;DQ6'T9EL81AF5E+K:TYDLX;;PT_G'JMX
M0C"%8PE/@I7>_'CRFLL2F&9+*E(4IE]I#S2E-.)=;5EMQ*D94VZA#B,YQXH<
M0E:<X4G&<*43'CH]/R,,H]%+B6O*TA/I)=SA3J6_!./(ES*4Y<PGPPO*<95C
M.<8XI77#A0A[&(T")%@QL+<<Q'AQVHS&%NKRXZO#3*$-X6XXI2W%83XK6K*E
M9RK.<\4KA ^ VN8XB%$0X1RG)!:(S*5SLI:]!.9BL(PJ5E+/\BGU\K\&OY/'
M@CZ.*5S'A0HC4=B+$BQF8;>6HC,>.TRU%:SC"<MQVVT)0PWE.,8RAK"4YQC&
M/#PQQ2C,&%&?E28\.+'DSEH<FR&8[33\QQI'IMKE.MH2Y(6VW^PA3JEJ0C]E
M.<)^CBE<^YQ/>,S/=8WO><-XS*]!KWC.&D/-M8R_Y?5SAMN3(0W^U^PA]Y*?
M!+J\*4KA$""W)DS&X<1N7,0TW,E(CLIDRFV$Y2RW)?2C#KZ&4J4EI+JEI;2K
M.$8QC.<<4KH;#B&8V(30L<U#PVAK$1N#&1&PTV\J0VWAA+6&L-HD+6^A'D\J
M7EJ=3C"U95E2JK$:,G"<)CL)PA+J$8PTWC"42%86^A/@G]E+RTI6ZG'AAQ2<
M*7A6<8SQ2NK(^!F1&EY@P\RX;*X\25F,S[Q%CN82EQB,]Y/489<PE.%M-*2A
M6$IPI.<8QQ2NW$6-C"4XCL82A+J$)PRWX(0_X9>0G'E\$I>SC&74X\,.>&//
MC/AQ2B(L5MEB.W&8;8BX;Q&80RVAF/AE/E9PPVE.$-8:3C"6\-I3Y$X\$^&.
M*5RF/'3E*DL,I4A;SB%):1C*')"E+D.)SA.,I6^M:U/+QX*=4I2EY5E6<Y4J
ME2)%(A/#4#!Z1TC+V9$!,*,F$_F2K*Y&7HN&\,.Y?6I2WLK;5ZJE94OS9SG/
M%*_2Q@US,93@Z"M4-UU^'E<2.K,1]_"\//1LJ;SEAU[#B\.N->1;F%KPO.<*
MSXJ5W(AQ&\XRW%C-Y3_S<H8:1E/\BW&^CRIQX?X.TTQ]'_J6VVO^8A*<*5@@
MS6%8%[ ([*:R4DV*76X]0&,3"+KH2J5M+\&82%5$*A+<$&Q8B(H02L:V&UOE
MIH@4M]W#0^*RW.>&/4^?S=%1CCGVO-_K4A\BIIQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*UOT=V7K^]KQV!HH;7NUZ9,Z];*<UF<,[#I^:W7KN0:;E+R=UT2]_F
M?**NKQ#7(:FN,P7W!DX$6Q%Q".07%=%>]FY%CA6"<]<+5,1M!;1<F&;?,Y3(
MA-DI&XN+>[1R>0-824 K2'4/M:RMA8K7PKBW-?GL(8E,F!(Y,M<AK=MO*P3K
MCJU*WC?#.2$G2I"L86FMD.<[6PK4SN%N.5JG7U:$ -C5S5-VVM? - JVP+3@
M$\&I<;*)=FN5MFQ+(V\$DX#TFO'F1311AZ!)M)&MC7VGED6([\CXN>H/Q\U1
M]4>XYZ\T?1)+7VN!.PKAM34VT[_8(K=_AU:L5<QHLSKZH[+!8-X!V=TAE5PN
ML@-6WX<%UF8_ B.S78(F?(,C&/1D>@\0?13/-PXG/I' \?TUC #MQ:[7;/C#
M\)NMZF-G.K,JESH)03FR8";LH\RZ3XUX@&:H1A1H/NRTI*. S;9&"@>RT*),
MJD29>6/BS\./)Z^BHS[7$#X,D'GZ.KI]-9KL3O?JX%- #M83Z;M9\P M-HDD
M6K_&KU;BC:G+#0)(:";B +5DG=C,PTTT  N01PE:(<Y\_9ZZS[BN<P3T'T>O
MEJ=0_P!>'Q^UP\H-5(ON7'L6RZS0@M#CC&+J&JA2G/;'NK>L[9;$W/6L/8@D
MA5JE8:TJ#:*\*=(,TZW_ ";MA>^5ZS#K&A&NB0T&N?*8_3Y>D#USBF?:SU\_
MH_SJ,-;]WK^YK&EV.^ZGC&9L3K%J7?VRK'5KC"C1\O;?D[$!4.O56MD0,%R;
M8+;8Z%'8<@3"8P%6$6%W$VRS6 :)9J<9YCGC@=&<#)-1JQSCHR3SXZ!Z?)\7
M-,4SM);15N:T\7U' C;Y*'*7 K=/B['3,H14%>*MM:X#[3-V,JE128H>*%:0
MV;#.0L:^GDVC@0?"$13,(Y"*8C Y\\./D.1[?E'-^BI!XX(Q\//GY#SU%Y7V
M@T$7$CQ9&L$P+D.B;5*7&GF[_!@2!T'5FW;SIUX542D"MF8=TN5K/Z\LTNM!
M7DUD!F+$;07N M<J$J4 )YN/-U\,]?#TT)Q_G@=/I\O-S>7A4F0NV\TG;Y$8
M?JR:O6<';VM-,3KY-M4<>>Q9MLZ_UY>JK.AZ_?!9DNAX>=EUT+9ED+"+)"Y3
MRY$ ::;8GM06/3C/H)SQSY*9X]&/.<\V>;'Z:S'<?8QW4ER57U45X]7@&I;C
MO#8=NS8XPEJIZ\H<IB-87AP90PA,LUCRB2W)$A6GA<6:TQ.Q),CG&8R)KH/M
M4Z1[=0=![ZMRZU9"N=7X?*AH-"-L_ ;<7L]*& ;T<D@WIFP;@$UW)(TZ9178
M[<J^1Q-/N8X9")"YH4S8("BDP2P<9^/AGS=?#I]KGQEGCCS<W'T^WPZ^G %5
M4ON8XR/Q=QM;?LL%_5U8LR054N5:NVN(3AC<QO6,RY/7V@5.UV-=5%LCE6 Z
M=C0"#H2J,?\ +.O =IA'8,1CU/#GR1\773/-Y>KCP!\GGZ,\?)QK@?V^MY>R
M5FPCJSKZ?JU[KON_:1YP#N*EF6I5AU??ZY58S@&^/LBZ1BMR6)K+C<RTGZ9,
M'Q+)->NH>K'*A(KTQCSY\W7\/P&HSZ,>8\Y]KHZQCCFJBO\ =Z99WD5VOZVK
MUHNTK:E2UB+:J.U4F-=DLW;7%YV&'LK&P)U#"S'10UBA&!UE;ATV:]#RE4H
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M.OT#I^(?Y<:QMKN_%,50]L:JZM+$]<ZUI=7NNZ2Q>SC0=DH\8ZQ.GF@M>K3
MXU#O!RAAQLLS:T9LE:%/0\QF:H6LY%Y<%ECKX?%\'P8!S3/DZ,GCQ\V//PXX
MX@U/&H=MVC;"-DDD:\8K=<I]^V/KJIEI]P8G2KP:UAL*ZZZL,YX5"!975PRR
M]2;7"D2912>]B=*1D:EH<Q**",>@'T\: Y])'HX5J=1.[=YA:T 6O9FL1\W
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MCBEX"2B@ Q!E.@39$0,G('97A(:=!CSJ^X*FI5(5%,#U\OQ\_M5D#77W5;$
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M2MQ\4R4UL%ZV;5_262?$6*PM6-L!(  ;3M:RFFY(FL#2I@=%!@)*HB(I4D<
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MNJGSB_3_ .M9?\%7W\L\?46[(_B!'OM9_P!OIWR/8;^VQ?O#M%^ZJ?.+]/\
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M_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\
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M]$<:=%J?8CN0792'7EIWO)DIRY@K[";(F-I1?)[MM%IFSW90L[#,Y^5!G62
M_"AVB5=8]P:?8-]BRIC-T8M[K$="N3\M6O#=I'=,8TD HK.NIZ$XQ>1=?S)8
MHSI2 4K1+:D[5V+"#'##4JU.RV9D%TC@*5 BB,A34H?&C.IC)(OY#W9(4B6F
M.U;(KNNU/S-VNZICNQYS&S[5_P"12WGXC=O2VIIY+/*X\R2PV%-ON+25EA&)
M&[#2'("Y<B]SV-W>XD .MV%R6Q,MDK:Q_93MC BQ)SUX6\V_'7([7S+;#ENJ
M0[&::6&A)<K5]*827[<X[?",84+C5M=<EIKXLNZ0Q8ZW:3[)HM'"V:;(A5AE
MVJ31V)+,9TZK*Y$R17X;8UUF1;'9+<*;<E-J97(D+FB8V9C\9+)A3H$141A<
MJ TAV>M-P:>T*6F(,(:1,=+Z5HO'L+-I5=G'+](;B146SM:\BVQ9JY(N=LNU
MP1.EM0+K(=CVMM=HD1BZVT[<"2X^Y;6$QEH<CKHC_C;Z4_TC(_[LG.;7LK?R
M>[4?V%K\\C5H>P/_ "N[#_WH]_VZ;5-WD_QLMW?Z6-?]RBN5]BS^3[9;^[C^
M<OU1V=?Y6]N?[W3^91*U1YW]>35^D*PE:5*0EQ*5)4I"LJPE>,9QG*%90I*\
M)5CZ,Y0I*L8S^RK&?#.!YC@X/6,$CR\01P\H(ZP14@X() (!!P<X/D."#@\Q
MP0>H@UO$UV6[*D\.'WJ$R<JLHV .UP?F@&\U:O-"(,VK0Q=<GC51IBQ,ZK%9
MU*>]_+DYF1$E+4*=&),QIK7F!V(V*8(BINCL:>B++B3'A=XW+YADO-7!R1-:
M?2XURANX1VKHDM1F&A)05.-+86XTKV]'9-[)4D*GKL;4VTNS[?.M\;N?FFTV
M],*/(L[$.VOQE-/&&]:9DBQ+#\V4^8;H0S(:EH:D(H&>V#X6K"8L&F"A%PK%
MMI+(VMM#RR:- H]"KNS : T]\G;"%OG&RSNS2\,DM<J"N+$'QY+1!9%YS+5Y
M6P*)$Z0MVY2)%NG6^Z*D3%/1^VKMUNTVQRC)92Q;F;:S%CIL49QE(:=#CKRT
M*92RA(59;[++D.TQ&6+-$B7BUW:Q(B6Y$:6+$Q8[!;]J(0A2%R;Q(O$B;,7M
M3,:DDNQU-,QVW$2527%%$=N=H+VW%M X0&J8$39M<!M9)%CHAE^.!"@H)(+
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MUN.*;?0XA2G7<J3GU%^-M$.*TG2S'98 2I*2PVAE2 I(0="FPE2#I2E(*2"
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MHDDG)-=/*JHIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*]B?9 ?_ +XW3_HI5?\
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M/SMWM(/M;[/_ 'J[^!<W_<9LOXEB?A?G*T/=AM-XWD^AGYJGSMWM(/M;[/\
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M3BE.*4XI3BE.*5]*GL^/Z"_VE_\ I99_^'^KN>6;2?R@[*_U#7YS,KU#9S[
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M]BMY_L[?YRQ74;%_9-:OZYS_  ':HO:[?TDG;7_61'_W4KG*]C/L7LO]D_\
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MKPBML.R='L"))(8+H(*%.E*5*TH4 O"1DE( 4DG4,J$IA,IDRG7VHX5[,N.
M7MV00I+8*DC4L>!DG !)(5C29^V1V8*QK;+AZO,P)VLX]=>J5? SZ-\G(0VF
M$QM"%E*9D;*M%K*OPWAVN:]!(G9-E>/&Y#ILV]+BE3,A]&MBVE!8!EMJ3++H
M?==1(WJER$*DK1(UAEE 4%2G5);#(;; ;;"5(0 =G)N[B72B&M"HB6E,MMJC
M[I*&7$QTK8TEUU924Q6DJ672XLEQ94%K)%GU_L^DV2/V'A;AL9NI2=T"J\[%
M.4^D1+5&AFP^Q -PDQG0#UIJWNHZ1"'28\9U@B^IAW#"%L.(4IQ-<F&^T;8J
M"VV\("G06WY"F2IM<5Q@'>!A[4H%0*@4#/$Y'-5N-,CNINB9SBV53TLD.,,!
MU*5MR4/*&[+K6E)2D@84<''"IH%]G-1UBJU>DAA)*8(8'3Z[?9C]$JT:1<@:
M=1FZ3!0_AXA/F(9E6J="L4D>HAA+$J)"+9D2"P@<ZW@+M,YUUZ0MQ"7"M+L=
M(D/*##AG-R%$$(2G*6$J:"@C)2HHPE"UBM@F[P&F66$)6I"4J:D$QVTEYL0E
M,)!!4HX+Q#I258!2%Y*TI(PGMAOC4VWP=)'ZTJD.N-!BI0A'&IJ4X'*IM>F5
M^L#85%8-O[ M,$Z-'D!<]]"1-<JHOU$8L341DM:3PZ#DV:W3(3DA4IY3N\0A
M)7OTN!]T.O+5(*!&94VI25I'ANO+P2V5%#+:E8]ZN,*:TPB(TEO0XI80&%-%
MAHM-H2P'#(=2XE*D*/@-M(R Z %NN)&DG-]7/4XI3BE.*5]('M'_ .A?]EG_
M -H9_P /SW/+]E_LZVO_ /5^<MUZ;M-]A&ROG9_-'J^;_GJ%>94XI3BE.*5N
M)J/=U-U3J2Y,CS-DF;(L 0(*%@IM0#21X,[5]MUK9%=-A=@_'&3(VF89"NR+
M'0%@Y<(_;VH).4ES"8!,!HYMO?F36"MMI,5MQ:UN)?<"G6G83L5UIR-NRA;^
M7,-R0XE3;!*!_/0[OH5Q8A0G@AQU4IQM"$-*904MN-2VI+;B)&\"DL8;RY&W
M:@XZ H_S5MXCKK?TN#MCKO:KXTRJK::V/0;3-S713.#4X96IE"@D93C3TR.P
M1,*JU  CHS>7QT5]T>AUW+<J9-F/7I5M2J'=&8Q.^GQ9#*=ZL[M*G1)4E(PD
ME"-])=4>"B K \%*4C'CW-7+;8])QNH,EAY6Z0-:DMF.E9(*@%++4=M(&4@E
M.3@J4HRKK[;.B]+0;XQ5S=CV 9/_ !0Q5K*<U57P;]<.R-(]CJ$-91"(VZV)
M\L"Z;$UQ8VB#3N,M+$R"34/!  -]\Q),*X3U1R\VU'0UH0\TW,=<#K:9]LDJ
M.I##!RIB-*:*2..L(*M#BL9L:=;H(D;IQV0MW>N-..1$(+3BX-QCH&E3KHPE
M^1&="@3C25!.IM(,C6'M=HXWJ.YUUNEQT7BTUA3%CF$Z&J9F\74OI/55/?M3
MY$1L*NBQ1"M[.K-VN@\@7J]D>CS2[5B$QD%;#88",5NS7!N:P[R@\G9>RRE$
MC3R=A$^6^&0E<9U:TO1'6&%H0ZT"$;I:BAMM59;MYMSD-]L,C?NLE+A7&U&0
M^Y!BLEXJ2^VA"FI3;[R5.-.D%8<0 MQP5YG<ZNN1IQ2G%*<4KZA/_)BO^E[M
M7_JWUW_O.=YY+V6/]BL_]JE?X+=>J=B[_:[O_9XO^(]7V(.?U?V_W<\1KV2N
MSBE.*5KUVY_Q4>SO_P O6Z?^&]EYLK-_OBU?WE!_.FJU]V_W5<_[OF_FSM?R
M[.?6U?*];)4SM?N&A5L'4ZZ2#,!*\,J8L;'DA(LIUIJE[7L^X@DKWEU7K(GI
MM%SM Z9+CK8<FU4X0KK_ )H<EW*M4_9H,AUQYU#A<=6\XLAP@$OPVH+@P.!3
MN6&5)2<Z7FTNC"A6U8O,Z,TVRTIL(:0TV@%L*(#,MV8@Y)R%;U]U*B,:FEJ;
M/@DU)3G:OLI:]9V#$.OP9E#J<*O5ZY68;5C,L4$^-:WV1IFIME9*R,NNU.25
MJ-XNP^$T(@@&+(>PJP%(QBQ1GB#F+VGM3,MK4ZI,AY3KK#2WFTK<W<J).>*!
MH2Z^$/QXZE%Q3I:;.Z04-$)&;VZNS\1TI:0J.REIN0ZAE92C7'DPF0LZRVT5
M,OOI2$);#CGLBPMP%1P2T;OWO4XQJG6\0FM.7.FU+$P<<JSXHE*J4_3077E3
M*PVIOHO(AF=:($SQQ%#:F2.931F.I;<A'CD,V^W/*;D,+WNX?>TK;>"T!Y,Y
MR4\A13D:FY>M*DDY3@H/-6,_<;DRER.^V&B^PSJ2XR4++*H2(S*TA1!TKBA!
M2K!"LA8SFKF&[(;NMCMM&MU<#L$3:BEA.W:H.U&>3%&W=@E]/B5M3F DR&9B
ML9MNM=6Y 9%$1\QJPM,0VI,AHS(@2:%VJWL;E>]<C.,H;;COAY*%MB,B<YE)
M<2ILG<RYF]UH4DM$J(!;2I-;5UN+^_0&6I*'5K<D,EE2D.&0N$V H(6E8&^C
M1-WH4E0=P,G64F6HW?:P1:S--RJXT;WY.<%QU;$-#ZW[@)@!NP [L+#BB8(P
M2.E-AF[.+9',59_S-PV)<]QL\Z(:!5@'AJV<;4\EL.ENVI"SR5M;NI:W+<JV
MJ4M2UJ&\+2BLNCBI03[&'"XZ[F=TCB6E+4T%W$Z$\I6EK2@-W!-P 0E"$J#8
M=2$!DY !4=YHT--XWJKNAMC2S>LJF?K @A2J>U1YR@,X;,AD;#3A>P(.Y0#"
M&YTN37&$E#.69BSL2M-S[$&DLQ#<PO$8'9B79EBA3S*?;>6F0\9"=XE:5(:?
M7&7!=)*4ATZ$:D[I3NEI8);2@J5JM1+]-@<E8>906&0PK=E*DK<81(3,:QJ6
M6AJ7A6\#6IQ! 6I8"-,7*[8;0:74&1$6H5X+0#0$Y2JR' N(!UQZNL7%$.)#
M1.GSR,F')FWZVF"."9*?+FEC#TAR7AIJ.PUE]IHA#Q6I]UR0VXV^\XX"XZ'5
M,%2E:4I0% 1F4(T(2E*$ !.22<,WJ9ED(2PTW&=;=CM(;(0T6P^$I 4I2BDF
M0\M6M2E*6O)5@ "S6_LA>;Y6GZY; ]&-/8&M@P]EF5=AZSU@!_R"N4%KDYR0
MJ) BSI5>C37)C@^29AR")] @F-BV O&EW&+7'C.AQER0V-9<6REXAEYWV7#C
MJ0-2B Z1I"DMJ"&BM"RT@BV_=9$AHM/-QUG0&T.ED%YIO#>6VE$D)"BV%$Z2
ML%3FA24N+"M?^;*M97UE^V*_H;_9P_\ ;ZW_ /VN6OGC>P_V;[4?_E/^[M5Z
M[MI]AFS?GMG_ &IZODTY[)7D527$TSMN?4&=@0M:7B72)+C#<>U1ZP7>!/\
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MA4VO:MQO;J_L*H@(B!_N#,66*JFNMOQFHRE.YBSK0N*F>MJR%)#4*L,Y49+
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M'"$N)<=2%)5C3P'\Y.<6%=2]Z'G6HM:$U6SRB%AKM81#JVTM9V*2]/M5RAT
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MN-J4 HN)*=(45:FRVH.I*04:DA7UU67;=.8B,3G&'D1GU+#;A0L)RD-J"M1
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MH=<#3;;KB''72AEU0;:2M>$'P:.RF&%(2XL@N)*DD(6I(0%(25J4E*DH0"M
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M+=[7S23_ #1%G".\L@\#NT+'42"#7D.T'8NV_P!F2X;MLM=4,-YU3(C';&"
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M/M1DX6EF(;EC<^#ELNB*#O\ @<.GV'B/#X44O:3M."A%E[H,)RVI^?VGSO\
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M  3#&GHS0,$ %.2!D52M?[5[/GL16C=GN@/9T@P"J\'<F=;5'7963"O35>.
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M]Q"5,6/?+R!!:X+I!8J)8B2*_65N/)S"4J6>J'=<WM1NATVY:SK%=OM@T_\
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M):]G+A;IJG%)(84F9(OT]I*6U8+B3%)< *4E!.1^3(3L ]<5S0.P=9P*)DE
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M&E6K"LC!.15#=YM#TGD;-UMKLO6MODK<Z*N3O&]6\;W"72[K1I5K3IU)TJU
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M+4[C#?BVE"E+\,)SG%;MMN+#6_?@366!I)>=BOMM +("#O%MI1X1("?"\(D
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MK=N%UO=V]3)BHT.DN(TM#2LE8PHYK]5W6^O:@&)URJ4:H5FOFE2%& @"N"!
MDJJ7%3!E*(CH$2/$FYD0D(B/YD-.9=C)2POS-XPGD3;Y>;E*8FW"[7*=,BA
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2BE.*4XI3BE=;G]7]O]W%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>business13a.jpg
<TEXT>
begin 644 business13a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B"^5F0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!N#8E
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              <P   7L          $
M                 0             %[    <P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   <P     4F=H=&QO;F<   7L
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ',     %)G:'1L;VYG   %[     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      +N0
M  $   "@    ,0   >   %O@   +G0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MM,\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX4%.:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z
M-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@
M(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD
M:60Z-S-"-3@X,S(Q1D$Y14(Q,4$Y04%%,S%$,4(V-SDV0S,\+WAM<$U-.D1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z
M-S5"-3@X,S(Q1D$Y14(Q,4$Y04%%,S%$,4(V-SDV0S,\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^0C V
M03(Y.$0R1#0R,35$0C4T,C-$1CE$,S@T-#5",D(\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<R0C4X.#,R,49!.45",3%!.4%!
M13,Q1#%"-C<Y-D,S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,X.C W*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW,T(U
M.#@S,C%&03E%0C$Q03E!044S,40Q0C8W.39#,SPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TS,%0P
M-#HS.#HP-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<T0C4X.#,R,49!.45",3%!.4%!
M13,Q1#%"-C<Y-D,S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,X.C$R*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW-4(U
M.#@S,C%&03E%0C$Q03E!044S,40Q0C8W.39#,SPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TS,%0P
M-#HS.#HQ,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HW-$(U.#@S,C%&03E%0C$Q03E!044S,40Q
M0C8W.39#,SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#HW,T(U.#@S,C%&03E%0C$Q03E!044S,40Q
M0C8W.39#,SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#Y",#9!,CDX1#)$-#(Q-41"-30R,T1&.40S
M.#0T-4(R0CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A
M=&5$871E/C(P,C$M,#0M,CE4,C Z,3(Z,C,K,#4Z,S \+WAM<#I#<F5A=&5$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-"TS,%0P-#HS
M.#HQ,BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,C$M,#0M,S!4,#0Z,S@Z,3(K,#4Z,S \+WAM<#I-971A
M9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ N )= P$1  (1 0,1
M ?_$ !\  0 " 00# 0             ("0<!!@H+ @,%!/_$ 'D0   & @$!
M @8,!P@$% X3  $" P0%!@ '"!$)(1(3%!DQE@H5%CE!455687C4UCAQ@9&A
MMO 7&")WL;?!T20W6)4C)28R,S0U-D9767:7LKC&U=?A\2<H.D-296AR<W6F
ML[33&BE"1$5(4V9G=(2(DYBCIZC$TO_$ !L! 0$  P$! 0             !
M @,%! 8'_\0 -Q$  0," P4'! (" @(#      $" P01(3'P!4%187$2$X&1
MH;'!!A31X2+Q%2,R0B0S%E-B_]H # ,!  (1 Q$ /P#DR<Z.>^[>.&\@US0&
M%"<P TNO3XJ6."E9&1\NE',LDY*#EG8(Q'R<",4?%)BV$Y3"H)E# (  $./.
MY<I/D?4GJG/_ 'PP!YW+E'\CZD]5)_[X8 \[ERD^1]1^J<_]\, >=RY2?(^I
M/I_Q)S_WP_KP!YW+E'\CZD]5)_[X8 \[ERD^1]2>J<_]\, >=RY2?!#ZD]4Y
M\?\ ?@& /.Y<I/D?4?JG/_?# 'G<N4?R/J3U4G_OA@#SN7*/Y'U)ZJ3_ -\,
M >=RY2?(^H_5.?\ OA@#SN7*3Y'U)ZIS_P!\, >=RY1_(^I/52?^^& /.Y<H
M_D?4GJI/_?# 'G<N4GR/J3U3G_OA@#SN7*/Y'U)ZJ3_WPP!YW+E)\CZDZ?ZT
MY_\ E]V']& /.Y<I/D?4GJG/_E_T8?M]. /.Y<I/D?4GJG/_ 'PP!YW+E)\C
MZC]4Y_[X8 \[ERD^&'U)ZISX?[\!P!YW+E)\CZD]4Y_[X8 \[ERD^1]1^J<_
M]\, >=RY2?(^I/H_Q)S_ -\/ZL >=RY2?(^H_H_Q)S_WP[_T8 \[ERD^1]2>
MJ<_]\, >=RY1_(^I/52?^^& :>=RY2?)&H_5.?\ OC@&OG<N4GR/J/U3G_OA
M@#SN7*3Y'U)ZIS_WPP#3SN7*3Y(U'ZIS_P!\< U\[ERD^1]2>J<_^7_1A_S?
M3@#SN7*3Y'U)ZIS_ -\, >=RY2?(^H_5.?\ OA@#SN7*3X(?4GJG/C_OP# -
M/.Y<I/D?4?JG/_?' -?.Y<I/D?4?JG/_ 'PP!YW+E)\CZD]4Y_\ )_HP_P"?
MZ, >=RY2?(^H_5.?^^& /.Y<I/D?4?JG/_?#\7[#W /.Y<H_D?4GJI/_ 'PP
M!YW+E)\CZD]4Y_[X8 \[ERC^1]2>JD_]\, >=RY2?(^I/5.?^^& /.Y<I/D?
M4GJG/_?# 'G<N4GR/J3U3G_OA@#SN7*3Y(U'ZISX_P"_$, >=RY2?(^I/5.?
M^^& /.Y<I/D?4GJG/_?# 'G<N4GR/J3U3G_OA@#SN7*/Y'U)ZJ3_ -\, T\[
MERD^1]1]/]:<_P#R^['^C -?.Y<I/D?4GJG/_?#X_P"KZ< >=RY2?(^I/5.?
M^^& /.Y<I/D?4GJG/_?# 'G<N4GR/J/U3G_OA@#SN7*/Y'U)ZJ3_ -\, >=R
MY2?(^I/5.?\ OA@&GG<N4GR/J/U3G_OC@&OG<N4?R/J3U4G_ +X8 \[ERD^1
M]2>J<_Z/7#]/Z, >=RY2?(^I/5.?^^& /.Y<I/D?4GJG/_?# 'G<N4GR/J3U
M3G_OA@&GG<N4GR/J/U3G_OC^/]@[P-?.Y<I/D?4GJG/_ 'PP!YW+E)\CZD]4
MY_[X8 \[ERD^"'U)ZISX_P"_ , >=RY2?(^H_5.?^^& /.Y<I/D?4G7_ %IS
M_P#)[L/Z< >=RY2?(^I/5.?^^& /.Y<I/D?4?JG/_?# 'G<N4?R/J3U4G_OA
M@#SN7*3Y'U)ZIS_WPP"[;AGN6V[]X^5#:%X1AF]CG7]I;/4H!FY8194X:S2L
M0T\0U=OI%=,PM6:(K"=VIX:PG.4"%,!"@4;]K-^%>'\6%,_].L?I_;T8!$V-
MT>6<HM5N;6U05<9/*N_L5KD;<ZD$HV.']TZ:UW$(1;>!@YJ8>F<JL6"CA%)D
M\51.X=/3BC'-UU&P&WX;5BQ[ALC6]A478WJHPUR&%9LEVKE@_M5"6-(SD,X6
M\!0'"#RMP]F&'59JI'<S"<4E_#3<G2,!O4N@5)"O1R,,Y66O(0]'DIQ@^D6[
M2/:25^@=DW:MUF/8IQ*[U[,2],JE<7: I(MR)STY[4+)'%P11D!\&)X]7"3;
MU]5Q-T^#7MIZZQJL?-2L@@]G[!:XEK/0=9:E9Q#Y!G*.H64@)%9W,.(ROL4K
M+!)/IMLZ>&;H@>O3^NZS<5+8WL1GKZPPOM4E!45C=JAKJ5L1G3IZC-N6ECN[
M"3B%G->*V:%"M-6"\U-*R9#,131CWIA ]D]HFP(3,P6%!PA7F$OL=B*UM;*P
M4[!)ZVA&EEEFUOBTTGA8R47B)*.)&)M%7C>7?NB-V2A3^,(B!]Y;BQL$9SVA
MC)BG6!VRL%KK%E5@7TZ_0J,Q2X0UCGV\R3W.I/7_ (B%(JZ;A5F=B.]=(+0[
M9-2;)[7"!XJ<6=B(NUF+F1JS)TM,TV"KC:1=3L:[M\C?(YS+5PD(QD*\V?L4
ME8]B_6DE[4UKB4&HQ7:S1F#H4450-MR6A;,A#ISU?L%/O$8XC%)=DI4WTRNY
M?,V]OBJ*\\GCYF!A9 JS.Q3<6W50<MFZBC1XC)-0<,#E<"!^.$U6B?;=)UI-
M6*)>^W^Q&-&G5JJ\5>.(@37,*D_4(L^CD&IUE0(K)1*J9'K5PR59N%0#QIVY
M0)#1_&RCRLU!L%XS8=.>O9F^L"TBS7*E+66T1E1UU:[FA.PDP6K1#>M1QI>O
M,*^_=6"MOV(>WB#MB^7,R?H(A^LC">Z]6PNN8VDNV[6<K%@LR4RZDJ'8[36+
MK*1D*U]JC5VU)6*I1L/'*Q-L![)(1[)Q%M7J1X!T\*H[8/V:P ;UL'%N<;0V
MH20@RGNIO5BJM*M"%A:GC*_"6G8L1%VBB)LI/R,!.R<PDF[CYL3"]5CIRMS
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M1FJBKIN@V78KNP,>X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'*B[,7\#;6W_C:_?KU/X!4
MCVLWX5Y?XKZ9_P"G6/ ('CL^T#2V]#\*/]H6T42&3#R3^S!9)W-]>@ SCQO>
MK[>2#@1."8?V)XMOT_@B<P'I<;*M#C9:^V?'M4;>XMRMV461:E"/]NUY,TLL
M7R%0ZA#L%')SIJ,E3*)JM3&;JB<IC=0/KFW+>?;>?G$WC1M*6*]U38CETU9D
M0%C8*4K/*5LL2D0X(L8R-"PO$$8\J9TBMT&+<@D2; 4X&X6W(:\I3<K8';&J
MRTD]N*>P(8TG"G50I5O;M46#.6J+5N]:MV:3&/91;%M#R:<K BWA84'$6NK%
MM%4P-F5'9$E5FTY&N82LW&$L;N/DI:"N,<ZD6*TO%"^]KIA!S'2$3,,9)L24
MDD#*LI1!-XV?N6\@B[1,0A -_O=[2\A1=EQ+QP[<6C:MDJCB>,G&Q;&O0]7I
MC8P1D9 >3JG>ME7:B<1%J,T&[!DR@:ZS9G5E?+/ C@/F,^0%^9R<_)%"#7"T
M7"U72PQ[B,,>/E7UTAWL#8XU=--TDX1AWT9(ND4T6CEN^8K"B]8R#9\W;N4@
M-&.[Y].P5]^=G'04-"W>F7%*/I[!M'.F*E-:*1;)*+<S 397"YHQR[\>ZL99
MY>3D%?*YI61\8X*L!EY+D?5*]8JK,TV'D(M/7M)OT;6&[*KP%?CY>VWA>042
M=S4*G8+ 2/AJ\X=L9E XRUED9&4A&Z"18>/79I0@$8X.ZR5=G*78XIG%(35'
MEV<['OS-#J+2DFPG/;YHYGC&<",B9%R";4O@^3B+!%- PB<#*F ]=>N<S6+"
M[LT6+4LF]CK5%K>/0\<W\DN,!+UN9 B/AD\%08R;? U/X0^(7%)7H?Q?@F!<
M=>)^IS?9I_7:?6)-*-E8ZC24B]KQW[0RKUNQE739\]KJ[PBR:KFN*2""\@E&
MJ=/(WLG+K,UVXR3H#@9#BN2>V(RR3MH6G2S3R?L<1;7#&>*XDH9A8(*V,[C%
M2,+&*.B-XA1E(-#L$2,@22)!OY")(0K=P'BP/AUO=ERK$8WB&2,"Y8M(*1@&
MR4C%^5@DB_ND7L!)]T%=,JC^,M<-&2,>*Q56?@-09OF;YDJX05 R8QY,2<Y*
M+-KW&QS>JR/NY=2["O09IT)26OB=:-,NIYE:K)Y=/L5G=1@73>/0M==7@W;!
MD[KLE%D8HLS@?GL_)J;=VIS+UJ K[>-BY"%DZ ,U#HFD:--0=(K-$)9H!K%N
MVL/'R,C'5.%?'B';><@HI]'QIV+=1Q%MGYP-AQ&]KY"32$^Q4B?;!LVUPT3,
MM'BJD9+5D:SBJL)R>/*)C@T8HA)&\(/+5/#4Z(B80P#Z\1R*N\%&P<3%1=29
M,8AXQ?/FJ,2\(RLR\?5IFF)&FHTDJ6*:J.:[8)=E*NJRPKKV;</3RLRY?3":
M$@D!\ZA;XM^NHQK$P<=6G32-M;JYPQ9=C(NR1,X^8L(UXLDU1EFC"23481C)
M!J$^TF%891(S^!6BI-99ZH!^6*WI?X226EHMU&M7ZS+6;#QWM:BN!&VIH^*C
M*H0$7!ED% %G#M4IA-PFLA*%.X(LB5-<Y, _+([?GG4]KV=C82J5L-7NFSNH
M0\#%ND(EHLVLJUM 7I7\C(R$F*TVX7764>R"RODZA6*)TF;=JBB!]A+D'L=*
M)AH3RR,4CH&&L,$P35C$S* RLMJB;=(G<+%5(JY<IR$'%,F2RQS>1P[)O&(E
M*@D02@?JD=_3+VQ^[!C1-:5ZUGEY6:=3\%!3"#]\\FV<HSE2N@>6)^U%!X$N
MZ<'32;)>"Z(W.F8A$S)G QI+W::GJM5:G*^2.V5+]M4:\_4;_P"'#*+EW)7[
MB!/(%. N85M)B[DXUDND<8Y[)RIVBJ:3]9' -^36^[]/2Z$V_4AQ?-W5]>)"
MC&^*2!;8]785"R>$3QYA$IH>-; Q*!O[%<^,6ZJ ?P"@>#+?%\8/9E^@>(\H
MGG]>DGXGCO#)Y36:38]?QOB2^/+XM/W/VF5*X)U$57@MW0&**(IG ^JIR+O/
MCV[QG&5"*D 4AU9>0C815%W95:[4I"DP!YP57ZZ!O:F E9!-(L8WC"/7S@9.
M7+(OTD'"0!IR*NK52*7/#TY\Z@1I[V!<OX9VNI"V:C0#.L0%S8IEE4VPV%.$
MBX=F_1=-W-=E3PL0\D(%=ZR3<"!BFTVZ9N+N-?3BJ2[J+@8BNMU4DA3,HPA6
MP-69W B<XJNC)AX3A<1 5E!$XE#KTP#;. , 8 P!@# & , 8 P!@# & , 8
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M7RQ?:< >:QX?_-2W>OEB^TX \UCP_P#FI;O7RQ?:< >:QX?_ #4MWKY8OM.
M/-8\/_FI;O7RQ?:< >:QX?\ S4MWKY8OM. /-8\/_FI;O7RQ?:< >:QX?_-2
MW>OEB^TX \UCP_\ FI;O7RQ?:< >:QX?_-2W>OEB^TX \UCP_P#FI;O7RQ?:
M< >:QX?_ #4MWKY8OZ7. 3*U#J.EZ.H<5K?7S1ZQJT*O)N&#:0D',HZ34EY%
MS*O1.]=F.NJ!WCM8Y"G,()D,"9.A2@  9,P!@# & , 8 P!@&@F O3K\(]/V
M^CX\BJB8KD+^>=MYIX8#U$._I\7[?E_%A%1<E_>%\.*67-,!K] 3E+W#U](A
MZ!](!X7Q=/1^GN](#T=I.N%\.":]%!KX1>G7J'3IU#Z?A_/]&3M)>V]%5+;\
MKWMG:V0-#' H=1_Y>[K\'Y/R]W3TYE^O77L2_)=^[@MMW'=R- 4*/P]_PA\(
M?C^+]OAS%7(BVTG7A?=YY%^4NG0U\(H=_7N[^_\ %\>5%OI/A5\>J "< #KW
M].\>H!\6%5$5$WK^_P 6ZX"_#'H:"H4.\>H!W>GZ1Z?R]V6^?+,ETPYK9.:F
MGC"]1#O[NOP?]CZ?S9.TF&>-K8+CVLOWP0IH"Q!Z]_H^,/A]/3\?00'\0@/P
MAB_FM[)A=;77V2_3'(:\[?E/,\O&%[^\>[Z/2/Q!\8_0&1'(JV3&^5LE3KEA
M9;IG@N&"A<,5MYII#Q!8@B(!U$2CT$ */<(% W?\7<(?MTZV_)?UCCTPMUPS
M)=,<<ELO6R+;R5%Z8GL P#Z!Z_L/]0XOUZ[EZ+OYBZ:ZV]S4._\ 3^@>F4HP
M!@# & , 8 P!@# -!$"AU'XP#\^/VOEBHUYGCXPGQ_%^G^7\GP>C)?ACTQPX
M].>7,E_>WCPZ\LP*A0ZAW]P].X!'XQ[A]'3N_/T#TCA7(BV6_DN*JBKAAP1;
M\"FGC2= 'KW#T^ >[KU](=.[T#Z?Y,73\<\+X(EURQRO;$'EX9>[OZ]?B 1_
M/T]&%6RXWSLJ[D7GO3QPQ073B:>,+](^GT (].@]._X@$?1\>.TGABE]V%]_
M@H/'QQ/I^GN'N_'\6.TG'WX7]L?+B@^=:Z*F:'D)R@ "/7H/?W (]WQ]/3T_
M)WXOA?/7N#3QJ?=_"]/3I^7K_5WX1S5R5%R7!47!<EPX[N(_-L<,=*/&D[AZ
M]P^@>G=W!\?H^C\?=D1R+96_R15LBI946R*JXHN266_-+9C]>N6N:<3Q\>GT
M >H]!Z=.[O$!Z=!Z?%W@(_$ A\>.TG91R8HMK62][JB)[^&\9Y<+^"'L$Y?C
M^( #X1$1Z= RWWV6W3=:]_CJ 4Y3>@1'T_ /I#IU >H>GORZUKY!Y (#WAWA
MW_H[L:QSQQQ P!@# & , 8 P!@# & , ]1UDTSE(8>AC (AW=W0H"(B/X@ 1
M_$ _%CDB*N%ULE[;DOPNN"7P5< JHF*K;KR2Z^29KNWYH#+$( B8>@ '41^
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M0>_H/3TX145+IEQW>8NE[7Q3&V:VXX'F @8.H?BR@UP!@# & , 8 P!@# &
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M2.)(W.NYMT3M*C41;_/WC9.7%GI4^C*PVR)6V5RK;&K36YUC6=H93D\?77:
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M;.01$O42^"/=_!]/0>@"(=>[T"/Q!^+KGP^]<,,++QP/I$R3"W)-QY92C &
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MLD4Q.\-:L;GD;-78=D>2EYZ'BHY-X$<=_)2;)DS)(&6\F!B=RY730*[%Q_@
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M*>T#D3UPHI<8 B=Z.H*94R5,XOP+/&4.LBD0(T7'AK+)(EZJJD(8#*0&*(B
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MC:G[@X:;U[H6H7]I9M\;AEI&27FJ&,UJW5=YGK1(>Z37S;8R;B!<[%FX67)
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MZ\>[5;O7+%PH=H=9F*B+A1(5$!,F8HC3&_'#KKACR-ZX*, 8 P!@# & , 8
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MN-8,7<F\65%Z$>>QQ*4G9]ZB*0I2$+:]YE(0A0*4A0WML<"E*4H 4I2E "E
M        .[ +/%/\C4_[PW^U' *JNQL_ WDOHY.<MP__ )#[!_HZ!^3 +6,
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M% %#)D&QJ"0AC@82$%102EZ%$YQ 3"&N![?W\G"_^ZQXY?[,^O?A]'^B#X<
M?OY>%_\ =8\<O]F?7OW@P!^_EX7_ -UCQR_V9]>_># ,RZYVWJS<$4\G=3['
MHVRX2.?FBY"7H=JA+9&LI,B*3D\>[>P3U\W;O2MUT%S-55"+%2624$@$.41
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M@: =(U4AVR;UV@K'QA$H2M^3&;.4EDW[!>!BG<?)%>,7K-)VW6# UK7,S1U
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MZ_'@'+]]A]***<J>6'C%%#^#H:L] ,<Q@#K?6O4>@B(=?0 #Z0]'PC@'8#8
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M_K/.WN.I$'7N4W"AAN/32-?9VXUJN[_<.NTHQXTV5(^U,U$HU.0;R!EDV\(
M6 SCH[*V\2 F XS'LO#\.G0GU:V'\X%RP1-_7X0XG."C .S#]BL^]5QG\?\
MMW_:5?&O,')%P"J[GO$\]Z%4=Z\@]"<NJ%KC7>L-16>_Q>I;!QT@KW(.W]$J
M$A.2+9:]/K;'N@2GW<<8$Q&(/[6%7$I".03#PQ,?#JJ+RU?\'VN#-=YW66"U
M-N[D#RXHFT]?[$U17KBYU?7^.\'KU^PE[E78R;C_ !=S86R3<K(P9WBB*B8Q
M299$.ACE;] * ?G>J^>/-,-W!<2S?!1@# & , 8 P""_9[?VD+S]:;E[_NDM
MEX!.C & , I_W1?%I'G]KZGH6IY7*[6K[JMK8I: KDL,JK;)ZO3,O6==2CIU
MNMDE(5^Y,VQSRLU#Z-G86':^"TD+"SE$U7L<UK7P$W^B:35\,"?/*FJ6NW:(
MV*RH]DOU<MD?69R9KXZXE#Q%DF9B.AY!6*@B/6S9:2!I(2)FOCT(E9C(.3))
M-TWB:*BZ:H>V_6OQ7Q;B\G2\EW$:V;[O/+OM_<89;74O&>ZS]QZ/XV,]?QI=
M\Q]H<-S^X%&14L;"ZI3#&Q)C;'<O+4Q6&*=$K59 1+9)[XW7'&ZWNOPIF2G-
MM@(=JOL]2XRU5D(%UPMJBNOFE>AI.,E(FMEW=8B.&=L>/Y>2:S4P>5*Z72?1
M;2':IL5$&YF1UDU%U&/AKS]/$886P]EWX9?.\ZQOM4.[M(>;X?\ =,;:_6V1
MP$Q1.B$!<%& =PUV7OO<O!WO_P#BMZ4_)TH4('3!$W]?A#@\>RV_?']:?56H
MG\X&S\%XZW(<6S & =AY[$._ @Y ?6-<?J)5_P!O3@&ZO9;GO>^J_K(5G]4+
M=@'7,X P#EA>Q$OPZM[?5Q>_KS5\ YB?;+>];\X/XAK7_*UP#J*L 8!/OLK?
M?(N#_P!9G4GZW1V =P;@# & , 8 P!@# & , B'S3CZY;M+V"@/EK*[LDA[2
M6RO05 :6F5V*H>G6RO/RV"K1%&LU1N*QZ_*JQ+AP^A)U@9@*R)W"AT5#(*AP
MUN7STNX^OPX2N3?14 WO#.^M99&:M2;579JEI]VLA"A8'XP\E-L[K9;=:(M9
MXR%-1&-E9YXJV; B"8-T#I-T@WZUQZ>)*7 /SN@#R9R/3_K"W?W=?\C-\?\
M3@'#4YK?]3%RO\;\MU__ #9W'T_HP..MR:Q]K' JP!@'+_\ 8?'X5/+'^(:L
M_KZUR;TZ+UW:7P!V!.4$6>2VB=O[K3JB>J>5^SN,)H!23/,J:XJFNK,>W%>E
M: T3E/=]7IX&98H6ZQFPQH-C*B[5\H%0")>"%DWI?KK?O( <(])\O-@M(W;6
MPNT:WO;XNF[SVE5)37+S6^C6-;N5?U5M2R4UM'R\A&4AK.-"6&-@$E)5:,?-
MED5G*WD9T2E3Z"KP2V28\%5+\>?EYETN"# & 5?=D1^"98?K5\R_]TYL_(GY
MUTX<BK\)[)<M!RD& 0W[1#\ _F']6_<'ZC361V7BGN@3-"&O9*?YY>?'UD-:
M_'W?]*AH3\GT]WPB.4%R6 , 8 P!@%7O:OR]47X\UZAO[Q4:M=KCMC7J- CK
MK:8"MU*6G6LL8R"MZ4FWK82T:.543=R#]JB[783:=?5;(*O!;)F S9V>#R-D
M.(>JG\6^&00>*7IRZ<(.(QW"!,*[$M9YUO3G4,[?1+F@M)D7S6AKQ[I9LM44
M8=0@E$XD(%K+SUJW&^^Y-; *N>UE_M(\?/K[<(_Y_JE@;_/XUI#B!^R\/PZ-
M"_5KC_YP+E@B;^OPAQ.<%& =F'[%9]ZKC/X_]N_#U_\ <U?\WXL:RU?J#DB=
M0#TB ?!Z?A]/3\W?@$1^?9R_O&N8?0Q1'][)O+N P=1_Z&MD[N[K@9FY.&AR
MAQ%XO )@ 0X^Z>#H)@Z]VOZ^'?W_ $?#WX!)0! ?0(#^(0'^3 -< B%R7Y36
M;CU*5F.@>+'([D(C88]^_=2FCJS6Y^.K9F+A% K*>4G+1 *MWCPBIG#0B"3A
M,Z"*HF5(< (($6../:JI\GGM,<:^X2<RT*+<;:_J ;1F:-3&U%@'L-.O:U87
MDX^0O+AZW85^9CGS*4508.%$E6JP))J@4!$"V3 & , AYP@IUIH^HK?#V^!D
M:[*/.1?)ZR-6,F@+=PO!6C?=_GZ[*$((CX328A9!E),E0[E6CE%0.XX=0)AX
M P#0?0/P=PX!QV=0[3-<NT%AR--Y["W([@MI7"IEGMIZ8UMI9:K09'<TF[US
M299QK.0V3L*(C7*81[&39$I4/-,TE7AK<N)S>7";L41/'=SO@GAZG(GP48!
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MOU31#>015 DIQ=AFE>T+KB'8Q,#!-6,.LDC%5@UY/ LBC)/5/%1IMDMFEW%
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M8(F:]?A#@[^RVO?']:_57HGP_P#S_P!G?!\']/Y,%.+;@# .P\]B'?@/[_\
MK&./U$J^ ;J]EN>][ZK^LA6?U0MV =<S@# .6%[$2_#JWM]7%[^O-7P#F)]L
MM[UOS@_B&M?\K7!%W=?A3J*L%& 3[[*WWR+@_P#69U)^MT=@>IW!N , 8 P!
M@# & , 8 P!@# -#& I3&$>@% 3"(_  !U$?R!U' (7ZHYA16U-B-M=OM>6"
MEL[S1KOL735OD)F#EHC9U'H5GCZC9)4C.,6]LJK(MG<Y RC6'F414>0<RT>)
MNBN$W;)L"X>=O7R_)QG.:IR#[&-ER>&7PPV]+CX B'A]W+2X]1\'O-TZ#Z>G
MY>F <"O & <OWV'T<A.5/+$3F*4!T-60ZF$ #_/ZU[NH] Z_IP#D\=OXJF;L
MDN8($4(81ID /0IRB(@%TKO?T 1'IUP#JBL 8!RRO8AQBDYQ<@C',4H?O;7(
M=3& H?VP:CW=_3T_!^7 .:MVD'+Z3X+\--R\I*_4(K8<MJZ/@'K2H2DRO",9
M<TU:86NG(XDV;20<MBMTY4SHHIM%1.= J8^"4XF //PY8^2Y+U.$!R/]DL5G
MEO&UJ(Y!=G#J_8$?3WKZ1KK=;?FSX$(YY)-TVKQ8#UB(A57(K()$)X#I18B?
M03)E(8PFP-:\R$''#M;M': DRV=SV>=$V#>8?:UAV52;;-<A-RLG5-9/+&:=
MJ-09QR:SV-D8VCH@A%QSN1055D6[<BK]$RAC@(:U^,N&\Y7O9$>R#M@=I=RL
M4XYV?C?3=4QB6N+5>AM$)L"8L;SQU<6BDDH\8Z0KT8AXEU[8F\-?RH#IBF7P
M2&\(<#7F<F.V72H42N2]ONMG@:G58!F>0G+'899C$0D0Q3$I5'DE)/ED&C-L
M0QB@99=5-,HF !,'4, K(Y<=IWV6=7U%/5+?'*+5MBUYMJ-F]<3L1KRS*W^4
M?1D[#NT)9JY;ZU4FIJ&;.(XZZ))50C1,BQR)HN07,0HABF[A\<>2W*_^+7:]
M]C7H*Z[Q6IW,)Y*)\B-NU^[HQ4SJW8L5'TY5CKZD:PC8).8=5TP.HY%E3V3U
MQ,2ZK8R1G:XN3>*0\<(8\O*V_P =;^%ZNON7/%K;-D:4W6'(C2^P+:_;.G;.
MLT[9-2L4\Z:L41<O5T(J*E73U5)H@4RSE0B(E02*8Z@E*41 "0Q3D.'4ABG
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M=PCZ.[Z?T8+I-=;G%MP!@'8=>Q#S%+P@W_X1BEZ\C''3PA .O2B5?KTZ].N
M;K]EM&(?L]]6>"<IA#DA6>H%, B >Y"W]X]!'H 8!US6 , Y8'L10Q2\Z=["
M8P% >.+T.IA  Z^[FK]W4>@=?H^@?BP#F)]LHH0W9<<WP Y3".AK7T # (C_
M )5'N !$1^/N^# X>GDOQ<ZBS & 3Z[*\0#M(>$ F$"@')G4@B(^@ "W1O41
M^CX_TX!W!A3D/_C3E-\/\$P&[A] ]PC@'E@# & , 8 P!@# & , 8!H( 8!
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M-9^-.K]U;,V7>;/=]54&W0_BWC!&RR$<QB*%!.(H!\CH]8<*&-&-SI/K++)
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M2\FZUK0X*G.)I%NWE58=%9([Y%H=11LFN*JROA%1.JH8G0 $!./?TZ!@&5<
M8 P!@# & , 8 P!@# & , "( '41  ^,>X, K:YH<F:T9@XXXZZV53H#96P'
M[R@SUDE9><8MM:*RT&Z-%K*RE:D8F4C)^2G'$# LY:)>22U%D)R-G[%!N8PH
M-G :UKS0^7Q8X<&/7W%AY)U6'MDH\L41;X2KW^#@;#<*Q?HF*9UVTW:?N;%R
M]8V.Q71:"CW4E+024'7;2P8Q%A=5"!FGTFQ("XWW9Y8>7GZ%G
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M@]DD+!831E+5N%9>U]IL:A)6BM-1C1?;6LOU:AZ/1@&@B!0$QA "@ B(B(
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M"MD-%S.R9%1G%M[Q=$' H6=[!LY9LQCEG#X'0$VL #W (_%@$-.97,6D<4*
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MC[51T@V;-$G$5"WU_7THF&V#.4Y9A#7![7F$PE',"F(S;AKS]_&_(G'@# &
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M(IMFK5L@F5)!NW;HE(DBBBD4J:2292D(0I2E*   8!^G & , 8 P!@# & ,
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MQ$+O*'-7:-FX&;KUTD8C9+&P,SEV*PC95-[K5I,MVM4:2#-TVD!3E9.,L]<
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M,22-BF"SY))FQM=FK$:N^J;3:;V'97>?JID(Z??O2D$3!KD3#P!@# & , 8
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M6=M0B&]@EY0D487PG7'YXX+^5)\         '0  .@ 'Q  =P!@IK@# & ,
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M<FX[Y7M@[2NM9IE$%>GTYS1J="4^A.[/(PZ+&"D+';)!S/2,G<9U],S+R8.
MI*LXN/:LV3+^R!,;\K9+G>_+#!,"4>"C & , 8 P!@# & , 8 P# ^[-!0.Y
ME*;.!9[=KK8FMY-_+:_V90GL>SM-:5F&81\]&F0F8V9K\]7;"Q(BWG*Y8H:4
MB7QFK%YY.E(1S!XV W7J35=?T]3DJC .9.4.O+SEFL5BG%T7,];+?:91S.6B
MTS:S9!JS]LIR7>.7BZ$>S8QK,ADF,8Q91[9JU2$MGOUEX+D9-P48 P!@# &
M8LW+KJ0VC0WU9@[<^H5E0DH*QU.YQ[!G+K5RT5>993T'(K0T@(,9F/!^P20E
M(ET=).0C5W;4KALHJ1PD!MC3>MMAUAU:;5N&Y5.^[!M*\*BK(TVF/J36HJ&K
MK%PRBV4;#2UGM\B#Q91[(/9-^M,F!=1VFU1;HMF:0'#7B9Z .G<& , 8 P!@
*# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>business14a.jpg
<TEXT>
begin 644 business14a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1PJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ' Z^<8(X0DE-! 0       \< 5H  QLE1QP"   "( D .$))300E
M   0KR]7_,-/(S&XDIJI^;[;*CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              Z<   =C          $
M                 0             '8P   Z<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   Z<     4F=H=&QO;F<   =C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   .G     %)G:'1L;VYG   '8P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      1IP
M  $   "@    3P   >   )0@   1BP 8  '_V/_M  Q!9&]B95]#30 "_^X
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M[<4_VY>P39DX.CK [^=:8K'OV,<'.LLK]_Z--4<]H#R.I/VV,<&.=C
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,CEWD96AL\;5V/ F0U*!@I/!\1DV0D1&8V=VAH?AM__$ !P! 0 " P$! 0
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MI:^@05W"!1@T5+:#D)/#9DZ?U[*?;W;9YI(UA8Q9'=XX34=>NJND%9-/'?\
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M65O.A".Q@!K(V#X3-ZKF,VAA=!-EART+H-C.'H(N/?BB;=!TV4UQ7<]TULX
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M>7E]):]C&-M_<]-M+\-O:JH:[&#+[W//[!P>NS0-- F;\7(6($ K%^!-(SB
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M1E$*;:,X;)'\0C[P_$F:6NVJ;6,F' Y0B!;)Z[;:Z("G+1+37;;&NF,9SY^
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M6)$I(RR-D1%^1;BDWCQ\>'9RP-.W"RC@HRSEJ^470_P?,'R&]BQ4S;K-0"L
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MO/O?_>.M_P!__P#O_P"]]_\ _P SY8[_ '^_M_+_ $_7^M1'S>V[^;][>?\
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M)8Y6;QN0O1Z 7 3K!80 J#)-A,I&%'  CD2XCQA@5<HEKX9V"!%J4)W_ &6
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M])V8H[K28)SH U<V]9Y0>M(&P4P"9J$FAJ6$]5V2#,Z0]>R0RU1)Z*;#C&"
M-T2%/IX<MK!6E(CCH=><LSK'!A _1)@,*@-><"$K)8]B[]P_?"Q8(D,2^.SV
M:666F[0SU0HMFI@V= 059"QQC=51E]/;L7V+N/<;XNTW7\+VDHF:T3(R+<8
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MJDG ES+)!KO/("IJI$'RLA'@YT@L)*JFF+<85#,FB)7P_P!^KXF+Z>1*0W7
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MNK&+5#8P:U*S-V?"I%&8')IG*X$?$L8O9%6'04OBI*Q9PV46W/DPDB#G$V)
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M)%6,5)DV!%"<5 $I>T)!9T2(X9F0R$)/B6C=^?8*B^(D[WQV8K_KQ!@5JS=
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M6<(3JJPC1B2C5G<;0BD7(RI8F@%15=)HGZ']U>LY4D"#,K%<*%C\D!Q)$:K
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MG[7^*&A J$0IV@U*$)"?-2F2&)Y)S!@><-22<:$-@9LB5?"!P<2FX;ZA&@A
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M 40C\G$E03_W5OA$LMU7KF\XNT[,5_:\KF80T^F+;6NY8 ,S>:Q$9$3-?"&
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M(-M8:4,RWC=FR2P@3]W'VY)-B8E4" Q)Z;&[ &LB5+%HVU-HDY6;V(I:G2*
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MO:Y$*;XV5;AE4'^NB>5,*;.]5DVK#&GMY'/NYLZYHT")K\2JK[FNJJZ._?U
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MIRB>?%^@\9@Z[?>,75<FPJ-R K8-<P<_]RTA!8-;CRMW-:"[*U0%UB"F<L(
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MG8]=RVF9;8<H<2542JB!8!K1AA65L!#T5$F*#T>N1>(FZ#B(XB.(FNWQ9_\
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M@T?:CS-@V!/Y6*;L6<DU;:(F$1[H=U5+%S)H/)YY+9<V>4\1'2M2Z3TIF$"
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M346CNQ<EU$JK>VPU8%?>FO"KJO4[_28G175=D^-6NJNRNVUWKTQL;.Z[WI/
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MCUJ@KE!9!REKNV<(+*9XOEN.YK(&[C-:MF8BL/55Y50L'MY 8&(,68]ZNP8
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M8S][S^_GB/Y?G^OU_.5_V[(3K.V<IT/9FVF?ITVQ%CF<;:Y^K.,X9??Q]/\
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M[#175=R]K]J[][]OM^4^FE?B)%VLO$;OM7W+M7?M7\[^U?SG\[[&_.U0KI1
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MZ TO';SAPFH[+DMDCI/%3MH#*R),R,@94X.;OU8;DGB8R205"SN"+KQL>73
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M56A@K.C8W3Q'%HNE-*K$R4DO:"VQ 3A#0,D>T%']\^6D<E#$E$9$IGS3QGU
M.3-!1)UIC95+7US1LNAG*B>-5=O3U\]J]N9A>G3?!M__ $G":'7]J]E.$#NN
MY57>ANN]U7?O<A[.F.<Q9[V'A+3A'][D.-=GY7CP[^IVIF[C':\JROTF7X,:
M!]EG=C5"5U(OT9Q][.,X_AQG&?Y<9Y*E#(:[ 1 3.J>FD.*)YQJ=8L6 15/)
M9+<?+LEAZD&*I+@AI@FQW#3%,$4T(-Q;Y,;EG[<Z;*LVZ^O,%QZ.5$L&JWCF
M>-_,'F8E6E2%5;FNS&\P36A(+)J*87B;0 +$_+P*]Z:ZDY+I'GN-ZCXFLQ[^
M,?;%)W)O1BU+>IF75BW($@)V+=D>_'K6!K,L[V4#5'XL&,5: FD8CMMRZ+6S
M,)1V%FD*2 @[#EFD3'LFN8HU,.H%',Q4#%FD*:1]J>+DG91[\,NC[C<^<7T*
M):JLT&=!^R-69')Z,_(:-/,:\OI*V:O0 !+.MMXTWG0A64$BYK"8=(MQ6YI6
MSW$1[Z_B%PG,<CT7PW+](\/PWPWX#G[Y'D>FN!OEGZ'KYC1A5U+R-<ORG+:N
M=?R.CC<69.//?+*XY-<=@"LMV#V/C?KVTLR-2\J5TA]\AJUQ!XZ/E@>\YRWE
MTC=6K@JIN?EL15)3"4+:!!X7U^LHP'?CX[(':PM>$A5U&+[#B#P@;T:&F6?F
M%81Q(!ZN7V#K>?(TS\9^4BU:/% )LKT6LP0X_2^41W%G?I?B5IZ4Y+AL>4.5
M^'F_JF^H^5?Q6[X?=.NX#BT='7A#]F\5S2D<%PX.Y#3R'IUQ):\^KE.-2.M7
M/<@(O12,OK#LX0L<I6C.:5X!B4*["P\U+Z;(8G#.3ES80:P$E=Q,]C"P 2TC
MIPE'33<N@R!EYH-1]2^$DB35^BAH\D<9U"_8_C[;D'&CE\K=O$O7LIKS6H4L
M\-::2KY7027"T:0[4%4+%FP&T(W3]9_"?'TW@ZKOC.HM?.<S\.^<Q=/=>X6]
M/-XSCL>_:[D,E:>G^4+D-C.8XW/R/&NQ-=R''\%K;YY]F7&_(;3SZV.NTA[B
M,/%#NDH4^ 2=13;0G$2%:N;_ (=)I;7T'AS]^7AT@8QE"2G#>#C=Z3(;$HVE
MIAD#Q/73#?W0*'C-6GWGF.H?A9OZ*X_IOCN<4SK/AJ'<]>?CFJ/3LT+0GD<^
MB_12(I6NL]VZ_P :ZQI8VC:\[9\=/H?XB\:D.L>3Z6Y?)T9R_AGX_FM&70OC
MFU^*65B-)JI++U$#[47J>#N[*29TBZ'8DU[X57MV[B_30NP*1RTI#6&9T[0,
M+C\I!).JV:FF=:.5AC@D((R):)Y)R11^$-$@NJ [#%N\=/'6B:?/%T1RO_*.
MKK)1JT<7GY.L(6D3[ORT9)/DA%E+<K..KTLPK>I;KMOF2P$+[T_[4SUR(<87
M<=!HMWOV\:NNUTKO^9V'<_I[UV'[WW[R\/GCZO/Z<_5C\/E]?.,N^WZ_7?\
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M1ZC=U7T>T^?Y#B0XSEM"N+!V;D4YTZ/VGPANX;C=/R.5O#[0<EXIY5:M3 J
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M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$J/W0_:==_P 8(?\ /C/$Q^=?TO\
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MDM[(N!51]ENPTDKNT[E@+6;W])>OU;Q:8GXE NJ=AS3X49Z2:@0-:"A.;2"
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-.(CB(XB.(CB(XB?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>business15a.jpg
<TEXT>
begin 644 business15a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.B^8W8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!ND7C@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              HP   8&          $
M                 0             &!@   HP
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   HP     4F=H=&QO;F<   8&
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *,     %)G:'1L;VYG   &!@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      .@@
M  $   "@    1    >   '^    .9@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M<\GU5)<ET;ZF](R<09&?A8Y]6'X[\3(R7L=4YK7,?NO?6[<Y='T[IN%TO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0 "70,!$0 "$0$#$0'_Q  ?  $
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M*=GTZ](#6V59H*U8),,6TNJFBVF;"HWM+1ZE$0QWZS5LB;OH9@J]BTGQ1?\
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M$31%1INOP=D:E86"&B9UB54JX,IF.9R;,%B 8I%@;/45T@5(!CE(H!.>4#F
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MN62U1KN@2455UJXF\*QPY8'$K+-;<[F659F:A!EHP3-YK<VM7+&:.LU.8SD
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M!Q%[$AH%SF5DG5FJZ:(FB)HB:(FB)HB:(FB)HB:(K9M<XO7XTCY!%)<YG2:
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M.9&Y8ZC,@ EE"TR23 !E75/JK9T10XA'E9-9.R&:&;\# Y[I,JLY!ST@="!
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M":ZH=&Z9K)B!N)DQ'F\..Z<4-/B6GNBU!6,;)354/%2QDO8"SCIW$> =8"X
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M+9E:5I'HS5XS6PU5/44\;8X#$6S<8#?7OD8V./D-L[K7%['2W,]?YNF#//\
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M*<P3* 0AM=TJX3<+Q[ Z_"H,/Q&.6L9&ULTYI!$PMGBDS$;G/O9K@"#?.UK
MWRF#:(UV&XC35DU51R,A+R61\>9""W5LTN8UEAML1D;F^Q>E(.H ]P-<7'D\
MGR+H*YU*)HB:(FB)HB:(FB)HB:(FB)HB:(L?9)_0^G_RBW_Z)QV^C61PO\*/
M^RD]05E7 &$7%_MC/6>58'#L#W ].M@!-MI]7L6*;^^_UBL8YFR*?%.-;+>D
M(D)U]%!#1\/#J/!CF\G8+388BI5QF\D@0=#'1RT].QI)*1!JY,PCQ<NR-W!D
M01/#GN:TN!!-B "=^XVOUZ%Z &L+DV)L=F0WG.VX99[>E1\ROEG/F%J>I+W
M<4R02=TQ=6X6VURIY"?LXP+Q:S5^P,9/&K"PS-JGEZ\T,SD(F5@[*@:?4>+-
M%:[%FCA.^HR231MN1K$EMK7)L>4#Y;<O,O;0V1Y =8-:2=PRM;/VYK%)]Y=I
M5BJN9:5H-;%W?LL4Z?N;_&F5IU@+/'%=K-A9RA\6LY6*R'1599&P*@Z9V]RJ
M5M'L&M@;K.8.P0[Q;P:F36C%[$NS&H3<6R!L#;;;ISO95>*&J\V#O &J0\-
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M@6SY I9IKC+I(6N[##9)FQN^T/%@0"2?"Y]US\J]K)!$Q"&'@(B4HB(=@B(
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MM7.C=#R]M*;/_P %;FLEH5^VT^_[CJ<O15HSDNN1?_\ E[WR=?4X/[_\WF
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M47G7*2@)K%0Z)%'F(E/SS'U_1G3_ !+1BBDHJ6CHYXY:EU4YU09=82.:UEO
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MFDD:409-I1=JH50Y54 0BGC*777<)I-D(AZSE55B1[MNY4(LQ ("'$!X@/6
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MHT@Q'":Z*"C,?%OIQ([6C$AXPR/!&9RR Z+]"U5>ON<H*'[-L<#[N,:_Z?\
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M5YQJP,W8M#LF\M:4&AFL6J9Q%MQ:ID*@9"-<&,LP1$@ILU3G4;%2.8PFO6\
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M%I3;A0<A"@,(:K&N@.1D JHQQ7'@Z0SOO:=V64!T'><603(A'B14@^Z7"*<
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M3TV>4NK)G(UQ ]!R$BB[:/W+QHU4=O5ZJFQASG<,'1#H33F/<(%(15=)))=
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MG]-IVLJ_Q6_"_0G9T%[?;/@'S[;IXR*WYWWU,3^FT[65?XK?A?H3LZ#^</\
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M.WS=NM*X9?VEPC/_ *T=_P M)Z^CE6<T#MVSKLOXD-V_CX[[1<=&Z]NGV#\
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M]Y>SR^?54@;=8;=][^46NO#6D"W("2<K;?ESV6VKD3!Z!ZA^U_)U#U\.'VM
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M$J2+",6ML>_B[8JW024(7I;2PE)!O8SJ<\\X#Q=24,Z5.)].QY]T$W+^Q/\
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M?F&63*?F$ IC&YHF W-*4Y#&-PX !RB(@!@XD70CIZ'ED!<1\@V<) YDVG.
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$B+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>business16a.jpg
<TEXT>
begin 644 business16a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X54H:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,2TP.2TP.50P,SHU,#HQ,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 Y+3 Y5# S.C4P.C$S*S U
M.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP.2TP.50P,SHU,#HQ,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$P-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%A045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$W>"MB:E1$>4YE96I"<49Y
M+W%19B8C>$$[=71*:TU.,E(V>3$T4TQ(35%0-79H-F5'2W4Q-WI4<6UN96-V
M2W5J5W-287HQ9&)H8C%'44TV96UI=6IC>DI(>#0P8FQS,WER:7%0."8C>$$[
M;F5B>#5L1W)%5U0R63!V54HY4$A.=WAL14)!.55#:6Q1,UE(-SA65%A53F(P
M8E1M4DY1=C=A>F511F\Q=4IK:4Q!14M3;V-I;T)D4B8C>$$[.4EY55E34$E7
M9WE!-6]*+T\O:S%%6C(Q,U0K0VYI>$8Q0V%'=D4Q;S(Q1#$X3RM4.$=F8V9K
M>#A34&5J8E!7.49V8FPW5WDQ0S)U<B8C>$$[;4I%;&MG:&UJ:V19-4%'4C)6
M4U-&6E="0C<Q>4)H24-Y16E13W=+3GE,2C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=28C>$$[>%8R2W5X5C)+<&0K;CE03$]Q<F-Y96TW>',P
M9'!C=79+3FEJ04US6E4P6E-.:FER=C Y62]W0RMR=CA!-E%R=B]Q;&ER=C Y
M62\W-B8C>$$[=2\X07!#=2\K<5=+=2]4,6HO=G$W+S91<G8X039P67%T;#AX
M-F)%;V%28G!&3$MG2G,W<V9%-T)62#DQ,UEG67%U+U0Q:B]V<3<O-B8C>$$[
M47)V+T%+<%EQ-SE05U X079Q-R]!3VM+-R\V<%EQ=&TX>#9B1$4X,'$S4U)2
M<5AK9')/-T%#<4MK;CDQ,D=+=DMF4&0U-6]L4&XK,R8C>$$[:F)3-RM#0CE-
M+U)T:F989'),16ES5CE8,6],-3)T-%1Y<7EL;%=P-E9.34MS;#AY0TM0.'EF
M26-40E%Q>%AG9U%#1EEW=W0V9D)20R8C>$$[.65.84MR8V%D<U92;C570V16
M.'IR3DE:6$=U6&9X;F)9.$1104)D:%AB+TTT1E8O3V9K;E=F35=P47HR*W%7
M=&QA45<U:E-+9E1B6"8C>$$[54=-<E!Y3#AR9U964GA1.%9/-4AT;51H>E)G
M3G=4.%-';DIJ36IZ*WDR3#9P*UA%1C%R<C9/=79754=P6'1R3&-8<UDP87A-
M<W-B4R8C>$$[>40Q0DE!<%%J,5%++V%02&M4-%AX,492-'5%,$0O3TQ!-'0V
M=C=!>6YY8C51.'AA3G)7;UAU<39R8F%H1F11=U)2=$)9,C%N2S=X3"8C>$$[
M>$Q43D-G6G5)1D5(36=!;G!16E)M>E)L14%#=FE3>G@T>D5K:S,X1UE::DYZ
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER4R8C>$$[3W)Q2%%H;%E!
M<7=.45%E:$)X5G9&6%EQ-T9867$X.3%(>6HU0CAX97,O;4A3<FDK=5DU8C8Q
M.5))<BMN;W1E>7565G)C0E0X5SE18R8C>$$[5E=82#5B+VQ,8UA%3GI,-65N
M33A+>4EK:3(K<$M3<WAC>4(K24A0;#9R+V%R,7AT5FUG9FQP*U9/9S-S5CEP
M;6DS<U8S0DUL>$1+,"8C>$$[97%0>&MI5C!J*T9Q<65#4W-O<5!N531Q>F8X
M050Q:B]!3#9U+W=$<$-U+RMQ5TMO1%A.8G-N<V\Q.4LV+W="-G)-;FQ:,U%&
M0F12128C>$$[.5ES5F5'-FHU0C@U,VQL8DMV;#-1-7)44W)M4CE#<W50;4U.
M8DI.379Q54M02$A11D))440O3E)A;6U+6'%0:U!Y-359.'5V8V%O;28C>$$[
M:GDR1W58=D]'.64S9S%/5THT635#26%,34I!4#-A265X*UA41D1)9DU'=#)4
M-D1Q4VE/-D)A,6Y!<EHS4VIE3G5P35%!>%8U9#5Y+R8C>$$[3WEW<V904&U$
M>7I.<&9R5SEJ67IM-%9O-$A786%#05A+4W1Z0G)W56-1<F)D.'5'2W=#,6Y)
M3'!)6B]Z.',W<51Y4G)6>%DS16MQ>28C>$$[,TYU>6-K6&Y+1FIG955H4T58
M;#9T86-45&]+669"-7(T9S(X,V569GIR,#9W9S@P,F5N-DYC;%)F>7IL8F51
M46Q"8T5W+T%A5%5+1B8C>$$[95%.3W9B3$UE;G-I>4%G-4YJ44IR=5)52#4R
M95<T24DT62]Y+U1H16]22VU.:E)2459*=#9N36LV66XO04-G*V)6-#,Y0UAY
M5G8X028C>$$[;&4R:&5N-F8K054Y36YK57)(>#5!57)4-G8Q=V9L5"]!2V]0
M;79J2"M:3#5,2"]01'DV-DUJ9FPY1U991456:C9(+V\S>"]+;B]60B8C>$$[
M.#$X8BMH3#5->#AP+VTY0F,V2&(Q,&$W:45#:4)22DE*2%I9;$-H;69H2%5N
M=G1M:C=1,5EW6F5'=4QR<S=V461M;E59*T\K2'E03B8C>$$[3U X06QA9'8O
M=T)7=30K.&8P>D(O;%EF>E,U=CAH2"MF1C,O04-T3S,O-G1D>#DT+W!J+T%#
M<U U<%@K46HO4&DW+VQA9'8O04Y7=28C>$$[-"LX9C!X+VQ99GI3=CAH2"MF
M1C,O2S W9B]Q,3-(,VHK;5 X<D0K858O:TDO=T$K3'8X06QA9'8O=T)7=30K
M.&8P>"]L669Z4W8X028C>$$[25(O;GAD+WET3S,O04]R6&-F95 V62]Y<U U
M<%@K46HO4&DW+VQA9'8O,6$W:C=X+U1(*U9H+TY++WE%9C4X6&8X<E1T+SA!
M<3$S2"8C>$$[,VHK;5 X<D0K858O:TDO>C1Q;'8K6C%V3$US9C9)=FXU5C)T
M-'I02G-+-U)O2VY,.5 R9TUS*TAH26-B5F1L;D1$:C1G530X;V5B228C>$$[
M+TUT;F0S4V%F96%C3%,W;G-Y;#E%65=K341C9E512&-Q9G=A;S=:<TA63&90
M4V%1+VQY8CE,85ID-G9:4GEW>6UW<TDU6G)H-4EP5B8C>$$[:VE+<$-68SA:
M1E5N96XX,C%C5F5A>"M89GDT=#=M3T0O;%AN;4=.-UI5:FEL:E,V94XT>DLQ
M0WIR8R](>&$T670V;GA5,S-65D]&528C>$$[4F-E5E!Y,70Y3'1(4&MF5V)Z
M-GES,&-C070W9U-23'%O16MQ>D):14-C4DIW6GI6:S0Y86EU2V]A=S!8.'-B
M5FU71#AT3F128GA6<R8C>$$[2FQE>FUK:E=+5GA6:6IZ<T965V-K=7$X:'9G
M5D)84&QZ.'!R;7EN=4I0>3DX=W=/,W%424IO8G%#4U=2:6QT-DM.2F-F0S V
M=4%Q1R8C>$$[;%)7;GA!659:=F]V;3-39DQ7;#9B;VQV-5HQ=7DP-C-*=%DU
M-4Q24%-J5DM(,5I:1FMO0DEZ8F)63&9S.4U696=91F55*V,Y37-B<28C>$$[
M,&585DY&=71C:6IF5E!1:7-,2S5N:U9(=7!%:VI*:'9,648S-69$=#AU;4MQ
M1V<V;3-L831M=#E%.'$V=$)&9E-H<G5:9$QU6E8Y4B8C>$$[-V@T,5DK<F9U
M94\W4VMR<W%%13E1359:5C57.#-A,S5H=6)M,U,R=4Y-:W19;UI:4G%7;5!B
M+S<P2GE645!R:FMS=31953))27A6:R8C>$$[6&]E668K5S(P+S922F8X07-P
M>%9!83-$<G=S;RM6-6%K9E=R4%E7<V<S*W1252\T*T0S>%8U-V,V6'!A6# Y
M;F0V2&5.1$IB:4I%3B8C>$$[:&-T1U5R25I5:59,,VTU6&='4$AK9FDK2%ET
M:%9M+VMY5%9,<GDQ671:4VDP=#1K.49B82MS6DDW:5 P=FA+4TE,:W%R2U)1
M9V1/;28C>$$[,4M91E)F;4-(6&AO3W!&-WDQ2V966BM11G))0U(V8E9O5&-'
M;C-9<3A:,7DY.'EA;BMC,G1E6'1,.#A83G)08U)4>%=7:FHV,G-C128C>$$[
M<E=65EE-4#-1-'0X97@O2$UG04-)3DY6*W%R4R]W03-2965F2T1E5CE,,3,X
M=V)M1%5*-35P2E=2<GE8-GA','-14E=:2R]:,TAX928C>$$[3T=.1S9#;7A6
M;$$K6'17.'=A=&0K66])+W=!>4QO;3)K5C%,0R]!9U@Q>6Q"458S-4)F:'E9
M;$="0DUB1$5G>7-#4T\K<2MA4"],;R8C>$$[5"]F<68O3D=7+VUS6"MP=&9G
M6E U+S)F=%I2;V5Q3EHV8DA"9F5F-7)I-55S6&Q-5C@Y87-34&ED83E-,&UT
M=WIY-41+175#4&,W>B8C>$$[4F%R1FEX:4TT8V-U+UI(+T%/24Q0+W%E2G8X
M06M2968P>D4O2EHO.550,G56+TM/;2\Q169:*W S*TE,4"]Q94IV.$%K4F5F
M,'@O2B8C>$$[6B\X059$.7$O=T%O-F(O55(Y;C9N9C1G<R\X07%E2G8K4D8U
M+U1(.&QN+S%1+V%V.&\V8B]54CEN-FYF-&=S+RMP-&TO=T-21C4O5"8C>$$[
M2#AL;B]W0E50,G(O04-J<'8Y4D@R9G%4;E).4#%F6$E*2CE,.#)Z6$555&-*
M1S14<%)Q5G!2>7 V2$@X;&XO,5$O86XK561.+W%)*R8C>$$[>CE362]W0T1V
M3B\O049-<S,O2E0O;79(.&QN+T%.55 R<B]+3VTO,45F6BMP,RM$=DXO+T%&
M37,S+TI4+VUV2#AL;B]!3E50,G(O2R8C>$$[3VTO,45F6BMP,RM$=DXO+T%&
M37,S+TI4+VUV2#AL;B]!3E50,G(O2T]M+S%%9EHK<#,K1'9.+R]!1DUS,R]*
M5"]M=D@X;&XO04Y54"8C>$$[,G(O2T]M+S%%9EHK<$@V8C57.'A7;FU+,S%'
M9GI69F%H<#!6<DI$3G!L>DAA0DI*6%I3<VY+0T-#;D%!.758*U93;T\P1'!#
M5U19528C>$$[3WA62U!-.2MT<%I19V%M=6Q3,T9X1D1$8TY$-B]*;4Y41T4V
M5F1144-E:#AE;4MV2S=8.'@T<E='>'8W+W=$36AR;7IT+W),,S5J,"8C>$$[
M1GA&2T1+.&-1:TMX*W!#27I%>6EN,FE.>G5/4E9.>C5X8E5,-C9J<U!09G!I
M3F)71EE).4IA4C%N;45L=69G85!K,T]D5F-563AA128C>$$[2#1D.%93<4QZ
M9G%L,#=A3$(K6G=86$=B-G%J;E%3<6EE85EY47-#-F5N=T5-3'AK-W(K,%=Q
M3C%78GDK5G9Z1F%D-48X-V-)>3!J4B8C>$$[=R]O=3%+9TY%<7AQ>$QC;3E/
M44=466=M=$]G=TMT;#AS+VU23$5S0C@T<D-9-U=/3#8R;6Y7>E!*8V@P6C=G
M>'9614Y%6E%O<5!I<B8C>$$[='@S5E18>3%P;FTR=VYN5%A.85A764=H='A$
M3CE8:71717E+5FU00TQA:G-/93=(<E%5-"]%<7AB5U!,97%88VPP;'1C6&UM
M;5-E8R8C>$$[<SA&;7,W2&QD4U-#4DAK:S0O2$=W2#).=75+56EU=DI(;G8P
M,V$Q.'E8:&YL:FEI4'%A5$%S8V),-E%K;E%C,TID=45P-$XX4'AG8B8C>$$[
M8V$T<7I(4G1,=#=3=U-$57)7.3%+-T1-6'5Z8FU$:T=9:T0P-#,T:FE.<U92
M,S%B4E X07%Z6'8O05-F.#$T<6<Y5G-.3FUT5E,S,"8C>$$[93A%=G)7-U9+
M3V%+:S9-+S=F.$%+1&ER2$E02W9M84<Y<W!8,4LV=5E)-#0P=F]P3D]61FQE
M3T]11G=Q4S%8,5I(5FU!8U5#,$(V-"8C>$$[<6Y7:#93.7 V-F%R8C-M<$M3
M<'0U:D(V3&=54$E-<V)+=E=L3W5+;W)6<DA3-71+=DEB9E)R,S$U24I5:"M"
M+W1S:$,O="M/2W)*=B8C>$$[*U91,E!M-C0Q4V4U,&$R.#%W:'!,=6%3-'0P
M=3!!:2M.<$%Z:&QP1C%*2%1**W%V2FAT9FTX-"]/;2MI,2]8=DLY.35D,41Y
M.68R0R8C>$$[33936$8Q9&%9>#5#5TUL65=U2#5-44]O5'943&-9;T<W67E.
M,7E36#AU-TQ8-$Y9.'I/5SAT:W5"-E%G;#!U42]W0SE.9C,V=TUZ1"8C>$$[
M8B]F;C=8=F=Y;EEC,6AZ4$IM4"]!1'-F+V9U9CE/3U5.<G8K9&HO-SEZ+W!X
M>%8S+T]X+SDK-2\P-#1Q:C0O3"]W0UE5:4Q*2'!U:B8C>$$[=6IG36IR0F%K
M14AC145,:6A'85@U8S@W9G!+,B]33VPV5CE2.5)F<EA#0S,U96Y8-'%55W1A
M67%Z:B]$;FPW+T%+=&1P+WE):2\U<"8C>$$[>%9&5VQH63)A36QP8GA7>4UE
M5$Q%:6]#96Q31D%X5EAX5C)+=7A6,DMU>%8R2W5X5DM03F0O<61H;V1X9&%:
M3G X1C5(5&A,<3!R=R8C>$$[5VEI=GA'4C!"655'+W8W9&-665=F3VYM=V%H
M8U%X95EF2T5K36-I;UDU8FEA3S1I2FQ65$9);V5H8FE4>$Y&,W!T,W=Q<E(K
M871F=28C>$$[,#E/-C%0>78Y6F=F5#-%8E1/.&)'64MZ4WA396]44U)I5G0V
M;T18<E55-4MP+S55,4LO,7DQ=54Q:'1-=FMG93)A2V)42E!7=#)K128C>$$[
M850Q*TIN8C1*2TUH3DYQ9E!!<DIS5F1I<G-695@V+V1E8EI,:6,V1&8R0T9:
M3'1:13%/8E9G,W)*9'E+9U57:VE2<D=)9T)S2S$O1B8C>$$[4VQ7<%AN-6UR
M-G-M;E@K9W9!<4@P5FQU9&4U=$HV;$%H26U#9V-/.69T94%/>7%/,"LT.#EJ
M5TEF,&IE-E(K:%!R378Q:S(Y,7)N,28C>$$[<C9R465L=S5V-F9Q.65D9F@X
M359::TQN>7%10TPV-TE/-$EU<BML4"M$>%9#87)E95@T-U9'=#<K-U=1>C(V
M:R]78C<W1%1O<CE8+R8C>$$[04I#8U99.6$S,VUT3"]3-#<R87EL<WE'1W-4
M,C$S<39T57E(9S!#>5,O1%-+;%9B;%9U.4U66F(V+VQB+VQT=2]W1'!+=CA!
M+VUV1B8C>$$[54IR1C4U96DP;3EK='(K.%<T4S-L849V<DXY<S11;%1U.4]U
M2W!:<E U1BM29%@X>6%J-6AU>&1F<$16235)8G)H3494:DQ$-D1C5B8C>$$[
M-&UH-&4O6$Q";$E&341!6&)Y-SAY+WES=%!,9#DU5C!V>3,U6C%(5SE09VQL
M;FMU67I03C9$4U1213@R:%%Q3FQR.%=7=VYD,E=%;R8C>$$[9U9S.4)U4'EH
M.&]E5DQ853E3,%A33&Y5-W95;59B;7IA955H=UIF54I8,#9-3TQB-51,251Z
M6FE)0U,O;W8X03AX+U O=T%J<C,K=28C>$$[45I/+U)F.$$U:BMF+VMD92]W
M0F-66D0U4SAM849Q,S%V.4LK5FXP=C!F5#E(;E!D+W9/9DQL5&MY+UHT:C<X
M5F5J,C%V1&)7.%9T028C>$$[=D-'1D9J:5-P3D9155563E0P1TMQ;4MU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5DM03G1T.5HP1S5J1VE195E7*T)K,&DU35-X
M4W-R9R8C>$$[:7)4<3A9-"]A1E(R>%9H:SAE<U-85G1*3"M6=&Q*3DQ&1#9T
M=S%Z<#=E:WI425AI-65M5U!P0W-T86-35F]0:4EW<6DY13!M-59!3"8C>$$[
M=CAV-T]Z5UI95V5.2C=36EEJ17!#4D)3<7%&:$-R>#1B5DI)03=Q<DQ'-S@T
M-EI(8W9P2#5F4E=K,7=S23E%86QA>'AC:U-&1DA'3B8C>$$[5U95:D1Y5C1I
M<#1B1#1H9U9--69.4&YI14I*2C509C!".5E.>$ET.4$W24EL67A-23!6,V-4
M1E)S=%=7=E1Q359B;CAY*V4W94XS:R8C>$$[.'!I4DDT+U5E4DPK1VQ1:VI-
M;UAG>FUH4D9&0G9Y<E%5>%9L5G1+,#%T1DTX8E%T26EU,%0O85%S2VQ7.7@P
M>%9G=79E6&9,*V]75B8C>$$[;F4V;$A:0V%,5G!963=I.6ML:%!X86A),&-C
M5%%V1U1)6F=H5E1S8U%R>E-0>4IO,FYY451I9GE00DI95SA+0S1..65R-E1L
M-&979B8C>$$[9S O<&UQ>592;4A,:WE63SE35EIR-4DO3'HX=DY6,#EP8G$Q
M,&TW,50P1&%80V%,93-5;'-T;4QH:D-H4C5E45!+16=K<4XQ239#;28C>$$[
M0E=5-DXK5EAK1%).470Y43!R4U9T3'$P36AT,U-79FEV<DU89C1$255O4V1Q
M:F)O3G-65&YZ0S-(5&MB8C1B<7I/-6].<G5,=FER0R8C>$$[-TPX,F(V8S!M
M,&EY:3E55SAD<C9E<S).>'IU<#0P:TU"15),3'A$=#A10G%&-6),=FA6;75G
M-FIQ5B]:>5,V:G!Z85IC>'I34F96,B8C>$$[8U,X:U)Q3$ER9TM#2$<K0EAE
M62\K564Q5"]M16XO-4Y.:7)W:E1L.'-F.$%1,#$P56MV9C!X-FHX:TM29E9Q
M+U5H5VIC+U4K>B]K.28C>$$[8WE$9FAT47)J.#%F+VY*2F9,2C@S*U50,'1*
M97!0.$%&.5A&;VM4;V8S.&8R>DDV16(K1T]'-DY,:W%X8D5V>7A0:V505R].
M<E$S5R8C>$$[<7AB1#9Y+W!W2U(O<%DO=7ER;79X95!B1&UU:&$T-G,P>F(V
M,S5)+S9U=70O9$8O>EAM33)U*W0K4U K<G)R9C-29C@Q-'$Y43AH828C>$$[
M2%I71VYT9C)D-6188T=P<$9)9W5Y3U-"959+061+.#DX5EI2:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&EQ565:-G):47IC=%%(;R8C>$$[,T5496YP9T13
M=E4X94QI:')(.%AX.4MD86EM2W9+64QE,'8W93!H85@X>$QE3V1B:TQQ56MJ
M4DYB3$9,25=->D$Q2%!N>%1K<F9#1B8C>$$[-F-A9W%J3%,K;4LS8S%V2#4T
M;'0S;%EC<#%%<5!&8E9K-5<O1C!A:R]0:D=W-4)Q0W4R2W S-60X<5<K=C96
M63-S9FU$>E9:=%HS0B8C>$$[9#=E-W904G5#-$UB3D1D27%S<DM/1D-N8FMW
M-CE!<DY03'5K,T=K-E9(650S,"MO=$,P;D,W=6U-:WI)>FMO2DA/-TU&24)0
M,T%#9R8C>$$[0W%:67$W1E=+,VUM,VQZ8G@R3GIP:VQX85)8.#DQ4$<X9&QC
M4EA%5%13>5)Q0E!+0VTW<3-,:GE&2UEQ=WDX+TQ4>D)C>$Q'-6A94"8C>$$[
M.5DK=6U4471$:SEC>4@O4C)93E!3<T%3361$>31#=G-Q>5AY4F]/<2M7-#<W
M-GIA4S9H3F1Z8S!U27)45$Q'4EE25FQI:TYV3U!6-"8C>$$[<S=.>6)F-&II
M<DHO,'!F9CE7:3<O=T-$=% X07%V:7%%,5<T,4<W=$9H5%-,<6]N=#5'-5!A
M531X5'!),RLW>BMY<'A69TTO-64V*R8C>$$[1$-9-UIB:C!M9UI797@P=3%:
M4%-J5TYW1&)3<4=6+VEO<$960F]'=S)T4%-F,'!F9CE7:3<O-$\P+S9R-$91
M=7(S5W!896Q8='!&<"8C>$$[1C!*8FE#5TI#>C)G2$HP2VEV-R]!351I<GE7
M=W5*5"]!335(6$5F*TQ)<$4Y4G@O:'IJ92MO=BMI1&)K64)B8F9A+W90>'DX
M+U)Y828C>$$[=V96>E8O>CEU6F]V3DAL9%4X,5(K6'<S2W1Q-C-J1S0O9DHP
M*W)1>DHW9D=2:FDU2%I:;F-B<V(O3&I58C%D83AY=$@U*V=U;E5F0R8C>$$[
M3T8Y4S(O,&UM+S%I,VI49C=(=VLO9&IL-41:64AC-W,P+U1/<R\X054Y,C,O
M271V*W%E54YI62M8=%4Q5UA7-T]/6'IJ8C,P8E-!3B8C>$$[84MJ0G!"+TM#
M54=+=E1C5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%795I(6F1'=4-U
M<G)O5%5"1W%-25=%441";3)U05ET,28C>$$[0DAX67%W5WHQ1%5H8TES=C5Q
M869/64-%=5E$839F1WAD:U9&<5!5-4I6+VI!-SAQ9$M95E(Y;'%.,TA:9E5P
M4'I$,"LU,4%*17AU>B8C>$$[8C)A,"MS:$9T:4DP;$-5:UI72VHY<FQT,GA6
M0S98<%@U:39L4'%,,E@U9S)C.6=#>3)-='!:5V1W5656,6Q(<DMO04)333A!
M3UHU028C>$$[.'I1-UE&5#9447908W9Q;&9--'1M.5IZ1E-Z=#55.45W0D5(
M16A'0D5T6D0X4G(P-F)9<6Y'9U<R=#(Y:SA7<UAA,S%Y2G!$1F-+:28C>$$[
M>&MW;'8S9DI5055';FAI<5I9<3AS,3-13E8Q3RM.>' S;4LT,%I"3&9W5#(T
M,&U3+U=763-%=VEL5UDW9G5X>"M"9&IX,WA3;%9P-28C>$$[1#@W<F-X5#-0
M;FTV94E32SAT;W9L>'5*44Y6;W95;W(W:F)L<V-696EE:#57+S59<G8X0392
M8B]!4#5O>%8S;V56=BM72S<O04]K5R8C>$$[+W=$*V%-5E%7<U)E6$9T14U6
M<&1O-75,5E,S,64K2'=T8U)H:'5N9%-2:7)(3$AY+W%Q6#)M3V1E;3%#=W11
M=S%*1S!M-&IK=65C:"8C>$$[9%-X:E%H1U=-:%)W-&IU4FEH;4AO959V*U=+
M-R]W0VM7+SA!*V%-56],5S1V3&EA3F9V1&%885-R8E1'3B]Q.3AT1T5:;V%L
M2T-H."8C>$$[8U9E4S8V=FY*9GIO,7E444Q443-V>$90*VI(12MM1%5M;BMP
M9G4K56)4:31(>&1E4VHT974R6DER:$8R,#)E27!D-74O=T-6<%-N>28C>$$[
M<S-M*W@P46%Y='A.-F\Q2S0P<$I"1#9S6' K:C9T=T]89C=&9#A-94AE<E%3
M9')P169L,6(K64<Q;GI-=C9+.'583$U"-E5&<E!P<R8C>$$[:E X03946#DK
M3&$T-7)18B](5#1V9DE:95%:435L;5@V3SAZ+W=$57 V2"]!349&+W=";%=5
M3FEB*UAD2#@Q4C9Z6E0S2&Q84S=3,28C>$$[16ES.3-"=S5O=CA!36Q,:"]W
M0E)X5C98:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U934'IR1E!,-61U
M56<X=G=E6C5A;U4P828C>$$[-65'3TM5<7=)2F4T5C1X=RLP2VI&5THK;&9/
M8F%A-B],1WE7.&UM:6=!33%J2U5I36I/-W1)<UI!15E14U5*1E1S1'EP57%R
M85I:4"8C>$$[1&9*8C-F-697=&Q:6$YX1$-*,&UT<FQ54TE/<U1,16MF=U)X
M3$5J8V1G<%DP,W)65FUE;6%&<$=L=D\R;E=K9&],9W V:5%Q150Y,B8C>$$[
M=D)115=I:6<X0F=62#1Q-T9867$X82]-2U!3:DYA6$XX;6Y3=&$S17AJ:G92
M<5!Q:U!R2$DK;3%M>7AJ945C95DK,5-P0U9Q47)Z828C>$$[4S4X='@V6DY$
M<DQE5V\V6$]N5SDO2"]Z<V)L16UT=SAK4F%/4V)L2U!Q<UE2;&9I94HU,%DP
M>%9N,VM84TY:9E9B>E9F2CA8;'1R*R8C>$$[,V$V9S%A57EA,&5.,U!&2#9Q
M:%IZ>$MM.'1Z6&(K-T%P46LQ5F5S*U=V.$%&,S%35"]%+S90.$%R9DIF4B]2
M=G)E;G<Y2D]F3#$O:28C>$$[<C9V3VQ0,F%D-C1&5E!-:6@Y34-%0F<Q>EIG
M<6$P3F)Q3&)B9D989S%V<&UJ>E=.-6%I3%)90F,R;&A:1DQ9-C%!,T8P9UIF
M5E,T0R8C>$$[*W!B.5-R0VI"84=V2W5&6'90;&UZ=7),>3EP,7!D24DW;4,S
M:FIM44YZ05I6;U)89CA.<T-R=DUF+TM087 O>D-4+SAM;7A6:3!8-28C>$$[
M6"M43&8X>$IF3S1N8V$V>%HU16%996U+=RMK5'<O,4US-'IW,'@T4F1S0R\U
M>4%T-V$Y.#!E5DI6,$,V,3%53$%85FY*245H+V92-R8C>$$[4#9C8V]0:G52
M;&U,:V0R32M9,E0K-R]+2'E6-5)S=%4Q5%1R2RMV-7136D9U<F1::5=)379Q
M5E-I1VQ'.75M5E-Y1U%O<VA%0FHO,28C>$$[4%%V*W!6,50O:V,O+U9(24UN
M=$]G0TYD0S Q631N9VI&<D-%9VM.6%%E;71%63!&4W91-UEQ:CA69&ER<U9D
M:7)S5F1I<G-69&ER<R8C>$$[5F1I<G-69&EQ4F5D-4Y-:3AU>C-'<6%P9#90
M63(X:TTP,3E9<S942TDU5EE,5D5K67$U2$9W1C-5;D98;6%A=BM7='4Y;T@O
M041&."8C>$$[=W4X='1B>E)O.7IC:WE20S16,&Q:4F(Q2'%T4TXK;%9Q3G-+
M<&AP52]K*RMJ:FYS4%!8;4=2:41.1#9S<W)#55-C94Y),G1X>2\S;28C>$$[
M3D57:"M)-T%T:7%H8F%N-4$Q4TLQ:&@X.6$Y2%!$14Y.8WAZ,W-02V$S0CE7
M4GA00W@Y5FDQ5UIJ-%EQ>511+WI4.&IW861A,DYX<B8C>$$[571X95<X4FIL
M;&QT8G-023!!:U8S*TM.;4YF<3=N8VQQ9&1Z=7%Z;4=A2V5'3V%*9SA5<6@T
M,TA1<7=Q0U!M34-R.%994G%(;4AY;"8C>$$[<'1W-EAK:SEI6G!B<#!76%9)
M<E):1$1++W="66MJ:FMV26IW1'%Z1VEI;G1I;%-M.#(K4S1,6F)Q93AL:71M
M-&A:,S%U0E5*9%,V528C>$$[63,Y4&E64U(T9UEO5U,K8R]).%13<DIF4W$X
M059P;"]454A*1F-C;%IX.69Q;TLW,5!B9G!I<61X4E)3>$I,1G K<7E24TM'
M:FM8528C>$$[07ES<D-O24EV845%67%P6#!.<DA!<EA7;#9S6796:$%R9E9(
M<4Y+;VI0.$%V6C)K2VY&2U9N5G9*3V]Y869'4DIE4U@O2CE+439T0B8C>$$[
M2UHK0DED<F-F6&IZ-&Q31'<X355*-3E6+W=#,5IQ,R]!16XO05!:-6EQ2#%#
M1S%J<TQM4S<P=E9M=%5I9')H5&9C9UEW<$QI;C%Z9B8C>$$[-&-5<TXX>&9K
M1W5S96-D6#AX;EA:-$1Q<TTP4#%657%S9G)7+W="6'%$>3=F87DT6F%&53%M
M1SEP65 K8V%51FQO,7(O:4\T+W=">"8C>$$[33AS+U!H=DHV<F\O12]&=%0P
M.%!J95,X2&TY6CAZ5T4Y+W!V,5=#*VPP-E-34F%88TA,;6Y'<F9S;%11,' Q
M>6AM;$]H95<U3E!U228C>$$[8FDY.'=8*V]V8GE.2D=J>5-R13-/37AL6E5,
M3TI!2SAL<C!B9D974R]83&8K9CA!02\P>%8S,7DS+VXO04%0.4U69#EC="\U
M+W=!1"8C>$$[+U1&6&983&8K9CA!02\P>%8S,7DS+VXO04%0.4U69#EC="\U
M+W=!1"]41EAF6$QF*V8X04$O,'A606$W.61V9$EU8EA39%0O0456<28C>$$[
M37$P='12.4)B;C!7<41Y.4=3:79T=%$T<7=Y-#AQ9FUG-U-M2#AY,FHU35=H
M0C!A>EE2:FLR,GA8;CA"0R]&."MT2TMP:DAO4&YJ;28C>$$[9E<X.5-'4#9P
M2D-"2'!L;VIF5U=M85-/-'%Y>4-I4DU)=E1P43 U5G)I<5A3*U90>E%:44DO
M>DM:1U93<7E(4G)1;F1M87)$:T5*;R8C>$$[5E@W4#=/,4MN1E529&58=GI(
M86%-,B]N=F=J,TUB,T)/;5<Y571K:F9N1D5P1'%7:VM++T5D=T\U;T9+<6I.
M-6,O3E),6G91+TU'3R8C>$$[5S1#1&=S;6M7,&%S-FE0.713+T1M>5!5.$=O
M2#)(=VI&5UIA-C-M3CE)62M81W,O,&]7:C109FE8-G9W-6HQ4U)%969,:%AJ
M-S!R="8C>$$[:7)'95 U,F96,U9L.'1Z6$5B>2MH3$HY9&I5:CDR25A+<C9L
M1%%Y.#9F-4Y/*TMO=654.#)*3&EF-G!&;VM-0U-2<D0Y62MT37IO1B8C>$$[
M8WET*S=.0E9V5#1F-TMO-E965&)Y-"]M:6$Q=31F33A&;4QH2FEK5%=837=3
M47-I:V)3;&TO84MT5VTY9'%B;%9.1&$R>'1F<6YP3"8C>$$[.5<T96PV3E!H
M.4]N2&I4=W!T:7%O:4EI2VE+1E)11E961D%!3F=!0FER94MV279.,'1P0G%&
M;W1Z85=&*SEX8S-K368Q*S0P=4=:228C>$$[<FTO:W0U;S1%=3=A5C)1;S5,
M9DA2=G-B;'-64T169%8P.#(Q<DA,-64P839T-VES,'1Q*V]E6%0K.&II:DMC
M3V1Q23)A='E2>4I!0R8C>$$[.39U<6Q62#-L:C5E;#!/2%90,$IP83-'<DQA
M4E-"<#E&:6MA1S92;6Y#>DQA2S=.0VEB2W4W9G,O6G=R84TP:CAY+TUD-61I
M,$55128C>$$[86EA,G0T>D1R=6AZ5D4W:%!H4DE/5E9R.$LP<3-1649E9S8U
M<'0T=&Q'5S%A-EEF5W)06FQT84-T,45+-U%$<#%X5C522G%.<6MT,28C>$$[
M<4U':E=-;#5O<V-D>'!L>F$V:&]P54Y/>4]J=7-52$M&0S U4'%%9D8Q,D16
M=W$Y83!:3#=5=$IT3E$O4V0S1#EB:5-94C!S,F](1B8C>$$[9G1#,T9F=7=+
M<SAW86)E<F]/<$UD5W5N071:>59+,G1$4TYT:E-!2$9745EQ-T952&8V9#EC
M;7,U9G)6>&(O535V6#114V-&;2M":R8C>$$[.4]955!.4&ER>#A13592;4MP
M9')M:F9P83)H9RMV6&UN*VI01F-E<EEY*VI)+W!.6#!N3D<U4G8P9&4T>%9-
M8U93>GI(;U,V-7!J828C>$$[93$Y96%C:G5J=&-7179O5$5)=UEP>C1T.$PY
M1TAC67%M34U9:6E334U70TM&-4UA<V%#;%-F2$952G)/;"]P5%0S<W9R9'I9
M.#)J9B8C>$$[-GI:4V5J35!49%@T:#9.45!X-'0T<51I<3=39$]45$Y,=$Y/
M4V%A-%-Z:%-"6C=L+U5M8U)Q1D134%%C;4Y.>FER97%A96UO,D5T;28C>$$[
M.#!S0U,P0FQT,SE/46-71&9#,40Q<%$K,DMT851P+S9.,'DR<U!R33DU.5=J
M5U V,61Y97)02GA(,G!:2T1K>#=M;4MU,6)4:S%,4R8C>$$[-W94,VYM=&MU
M-&YH831T;CE+6D$T-#AO,T9E3$-U>'A66F]U;$13=%!7>D8S8S-O4FY96$8U
M2C8P>#5U6#1L-DPX2S$T<C1$1E9E+R8C>$$[=$)E5TYX84=A5S-&>$<X6'(R
M-VU/6D]A;&5C8FHW3$Q7<6YX>%91,&)34G!D<DIB:3AU<C!03DQ/2F)Y57I3
M2TI83"MM<D5!.$5R>"8C>$$[44AO3S5X5D=S=DI3=%-+:6Q2<V-64W9Y.35E
M5%)B9#16=C<S54=K169/82]M.651;4M.638X<4QU=U=R94HS>%9.8U9D:7)S
M5F1I<B8C>$$[<U9D:7%16%AK>E1R<&U-.')3<3!R5$MK<T9N349:<&IC04M:
M8F0R;W-R8VQQ9&II<45M+TQB>3-00TE*;TE:65%V<&E*-TQ45UAH."8C>$$[
M2C0X5&$P<"LW6&(R2&AI<390.$%,=E%55T)11E Q5DDT-V1M=&)",E))54UC
M641.8D9V:%(R56(Y0V9(1E9S2#5A*U=R968V>$)"1"8C>$$[1F-",&PY6DQ(
M5%9F,4EY1$<O25=T95-%5E4Y<U943S<P4U<T:E=#-#%E-DMS-D]Q1F)15F%*
M:$EV*S9..3!R:7%6+SAQ,#AT9T%*1R8C>$$[:U%!4F8S5G!P.%HT>&A1<45P
M8DQ607-A<G@V549/;4MP;F%A03)N,E5D=&(V<F115W1S9U=.3TYP4E5594IG
M+T4T<75U9$1U3'$Q;"8C>$$[=#5D6'4R:&Y2;S5!1G1"5EA&1'5)4$$T<6TR
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5B8C>$$[,DMU>%8R2W5X5C)+<4XS6E=L,T=)<FU*6FM69S9Q=W)2:#!9
M94)(631Q=V)54'E*+TQ+*W9,935K,&M23$)'26UT-%AD23564TEW>"8C>$$[
M1U-H-3AO:THT37)!:G(R1D969E4O=T%Q=DQ-5G9F6&UH85AB:EA*>4I96'9*
M-WHV=5IL.5!I,&=J:TQ!1#!L*WE/,DYQ>&5W+TM(5R8C>$$[-U%3>B]O<E%'
M=G!6<T@U;30Q56A:<D]*,%E+>GE-=U5%:F=2=5%7-3AS2V]E,2]*6%=046%4
M561/,$\W=C0P;70W9#%U9%IJ5F]:>B8C>$$[2TI';%IP-51Y9%IE;D4X9#9.
M,&]Q<U0X;R]-3C=B.#=V471%:$YT1F-7=&QB>3-7<&QZ1F)Y;S)N3$EY5'EJ
M,'<P6'%-03%F:U=C628C>$$[<6IP=GEL,657-"MR<'!7:7!O<U4Q<SEN1$ID
M-G,Y=VMC15!2>4IF5%IH3DA(>$@R94E*3E-C5F8O.6L]/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^,C(\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^<G(Q,S X,S<\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C
M=6UE;G1)1#YX;7 N9&ED.C<S-#%$0C@V130Q,$5#,3%"039$1C(V-D9%045#
M1$4S/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.C<S-#%$0C@V130Q,$5#,3%"039$1C(V-D9%045#1$4S
M/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/G5U:60Z9C%A8V0Q9C$M-F,R-BTT9#4R+3EC.&(M.3,V96$U
M9&(U.#=D/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I296YD:71I;VY#;&%S<SYP<F]O9CIP9&8\+WAM<$U-.E)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YU=6ED.CEE.3 V,#$S+3(U8C$M-#DP-"UB-3,X+3-A838S-V0T,&1E-3PO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HR.38R1C4V044U,3!%0S$Q.3@T0T4T1$9%1D(V,C,R0SPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.F8Q86-D,68Q+39C,C8M-&0U,BTY8SAB+3DS-F5A
M-61B-3@W9#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z<F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C(Y-C)&-39!134Q,$5#,3$Y.#1#131$1D5&0C8R,S)#/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 Y+3 Y5# R.C$T.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW,S0Q
M1$(X-D4T,3!%0S$Q0D$V1$8R-C9&14%%0T1%,SPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP.2TP.50P
M,SHU,#HQ,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @
M('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S
M/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L
M951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A
M<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4
M<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM
M<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=$1I;3IW/C@T,"XY.#,S.3@\+W-T1&EM.G<^"B @(" @
M(" @(" @(#QS=$1I;3IH/C8P-BXU-3<Q,CD\+W-T1&EM.F@^"B @(" @(" @
M(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @
M/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^
M"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC83PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/DAE;'9E=&EC83PO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/DUE9&EU;3PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^2%9?7U]?7U\P+E!&0CL@
M2%9?7U]?7U\P+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y(96QV971I8V$M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/DAE;'9E=&EC83PO<W1&
M;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/DA60E]?7U]?,"Y01D([($A60E]?
M7U]?,"Y01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X
M;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA
M;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^
M"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M
M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M+6M1H_+AZ[*#)F0"J&>S/GAZ%> . . :J5.YO8'WL.OS6)4O,YC9<UIL.ZM
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M%(\XD-)"SX/T49U^!+JR)X,-RW;U]?!=2CDIBBJAJG^.S$?^4-X+_P!RK?\
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M1&RTC+PY: U\1T>KWI"A,1SUQ<J*Y<5._P#!X\+WZ0-??>,@OXGS"^87B_\
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MU/#^.5[XLOJ__P !./K>M_)<?,+Q?_8VMZS?\(=]#QJ>,6%ZFA_''Q9?5_\
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M5!,PG8+0K&SLKG<WD$/,(!9,P0+PF1R:RIB1D<*(I.8J?T(,1Y<0\&1Z-LQ
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M'Q,?:_Y34C];I?\ I]P+BZTZ]P^)C[7_ "FI'ZW2_P#3[@7%UIU[A\3'VO\
ME-2/UNE_Z?<"XNM.O</B8^U_RFI'ZW2_]/N!<76G7N'Q,?:_Y34C];I?^GW
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MGA3&-L"S7*JXTS;C=CP7' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MUA3;7;.F@^/@89&A:&NFNFF@^*P.)1&&",9UV<J"(VQ7(N'I15Z_="#)/ '
M' ' ' ' ' ' (H=;&[=V6[9-72"+EJY[1S5NY;.$M%F[ANM6E5)K(+HJ:[)J
MHJI[;)JI*:[:*:;;:;:YUSG&15OZW]I?<84D/1>9;12-QNN.PLMJGW/"HR)\
MV#)'8\%>X'.;G<GR2T=$RUH(U*F']C5^<R3T::GO7*9C@_!YNS(IK@Q>N?LM
M>?/VJ8P3Z;326SR7BW?=HF7G@-I:V2PB-R6:L9M 65S1"K$(PRW9!+>;F8W&
MALJK=&S1HT@EZ0PJ?]D[%7R3)R>/!5-6K/CK]J>;33-3+C3I38Z4P)OWO:2U
MG\!>F6[IK"-Y18**@^+(W@"L[,&3D2-@:&W U6)!WE?KF73Y8RY&G2#%53W)
MYWBKD*[$KK_+,<L+ZDQIB I.I)_<F9_+*GL6T[I*[;&# ^:3QU.,2?8P4)M'
M$U+'&3,:<M5DX,+85?!GV'@M%TS:.#B:FP5S[?RU<Q:AWHS=SS_4"]R[8&-L
MPR(@W+58K+GFA$T*=0E_+'BSEY-'9!JPEAB.20]C*+Q4H(5FSV-LGN(8Q7 &
M0KL3H[=&.*&39ET^DLOGK*9J7I,A^B=;5A!3#,8ZE85:3$X#.HU(2LHD:\>F
MX=N<6E$49S:&J#2[1^B.;S\T\T<.M=G#1Z(,:5[T4MZ'!G LEVUL8OL.8,-H
M5HW?3D:'BY\ !F[&(.]PK2Q$4CD;BY"31A#,//N2K"3A*[!-Y(Z>K.&WL(2J
MU7,G:FE*9Z=:E_5KU(M"'6[&+!EO8J1V/'8L4 EVD6D;(Z\46*!*CLFKEC"#
MLG+RK844/XLA<R?4:LED7;L'IELFT;EDV0(%5%T4Z/<B$\^"!P"(G3@N) =1
MJP-'28X*'& 9"\)%BSUL.&#VB,LD.RSI\_>*HM6C9+7&=E5W"J:2>N,YWVQC
M]_ ))(SB%.""@EO,(LN41?#1BHU&0"52"1(R,7-!QZC/1WLXT?%0S9R6&M-D
M\+OAC==^U35:I**Z@59<T&;()N7)88W;+,7)1%PN_:I(*C&:*;EX13545U34
M8M&ZR2[EWKMEN@BJFJJIIIOKMD#JL93&294B"&R($0-B%5$"P9B7'NRHM=)%
MDX51(CT'"CMDJDW)#EU$W**6^B)!DKMKC1TALH!7> . . :&?VA__8KK#_FB
MA7_2>[."C\R<_N4WS<%QP!P#PM?M777^^;@[2=82]2TE;MHBA- F!Q0G75;3
M*;#QI#>Q#CG1@0>QH*3;,WN[91-QJU<JIK[(;Z*X3RGMKMGO^"$S+P)2;2-'
M@P5=,-5J18K(:JF3:E41[D54KA5#C.$L"/%FI=84&+%1("HJPX;WHBY1RT56
MM5$6F-%,<?LK777L%47?^Y9';%%7)6$>?=0)R%9'K#K&;0H,\,N+EH=\@):E
M)(#&,7!-=D.(/$6"2^[I5JQ>.-$MD6R^^GIPNF9:-9T!L&8@1G).L<K846'$
M<C<A,)>5&.542JHE:4JJ)I*<&I>/"GHKHL"-":LI$:CHD-[&JY8T!41%<U$J
MJ(JTST15T'OLY\\.V-&_BD]4[_[%V]7I2F8 K,V$9K?1@<73DD0!88NR$G/N
M&B.4Y-( JKC*R+=7?SVB:Z>GF>:IOIMG77(H]JK2B:]1K&^+$[T?,8Y^T*J?
MSWP4N.U=:;Q\6)WH^8QS]H54_GO@7':NM-X^+$[T?,8Y^T*J?SWP+CM76F\?
M%B=Z/F,<_:%5/Y[X%QVKK3>/BQ.]'S&.?M"JG\]\"X[5UIO*O'_#.[PLCX-X
MZH]RDV:%QKIRKFP*KWPF@@]156WSHG.=]]_,3TVV\W37;?;R>377.<XQD+KM
M76F\]=7![#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@'S.,YQG&,^3.<9QC/DQGR9\G[L^3/[L^3^GR9_=G@&I-*A^XD&JP8$IB.
MPVO;88@(8'L*S4+$6/O;TL.)0RQD2=GR4*6:-0_J,JG16)2$A+3>7%H2)51<
M#.XX>AL5%"RHMA5<<,:)37H\U5Z,%QJ7,4I7O0PL0O*(S:9%PE(F['>0K$)?
M$-!2D4%GKZ<O8)%P.U<JIQV:+AY=3;6"SA5(B/%;Q60.94JZ7T=HSP1AI[9M
MN.;92N&HM!2MO$+EFU@BUI:\04C=G0LO"<RZ61@?&B<-C<@Z\V7$8\@] UHJ
M4>R\ F,GP&PK"4;&HG)C*9X&C'CS-^@E'@PPP3;GUKMU<QS":(\0!\:!&CEI
MJ-G[4D-';%-S\>SL*B#+7L"IN2:QI\,G0AA82K.U( &5+MR9W*R$)*#'QDH#
M;B%#(535KZ:>;"I-<3%>RH\53XY&QHEG6.6%-M;2=RJ++2PY,*OUS8#>O&[8
MN*/0QJRD:0]:!9.O-1"SAP;26++NG+0>4#2@,,<^;#GT]OYI&&WJ&[1N;6G,
MYIE&!,)P5-3\Q#[IEAQRLY Q4WUT4@,#K_0(BW6?IM(;<39&5+P1Z/.5$::%
M'=J$6[BU6K<8F"4PKY]N-?9AH7S5/P+IWOTL+9$B-\/VIH>UD&PP+HXAC,8M
MKHI8IB$LI2WS%9<Z=/6S]:J0TG61F!O+H4",M,'3.A20$9.&&K#W8:<-NC3T
M67,.O_>F7L KIU/-]9$("6 R.;NYW%%1<IETBHZ4PAF_&BQ=8B$F50*6M(&T
MS8US+7LG<M PY @Y3;E&XN+"@PQPSYL^&;6O3GV8%P5_0'=-B7@8HQ9[Z.P,
M!%4HE(5M)5%9!.\.E)M5I&3$H;)5*^RX&1"10B,E08D*146DH@HV?DW958D5
M$F!P*J:$TK[J:=&/; N&"U]W^;UCV"9VW9 >3SN041(PU=8B6H<(U;6P[C1=
M*-D(P199%JBEF"BK!@;?O!T99+R774L-:.6*/M)0,,*8:U7'JU(7P%IKLFTD
M]U'65GLVD?LUWUYTKW(=N5CA:O(%%+<E#J=1D=%Y9K* 4:+-*&+!HYARS$-M
MI)-6Q X]'!B*^VR(53##-7S]6;KVEAAZK[_!=(4T6N+,DW0<1!\;)$CT,:>J
MEL,*+WL#0YJE5:^#<2>-@5]AHF/&#,/Q1^:1DP\;O&^C$Q7X8:J:^?&F?S5Z
MMN4>LD3[) )0S4O$JX+OFM9/ALI.+JMMV\E)+S]Z_KK5LW8."8L>8BHK-B:2
M-!@:+9<"I3!G3MZEG9O'8P"TT4Z\.G.G/I3,FF<'! X!%;K)_P"GNU?_ #4S
M#_IO5'!5OZW]I?<7'?0V#%EJ]83"?2.)NW4F]6 1\4DY.1N:NE]V.F[&Q83J
M),C3\(8._9FY(H;2$C8XX>,]\R8$Y)MUEQ8C-.H'UVATR[)8FEW;,4;$8-4K
M!@Z.A$ZM%$['&N)8X?RQBV7/I*#M8W4$PD@A14''64(K[2?FY0X(1I9J7$B=
M6'GS5I[_ &\^?'T@Z5=94$)!6K6]XO#=L"9)[H(ZU>5\/DT4:+12'ZFC<91U
M>LG,#>NP=:H(V 6U&KIRBMW$CC)C5L-]5*B@KS+SIS[^I-1TI7UOZ6PDZ8GQ
MF[Z\BJ6<JR@+J+V@*92+(R.QQ/8(2XC*@WUI\D+]Q=>;1&"(#QFN^8"K(T!*
MY%H328M@\)<,5KOIT5\U>8F]UEC]<5C6<5J"#V3#YRF$'&Y.+TC9(3OCW,26
M8'";9X,&-STC+*QMF0(. K(X7.2$@2<,U%2\B*%U':^P@D?P!P!P!P!P#755
M  ))?#_@8^03<!6S%I[%D;:=R;7"@6+G8?=2,LC!1RCM(HJDX71DH03J.:N#
M;=JZ);LV[MJ5;*JB7P)T]NU3']3=.Z3*"FT:C-\P2P_<[6E80&'O81HS<FQ8
M>MWKLSI)Y#H/L>1@CQXMF4[.%R["/QEF_(O TLF3:;S03&)**$U]^S12F&C9
MJP2AD:1P2!7,S8T[*>P=9V9("E"713)S976+K2'!6U'< FD&EXBNFI-ZCLG%
M T(0*BU'I/+]\@SB,C:F7#AWL6<@E4T9E1>C^9DD)UA-!.P/ORXEH)5@[E>)
M$Y"!XT^C66HT:&[%L1H-5O[H3@HH_,%^QA.128^*90UJ4,0UL>+1LW+9:<DJ
M 5V=/FS8)JVDQN"!P!P#0S^T/_[%=8?\T4*_Z3W9P4?F3G]RD!_VIWN)VDZF
M-^C&W6J][)I+:?+=E]9IFO)(\C^9-B+Z4%F.X+^J;8];P&S(CF6'I/+Z#VH]
M\W_Z;;G9<$I*4G.Z'*I>%'R?),GE6HZY?Y3>NUS7KK:Z[J:CFN$DW,RO(N3Q
MXD&_RF_DW*V]=R%VM,]+SJ<ZFLK]GP\1;O3V-\3&MJNO;M5=%K5V3KRW21"&
MS69D30!X_#0E^^%.W#!QME)1=@\3T<MM\X\J2VFN^O[\<VO".S+/EK*C1I>3
M@08J1("(^'#1KD1T1J*B*FM,%V&NL.?G9BT8<*-,QHL-6155CWJK55&*J+1=
M2XH?T$^?.#N3Q4?M/_>3M_U4[+=;HOUP[%VM2\=D]&%C\@#U_*GP!@8-(SXT
M.2)OT&NV-5WB;%!%KJMM_K813TT_HQCG=<%)"2G)6:?-2T&.YDPUK71&(Y6M
M6&BT15S)7$Y#A%.S4M,R[9>8BP6N@*YR,<K45V4<E5IIHB(0,\(OQ)>^MQ_&
M7>^GVSNZ>^]=X3W<"WJ\]TLU)$O<=9\,3@68I.@/IML^H2,!D@^R,(I>19MZ
MTMYF?]?/-A;5F6? [E9&3EX>5MB3@Q;L-$OPGY2_#=K8ZB53,M$,*R[0G8O=
M'*349^2LN;BP[SU6Y%9D[CVZG-JM%T5-0/QQ?BE?3Q[*?:08_P#?YNNXED_=
M\K^R::ONK:7CLQ^T4]YEW^()?/72N^H+^,(PR7F+8ZC4S-)H<L,8?.%R,C4!
MY6>$?6A4G 8RL2=$G;Q^HY3<J+N5,J84T\NVNWR.;:UDW-,8B-8R8C-:U,S6
MMBN1J)L1$1$/I$%[EEY=RK><Z##<Y5Q555C555VJJJJD=/CH.UGR2HSZI37]
M1^8Y>^NI.O>/CH.UGR2HSZI37]1^!?74G7O'QT':SY)49]4IK^H_ OKJ3KWC
MXZ#M9\DJ,^J4U_4?@7UU)U[Q\=!VL^25&?5*:_J/P+ZZDZ]Y5 GC)]IR1H0.
M7B='ZH/RC!DMLE%)IJKJDZ=I(*93VVL3?753&BFV=,[:;ZXV\F<Z[8\N,A?7
M4G7O/3GP>HX X X X X X X X X X X X X X X X X X X X X X X X X
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M;5KX='A$XM!&9]A[#%SY[9#263M>-TB(['AHE%'T>)QIUHA&R.:"D)N?#E9
M+V'RGW%X4=F]9-J.A\\$I3&N&K:M%]Z8\^@Z >W/$(8-X^M.X+!DAA<8R7E)
MZ)T;.S9"O7&U=T/*7"S6 C[L+'K V=6#8=GUAJ($OQCT.RKE29NG!% 289%
MPT>W\DV=LU#-6'XA4]< @#BLF]7(J6Q0C$@<CH%^]_\ D[-G?+>KAV03LE77
M5.)KMB\#;+(M6+@E&18ZXHT2UQ8@8#7X8:]'7T9LZ]6&F[*IM[Q!),A!2%A5
M76L937E8E">AA,*L3=XV#$I9UNCYX0Q)2>3QG#!W"&$\[ E\RMB'F,7EK2L
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M%9XS/B5]B_C$_?E[+NYG[QWA>]K^PE6^DJNCP?N5N"M](1M"YCI[F:T#>UU
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MBL_#.$T5,Y5PV+0Z;Q<V@FXT0?,]2>1Q5FP+,GS!L(I3MYB_N . . . . .
M. . :VZTA5GDY?VWDT=[(%*BB8WLA,%B(K2!UF=$L=1U:5BZ)'7AV8AWCUJC
MEMC"CK"SM-BS1:Y6QA/&5=LBC45;U%7ZRYJ>]%+PAN)S/]76(EW_ 'I1TPV9
MZD1.]2TH-/B_:>Z.@G8K'2T58G1:9G#EHN%5(#FR9EH]8/1>SMF^:+K"U%UK
MU;BI!HY9)SV([!]\7!#W7 $),"<LJJHE3VY'ME@S5L4:K:QK'K+3+B3 VR.<
M[9V],98HZ:>>ZTUV"BZUZMQ1UU9NUFCVNW/?PFWF@]ZU&.0"U.4XF[]K/ XV
M1(!FRF\0PU>F_<X8&2)<,R<."C6/O$3CIHB+SL[U"BZUZMQ?WO:7EZ/*WPVS
M7H<-7CW*OO3T7Z/#,<KA$@[SO[G/-PU8K;:I/'&<^B;*YPFOOIMG&.!1=:]6
MXY,U?>^-\IY[KGL*:K-&^VF:DHSS]5R&NN[!#.ON;\N%GNNVNS1/.//<Z[:Y
M1UWQG&>!1=:]6X[_ +S78OZ8LM^QBE?ROP*+K7JW#WFNQ?TQ9;]C%*_E?@47
M6O5N'O-=B_IBRW[&*5_*_ HNM>K</>:[%_3%EOV,4K^5^!1=:]6X>\UV+^F+
M+?L8I7\K\"BZUZMQ$[K##+9 =5*\EY+N*6K^(M19+;=-]6%.JC17K$R+#FS;
M!,O'E';EP2)KHMV+=155T\(/FX]DFJLJW0V"BKI7F1$W*IEI5V?W=#AJWB,A
MMW15I#2XQJI!NNN^SUC.M"#Z!$FNNP7.JC:5:!"#J+N],Y3+98[*#E%MO19V
M"BZUZ$W'>ES6:UZB-(SCQ M8>@?8+$1KR15C0P?0D-'IH+NG:2[V.(85:CFK
MW5^\5VV]&P&ZO23C*+!D_<MPHNM>A-Q>XFL;W.LM20?NI)"3'=P^:>LM*=I-
M5/1X,?.19-DKY(QYR+T:39O!Q%FMKHY8OVCEDZ22<H*I:!1=:]6XJ7O-=B_I
MBRW[&*5_*_ HNM>K</>:[%_3%EOV,4K^5^!1=:]6X>\UV+^F++?L8I7\K\"B
MZUZMQI7\=JO[8BW4:NB$YOT[: E;L;$6;< 2KZNXJ@S(J5E;RZ)C0A% H\BL
MJW;-W;+5DLMLR4T(*+J);+MVV^@J_!$QKCF7VX4+!_:53_AX T.F/P]X!VDG
M.CI7L-[U6.M,FKZ.;"]D=*/]W&9IF>9QAYA[A6(^YWV5^]OEH<]=_P#IVG.L
MX+MM-W+NYT24ATY-EN5-BNK7E&3R>3S4H^]7/5M,RG/\('2"<DY<R9?7E&2Y
M,Z&VGZ&_?RBXU\"[34ZN@UI>"98_@[,.]\<+=1ZA[WQFY@54W.>&D[MFU/G(
M'[G@T"*$92T<CHJIH74*O [=P@%WTWT;)O\ =+9WOJAC;;&UMV%;:V>])V-9
MSH#HL!KDEV1VQ+SHK48J*]+M$<J*[33,:^QXEDI.M65A3S8R0XRM6.Z"L.ZC
M%5U48M:JU%1-%<Y._P#TO;I!]&OM7_@ZB_4WFN^1EH>-2?3'^"9ORIDOL)K^
M["^*1;\9SM#X3W8S;HYV&[=T]W<+/KMZMM+%JMA2TKJ2-ZQZ!2"6E7.!,X:R
M1\036E"13+G?94,^=C=6FR6FJ^ZF-L\R[#E+8E>7RTE&D$2!-Y*,L=D=UZ(U
MB)6&K$3P*4^LB+4Q;6F;+F%DX\U"G56-+)$A)!=";2&Y[L'HY5\)%K]552BY
MS#GA9R_P:2'QAWP=:A[[1_U+PQ.U;^\/?3G-.D_;77QOI"??' UW[GML^S[/
M(XW$>Y0D;\@!KE)][1S_ *Z7/:UV6VG<WE4:SG5M6427R,..EV97*9)T6_GA
M)X5]&^$N%#RLUUD+R_(0IY*6;-+&RKX*UETN91L.ZN$5?!NJ[P4HM5-57N__
M &=SY@?%+^TWKW_[W-QD^$WC%D?LIG<:V_8/V-I_WY?>>\$I#_#RF->=;GM\
M;1X/'T>K]+^\TPM2Q2<5E3:OW(-TJQ;$LQF2 QQ4JV98$HFGB*;AO@CJKZHI
MH@IKKM\MFKZ34RD16K$R\;**RJ,5^4=?5J+BC5=6[7&E*GT"%D\A HBHS)0[
MB.^LC;C:(Z[A6E*Z*YBU_>?\&3^UZ3^W*:_J!SP+_1]KP]Y_P9/[7I/[<IK^
MH' ^C[7A[S_@R?VO2?VY37]0.!]'VO#WG_!D_M>D_MRFOZ@<#Z/M>-A'6*/=
M<XS6RPWJ\XC3FM,R0HY64BLG)2T7[I56P[4KKDJ5+&76'6&R8W*S7#S"2.N4
M]]$=-E=\[B[:4\'-VUDB."1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P")[/I!UI9-H8S]Q$B(-*]$:QV&MCMM7'(T0,:10#
M-VD6:IGY^3T5BHW0 *W$1AUAP!#.$%G8H<S=/GZSH2JJO\D[=DU(5)WTXZ\/
M0#2,*0PXW"M!)0+LV&V=:PA<DT*2&42_5P?(BINR)R4P!F$TE,PA4AD+PF?K
M^6FG<G@Q..G?1$$Q%?=U'56Z4]:';%@))5TZ-!1JL>=- $@GMDR&.8(Q3V0W
MCAI>/&Y@0"/)"'# 0T/9R)XP<'$Z^&M*XR0V@:6(YP35:UTE4VZETDE!8_6K
M"-O6\* 2&0R#V(1D<DE/MG,PKR651+!9TM+"YN0$!IJOYM( &$MBZ:@[10>L
M.4;X'-TN!5<_;7[4+CVZX4XM$4(.]BSTO'T7LU);X/2^;'S;\E8@XV(F1$S*
MS4C?RHX^-"Y$6'[NS)I\X9,UT&XU1FF/':M!!:I+IWUW*N9,Y=0<FEF8')#*
M9"V&V'9H8<^EDL*Z%I++DQ0>9,1@^7FLIZA2$J&M&<@7AV=X)L2]Q2B@#837
MMS)0R/4U.PNEPY<!!6:HX.4(A':8[9919L+916 0JK(J&'97V5<X8@X'7D3#
M)J/'+MZ]68."3UTLZ>K9P(,J< < < < < < < < A342@1$%W@5DI!R)CB5^
M6FI("K-##IV,":4_6FQ4@U;;,2FKARR88<.4$-AA'"RJ>J>6+O&WJZ@JS.O]
MI?<0KUZ_=(;!C4E9NNTDH@.[99,<<&2C$ H8K%!2L"39B T:K^=5K#74#A&0
MMM,Y<W&QH&/A9>5R_))1LX3+$ JX],=6&:NC"FE,^;7353 KQSIQT57:#XF:
M[2,Q[^#$3HU=JSM.DXH\;J#H$-JX^*E 4$ #-'ID5&HXOL<?FQZIM>0ZK$Y8
MJ40%,1C(,<U,^.9<U:]&CV8JM<[V)"^JLVE9V9R/M(,U'NK2A]UIPH/85/K"
M6%F,*G UG&RHQ/2/D9D25/5U%U4!L96-$F)E8J6)C1;EUJ)W%B*+J7;GT+C7
MF,-!.B_4 <1A8H9V6D6) 3!B ,*$*6;6^I(PW RB8$F"4= Y"I.M]\OI3* Q
M% "V0>-5$]6X%>-NANVF!-5U(B5773&F'4BT]V!8<;ZU='4RPT2Z[ W"(6B1
M:*1=FXL-IO6T>.K=>8Y.*D?N&1F35C$(C+=1Z$8DK&1S.-.731J82&.LD4O=
M>P]T@+75T8TJM=M*YN8VP:WO1^^_H]+EJG=3#^."\IZV'$=M\$Y@P=E(D.\W
M!C.WK\I&,'Q&.,_)ZP;8,G;P8FZ;MEE-!4[X.XZBE!(0&C5J5O(BY_!#((4#
MG$8+$C>!"2RY7(ABP*.'1+ Q!NX6(>II+>I)(+*.?1:);[:B:+J7#/L,C\$#
M@#@&N*L(G YOX?< CUDN"K:**NHP55V"QE>:D%C\;O9E)88QTAS>/RI26-2,
MS$1\>1C68\41.CG+L6X;ZMW2JJ8E*UPV^SS&'(2#\/!@/]&,MN8'=K*B]*QI
ME,)]I/9'N;5ACB;L@,[B<BG4.= !IHAH5/0*:R*->J1J#)L&=>ZLX*[PF&7$
MU=AHI5<U*5Q]RX&2[[HZD,1+4;;]\V8,C;2G'6)?*CSHB0L_:+^W9/'1SM63
M;1UT<CKHT-O&>0=P*28-I1,!V@T JF: 1N=@S8574F*KHPT5PS843/FSKK2:
MU&!P8. K,X\83-L%[$N8PX<)-73+0>=D-Q3P])XUAL]QJZTS#Y*2+13=1?1)
M1?<+LXV11RKZ+05,O\ < < T,_M#_P#L5UA_S10K_I/=G!1^9.?W*17_ &E3
MP^;Z[WH=,=*0)5(/S5JO8?:3>^G:T3K'"V)MI1^ WL+,H=M?;>4\Q,K[3PQ]
M)[-\]AZSYOK[?SNLX+VE+6=R[E"1ERW);F1@OBTR?*+UZ[]7ZZ4KGQIF4Y[A
M#(QYWDF16$F2Y1>RL5D/Z^1NW;RI>^HM:9L*YS6!X,W@Z=NNL7==C9]C%^O9
M".YI>]8AHT@5_5_.)"J8F=<&@ ;"0 $_<$%&?M!XCZ\\T3RBQ;^>X7SA/3.>
M;6V[<DIN06#"291^7EWUB2\2&V[#BM<[PG)2M$6B:5P-=9%E34O.-B1%@*W)
M1FT9'AO=5\-S4\%JJM*JE5T9U-?7^B\^++\W]._;5%?_ '>;+Y66/]I'_8.W
MF#\G+4^SA?MF&PSQ*O!C[DVM4/AK5Z#=4*!E/7/I?'J?LEA.;V@L,]%,A<D*
M/'F@#8Z\:['Q*:2^FF"['39ILMC='&WGZ;8QK;+MV1@Q[4BN28<R:GG1X2PY
M=[_ 5B(EZZG@NKH7$SK0LF;B0K/8BP&N@2;841'QV,\-'.5;MY4O)CG3"ITO
M"T\'?MOUZ^,.]WQOKNY]^SPQ.UE PWW(]@:]E?J\[L32$XC[F3>R2"ON;B:6
M13KVQ*B7HQ0C&6^7BNGIT_*M:VY*:[FY)LS]!:LI,/OR\1E8</*7D95/"?BE
MUB>$[&F8BS;*FH'+[ZP%RUFS4!ER/#?X<3)W;U%6ZW!:N7!,*YS57_H]_?;Y
M2=2/O6U/^*\V_P I;._JSGHD7<:WN'._UI7TJ%_J/:5>7AT7!V#A750''9=6
MP C3/56H8!*,&RYAXS>FV8E5FY7 D8X"-LB0O5<2YPB_PLDFZ2W17;X424QM
MCY=-/;$FIF(VMV)'C/;5*+=?$<Y*HN*+1<4T+@?0(4-R0(#%I5D*&U:+5*HQ
MJ+14JBI5,%TD=OB4.Q?SG4K_ !&<_D?G@7N+K3KW#XE#L7\YU*_Q&<_D?@7%
MUIU[A\2AV+^<ZE?XC.?R/P+BZTZ]P^)0[%_.=2O\1G/Y'X%Q=:=>XW*]#^MD
MOZK4>XK&;&XV?,K3@_)]7T56*+C,,BS$*U00VW+C!+KUI/<8MLKKAKE+&NZ7
MF*[YSOC47:BHE%U[B:/!8< < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < U"0SKOW(K^O@3.LMF=7GFE555!9:+%3Z/EE9Q;T.K
MRVAI>['VT@C<FC# *6LR156:FBC9KBP[%B46+:2)J[4 !(=+Q951>NFQ*IAG
MU5PS)7HR[%ZD[DD+NKJ6V7, Q2!0^T[E/Z-6QH,F^;U?)141:51%WB >( 7+
M\]'E6LNQ+$UR!8<06<@G^39Q=DUR)$8:M"=-4JN?MJ.Y7]676XO^'S&5")2P
MCD3E=SD"TG1F[K.)$L;LCL2E% +^)D)(W'-ZZU@$UKXVAL'CTF-20H*J\45,
M15G1R XX';V:>U-M2EJU9WO&[K%$+I*2#5\1 J'(ZJ_K=ILG%U"(PA/!<%=8
MK<>F,ECH.-<QN!DCI'<<+>$<$"CULJN_-)AACGTTZ<-.:G7K3 Z,?A/>)M)A
M^]BRE62#-Y=U_>1_8<M&],QU$',*N<6?AV3CHD5J34*5<PO ;-"A$+!0KLX>
M'BHPUF*$OC@>LPPT;??S]NDV:<$#@#@#@#@#@#@#@#@#@$&JW<1MI#^^+J9(
MO7$0;7;;[B5-QN<X(KQM&EZX4.(C\X50SAZJ+U=:-<X71SZ?9/R*I_\ S\"K
M?UO[2^XP,^FO0$A71B0LM3U9 X)%4QZ[6&1@K&S<>9QZN"!*0"%0,8%$&D?E
MKT-V$D=2'F,E9"Y(4LJ0/X0#UWL$:#<("^.;5S;$S^;H354HABI>IM9V?,H/
M<<T-NGDCJ-&5PI@YC"PR*U740R]F=G5]!&88TM*WDKGBUH!'!R/QTE'2J$@&
MP,P%<0EF+0=!#0G%:43'%%TJNA575GS]:J<^:D\.=#9$,WFI,,S2+UO%FPIA
MJ;"#AV[8,J]!#F[EO#6NXIOEBX3;SZ9:/VQ2/A,,*NF<L!0#U: [!5:X4KCF
MICCT*N&;SHE<2Z0[#PZTY%';.#R!!4D))N;T%O5@LM,X?J63/H@R"$AZ9J*$
MB+;>8VC6<9*UT)BBHL_+C(U_O$4C4=/GV9411?=YTW)G5<U5KB5Z+U-TZ[ 2
M9V!C9Z7V4X8H'+=B\C<.'!>"Q\?8TDFSTVT@:YT&I!Y,((RJ:R%Q)!2HN7CW
M!,2.B\U7=XA[2-C06OLZDPZC(>GAW=;T!R@MF,DS1!1R-=;N/;#-^576'MI'
MYRY,X7$$3,@?/#4J,2A4Q)'Y@XP.KZ8!DQ ;3(?8+RY]E.W;WEXUSTFH>KIO
M&;#C(1_M*8DCLV"O2:@EXFQ;HBI4"$-QJ&H9#2.H!@\YF+7",5]@I29[)2LD
MGFDMEB^IY,*KV\VY"6_! X X!KNJ<2#->'I'64F;RIW&TXR1)R%M#3<2CQE8
M&$L4@9+)K$IZ7!0K,<RP8./=D-E)),$<A^#H0DV(M2"@UV)3.GY^['FII.E2
M42ZOS&0S 4.A\^C,WL>.1%C*6,^$ H-,-A41:[EF\?<K1/ Y^*-.71(\N2 K
MN4I$L :*K1]JVIQ"#J[ABE.E//\ R\W.40M#NI4K1"P$T/GQ&,%:_2AR6ZS
MT('DA$IN:1TS#99'IH%<!!X]+$@MN>,!PJ$[:#1D LH>L1 1^.-8Z-T#&NU,
M?.E*X>U=--)L#KZ#L:]CJT>8.EWJ;J4SR7NG"^N-,[EK$G4CL YHBGYZNZ3)
M S)WZ Y)9=RX18)-DG+MVOHHY5$%[< < < T,_M#_P#L5UA_S10K_I/=G!1^
M9.?W*:=/VR/_ /)O#J__ '_;7_\ #ZT\[S@3_P!9_P#LO_MG)<+/^@?^Z_\
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MA0$<Z!)MA14RL%MV(CG*K:NB)>HBIBVK=2DGOV=KPE._'0KN?:5N=IZ49UO
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M4438ET1KLF-+CV1:(J43'^>!-/@@< < < < < < < < < < < < < < < <
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M#JA"49$J.V9!811->BN=,]/<N%,^E%T%,J/N/XC_ +G^M\<N?KA*@3Z4S(=
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MU5/1HK1%/3TBZNZZRGFZ2;77SUEE%%E=_)YRBN^ZF^<[[;9R!R^VB7R1D/\
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M!L&HH.)9H#QHYDCJ@T9,VJ>J2#=!+3&-=$TT]<:XQ_3G]^VV<[9SG(%2X X
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M"]'.KY[HMJZ5$&7^ . . :&?VA__ &*ZP_YHH5_TGNS@H_,G/[E-\W!<< <
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M73N^2F]2+4DV6BK=!LHJ$$84VUIGS]?N\YL>X(' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M=-24C'2V70YV^Q&0\9<% D5)EQ@.2*'T!TJDX3841R(7MVHA,'@@< < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < U1=</_K/.]7_ -G*[_\ ^)JG@LOU4\WM>;7>"I;.?_SRT_\
..LRK_ /[5'@%S< < _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>business17a.jpg
<TEXT>
begin 644 business17a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5B^=1(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              I$   ,6          $
M                 0             #%@   I$
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   I$     4F=H=&QO;F<   ,6
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *1     %)G:'1L;VYG   #%@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      2\@
M  $   "@    A0   >   /E@   2U@ 8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ A0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]$?FY(R+*P1M:Z&B$49%P,.T/@1"I7!ARKFV-#V.<0]A
MX+2(<T_UFK Q/JYU?$QJL/"ZF,7&8T&P5-<USK"7>HYKO=[7M]/W;O44$9&S
M<NK9E$ "HC8/8-O<>2%,6%<K^Q/K"=K/VW9Z>W:]PW"R#:;;&M/T=]E+FL9E
M?S^-Z'HT_H+K58RNE]>MS7W4=4-..[(KM;7[B?1:W8[&V'=2W:_])_W=W_K?
M\U6I ?%B(_JO1FQPYT43<X+)Z#TZWI73*\*Z[[0]CG.-@W1#C(;^D<]_M5XN
M0,DB'@S=D6#@C[D"S-R&C0C[DSW*O<?:5'*9[LL,<;U =?'<Y]%;WZN<T$_$
MA$4:V[*VL_= 'W!9=GUCQ:G6,?3:ZRIUH?76W<0VE[:W6.W&OZ3;:;6?\;[%
M8B"1W:LB++K(&9;93C665QO: 1.HY0NG]29G&YHJLJ?0X->+&P#N&YKJW?G?
M]6C9;-^+:WN6&/C"(%2%]T2^4UV+3KS\APUV_=_M1VY5AYC[EFTNT!5ACE-*
M [->$SW;PN<?!2]4JH'J6],X603+9-I4'WV-\OB$'?\ ,>"PZ^B78>%7B].O
M9B[<VS*NV!S ^JQ]SJJ'>FX6?JM=F-M9N]"_[)]GM_5[$N'P3Q>+NOR[P)$0
M.\?[4/'SLBS+KJ<6['3,#70$^*Y[!Z+U+'SZ,W.ZB<U]-;ZWR' NW>ML/[G^
M'W[=OZ/^:K_1,I6QA']?J_M?]24X1'#(F-:%C,SQQ E>H?_0[G(/ZW=_7*FQ
MR#DN_7+_ .N4F.5.]3YET.'TQ\@V@Y3#U7#E+<GB3&8IMRB7(>Y,7)&2A%D2
M3PJC,W#=DLK]3U2UTO92UUS@&^[W,QVVN0K<-MN39;?:^ZBP,#<1Y_1,+1#G
MAC=OJ^K^>R[U&+7Z30&L-H :SZ%;0(  ^EM:/;])*(XI ;]53)C G;H&8ZA<
M_6K!R'CL2*Z_^C?=79_T%'[5GEVX=..X" 765@Q_9+U=>]E;=SW!C9 EQ@23
MM;S^\Y5:NIX]GV</9;39E/LKIKMK>UQ-6_?O]NVICF5.LJ?;_.L5EIK#-S@?
M=T^R/%EE1_ZNVM+]J-;(OQLFGXU&P?YV)]H:G'5<<T961ML-&(XM-C&^H+-H
M#K'8S<?U;+O3>74/]F_UZK:T:K,QKLB[%KL#K\;9Z]8Y9Z@WU;OZ[4E.%3=0
M][V46-M#"1[2"0/S=S/I,_M*RUREUO!ILL9D65M?/M+HAS7#5CF6MVVU_P!A
MZIXXNK):ZTVU1["_^<:?W7V#VW,_=>_]-_I/65D'B +3D.&1'9O!ZEO5</3[
MTN%(DF+U!SE O4'/2$5&2[W)\ SGU?VO^I<@/>I].=/4*?[7_4N3B/3+R*P'
MUQ_O#\W_T>RRW?KM_P#7*9KD/-=^O9'_ !@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^@<^NWRW 0W\AU$DD+9)(P!V&/EN3W]>ORJRBA!QM^WICI\,?'L#42D76X&
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M5YC=O=(S+T<+S>'R-]EL9.!A1L%TW=$-7Z?\J/<S?GY+WF^3]*R!7;4^DZ]
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MM^P>8W.WGYU>D'H@&WB\7'GL \\^8^@!MMOZ=^-2DFZY;<GT_)Z=1DU >#R
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MFU8=_'C/UMX3_ ?"O4/L_/-P=H9QC^QI!Y]+J?\ JZGXUHEU-K^#-]G+MO\
MQ2O;AZ[P,?Z?[.X_ =>3N/7QQ;J SC]'98 Z[VD1SCY8^&0-Z]U>RN,MP)I9
M[&;4NVVVHW0Z^?U&W8UB=DZ$ #GGC81_$!#;\-QW#D.0#778I#@;@==_+O\
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MY[[;CIT[8QM5V3? (?RM^P]]MQ[#N [\;^GE\PUG$OGE=SZ?#OOGSVW[5#:
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MG(W(\]\_&HX\?#][[P;B&X!OV\@';U'X<=MOA-CB"@; [#'S_/3ZYJNEFP<
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MS'D?0-^?7?SWW#[O;4R*$GJ-^H'?MCL1]?A\:Z:XW('7\_=UZ_/)VJ)/WW<
M-L(AQSV\M^>>?+R'Z#JSAB  SU^!Z^7;I\O3KFJ]WZD]3ZGO^P;_ +\UWKZ/
MSB?IQQ@<1W\45*\__4LV'[->3?:$,<9ZZ/*X@_W.W_9CM_#VU[+3S< \.'.<
MVUSO_P#:%W7,7K,<^SZD+P7?8 :57D?C5H<1_1V]1#?OKPC[5G(XZU0=/T&G
M8^>GVP&?B!W[],'.?TX]AT7-[,M"( R;C6#YD_\ *]Z"/]4=/+.VY&O39V'
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M6>O7Y^9_"HH]>@ &Y^\(>NX[CSOW'COP/'KJ6B<Q7(P/VG8[;?7X]*A2R9R
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M<)QW_E0\J20:)(CN&Z$=]G%  V3,0?O!L#2O:EQ7IW*EQ/;ZK"H Y;Z+,Q&
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MJ*(LY<3 U=BUF_=WDIU5EU;V07YEB6ZU;V=WUQ^E@'-/>\.SRM@-%G=[<D
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M>ORG4M>U-@SI;VZRNQ2)26\./G\*WB#W$[-(TLKP+!&$+OG2\M.J#J69^!T
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MJMKI.N6K2PRQ31:A!#ITOA:@$C+)"TK%@8_LY:/Q1'#X@B2REAX-@]J?",_
M6H7=UH=]KO#=XL%Q#<6\^DW-QK$2SZ49)PLDZP1B-Q,ID4+-[OX]R83<2UG0
ML0I.EG%PE*4OC)<3&\)0#Q&&_P!JW,80[F'@!$>> UD]D:@>SSAP@ 9CU$G
MQDG5[_)(&V3C)]:X>W9F;VK\6\Q)Q-I2C))(5="TL ;GH -OX;X9Z&6R']4?
MK*?E:H&?CG:;;>\BF0KD[<DS:52-A<B4RGL 5$5"IB82%4,8_A\6^O4OM.9A
MI?L\CYV\,<)V<G)D\@=H+4%PF>4,0N"P )  ). :\9^R*-/Y9]I\HC3Q#QC>
MIS\H\0H+O4&Y&DQS%"Q+!22!G._6O;&G3UDC,>676>>JF.;-#5N1<,\68@*\
M:RL'7&C1T(H34B=FLJQ?*'52!T@"OM%Y5Z!).1309M8F,1P:OQ7H^@Z"G"_
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MBS^];B3_ +@UCT_]'W'Y]>E=HX(_OTX0_P!*- _I:TK"O0Q_>L8L_P W</\
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M5\$-Q >>!W#GX"'(>??S\^=/S^?/YY%*^ 4I>P>H!\A'?;](>?/QTQ3%?0*
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MLL9<N6D%Q,K7<C2\[BYEE,<B1,L2\[73XK6>XN(WD9[LEKDNRE99 S%).4*
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=I_$TIK[2FE*:4II2FE*:4II2FE*:4II2FE*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>business18a.jpg
<TEXT>
begin 644 business18a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &"B^880X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              T\   4R          $
M                 0             %,@   T\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   T\     4F=H=&QO;F<   4R
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   -/     %)G:'1L;VYG   %,@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      -P@
M  $   "@    9@   >   +]    -I@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M/4LR[U&5VX'53:PFH'?6*1AP[5OOV[ZV6LL_P?Z7Z:Z6ZIMU+P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( 0\!J@,!$0 "$0$#$0'_Q  >  $  @,  P$!
M    !PD%!@@! P0""O_$ $,0  $$ P ! P(# P@'!@<   0" P4&  $'"!$2
M$PD4%2$Q%A=1(B,V06%Q=[<D,E:1D]/P&#-R@:&Q0D-24U=CX?_$ !T! 0 "
M @,! 0             $!08' 0,( @G_Q  ^$0 " P$  00! @0$! 4# @<"
M P !! 41!A(3%"$Q\ <5(D$C46%Q@9&QP18D,J'1"%+A,T,7-4)$4V+Q_]H
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M$8B,1(TY/_1:5_Q+[1_G%>\1)*VG2O3U_/TWZZ_LW_U_'UU_Z>G%UY_7Q?\
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M)I)M/5/YS<2M!'N5;5VAH)*ET^D:"H?B>68F)'0(>"KXB8(T1"PA:*[0WT5
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M28J[)9VLR"R KJKL;L;\>:J_\YE\FR/&(C$1B(Q$8B,1&(C$1B(Q$8B,?O\
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M<K>M:]=_EG4YZ<X6S0Y2%U=5;',!85=WXJK([$:N[_UGVM;''[%+-IW5W0+
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ME=))(T9IFSISLXP* =B3]0]/)Q7XDFA3'"E(*1NS<AK\NO4IC\>C0G3JS/)
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MU&,%H=L2I)EP\F=]@\C-CYG6Z?81NZW/?J/=Z?8[K!IOJZ,9+ "Q\SE=]/\
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MX-WHO=A^71D8P=?(V,W\Y=4O/1F=;^;LS,K0:[)N?VIZV02"C@51LR%H$6=
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M[K"Z_LVZ[_R<]*5_K//DA#K7FSQ;D6G='ZN%Q6/#$3QB:)7%3+08 \?8I/\
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ME.U;WO65M^B/1EK%)>D?2Y) K($WZ?Y5K B_]1"%Y; 2+\>XJ&O/B6=>L_6
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M\EC/Q-K;$E^'\XIP?X@QMWY]LG?;0S?W;6WOY[;9'R(V[_.>GO\ SQ$^2O\
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MH[W4^A?NNYO)]'LS36X2JKOUS%FJCSLJQ.-U-RZ@B[Z!*U.DIE+&*B1[X3>
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MWMMKAF>8P7?8BH#6GG/*NYWVN.V*A\MLT_J0;'@NK6FJ;;LU:K,HJODS,/(
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M\>1[$+-\'9ZZ;7(7G3O:J[%V2DPO5(YVYT*GUN<B><]!EV1N>'RCSDG1H?I
M!THPG/[_ '_SED&(C$1B)P9Y-^>W). 7R'XT2Q>K??IJLSUMMPO)XZ LEJY-
MSF(:CF9KI+]7ER5'W4ZK,S@5M,Y[1("^]!31HRP7E5$D:U"/[,1^_P!_NI!O
MB?\ 36K]"LP?6/(D^/[IU.NRNC*C;K%)S=S!E)>/L*+)'=V#C[X(98N77R]O
M,5R=O')*[9YSC==Z34A.D<[AJY8))U02);+B(Q$8B0QW[M47X^\RF.H3%3N%
MXCX,R):*K'/@HR9NYX1LBPQ*%5FLGRL4=<)*#A]R%AW4:MJ7NMB$BB8VHUZ?
MGGPHLE$J]@==&^H_8>?=OIIQ_"Z_7*.NJV"H= KB.R\WN'*>SEPUE'ZWX[=)
MJ5F&XW;KC<>:1UHX[>AK!%6\SGC\[,14C#P9L''E7U'[_?[_ .DMFY3RCGO$
M*% <QY961*A1ZRR0S#P@A!YWQ;,+?D#BC).6+D)>6DI \HDZ1E9>0.DY PAX
MHTM]]Q;FT20\1&(D1]=[UQW@L7$3'8.A5VAB6(XZ)K#,T4O\5MLY'PY\\]6Z
M?!AM%3=NM1$5&'$1E5K<?*6*9<8V)#QAQKC0[B)5)TF&\AO._N%(D^7]:'C_
M ! 8)YAV;A_2N8#UB4K9ZZ3-J#NEH?N<S2+%8:)Y3\UO9B8^-Y!T.M6SBG0^
M:LVBL6"&K_0XFSR=/3C_ "_Y?I^_Q^/^DM?X?Q>C^/G+:?R/G@A U7ID2U%A
M/'N#ORLDYI;CY<I+$""A".'R!CSY3S0(($6%\N@8>-C(H8./&3G]_O\ VDL8
MB,1&(C$1B(Q$8B,1&(FO6RVU>AUF>NEVL,+4JC5HHV<LEFL4D)#P4%#1S"R3
MY.6E#W6 P01!VUNODD/-M-H3O:E:Q$_G\[),= ^J);^I\2YO)52?\>]W^HG1
M\9:+(B6:(YV[1AQ:CY2U >F6.C1'5O'6^V@;JW+)6BP?12^O\@[) 0778FP4
MWJ'/T<WJR)=1XW>/U8\;^91E"A)$ZT3S^H^5Z)TF?&C6KGU>]L5^%KDGT.]&
M1@@B)FV3,=7XD>2FCM%S,DV ,3.2DS+J-EC42?,1&(C$2I/S)\N;$9T8+QW\
M;YTJXV><YUV>-N<?0KM1Z[+3\_!NU2+M?).+=)D&90"!\V^<4B5L/6J1S2QF
MP@;\+&./VD-H&0"M-.1-M^G;X,V?QK@3+[VVV[OO:I^-?KH!3<W9)P6C<U?D
MHZRB<\58+)H6SW>."NS$Y>:F+T5=LDN)_MI8.8<ZM1%08-E;,B6?XB,1&(E,
MWE#Y== [#TF.\</&_D73NH0CAGD/5^HQ+(G(:M5>WC<J8!Y?>J#&7'JMC'&&
MYW4.H7"'J'>&@=4'KK]=EF[3PXVVQL'.J?1.O?"SPCH/AY6[=^#2,M:;[TRT
MFW>]VB<=CO1,S)@Q(!,?!1L)$P$ "U]I"1+,_9!H$*S]#D(L*>NY\H8%$#Q"
M)VYB(Q$Q4].PM7@YFS625CX*O5V*D)R>FY8MD"+AX:)$>/E)22.)6V.&!'A#
MOEF%/N(9''9<==6E"%;TB5B==\U)CJM)%?\ %&OV[HXM1["/3?):HTVL@V/L
MT/R:<J%KF*+;>?5Q%R@6I/GW>2QZ9NE=SIDM;P .>VLR\5^)D#*Y8U5!'[_Z
M?_/[_$SOT^/I\4_Q)@IFWRT?'O="O<X==H^LH 'W"<$9ML8&F:Y[2%-RTU$K
MFAQVPJE>^DU0>IHZM&T^H/RM=$9@P&M/W<X_Z?\ 7_?_ "\?O]/S9GB<QB(Q
M$XR\L?+6!X)PE?6ZN;69V,G9 VL5_ILK*;=X'3;*D>71$G=KZ/6M3CG-.>RU
MDA]\_+Z6["3M;IEQF875P;"C5$KTB5M>)WTX8[R%YN)VWRJ(Z>3;>C(.M]?(
MM\H.WU-I5KL%8OP/2)J)G82>%X'UW8H[_+KO6.(6%CD-S@J=SOJE=K-&N<'2
MQJ$B7I5.K5^C5:M4FIQ8\)5:=7X:K5F%$VYL6(K]?CAHF&BQMO+=>V/'QP@P
MC.W77'/C:3[UK5ZJVB;!B(Q$J_\ J9>93WCC1J[S.BWJ6Y=W#L <Y-\^ZDFE
MTZ^4OG,)RFQ<]E>C63H%:MUFKS\[5 ZQ9T;MT?2A;+>(.AOVJ]Q,&XJJM[>1
M->\*_!LB(%;ZGY1<XCG^M W.^RM0#MMBCNCW6'KUON^^D%P/4[]!R*ZCWH2J
M]:=GKSX_W&TU2+NW-ZM-10C@,!<=V9PM$MAQ$8B,1*QO+3SS>YK-$T3QY-I_
M4KQ'<@N_3KJU"0,[U%7*JQ%VNN4:%ZO8H&BSX,K;*+6+:?(@=)I-)U+]0&KZ
M)"W5V'/_ &0,KMD1-$\'/!ZQ05OO/D1Y'0"F;M=KT%=:GS6SV:"ZV559. C@
M@ZGT"V] T(X+=NJ4O15SIO*^N1L?4NC.^/\ .5>C=<>L\]6HMNKHENF(C$1B
M)&?7.OT'AM(/O_1I<F,@Q"XZ*!#BH>9L]HL]CFRVXZNT^DTZM 2MINUULTH^
MQ%5JHU:(E;!.R+[0D;'D.JWK2)10TKR6^I/Y,D.PUD#I7C11H2_3O#?)KF-#
MF'6*[!=" $J7V%7G>F0J8&T=K-@VV24W6ENT?L?AOW6@=(HEIK4G4IR,<O*/
MU_'[_?\ UE_%)H]2YS7!*G2*]$5FOAD29R(V%C@HL5Z4G90R=L$R2P P,P_,
M6&>D9*>GI-;6RY>;D3Y0YUXTQ]Y:)M>(C$3'2LO'0@:SY,IH0=+C3"-N*_G"
M2R7$L!@!LZ]73) XE;8H  R'2SBW6A1677W6VU(G\^ZNK]&^JCURRT&O\GL4
M%PFF;YY5.AT[KEEDJ)*<=L$)V:QR5L[/5"N?P\EJQ]Q=K-5>HO-QH_J-7O/B
MUWKF<U*RU=E*Y/"6>61_U_R_SE[O.><5?EU:9K=8!&9^8EV7L<UJ+@XR9NUO
M/:8_:*^V]5>BH2-E;I;C6=R]GFVXT5<I*/O$J9:2I#2$3?,1&(C$1B(Q$8B,
M1&(C$2+.Y=4 X9Q7KO:Y6"G+1&<BYE>NFR-;K VC+'8 :+6)2SE0L$*K>D/R
M\FQ%K"CVW%);V4\U\BDH]RM(E+5OO?F_YE=@Y]PV0AO%>#J,)#>/GE7)1_.>
MP]$O%,Z5P*_VNXTNT$-]-&I0<;-6"(@'94VCTFQ\C!KTC?*[0^VT7JFCJJ;5
M(-$MK\6O%SEWB'RD+DO*ACU1*):4L4[/S2(1%AMMGFG4.2=BGDUJ%K=>;/);
M9%%2Q!U^&C!Q QFAP&U)<<<1.C<1&(C$2EOR"\\/(VZ@E4?QNXA'Q%5ZYVCM
M'A[R_P AY_LD77YP3MW.P>I5.?\ =2 >?W@_FD@U=.;VMSE%DN %H@;,;68X
M:\0O/X>Z0=C91)B\$_I\U+@,I)=_N==_!>W=7J?.3;5S@>1CI2D\<L\34V19
M^!K9D,O4??).'FY"Q1->Z=94R]OC:@:3 0\TP+8+D7:T2T+$1B)ZWG4,,NON
M;UI#+:W5[VMMO6D-IVM6]K=6VTC6M:WO:W'$-IU^:UI3K>](G\[W=?J'K\\C
MJ;XO^*<+/-57KP=;19>C'-2,EN)O$5>94.W<(Z?3*M"3<;)T4,6&JKW=V*[U
M>JV K@'37>N4"QRE/%KJ^D(EK_B?X7\@\78EZ7KE.AM]3L83K%KZ#(ZCK7?M
M1)CP1@W/'NLEUN!O=^J--:CXBLUR=OKA]RF:[5JLJU2,@9#@?9H_?[_?^\[&
MQ$8B,1*G//ORSZ#$G6GQ8\;I]FE>1Y,=Q&4@)Z9D:,&39U]9Z0?7(OGO.(*T
MLV$^1LL_7ZA>C';Q,4QGD]=5#[@+'T.FRDD18JBB2WX+>%T)XZU>'O-KKL=&
M]LFJQ(14P#'/01D%S:*LLM&V.T43G[L'"Q L!4;):H@3H=@HD&X[S.L=,F;H
M7R6%J=6GG8TE$L(Q$8B,1&(G$-?\%>>U'N9O4ZC=NC57F\G9WNIR?C/79[<-
MQ WO1#909?8E0L>V/)LERH!YAEAY\Q)-\OLEXV+U":J!G0A$6%:)V]B(Q$8B
M58>:OU'Z)R+G-SA.(6(.W]953._ELV:%9J%HK7&#^!RE,J?2+!T*KSM]H]@L
MQ?/K#T>H'RG.*&Q:NCR5=?*L4+3+!'M A3:)JW@_]/<:GNR/9O(VL_M!T^VV
M,^Z'5+I E!NLN-=7I]NR!WGILK7ACN>="['SRT/W*&XYWZE5[G%T7PNRURF7
M:&U(UR- KJ);QB(Q$8B5F><GG[4>'AWOB/*[/'2'D[OG1LV&XPJ"EJCPLV>=
MBH7G5E\@3WB))7**Q=['/Q$)5[K;:K+T6&E)&,G>A[B:.I^2(1(B^GGX G<^
M)A/(KNM6L=%[:3:.E7HKF11_,'(6,Z;TCXXF[]H>&Y@S,1%/O/2:ZRW#7BD<
MZZ"OC%K1&0'0IGGL;TO2=UE^_P!_O\1+D,1&(C$3FGR \K>5>/(9H4Z5(7GI
MS=3/OD%P'F>HNU=]O=.@C6F;--\]Y9J4"L-O;@ $R4J^-%LK(/9AI(*+29)L
MI#6B4NQ<3T'ZM'D!"RUI2 ]XK\\*Z4?&OATN3EN=?LI*S_/!:)%PO2X?K)U2
MNW9NI<CFI'HT+U#F(-%[/X4=4J**\_(%Q-AD8.ZHG]!],IE=H-?#K58CVP8\
M53Q!#NTH7(3,L:XHF8L<^?[$D3=FL,BX1+V.P2"GY2=F2S)23)(-*?>6B;3B
M(Q$T#H/5N:\H&K9?2[U5:*/<;5'T6H+M,Y'PG[57>8$D#86FUU)[["IJU3C$
M4?J$K\?HB5F"!U"1HA)2VV5HE C\S=/J^=SK:0H[4;XK46J\IZ8'4Y^6YE>Z
MP(-TN/O2&YGHD%2>AR3\M<.A\]3:J]4Y&L6R@]U\-.QT^OV(2'G:]=2;-M$O
MRY9R>C\<JS-5I$.,"VZXS(6.==&!_:B^VG\/!CI2^]!G! PR;A?[(B/&*L]O
MF=$3,\>E19Y+KF]>B))&(C$1B(Q$8B,1&(C$1B(Q$_*T(<2I"TI6A:5(6A:=
M*2M"M;TI*D[UO2DJUO>E)WK>MZWO6]>F(D1\E\?^%<$&L0?#^-\PY );I?<]
M:1N9T6LTABPS/HXE,C,-5R-CFY EI+SR6%DI<^W0\\EC3:77-*1)>Q$8B,1&
M(G-L9X@>-4/W&0\D(SD59"[-*&DS!EN95*)9593H1-8D+JS5MR.Z<)T&2K"=
MUF3Z&)7V+Q)5MQ^ .L!$00^&XB=)8B,1/RI24)4M:DH0A.U+6K>DI2E.M[4I
M2M[UI*4ZUO>][WK6M:WO>_3$2I3RJ[7TGRTX=8D?3/['6>BV:A=+$HG6:O4H
M[F5C(G )A(#+8$VGK\O6:X7R29KDF79#I>KS,3)=#J! ,WRV^/BADB3J)U)X
M?>'E.\6*P04P5+63J%LJ?.*U>;?8)U5J.'@N:5ANO4KF]>LID-"V"5YYSP=^
M5 IA5Q3+W8D$YTFTV*9D'-.LHG9.(C$1B)39]0'SEC]C[\8?'WI#,?U*_P!@
MK%)E+E2"9*PW6$'G+C'UN83QRN5:7KDCV*P529^QJ/?Z;R_H]8[EPNC= C>M
MP<:0_&@Z4B=O^+O'^DU_EG*Y/RN)HO4_)>DB6X)'4&8*ORE@KD#89Z3<BZU%
M71JI58XD@*H+@X"RS<?"P/[4F1SQTFQ(D.NR1R)UIB(Q$8B,1&(C$1B(_3]<
M1*KNV_4FKW[O+W)^,0X-YFJE;HV)/Z#,0[MRY[7N7"65NH=&\F6*+2+9'=3Z
M9PCF5S;D>?6&TTT(,4NS1-IEZZ9/U"@7&8 1(Y\'/IR%5:UG^17E% TR?Z=9
M"#IECGLK6*U<EP=Y9Z-:K1&]5N_1"+!;(?K_ %&M1\F+5.,=NB:ER/H,+Q?<
M;5;K"?C.G(NN(ER^(C$1B)5%]1'SUNGC,;*\PYI5QY"T37%R;0YTW;^G8SAM
MKN5U8Y[QB;Z6+8(1NBPM"Z-9PK;4H:^S]G>@:AT&-KSG2X&,YK(35NBD3T^#
MGA/,URS6+R/\@0KD]U>R=-OE_J,#T<?EPEXJA5F!*I)]XM&^*'R=$A+MT[FX
MU4@^I4"AV0WC<\?1:;T%5-B.E:E2A42V/$1B(Q$8B5B^;GTT*;Y>6%VY15YF
M.87.T0T!2>A6%F6ZK+#&4VLL7#59GZ72JWUZ@\\A.V4(V[3DCS'J5SJ?11Z5
M)&N2;%2/D!P2!42Q6J4ZK4:+7#5"OPU<C7I"0F#!86,!BVI";F"G#IJ=D4 #
MCH.G)N0=>D9J6(2X=*2#[YIK[Q#KCBD39<1&(C$2B#R1^G_Y,=6\L2I ^YR'
M5N =AZ33[/=V;'&5N/J_*.954@)DFIQ$U8>OV'HE1ZM6(]J4D?'Z_>+'(.-S
M5=NTPNY]*ZC+2+1S,LB7%\<XU1>%4>/H="CWF01UN&S$Y*O(D;9<[$5I.Y:X
MWBPJ9:-M%OG7T_=3$]([666[M*-;:&9''91)4Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B4N^7?E-TCL78>=>+WBS:[1#CREXM]8Z7=^<CT0NY
MJL%#3(U^^T(47I@Y];KDWQ21G^;=GO/-^I5ZJ!>0O#9<W?*^@NZ'W"7A$FOP
MU^G#%^*W3ANP%]/G;;9F>!UKA0E<9>M2ZQ!5Z,(K<L3"@R5SN5SL\O1JE,UY
MUGB-4ECTIY77++<(O1UDD+,?,)1+-\1&(C$2HORX\Y^FM==JWC=XDPD39;>\
M]!3=^OLO6Y^]U/5<G9FST$&$K]>I,K%W2?J(_5X^O<\[_P!KYKJ\;\6E6F%D
M[=2I!9D@16$?O]_V_?\ SFKP2\&*UXI5;\6/?(F;S8:CRR!<"F(/FX[W/H;F
ME=L</5JUJ9Y[4ZK'WFYP<;=)ZKVCLTD FV]&B@H1N7=;CXJ/"91^_P!_O_:6
M%8B,1&(C$1B(Q$8B,1&(G!=4^G5X_4?R-LWD'4F)^NBV^SQ?49_B\*6#&<=D
MN]1(TE&A=S-KH4>Q(&7(:)EC_M(0J7=H(=J-.Z6-46^F%*MR4XO_ +7^?[U_
MM.],3F,1&(E5/GCYH]0\6.T\(ASX,2D^.MW8E1[#W.;E:Q$TM^^.CS#+]#NU
MTL0DTWR<:JTD:3ZC4%A4R[6KNU_B:SR.F1H/NLVY)$U#P;^GY5HK]E_(7NH4
MOTGIFR-VJD2W5(V45:EFGRHUGB.TV>DWN.-L?#>X6D;4&QU;EU/M#O*E7&DU
M_H4;4JU<DM@5Q$N%Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$Y[\D.%F]TI<6#5^BVCD/3Z)8AK[R/J%5>>(=I
MM]C8Z2BPRK!57#!8/H5+EHN7E*_<J%9DO1%BKTJ>PTY%3+<3.1:)K?COX\%\
MZ-GNN]@)Y[T+RIZ2PEKIO8*IS:NTSX8%K0'X+RBEF,B/W3?*J8W&!-P0=SL]
MDGI22;+L<P?HLYB/C$3JC$1B(Q$I[\T_J 'QM@F?&OQPA+[9NK20MEBDW"I4
M*4M3'[8TXP5V:I5$K4F' Q_=080P=FC^2T9R?H$;U3A=:OT7>X<5>J]<Y_G2
M))?T]/I[U;Q,@):YV**B$=0ODNY<-U2-=5*5#AKDW%Z$.I% +=TP%+2T;%O,
M46?ZT#7ZC8>CTVJ4B*L$4P%6(X9*/W^_W^99SB(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$QTI#Q,X*D&:BXZ7"0;&R2 Y0(8\5$C#2 LO$'H'+:=:2;%2H04G&E
M)1I\&1$%-%<:)':=0B9'$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E:WD#Y2\OZO;>C^#%3ZY>^%
M]8N>G^453O;%:E(WGR.VM5VN]'FN#5>^IEZV^3UY[E<_#6)V*K<O"2ZZS8Y)
MV@W!J_5.9%K:)KGB/]-JH<Z@*_?O)Z.@^Q^3;%O;OA=Y<GYN9A:S98F6KQ-7
MFZV$+#<YIC_0PXFF5&'M78HSDU+Z#T**B!X&]R%ECVBWI5$M,Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B8J<G8.L0\E8;+,Q5>K\,&_(
MS$Y.2(D3#Q4>,C;A)TE)GO#A ACMZVM\DI]IEI&MJ<6E.M[Q$JJ^IYY.7"BU
ML#QLYJ3<Z1T7O0$36ZW>H.)WNPV",NDK(4R8B_'<MQ]J(OG9Z!($5VV7SDI$
M[SR]G</E;5=^3W *RU5V8KJ)]7 ?I8<<J;U#Z7U*&+?ZM!VFJ=#(@HVZ&72!
MKLO5FZ7.5;GN^G62LP_5NI<_YAT6H#6OF1G0I)=IBXD:K\_FY&;H=#J-?BWC
M]_O_ (?\JB6P8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(F"M%7K=WKD[3[C 0]JJ=HB9"!LE:L,<)+P4]"2HKH4G$R\6>T^%(1QX;SP
MQ@93+K!##BVG4*0K>MHG+'C9X=P?CC,2IPW6.O=-B8R+<I'&JSTJW%3L-P_D
M:S6)IOF]8;]6G;,L:;2XR/?[TNQ=#13HVI45=C7!5AE)R)V)B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
*1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>business19a.jpg
<TEXT>
begin 644 business19a.jpg
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M<*8:L$MDV+8*J+5.W01Y])$?VB:G J' !P < ' !P < ' !P < ' !P < '
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ME&H_-CC5+2!+-;$+N5HXY;G#B M1^('DY$&1$5[G?+*V697*QWSZ<BSR%NW
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MY@R2(F39PV3(F31@@^*%7[Q^[<.% DS,SN>\QT;@0' !P < ' !P < ' !P
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M ^<X@WU0O)3^P'V)^R7 !\YQ!OJA>2G]@/L3]DN #YSB#?5"\E/[ ?8G[)<
M'SG$&^J%Y*?V ^Q/V2X /G.(-]4+R4_L!]B?LEP ?.<0;ZH7DI_8#[$_9+@
M^<X@WU0O)3^P'V)^R7 !\YQ!OJA>2G]@/L3]DN #YSB#?5"\E/[ ?8G[)< '
MSG$&^J%Y*?V ^Q/V2X /G.(-]4+R4_L!]B?LEP ?.<0;ZH7DI_8#[$_9+@ ^
M<X@WU0O)3^P'V)^R7 !\YQ!OJA>2G]@/L3]DN #YSB#?5"\E/[ ?8G[)< 'S
MG$&^J%Y*?V ^Q/V2X /G.(-]4+R4_L!]B?LEP ?.<0;ZH7DI_8#[$_9+@ ^<
MX@WU0O)3^P'V)^R7 #KW7?O%5W9&QYG4D?@?8&L;%@D)C5BF8G?]&SRDS3B%
MRX[(8T!D(8?.QPQX7&/#D4D W5XT0W;8="GB&%=E6ZVF@38[$? [D79:_M(3
M+X$!P < ' !P < ' !P C)VFNV9T77Q"8P6&Q^P"X8!+I<^B)"1&1TD, X<%
MR0<LX='HU%I:?D)%Z3<AQ9%^F/1#0P41<RL\X6:CTA9()(K]&[/W^L84%V[A
M<]=V)%*O$.Y=9E;P;Y;FXJ_(-0 !)J2&A34-TVFZ:9E@\:3D$;;G@[Z-CI(J
M&&(J(S5A%3SD:#?@MSR[._N'#V/>.>'6< )1JIXF\;R>"]62)0<9L(J%,?+O
MMF&.K0D< ;-8.;U>0>*GAPEE*Y2OZ"&X-W,38X%NXKU41* $5^//U9^_NZ1J
M5L=[+<Z5U&'DW:#JYV$M]]B12)O*+%Z\C:,*0$$WE-\%J\IX.^0E]Q5N99OY
M()-0'06S9ACJK1F8'[2HYJ?U.>[A))UMQD70=[^HCOXR&R_."6[^2R\C?Z$Z
M@?S@<"=0OGH[S^Z'S@EN_DLO(W^A.H'\X' :A?/1WG]T/G!+=_)9>1O]"=0/
MYP. U"^>CO/[H?."6[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_P!"=0/Y
MP. U"^>CO/[H?."6[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_T)U _G X
M#4+YZ.\_NA\X);OY++R-_H3J!_.!P&H7ST=Y_=#YP2W?R67D;_0G4#^<#@-0
MOGH[S^Z'S@EN_DLO(W^A.H'\X' :A?/1WG]T/G!+=_)9>1O]"=0/YP. U"^>
MCO/[H?."6[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_P!"=0/YP. U"^>C
MO/[H?."6[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_T)U _G X#4+YZ.\_
MNA\X);OY++R-_H3J!_.!P&H7ST=Y_=#YP2W?R67D;_0G4#^<#@-0OGH[S^Z'
MS@EN_DLO(W^A.H'\X' :A?/1WG]T/G!+=_)9>1O]"=0/YP. U"^>CO/[H?."
M6[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_P!"=0/YP. U"^>CO/[H?."6
M[^2R\C?Z$Z@?S@<!J%\]'>?W0^<$MW\EEY&_T)U _G X#4+YZ.\_NA\X);OY
M++R-_H3J!_.!P&H7ST=Y_=#YP2W?R67D;_0G4#^<#@-0OGH[S^Z'S@EN_DLO
M(W^A.H'\X' :A?/1WG]T/G!+=_)9>1O]"=0/YP. U"^>CO/[H?."6[^2R\C?
MZ$Z@?S@<!J%\]'>?W1*/JCV3B_;FBXO?,/B,[@0:3'[+BZD-LQE'!\YCIZJ+
M1FE12T:?:1*33&.IK(RN"&LM-Q<E*HKCMF;A15%=59J@%3+5.W4>5^)$?$B/
MCR$BN! < ' #D$@H"E)7*WLVD]80V024FV<MB;\R%:D42F7D7>P9T])C'>JH
MDB76@Q(A"-SCUBN9S#7SN*8?X .%AVX!LZ=95TBF@BW@T3:(MI:TGB*+(",9
M):35@S0'LY7[)JV1TVD#9BV;-$BNVNSS5LW01]M[-)/74 ^"#5!6%9D9(6@$
M&CD2)2]=%:1/ HY)FL2U;$#1=JSVVT].&PIH8DLF,LP[/#<2T,261%F[)(@>
M+.7@!!VD/QJ/D$_-<\>?_,O=?@6/T$_65[$#6.\?=?MUUP*!6-+]$9_<@1_,
M&832=M2C*3!CK!0<T=J(BHM6;N43J-.W;UPX%-"\Z" AJ;EAOLV9&/>TDDO4
M,$X,PGB)MY=9QQ H[S<1;QP5M+C/,+)Q:"4[*J28L&2A"$I=6S">?<-+A$I;
M.HHSUFL5>J0%(3$HS\M"G203Q*)Q"TFDE'JMQS<?;,U&:24\A";I,R)5R(29
ME-_6O&^J%XWW(.OTAKBPZNJ^T)T J67R:(2]W)'D'@3R6!==B=7'Y.VP-.DV
MVP?9EHLWDJ66KK;X2ENLQ]XT.KPH,"7L*=5XU;C[,E>618LZ(V2S6M)LFU/C
MQWC6E*4K-:$K:-+B22XI1+).<B.O/MDN1%<AK-5C:==8<5:R3U]=AQQ%C,S*
MRC)1&DS-)$97X[K?U@55*XC7.+DK+M3.;?WK_6&CR.PRF0D.<R6"7C8[Z52&
M=P&.6.-9U/-(W2A]K40O:(RN=*R(:[9E)7*01)6113%CM6WG:Q9]/(K9\<\[
MF.'2+R<V(7J@Y9=9T/$V8@B$:)5T6L"TR7O;R9.>M-9]I%FTLA\;KQRW81%I
M!IV6!('@T^*$"DLC3=),(TCA]*2#@&1%O/GPY&9<^C]XV@[Y1FT796=)#5$2
M%>'UP8FS+14(<D^)C)V58]APO6Z<(QR.3.K8-')7,7<Q/-"==PJNIW/7<M'-
M7X&0$8)8*P"%GP:N9%?>1>LK\#/(N-['T9#HP;NA/F]*]MK?FD&@.%:;.P6/
MT]%:NEYZTUK"DEF=<^O]DP&$Z%A46'8EQF9VE=PF%Q(M"1>[>1MS0AD-$*KL
M=#4E"+;K7S+[3Z>CF.15OY#K(0@X45+*T:SF?UJTL=#L6>-XF77DN-8UI:5;
MPH?*8_3,TKDS*F<BM6M;7@-Y1J RUU"63$!($1#N4-=EQ[M<),B+U6X[[\<B
MWD9?8-,">0KL0ZE\#$OH'3FYE[7DMG<RBSFT'T/@R@R./NT&R>\>GA2MSLD;
M&$ E%M'Q1D^CCP<X<++[^\QX.Q*ELA%N.=NK/APOQOSZ1V%#R3NBK2(E@5)M
MMA%M2<S!:?1DEGJ1V4;RV.7U5/7DU]VV,I5T9VI^*_+"U1I4/(1!&SWI*/("
M\N(^-D$NC$?(!-BY[M]BZ#/[,[D5NP9?K9WIEEF2\%4<YK\5BS)/:5V-A[F)
MRY$M$T*=K^YNT=?N)HS)ZQU@J=95\3HN+UL:=MV+;8V:LZL)*_\ DVG-\"AX
M#+CPR[[$?9OOV#%3[NU/X+8CASH%$&H6[L*^*W 1!VHG'%_B]:R[KG3D6(RJ
M:;LC"L9CCRS+(F4KE4GT!ED@=8+B":($BZ".,&0BWLOZK^SUC2"W<RZ['*7*
MR!.@E'N>NU?2.5&!$3=US;VEF2N+7M=%,3!9E*[=)TA'%:DJ9"GV$NLUFT7@
M4_R/LZ-CL2>%FV+,7*'CH$V+I.YET'P/IS/<7#(]_":G6:^WUUKSCWK"#D6V
M"TQ8L+)MA^XW*D'NJIH[-QPDJW466SH<#R#$HURGZ<*(QAY%$WJCPGA^1>!!
ME;U^H[>#]PE9P(#@ X . #@ X . #@ X . #@ X . #@!6O&?QP-U_Y;?6/]
MYWMKP+'Z"?K*]B!91P*AP < ' !P < ' !P TJ<UK7-G#F@BRH!"K"$CWOQ)
M@+G,5!2P<R(^[.&7Q!HR/L"#9L]]S=NVGO2*6B_NSIPA[3V2RFFP!F4(Q&VJ
MFBK6/ VRJ:9M)-1 2P14T2DKU E(T]-TV^NVJ<@(M6I WIKG&I5ZV0=/\+KH
MIJ:@&O:U55^A^*RO6MX%K*(*'3CL)DFL/CVI^'1]%H['I XJ8P.P1CP=)@0?
MLDQ@ARS9:-'KMMJAA%RMIN 01\N_X!5E?[T^I?[W]#\"R/2+M]AB2O::T[^J
M.N59-UVZTO.T,TUP6]K"&=GP^KU&#=F"(D&1'8A+M=]#6'95LR$X#!TU"JN7
MWMT-=L)9UV""(C.QG;I,4FTMY)/*?9?6"1SOLGT0.]1RZ=[TK7+6V6KV.5V_
M;1N?]B*3K4JQ"TEV:<%"R9]]')U)18:R)4X5JY,QJT,O$FK 603T>,NO[.(N
M:4$=B5K9&>7.QG:Y96W7X]HE%5'?ZT6\H6K&1MF,XEFUFR.K@,@L&:UI$HD.
MV5?QZ01<K:E@TO#YG '9G:('$Q*)&KMU8Z]GI2-U(3CH>?8D980%#^R_MW;N
M/6>5[F0U77R*7@^^6M@K,0L?J&:V9U;J*L';(>TD.:RLBP&%$R"1"B\JRP:L
MYO +I"6--6]66$_# &[4M&XDR1;K$K7BH@.$V+IO8SSZ+V[<LRZ\QLLK[?W/
MUDL>\ LIFTK[$MX=:<KK^(B;#TK*K8@.BL(ZH=:^R,@/'YA4_7YP5VG[PQ;Q
MZ/@D2*86!M((Q+R0_E)[#UGA@%KD5B(N_F9<SRRZ3O8BWCJ)'O3;<X,U\PJJ
M#U0)WF-_2FM D;EEQZXL!\&K.P9K5DW6LF'#JW.+UZ**&X^E)(L<BA*?[.A*
M+$>14#O3R&$P6L6=[V(^C.UL[].?([\AZ^P_>&U6% =;YU1\#..;;MV,.[S.
MUM%H5)KH?I5E5488R>P86/WCD=3<HZ3J>':ZI(989@+'F0)G8J\U52$/PR3'
M0!$1GORO:^[?^ZY]EMYC%6?Y&+"2CDHDM0UQ5Q:%O3#H-4ECG[5/>Z2S00*I
M><.I+(HVSJ_9".Q,W [.+J"'S*42 @W+@!VST;@:<6=A0$GF=N>[+,R+CS+/
MHXC1Q_DNGT*<W%)Y?# ,]@,$,/![:*AYZ,TO/15A'KG.9UBD%%UP*'38,[VJ
M=TJN2?FH\Y#@=C1#5,VI#2BAH&J1V.]KEG?=D9$?'QVY9FZO)!9L9A5Z@(S"
MZ5$635U67',E9VVO1625>LI#:THZ7Q[[F!9]4H_[ILW3=]@8S[[ RXJ)M%%
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MLV"<\[W[;]/LL?4-^1D74"Z2,DA42D@:7)]B"4R&&)= 9(V=,-IFUK:%+DP
M^0CB.[P.7L&I8H-EK$<+;*P^Q8;7\A-$\%&:CC4^#,MY;K'8R]9^S/G8==@W
M4_KU 8+"J['U3"CD>KV1'9C$,3",@)0\ 3"3'WLH.R<(L5&+(QXJ]./W#IOB
M.-Q# ,VU9" #(4%&#!S,%SYGGOZ>L=6B%?Q*"+29>+"$!2DO-M#YWW?TZI.'
MPV,1Z%"4FS;7U6HX<'B<3CH$8,'HMF+5D+2VT0RZ6=N' 0-SX . #@ X . #
M@ X . #@ X . #@ X . %:\9_' W7_EM]8_WG>VO L?H)^LKV(%E' J' !P
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M3SB&R49$:C2C6,C6JQ&9(21J.V1&(?1[R0]"[PK61'(]:T4L8:W+BXTI53X
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M,:C@9GC?#02"!,&XL2-;>TW44]@Q8-6[9+VBBBF4TM<[[[[>G;(!GN #@ X
M. #@ X . #@ X . #@ X . #@!6EXC/P( /YR/?C]_GLUP+N>F?4G]DA9;P*
M"NKR8M 1&E*_&R>NI+=4?>W;&L%Z+@;$^XLBYF3*&6"45A<!)1D&6,@2K#W#
M$ZD3U$A$696O(=-(D8EPH-)""3P)+KMEOX=N_LZ;#M?2./%HIU9J  9CIF(.
M& 8QAC$9*.?C95%(^ZE1YY%8S,,E0$7*&9F C+@0)F$M(@V3Z;25F5F+O9XN
M<4?.0'O.WC]W+H$JN! < ' "M:D/QJ/D$_-<\>?_ #+W7X%C]!/UE>Q D-=O
M2GJKV+=,R%QT?"I>69%TCFIS1L]CDA>$$6Z337XQ(8F]!&CK+9JW;H+"C3\@
M*<)-V^B[)3""/J8.IX:H584E=1ID:0XEPG-J25,O*62226T>CJ:==3JD230X
MM:#)*2-)V*WK> -/>F+1>R_&P-I K]$AOPET\Z>;K%4IC$9QU;ZO(:968]1@
M4Z03SCKB)D"-&F-+==4W(0;KFMT0[0E1FZAGU%(0:/Q>L+*B4KA<KC,(%L8<
MT=AII'UXN?W;8C[9CJS)N0Z^6Z91#3#U'9%LIHKZS=+U<K'BQHC>QBQV(S5S
M5LX[2&4:QD1&K4;2E.L9)(C5:YD1%?(AYU6L0U[$L[SGB.MU:OU'9I9\OK51
MF529L4+<<0SY3.>?>)I+CKJTMDLD)6XXI*2-:C/A;OJ3+3)*,RZ4=H[GD]C5
M\="&ZVE1 ;6;4+$UQ$+L^O"#U:N14)800[(YE$K=EK*9R9\&T?/'+>,J1Y*,
M#P"0MQSC$7Z"]?=OX6&BX\;U0-*MTJ<-,K%%!&CAT[%D\.HP\-,G2G6.+=6F
MCA55S&<L'V[.(Q$5)<ZKL,).93LZRHGJ#W1#H ONZ/>9_;P&O%/%Y2DA9V9'
MI-+)L8A5JO)II*8WHTA@M\[C%G6^.O&RX9M-1\71FJ(*6S@,&:*;C3@TFRB@
MUL,U?N#J2$G0"249?9T96ORO;F.QO>HVN:?["5NC9TED!R^!\=(.9;+QD:V5
M%6'#Z7K6H <P6'Q,-&&3Q AK4<+E4D!HH-!S@QDZW#)!@Y%L,'A%\R/E[[C3
ME.AD=D!ED>E]E3QPD-LTK<L<A[#,*V"0B<RWL96_9R9-11[2"BS\F!.IO68D
M (S)==G;.+&)+C?38B\!+1@%^@MUKY\K<^0XNV\87PHL-CP2]9LQJ4Q2_82F
M["!-1D"%K*1.Z$NN(#:(UU#A\!Q *Y!E(S3\F*2HI"A\65:SDL,*1V/HAW;P
M0+"=;VD?'A??G<SS'1PWC;KJ*R]*>0VQ9I')9&)Q*9[51?0#71-Q7A.<R:22
M28C5'!.(.'\P!FTY64C66$@?;[-H\W#.M7"DU$MYED(N=K>_@1%SZ"/]V0V!
MQX\ZP)$790_/+*D3TH3@I8XZ).HJU<G7L'D74N3:N'^P.+!V[=60D.H,)^-9
M#-A2*>DKF6 J C"@# (%^KQ?WF-H@W4PO"3U (O+3D$]B-"&'<CC:DJ8Q8;(
M62T>HZ1=>:YBK5M#8G'!+\,E"+*LB13 \44V,OIE@!\*9-0"V1@(%]^5K\MV
M^_2)J\" X . #@ X . #@ X . #@ X . #@ X . #@!6O&?QP-U_Y;?6/]YW
MMKP+'Z"?K*]B!91P*AP < ' !P < ' "B/1U"<^6%P";FIZ[M'[M:!PA!QYE
MJ\Z\-*X1ZJ8RUDY=)I+5G8F\V\D>8?Z10B*0W7R19RW[G&6+T?<>KP?1EX[Q
M:_R;=&7,\_9EOZ-^\A>YP*AP < *U/+O^ 597^]/J7^]_0_ LCTB[?88L&E<
M+B$[$K@9M%H[+PCE-=)<1)@PXX.5T=-EF;C79F3;N6^?;M'"[93.$\;;H+*I
M9SG13;&>S%F2X+J7X4J1$?2:32]&><8<(TJ2M-EM*2KY*TI46>2DD>\B'"XT
MT\DT/-MNH.]T.(2M)W(R/Y*B,LR,R/+<9EQ$4=^@W6Z.5:0K2FJ_CE(+9FT.
ML^/S"% AKR1@;&KR<16Q8=(%'<B2*.#(YE*(5'M2<:(.\BBT?0>1[.K1F]WW
M3RE:Q-7\1.)=K56FU!2&T-)2^Z>R2ALS4@B9;)#)&2E*4:MGK*49J4HS.XZT
M.G08"33#BLL$:E*,T(^49J*QGKG==K6(BUK$16(B+(:C/>E,KMEH>(6!V(.'
M)3/H#<=.3MZR@PIK#6]+7J&JL).874T->'RZE=$]-*B F@<J+R6P5-)+()D2
MD0J3LGL:%1/!#O7W9%E8^Z_O']F^@4/*HQ5-M/#P[:+G9>83SH*9[:/TIUV-
M4[!R)HYV:NV+Q%91P\*Q=@2:O4G;3#U.0J^]/6ZC1T"_V>HK>OCS')1_BUC>
MD3A\:,W3+3#FN)164R@9QT!;ER Z1T)&R\?HE\96G)V</2;**.)+)SDOBPA_
M&81,7A7 D+%X)%,EX\;"=;H^PL]^ZW"Q9F??:TD273J.2.$1.N);.YD[A45[
M"6;V"481,W(ZT,G"<YF%G6#'HX2F$%DP:5,6%?S:R$Y0))1TL$?D2\*B2K[U
M&R!1J3"+\>@BY\"+UV]8Y, \;5>Q^OGU9M+!F"D:P_ M(WEPV8.RL7@$)B=G
MU]75?-2Q#=\])CX/ +'0BPPL75=DG;>+L'C_ "NZ($=E0G6/HZ^TC]I=69CT
M(^/'30P7)*W,04:ST3'(_;([2 AT\R<*%>5V5?(1 BH97(0%X8)5TT1R^RO)
M\#PQPL@V;[2%I&Y2!"".W8=RZ]V?/H]=RR'MC_CX4BCRO#L?NI^C)Z6B$&JF
MG2)*O )04"J&!0JXZ]%Q^:@MBS=.?31>,W;)MG$ZR^CK34P#C#M"()C'-@!9
M^$ZW,LCW].Z_>9#8.I/3'[W&PI8?4(;OXT$K*IZ@JIJZ((/GJ3:)5K6\(M*Q
M5FK42-;1E]<>E04VF=BC=R9:MR=68DZ3])U+B+- (,[]]S]=NZY^"'+U.E%D
MU]&ZTEE9E QJX:/$5%7%=-3!)-*+8@E%ONSD1ALI.-'0S1242B3U'V.*,I=&
M'!B(LQ\I:_' $S]Y#L<&0DCWWXWSZ3M[#*_'J&#B/C(?MZ%CM.22TP;)L=B]
M0&[72;5E%)L1%WQ6-.P6GM['HR:R)J(Q7&"L5KZ,QLHKK!G1)4,-=/X4I61^
M0%'V &>>6[,BW[C,SL>>>_C?IN0L%HFMRE;1:3MSZ[-:03:U;7M ND.657'#
M=K#GIR1B C559%OLMN"C;L(')/-$$429EB2*HHHI/M$M @\^XO':.T\" X .
M #@ X . #@ X . #@ X 1W[,=L^N73B M+0[-VU%Z@@Q&0,8H,-R78@MDK(R
M+=X\:AA(L.Q)F2K[9B/?D%DAXYS[H.8O"#O*#-LNOH$D1J.Q$9GT#L<-F,4L
M2(QB?060B);"IJ $2J)2D ^0) Y%&S[! H%-B"#;=1N]'$QSIN\9ND=]DUD%
MM%-<YQMP(W;QLO !P K2\1GX$ '\Y'OQ^_SV:X%W/3/J3^R0J(\C/7"P>RWD
MI+0&!]:'%S!BXWJNA.>P>WRY -^LNHPK*B>L(>(!9]%14JA]I"MTEK"GPD<0
MF5<14J3>1P=)Y7&(@.%!*3LF]['G8C_.O;/L[LLSWD=GGD*@L^$=+J6KQI*K
M2E=H1V25[&6$NJ&3/HM?,QLX#4<Y&QPU7CE*1A7;PI);":!WUE-LO2#X?3+R
MTI$Q30+@V1P6%4GF9Y6Y&5RM<CS^SIL)?])2SPYU>JLH[+2HVFZ:2? DE/Y.
M_F%CKQI";25M$T[1.$STF>;6JTC"(AG: G<RY1CD_;R..-$!S02@-:!![SW=
MF[L$J>! < ' "M:D/QJ/D$_-<\>?_,O=?@6/T$_65[$"RG@5#@ X . #@ X
M. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X 5KQG\<#=?\
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MF1_)\9(1"B11H2$$-R\BD^<,PBWR;V*_KWEPOUENX$+P.!4. #@!6IY=_P
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MD)DY!)2/8$XB3)==X\>/9GR)39*C-1),RR(]YEQMUVMWWR,?INX'&' !P <
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M5P$F^! < ' "M:D/QJ/D$_-<\>?_ #+W7X%C]!/UE>Q LIX%0X . #@ X .
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M7]I/_&8=_P 'L/\ S><?Q\Z0?[32_P!&-??'+_)@T4_V*M?IE_[@?.7]I/\
MQF'?\'L/_-X^/G2#_::7^C&OOA_)@T4_V*M?IE_[@?.7]I/_ !F'?\'L/_-X
M^/G2#_::7^C&OOA_)@T4_P!BK7Z9?^X);=8O)45F$P#0"\1 $?F1/6XH).(\
MBX&M&Q1VIJBQ:R48Y=O4=&SYRIHVU,,%FB#!39#WQAEKNY(-/2, Z=Y-3J<6
MC8MC0V?+G41HE6A)6PVW(<,D--SX[CKJ";><,D>5,J:0RHT;5C9&X^WY!I3^
M#'$HU%FXAP),J$CS:PY+G4&HK;E.NQ&4FM]VF2FF6'%.QVDFZ<.0AYR0DG-A
M()Y+49ZX/GTT/C0. #@ X . '\*I)KIJ(K)Z+(K:;I*I*Z:J)JIJ:YT4343W
MQG7?3?7.==]-L9UVUSG&<9QG..0I*5)4E224E1&E25$1I4DRL:5$=R,C(S(R
M,K&61BR5*0I*T*4A:%$I"TF:5)4DR-*DJ(R-*DF1&1D9&1D1D=Q6)W1FD_KK
M2M^K]"V!*E[C[GSN2PF*BG#QN^-TW5NH)T^O"\8Q+G31T_B@*FP1)N9C:4@:
MRYLYGYB"P&.M1+0VWV%ZV='JT3:)H]>4RT],5*./682JTU&9<-2GHD!:)U,F
M,,FXHUM)DRIK<4K,1VVHR4,IW!-?H4\VG,0881(>C4]$-,K#U11AQ^8^SJH8
MFU1IRFUF!*D$TDFGUPX--=F'K29CSTM2Y"Y5]>NK\#ZZ0.OZZC"RY>.5)'FT
M0JQF4& 6R<"C+4<F)W:AMQ@QH\<&#K1+5S,).8>DSLG+KOR+QVEA^NVSVHE&
M-N8JH5&8Y5IB'GUT]<F/#:;I#+Z=DXQ3T,,(<1M622B2^^\^^_8RVC;2MD71
MGXAVM/12J33VJ%3W6(J*JW$ESWW:])BKVS<JK+E27&G-C(-;L.+&8C18NL1[
M)UY.W.2?,V-;#@ X . #@ X 5I>(S\" #^<CWX_?Y[-<"[GIGU)_9(4&09VT
M@GDGG?9"+^1Z(#C=L>4%>@[$\>;:W6V>P4BCH;M:\ZY@3IHNYF3N5DX8&)-D
M[ #4@XK=*$@.O+I82#.,7N^3R@7/T2+4_-(]>QVS*_271>Y9\.!WU^2T =.Q
M[KXD_E?6(#4N;[!-;$:=L:A>692^V'D,GB#$Q8B[BYJQBK4$P:[D6D* 2$64
MQ(KX(TZ@RD4471P_V>#'&GCOW<#L?L/KZB,2/Z4&43W5ZIB#>/5/%T=!9T9H
M+H:,)1"CU< Y=( F3=/!T2QM)2KY1L.S)H&>3(;:2R+EQ<KU:C<&OAK0(/>>
M_MW]H\61<\ZK^^@L.6'0A6KG_6'L-<JKX@2?AY%B84M+:$%MV)(^\SB,QR(N
MPMK%E'CUPR*._>6B3]58<R%KMRCQX]86RZ;D5N_Q_$<]V[5367@Z6F4&KY:$
MQ^:]C U/3R+7(,)AK:C@,D-56T<.H4-<^QA\C?N]4RC!K(BC[&T)>1^2Z,E_
ME.@T%@MOZKETYVR\<!'.%7QV7[/+-@4(,5MJ:CXB 6U(P44>S.%J55()"\NZ
M)N.NM[$A-@O#1@K$ST>A[Z9ZA%(4>66CDK6W@;D>]" %@;K]V_JSW;CX='$>
M[J/([%DGE#\E*]CULUK-Z,I/HV#C3!K-QLYUD\)%S'NHC&)TJ[&"Q:8%>4M-
ME'BL3=)NWP#9/W9T_=[[XWP$GZ*;9YJ[[(R[!;?P*AP < ' !P < ' !P <
M' !P < ' !P < ,')I* AD</2Z5EV(",Q@01/R X37U;#A 82T5?$B+U??\
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M6CY\ B(BR,[FDSM8N7/6X;]VXKV(6J=^+J=T/3(*8KRYA (40L@#%K-G#N(
M9TZC,+- I1E%V*C<K+"(P]=OYFTB )_N;4>HMX^6-+CA9 [H);[!4BN?LW_8
M1\+CLW6:R =NT575B1J<KV4$D@AVHQG+F/#(HK(=1Q@D(6=YCX;_ +)&Z).1
MZS-%,=G9FLBVT<MU%$U]=]@@QW;@ X >,:ZZYVSKKC&=L^MMG&,8SMMZ,:^M
MMZ/Z\^KKKCTY].?1C&/ZL8X 5KTA^-1\@GYKGCS_ .9>Z_ L?H)^LKV(%E/
MJ' !P < ' !P < ' !P < ' !P < ' !P K[G6V>Y%T.Z989]ZZS4))QSR^B
M6F<J#;?N$,HU-1RB&RFOI;/XE '.!LMMW3.SA%\<Q&X(X1TU2DB>NI2C_**I
M*IJ/E42E/(55EEFBHU%LTNLTHC]%<>(K4D5 LR4[L8ID5GB'TKAY):#<!LX[
MDEL=+&D>D2F-'$51$F5@C \]+T"JZ17$G_.QJUB5GRNB8)61-.1Z>=5Q$TXH
MUTI9R![&WX,H.%L'K,&ZG-F3<PA":9J@,LDB?LNPB**FXT(SW4]*8L$-026-
MS*4.]<#(G%6!(R^VWR@W:NO3,/4)RNS%MK?1!IL)DYE8JCR3./3:>V9$X\LD
MYN/N*-+$.*C^<E2G&V4$6LI2?ERH3BAM$K54_)?7LHL=)EM)$A9&:4$9GD@K
M&MYP_DMMI4M6ZQPXH[QB0>)]A8YW;N6=S:PNVJZ)4Y,W@\L/%U*A+Y$"?QQR
MC%8RB 0D&@"(Q8CK"8J@4D:Z2X80/)DQN2BBN4]OK>DN=*P_(P71X,*GX42;
M3$-"VG':LJ)'?;D).5).0J.;\N4V<V4;48C2\\XTV[LB*^*AX=9:GMU>4^\_
M4SUUNJ2I*(NU<0IL]FV39.$AMI6Q;)3AD:$I4I)JN8M*YYB-C#@ X . #@ X
M . #@ X 5KQG\<#=?^6WUC_>=[:\"Q^@GZRO8@64<"H< ' !P < ((>1E;K4
MRZV.RW:^K;'MNIA,]@;G:-U4C,5)@SESPS@-#S+):"RJ&2%IJB:*(#4UFYY#
M19\49,<(.EWB"&X25[Y;^S[1%[Q(,*P3(]U2=&U!;5,TXXOJ( XM%[K'35E/
MD9'$::@X"QV9M6PI)+I:H[$39N48*L2YYPL'QJF/T:#D4TFB<%XX7R+^'8)5
M?*]MW1S/EX]8Z4!EU/2?R 2L8SA77 98<*F^ )1W(^W4B%7L6E?W"0A)*Q(U
MTY9P G C9Q>!'V<*8V4^FHN=J5LR,>E\W"CDXVYD+9<>[+?SO?LY]XM#W3T4
MU]533137UM-_5WUQOKZZ>^JB>WHVQG'K:*:Z[Z;>CTZ[ZZ[:YQMC&<!4?UG&
M,XSC.,9QG&<9QG'IQG&?Z\9Q_9G_ &_V\ /CR-'9<M'F6#++M@@LU8NLM4,N
M635QA+"[9HO[/VK9!;""&%D4=M$U,(I8WUV]GIZ "N'R[_@%65_O3ZE_O?T/
MP+(](NWV&+*^!4. #@ X . #@ X . '"K]Z\U[V+B*<6G35RDN/65>1V2"MD
M43D=?K::IK+,5EDET56CS1-)(D-=)*M'J:2.^VB;QJR=M=0QE@JBXXIB:=5V
MW$K86IV#.CFE$N"\LB2M3*E)4A3;J4I2^PXE33I)0HR2ZVRZWONCW2/B/1M6
M%5:@NM+;DH0Q4J9+);D"I1T*-2$/MMK;6AYA2EJBR6EH>84M:2-;#S[+U8CW
MQ(FL.EL#KO%J,O7VRWV>P5VBZPGG.<ZZK:(2==+.^N/1C;?3?&N^<9VPFGC/
MJ8\#=^#;*)Q6QQ:P;5SU#=H[B7-7@2B14%)N19&9'8]]DWL7U,Q\,"";2/*<
M"RTOV+:$Q7F7&M:V9H4Y2VUD1G<R2I)FDLM95KG\OS24G_QL _\ !9#[0\X_
MY-L[^]D3]$O?\\.7^5_2O[CU#]-QOPX<ZJ_QJ2"S8T[DC:V XE-I+)M%,M5X
MH]=[[JPR6%XJL\PJF;1UU3?J"=GB:.=,[(:+ZH[**[:94VP>']!$RO0'9R,2
M1HQ-5*K4XVU4UUTS52JE)IRG=8IB"(GE1C=2C5N@EDDU*,M8]DQ5\)RG86J;
M--=PC-F*>H]#JY.MU=AI*45ND0ZLA@T*@K,U1TS"84O6LXILW"2@E:I=%^:2
MD_\ C8!_X*(?:'F<_DVS_P"]<3]$O?\ /#6_Y7]*_N/4/TW&_#A*WK=X\J^H
MZ2,9W)I"XLF:"5/> *K@2D%CH!YZ,XT(M1&7I1=\6:^G/N;]Z_R@T4SJ[;#D
M'Z+9TAZ)@;0I1<)3V:Q/FN5VJQE:\-2XZ8L*&[P?;C;60MV2W_[)YU[4;59Q
MMA#R4.(\DTF?".Q%CNF2*!2Z:UAFB3$;*H);EJG5*H,W^5&=F;"(W'AO6+;Q
MV(^T>3=EV2Y'6ZRY8;SVL?.0< ' !P < *C;<<;>1CLHZZP <[/NE_5:;!#?
M;^1(Z^V!7S?<;<,)-!.I0UUC;+,O$*Z(:"+$[%IIZOFZQ1"%U8^T;+/)8@B%
MMQ7XGNYD7$^W<7:?(Q;CC&-<8UUQC&N,8QC&,8QC&,8]&,8QCZ,8QCZ,8Q]&
M,<"H\\ ' !P < ' !P < *TO$9^! !_.1[\?O\]FN!=STSZD_LD/?IXVHYI;
M&DFQV,["YH1*_L]IDNH>2E?_ '%4[X^Z5M=.)+J7^0/W5_DFG=6WW84JX^Z#
M\DD[%QJ6U9X%ZZA,!&MT%>UM;.]K6MOMNRW;A@_+E(Q,,ZGN)@<-,X>+CTCD
M.SVQ#"B6(Y!&T@I.X8<Y6/I+B2C=32P6TD6I>-NEE!&@*<V=%)-J625")M'H
M$YG:U[\/%^NQD9=%["0_1 JF=ZK5D=1DFLU0-N[$,H3MNDR:B+!1*6C-7Z5A
MQ86-%A6$?@\^3<:S"!Q9J.11BD,- HWJJ[^%^^. @]_[[[O'\!+O@0' !P K
M6I#\:CY!/S7/'G_S+W7X%C]!/UE>Q LIX%0X . #@ X . #@ X . #@ X .
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MZ4D_H.O_ (6'Q-Z1?H.)^LF%_P :#[[[KY_?4I^KRS/L=Q\9>#/I23^@Z_\
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MQ9_+5L45+Z(T=$EQ+LA#+:7W4EJI<=)!$XLBL5B4JYE8DEGDE.XN@<Z YPX
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M5HFU:?*/4*;)=B2VDOL+<8?0AYI9(>9<6TZC5<;6I"DJ/;^=@80. %:7B,_
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MVJX12TE5B1Z FDU&RN45<.XS/'D;DK#&=\>E'=\(;Z.4MM%VVRJ"B:FVRS,
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M=)VFW=-E]VVZFJVB+A!7;3&BR>VP2?HD7'65EV(%I? J' !P < ' !P < '
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M(=)#)WR+6=DLD5S,\DEK].Q9'EF]&V-YKVL^G^K*?C9ZE:9U_P#Y]]U<9_\
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M587%<"H< ' !P < ' !P < ' !P YG;U8C;?@SJ%$BQ,#MK(H',P9X/JQ5(
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M#'PU*(^W=#\,?>7K,))2L^.71ET[NSMYV'=X/XIO$[9$+B-APGJ-39V&SR,
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MRNV<F'(6&@!\=%N"KEFT'LW!)9B-04?+M6#)LJZV540:-DMM4= 'F9GS&\<
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M-7N;PK].>LF5:D7\:U,Z*O1P^XS :/56^(J(IJ-![2?'I''0T7<O7*")4I(
M;%MOLY+CDW(+'RY^K?W>-QC^;SZJ5;?B:2LJ;O!QA(W'#:Q9DRB\B:E=HLB3
M1$"Y)#+&C<YKJ4!&^2SAXB/D,.(X8&VP>3B%ALGCX$R- 1F7K]?CWY#J]65T
M#J&M8%5D9<E7D=KN) (8$=''2#PNN+CHUN+8JOUVC5@Q]XV;MD\[HC1PT6UQ
MZ&HL:/'HMF2 0>9F?,;[P < ' #C(NAZ^!S*#S$,U(CON>B+$'QJ,)OL.(JV
M*6<0C#R13!5B^0=O]Y@V:1M<"$,)E$=!4>EDU%(M=D9&[SJ#]WJ\>P=FX .
M#@!K4OA\;GL>(127"TC4>*9:9?C%U7*"3G+%ZV(M/659KMW&OL7K1LOK[-;3
MUMDL:[^MIG;78 @*9\7'6N0OB*Y=]96HU>1322B D9D@:O$0+NP)K(9_)VNQ
MVMXS$9C,V2\CDK]43K9DFF[F.,\>ZQ]R-^('%"X6UC[[7Z;%;B+'^!4. #@
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M9O?78NUNP4QV!>]_)\2[FSL6"BD:#*/V[1Z[2C%:Q"# 2A1RT9;')"/,G$F
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M #@!%3MMVR@_42%Q&:3?0:NRE$\'1=1(E*1443&QUD),S&P9;JZ*)K_$UHA
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M2T!7>"[30.4&LE5R3..QXAI[Y*HM)Y- E8Y*Y* BOQ+=?U[O'4,($\C-!&T
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M4>UB2'PE,;Z$6*S,%_'CK$D<8QC&,8QZ,8QC&,?V8Q]&,< // !P < ' !P
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MP7/?[^=^/(['[=YWZ_OU]C;PS%#;CNK=;F<Q H]K6+R/65]>5B#!YM''8M]
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M!IAVS?- 3)FN$EN,^1%NXWN6?>)V(]*8TWM,K9"$R>IMY!8X"QS03$:"9?\
MOT/L8Y;L99 91Z<$(]JO/)3(4YL]:-E7,W@^X6&/L,M!3HL6"+ER\<S_ (D7
M0/=(NHYPL-D$5$7?)8[ '-H%[KBL2;Q6/O,A[*D%T,[[+.I*9653>3.)MK$U
M-D(_%MDP6XQM)'K8B:._"8NH!!^[U=_C<,%,^E1.S6MBAK%NHN6C-L&8W,)V
M# 0>/QW)>;PN'@HG#R:!%9Z:=C@01S$XC+<Q]E[)R0DT>;8>'=XZ]*QY\ CM
MF19WX\N7[^GJMILL\:E:R,[-'S2=2\-'[#08 Y+%&OH;,V<+>X.O;%B<4+ 7
ML>."QEF2>2'9C)0YY_*X4XDALB_?PLJHPAV8B CZ.71F6[P5CZ<SOGY_X]*]
MG,U/RG:>6"W926'&(J1'R23RVS"B&YZ'6/7I!XP-V3*Y.WW:ZQ&UI?H*''@9
M_< ;^#N0) ;&VI2)&@7[^C+IX6\=EN*U-T+AI*967&SLKR8B%+7E2R<7&JPB
M*-C9S-:4GTLD8M"=R%%#U90))"JS!B2P;X2/9.S#PE+%<;OD0#,$#<1=)'[5
M$-S$^,B% R$>(#+2F#=Q'#0++-\HD](EUHC&I*,E@D2^?&)&2;$CJQ<8GL>4
M*#G]7GL;H$W=.ZRD/'I(("=8^.>1D6[CERW=5NL?R%\7]<-(^7!'K D4A2*A
M_@B*;D0R=, ;1"E;]HUAD)I)WTK.)[MHY?QXQKJ3D15%B8%M!<;2CD$U%PP&
M$7L=R\?NN.']28&,NV;^0ZN'*V8X#&'AM(#7;0:%?F5T8?V![6S[Y12AZH-:
M)S+XM(YX_0(A#[5PW?QMK\)-/31 N?.%0DSR(^D^K*W+=TV_A(97QN0TA,C$
MV,6*:4)R&8QBRBS8!'AT5#HSL%(ZT./O@$9$/]8>%AQ5"L!+=03F-OYJZ*DB
MTFE%D2PRXPKJ$7RMXY^_/I'<>M/4X-UJ+31\#FAJ1,)6*C8AN)?M,,VPU$ 2
ME1I1[LAH0=C$R) I,"RCC,9%1(8]U]!8^*/S8C(ID< 9W$MN! < ' !P < '
' !P < /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>business20a.jpg
<TEXT>
begin 644 business20a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * "^$"0#A"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@Q,"LP,# P.$))300E       0;F(:> 58=)+&2<A\C$
M?:QCA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           @T   =D          $                          0
M         '9    @T                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   @T     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (-
M   %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !#A"24T$#      ,Q0    $   "@    +    >   %
M*    ,J0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
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MLVR"SZ6M;K&;?[2J_\WNCO#2*G;=FQK6VVAFWT_LW\VVST_P"8]F_:J;PX=
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M[V^K9M_P""K_2V,5>W!Z9TS"J9=B4Y^?;+*F"FIMEUIE^UK6L9776S\^S_
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MZOV/U?=&W[-ZDL^R_;Y_2?S^W[+_@/M'\]_@5K)*8UUUU,;74T,K8 UK&@
M#AK6A22224I))))2DQ( ))@#4DIUD]>]#;1]OW_LS<?MD;?2Y;Z/VV?TGV3?
M\ SO\ @?\ N7^KI*:^)@XG4LK[77AT5],9/I$U5EV42/Z0=U6YF*SZ6,]EF_
M(_G?YCTO59N#@]2RPS#Q**NG8[OTV2VJH^N]IVOQ*6OJL;]F;_ -J@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MXU+0XRAS2VUW$N8QH<VS8A(#)>^G-M^UO9'%4 RS6 JO[$5GBS![KCK;?@]
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M<8P_<W2\,<6WONFUE8'=MN6< LB'5-4[:L6,B/5G9EMDY/;KV0-HJE'ZS,0
M$YC[!O'-V[W+TH^L!@N7DRSQ1C"!+30@X R18FT8)SJ)L";:  Z\=;]'@MJ>
MBXXJ(O5KQX6U^WIOH.FQU7&$^X,[E77H]:<$"UDI)U.T%=]>X@Y]_2\TK9\-
ML&\*TJ=I.-#038"^DXM(;/5I".7$[BFQQ-FR41V9MWFV$^72+Z7,@U&O:%X
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M[@4R5<E4)#&I2R=H-6F9[<>%B #_ *I-K>9SAY]%BO70= )(\]K^G='H\:C
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MN>/P39O_ $@U?ZNY>5AG@'?6@[!_.J _,H=S(>PGO/K?+]9ZCAJC+[H/\-.
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MPTG@,+PPG_SU8MR7(6!/)WS"!J3G#-@ ZS[PX#UZ+3/0/?/I[<3JNZSK'L!
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MY H>?NI(14?L1.BS]X5)NBRKIPLHZ?.'/I.-[HRWC5164&#8_3DT-5-!28E
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MN+W"G9RWE]:SG^/]_DNI_P"Z7G_1I[]?]W,#[?.X&">6'^I3K8=[G7\(6?\
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MZ\^FS+@U55TE#%43"JKF224L4U#7TW.MBC?+( ^HI8HVO9'&][HGO;(UHN6
M%M[CQ+95GK"<$QC,=;A%-[S8!/2TV+UM)CN7L2%%)6U,%'2.DAPW%:NH?!4U
M-1%##4Q0OIGO<X-E.X_=N.Y[RQXG"**W>CY%O;+\7*Y_T>R#XOU^+SYY>-]Q
M\6\FU_JDW'VXV5U9%[]\F_&K+WUO1K!@6_8LG^#WGW/_ '.K_%C^SD!,'[K8
M7Y1HO6HE^C3-_>EFCXNXW]6U*_1R;_YNA^XI?T->;$'<3XS\Z_- W@/$/F7S
M<HJIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*GCO50U>V5V-KN5
M2F:V4#T!@XJK):[C?3#L=V'JBXQX8K+U8F)N]]6Z#VJ)J-A9XT[E4+C4R'KG
M*]D:6LD1=H")"Y9$4)W)]X=L=]A#''=8V4!A;.PN.ZR=C6[C:AMGL#B"3N,+
M$QO!NNT&Y("X6<]T1OOPN:WMW0N)WGPF[7FY &\_>G7V)KR_;!^EHE2EJ1^M
MAT?FH4]/&Y0-(ER<G"L3@%?<>,+ Y$*T9(-PR,DU= BXLR(DCUX'0([,F+!U
MAYU[KBYW;#<,%5&VP(<R:6FFBBEOO$.YJ5['@%MVN&^+N:T+FPL:T;S"\\Y
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MHY7WUV5V]#91628ERB\AXA*UK):[.N"UDC&7#&/J3%.]K-YSG!K2\AH<XN
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M9OA%?M>U"?OJX?T[6=R6NSGO'RUY+A_KR+3=RH+?W?\ :G;_ *3R^GL2DO\
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MAN%A((YT20FH88K@;P="'/Z" Q[7!KVN:/%B>\U+%'XUMNWFH<>_>:[N9(>
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M/[>GK*TS<CVKU6<_Q_O\EU/_ '2\_P"C3_,#[?.X&">6'^I3K8=[G7\(6?\
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MY\L$QBMK,7PV!\CVQATK7-;4UKA(P4]0\"5D]5,QY#K&Y;O=J "  !O[LJP
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M=UK**SY]A?K#)_%]<RC_ /6"KW[?]GV/X^:E:#\I[-OQDVJ_4F:_;YEL<G^
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MJTH<0CY65V%'V9$:-CLV,G44X^RJ0)(C4>3G"9+1V'WF!2H0KP;:8":V'#8
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F"?V5L6GI<R46(I@<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>business3a.jpg
<TEXT>
begin 644 business3a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D"^9R X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!J CV
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              J    4@          $
M                 0             %(    J
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   J      4F=H=&QO;F<   4@
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *@     %)G:'1L;VYG   %(     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      /V@
M  $   "@    4@   >   )G    /O@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MNOJ?7+7BNO/RW/() ^T6#1H+W?2L;^:U&-_UH]1M(RLXVV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSW7FFNTAV<00T[$C2T/W0N*#?"8(:@:M>*+MKM_/EUY7HGX2#U(_D(V;^?\
MT?F'[Y?G^UKXF.!]X??3B=M(S:0=VSH'?(Z$\KY^Q4_= XJ-\'@Q>ULDU WJ
MWCT>!\%7\)!ZD>.?O#[-_#GV_,..?A_1+]CSU#]QG@0:'??7B0:2 '$0922:
M ![&K)T&IL\E/C!XKI6#P>NOF/U&NH^4\-]M"J?A(/4C^0C9KMQ_Z_S#S7M_
M5/W^[Z>-/B9X%K?%.)=T@.T@T+O-!^1T+N0.IY!/C!XK^9X/F/-?N+L>?OI]
MO-/PD'J1[K]XC9OA/_#\P[>7FORE\Z?:F@^XQP(@D<4XD0-R! 0-0-2(=-2!
MZ2.JOQ@<5V^!8.P+(R/L51-]_E8]HZA/PD#J11>%V'V;^CV_,$7_ -)?GSH?
MN,\"_2G$O9A^F_XD>'OJI\87%#=8/!?JO.O]I]B?A(/4C^0C9O\ O_,/WRT^
M)G@7Z4XE[,/^Y3XP>*_F>#_5?^\3\)!ZD/R$;-HOFO\ H_,/M_HDG^73XF>!
M?I7B7L@\?]ST_:K\8/%3_P!SP>]>:_\ O_Q3\)!ZD._^D1LWQ_\ "&8>[SY_
MEE_V:GQ,\"_2O$?9!^YZI\8/%?S/![_-?[?/V^GP3\)!ZD/R$;-\<<_T0R_[
M>?E+R_/G3XF>!_I7B.^FD'L_%;^]*?&#Q76\'@QK\U^GI[YZ>^J?A(/4A^0C
M9OW_ .^&7^?O7^B7V_MZ?$SP/]*\1WZ0>S\5O[TGQ@\5U_DF"/\ P/\ 5=R?
M9L4_"0>I!/\ B(V;3X_RPR_R_5+Y_GXYU?B9X'K_ #KQ+PT@^GY'7Z%1]T#B
MI_[I@O1DDOZ'E5_"0>I#\@^S?S?RPS#]\OG_ #YU/B9X'RXKQ'V0?NN6OOO/
MC!XK^9X+]1_L_&;^_BJ?A(/4CY_>(V;_ +_S#LGT_*7Y^>K\3/ CMQ7B7L@_
M9".:?&#Q7E@\'?\ 5?\ O/>_37I7Z+KTLF[77;OOE&UN<[;8#AU30;>6.916
M&+$7\U@0:'=TE9$-*EH9./[*Z*TFDD=X/6K(R)$>U/$C_I7EW]SOA?DMP>'B
M6"QN-Q$SL=A\.YDV0,RR0SEQH-!(:6C8^D$K[)Y+>5>.XUQ"7!XN'#1 0/F;
MV3762US0:.8BP7<QTZ%>^NOR1?H"+W_8_87G4(OV@^PVB\YO2?=86=]$/3D)
MO)MYCV+Y->S[@X[B<E;EL=E)5^P6X%V3/.SY*.KR4+BEK1TB5T[HO ^5'1N5
M6*W[KY!^3>$\J.-3<.QLTT,,>!FQ.?#EH?GCD@8UISM>*(E<30Y-%\E]:\J>
M,XC@G#H\7AF1/D=BHX2)0XMRN9*XFF.:;M@&]:G?5?GG_"/NJG\C.QG]RS7[
M/]LWGK]@^)KR=_/^)?K0?N/1[A?G_P 87&/S?!?V4Y/_ %?3[E/PC[JH_(SL
M9_<LU_A-]NI\37D[SXAQ'J-8=^M]CZ$^,/C'YO@O'Y*?Z/E=4_"/NJC\C.QB
M_1%FO?\ ^LWY_-J_$WY/?I#B7ZT/6_\ 4>Y3XP^+_F^"_LIOWJK^$?=5''/W
MF=C./_W6:_PFU/B:\G?S_B/7SH=]=?Q'OJGQA<7_ #?!?V4W[U4_"/NJC\C.
MQG]SS7^$WY_'5^)OR>_2'$O'O0_N$^,/B_YO@O[*?]ZGX1]U4?D:V+_N6:_/
M_P",WY\Z?$WY/?I#B7ZT/[A/C#XO^;X+^RG_ 'J?A'W53^1G8S^Y9K\.5_X3
M>Y/H]WQU/B:\G=/Y?Q']:'3T?()\8?%_S?!?V4W[U/PC[JH_(UL6G_R6:]O_
M *S:OQ->3M_YPXEZ<T-_]#IXI\8?&/S?!?V4_P"]3\(^ZJ/R,[&?W+-?X3?G
MPNI\37D[^?\ $:YZP[\O]#U^WP3XP^,?F^"_LI_WJ?A'_51^1G8S^Y9K_";\
M_MU?B:\GOTAQ+P[T/I_U/77[:3XPN,?F^!_LYOH/:Z^^R?A'W51^1K8S^Y9K
M_";4^)KR=_/^(^V'Q_W/+3Z0GQA\8_-\%_93_O=$_"/NJC\C.QB?_)9K[_\
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MI'V96RQN(S !ET*H?%8K"X;#XN)C9,0R-\.$F>T1AYA=B6.<Z)S=@<K6R$$
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M:^*-YD?E[1YE>UX#>]AO1+@&2ARXX<?NC394W&NFXH#=,IM5'LW?YIU)Y)@
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MN[,N[LJXRS?$5#\/AN!X+#8F?B)D?B)98L1AX7XP1/9'#C2#-F)9%/B7O,8
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M;<W-=@0"WFW6[=Q1.#LJ8_%:6VN<;O9TE;'Q$'KVX/@6%XIP;BF'9/POAL'
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MM[?VF:_F1?M":(O##^*#O]PE7?/O9@OP_J1E?S>Y/K\^..VOU?[C?_:O$_\
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M\'^.?HGB'_*3'ZF:*GZ%EZ0;R_C5=T>%7^IH7/"_/[=PG'P\NZ^6GX:^2?\
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M%Z,CTJ-9:T-[6;&[MUUWBU?%58Q<@9O1!6F.5D#BGP5]$>/E["J@*%YQKXQ
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M96D@.()!SAKG#F-@36]L#]%%Z2ZO>!*!TX;BA2U<\A=;()DN+#25Q<OJO6E
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M;OH ^U/5K^G7[$_/W)IE;\T>UWVJT==?1H-/?E^W6^2,5%3\951%YXX3\_\
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MNE?]4.Q%"-$0_<S&;-\Y.(C0A4=@/<'/3-\@QK&: MHP3Y9%!FM,PQI"R_\
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M^(O*\_M19<1N,2G",.H8!$@N@-P:V<VO0''QI*AP=?N-:A5-56/&H*L6LIH
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MEM0LUI9B0E@OGTQID>R)A[T\K(&WIWIY>RL4+#0YQ%CS=,M !-39.S0VS0H
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M;,>@R"9V-RVB2<[-][1O8/(.@)DS1Y "XAN8C-0>0UQH$V0%7$9'9:S=HRZ
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M=]./MO=1A9/?MMK@LJIP<@.VS21<OM+6G$-L\M46U/QL+ ,EM0OD:8O'BH!
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MJ_<+$HPS 4F9.?;#@QHZ>2)LE-AH<00"XL/]!X>YF1W(.);8HD97-)(ND(<
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M:]A0M',.7"+$6ZS(W#R /;F+*(#HPX 97-=-WR='90 !>O28AY@H "-LF8L
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M_P!GX?7HBE%ZN1KE8WQO1KE:SQ(U'.1.6M\2\HWQ+PGB5%1/-=$4<_=)N/\
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MQ LE\4>8@G4$FB0XG3B>WFF+0XNGQ;"V[ D^$RME% T<DKZ)RV:&N4"N]4=
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M_)/B?!?*+&<3QGP6/"<2FA=@6-Q$;L5,QN'C#I#APUL@C:YKFODRAK30+N\
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MB&Y5KB =!B7W/UF0D84^XR"YM:^82]'V1R#?@K)K26OK+-@F&BX[CQ5#-Z@
MRP?<2^U,D08=XLN&?*!^31V:<- LN#HFP.H#FYXF<YK=,V7*=25T+0UH<7;=
MGG!&ISR.9I7S6M!]=&J7TO\ JBR';[;;93/=R-LG5[]SSKQ,@J\?OX[!^'4X
M6 YGN!23L^6@<>(M;:V QJM *JWC@1T]C:%1$GR#URE$Z+6LD$>:RU@S.-!H
MDIO:,:0*(:^VCF6M:X@%U*LC=)GJM'-:T:]X..6[UZW>QO397W/^I&QI-C]Q
M-U,1P20[(-M[BWHLGP_*;D&I^2#L?D@6\DGM:1V1 6D8M>3"8%%43D)8RD0
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M4>H[LKN\JS=@YC#FB9+;0I4/GB'2"!Q./T0-/0V#!W>,D>$ZNGCC.>T[\8N
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M+!@Z'HYPUM#N#BA65Y988SN)A=CMG8U9$="UU5MR>=N)=MQFI,AJHITF%O\
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MBJ>LFN4AIS#K;7!S=:[P#B-M] ZVGNG2]:72-V42:U<9!-70#F.)/@ TDDZ
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MKBVRMQS-\WNK([(K7*<&Q49X(U/B=3840-G;QQ11%6-G>Y#0%V]F&A)CG B
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MN,Q10DOC5KYP1K&"T]6R.15>-"=+8^!K6-)>6J/<_';X(/L8#,P&\C\5*0X
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M$T1-$5OM:^.UK+"LF(-%AL B0Y2:TXJLL8(R87POF!L0I83 "XFO5XY8LT1
MTR,FAD9(QKDAT!]!3W][7FCT*P9*_=7?:Q^4=YK? BAJ 3'[G> :]E?;&UN3
M9G&\O"\A,FL*O)<96ME#6.Q2S=9NDE;/,.^ UDVD! PD>H.9T9:#5M'893ZZ
M8R\H L 7E:P-N(LXBJ +6R@U8OY5AU%;><6V3JYQW<Y>GVJHHOW7_H/BO]E#
M:[_'FDT12AHB:(FB)HB:(FB)HB:(FB)HB:(J*O"<\<_G^?GPGQ74)H71/@-S
M[:'M('BGOJNF;8A5H9-A8%# @!#REF&FD0BB""P,=).221,]L4 \,;'22SR.
M;%'&USWO1K55)F&H)HBSE-@@ "R=* !-$V>75-3L"1L"-B>@\5J1N7UA8  %
M9XWLC9T.^.\1$1E=BV"X5?5-N&N3>J(CKA\MN!;*$.CK$/B8RS2,N>Y%K_:[
M6.KEK:ZQ+$^2PG#<1B71OE;)A<&YKY),;-$]F'$48!>8I2&MFD +0V-A)<YS
M6V"X7\?B^(08<.:US,1BVEK&8.&1C\29)#3&OC!+HF.(-R/&5H:XZ@$+NX!T
M_P"8E'VV:;RYP'<9WDMD87:NP*K?C$-91/G:RJP:FRM979H-BM;7 4K"@ZRQ
MHTO+0,VUN&FSV92OT_%8"$%F"PH>YM!N+Q5NE/5PPQ+H69M2 \RD:$.ZX9A\
M;/1QF),;" 3A,-0C%WW78C*)9'-U[S1$*-%IW4X";2X"*0I3Z-UG.DX1+)<@
MM+G)GPS5TJ$ O@=D5C:*.HI*(3$D'JVM(;'/X?6Q1O;S/$L;D+!-E:<UB..*
M/S@ [S&-(L #0BA=;F^@X9@L^<PAS@ +?)+("&V6YFO>YIHD\M>?02%#!$/&
MD4$<<,;556LAC9&Q.5Y7AC41J*JJJJJ)WY^.O$YSWDN<]SG&K<XYG&A6I-\A
MZO1HO8R-D;<C&-8T736 - LD[ #4W9\2?2OHB<?]?FOTKK->OT^^GBM5[^]V
M?%5U=E4T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:2=?&:WN$;+4Y=!E
M:825<[D8ICY.3.3 $^3038;8F9S9=T+[&,%@=,\*(=)+V]KV.258@G$6,H@A
M')_GQ"P,SG-UKG&_D2"=KIMNZ!=HA8FTOY+3P/:1T=+]]M:4X=.=>%5;&[3U
M]<6T\$7 ,8B&.854&L-B2L'5"V%8_>9-0S,(55E:^CO[BG\+T2ML"!$A>OHE
M=FE)(HEK'4;&CFCDZG<A=@?6O.R\IUOY24WK_K#Z1]1Z@+(:+>7:7)\LLL#Q
MO<S!+[-J:>R&ML2I\KI+')*PBGF]GMASZ40V6P$GK"/Y ?%./&\27^1SHQ_X
MNN8-[;=?:M(S^G"1_8U#_P :#M5%)6B)HB:(FB)HB:(FB)HB:(FB)HBHJ\+Q
MQ[N>>W"=^._*\_L:E^L].===:"E^SKI2X.D:Q'.<J-:U.[G*C43Z5=Q_V]M
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M$T1-$31$T1-$31$T14<O#57X)[UX_9T^GT(HMS_=K'-O) !+5'E6=E"2;"%
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M?"W'9VN=%#B)F-<6B5D; R1P<6D,S2M?33YSLE  G:UR&(W>OXO;'1X?@0Y
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M)U4[4;3R8D,:(3CMI?P92ZQ>.;56-I29NUT8]4TB.6Q"]BQ20,TME<=6@SW
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M5>6<3$4!$58$MBBC&&:5ZI306><<SBUU#9O:3D.)J@*R'QS#6B%U#(+?WW:
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M L^P GT:KJU67XG>ER5])D^.W!\,1$\H55=5M@7%"(8^N*FD&$)FF9$-812
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M00:!HZ&CL?0>2ECJ-R-QN-QZ1SZ+5[J(S2@P++=GK_(\ZO\ &*L.VR0TR@J
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MUW/F6D>) %78R\MRO%979V$-)U #HSH>8H$\AN>2]9F]FM1.R(U.WP[:Y@4
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M $3C1K&6 %@_,L:\O#F@AT60YM&N#GAKF6-0',<X.<-6,+G-+7@%;:XM;8<
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M/42 CEWAI0H>V^&69MSB.,6]E3RX]86E!4V!M#/&^*:F*+!@GGJY8I(XI(Y
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M!.#(\*6*=KXY!'O&>U87.8L+0[ND"G L_P"%U6/18!]0Z*%V747IJ/2-!_\
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L^?Y_;HB:(FB)HB:(FB)HB<?G^Y\/JT1-$31%141>RZ(JZ(FB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>business4a.jpg
<TEXT>
begin 644 business4a.jpg
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M              $$!08'" ,""?_$ %81  $# P$$!08)" @$! 4% 0$" P0
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MDC:[BR):>!RH;5F+%9&(V1[[0YA3/$'N]I/XU:UOZ ZCND)(\I9]@QHOP;:
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MV9*3^G?8K_%!V#^\?D9/AZ![*8'CZ3[:?9DI/Z=]BO\ %!V#^\?C)\/0/93
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M]^],ZWT9TXTJX'(VK , %%[MF'"4QW7&LY</NG9-PR+5!U=G6SQ"W[4BZWB
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M]7\9S=I3MJ^,K)XUXHCL-NNOML,H?D;&_>0VA+KV[!2WO7$I"W-VDE*-LJV
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M541UCUWBEGZA((WB=/L^P:_MDSL";;B#VQ).RZDU4H=5N2+"G#;+$\ )H=/
M1!K(Y%=F5T$T#,!28R>8C$5,G.?#&.S';Z?MXU8T_H[H\M-:EEW=D&64E85E
MDCC.S;>7A%+K$UM&U$]>S*B1&5.+VTCKR ,KTXD0FR&O2'-S(<2&0G%Y1)3/
MJ_G[:JEPZ6Z"O!2J&3M9GK*4^V;(MPR=&,RV9;DG;>P8.T;\,D2E>I)9%FKJ
M*%E&U#71Y83'AK$!BH\,3-0":F3Q\1CT#'V>^>-5\-U5U!7BFKC00<='$]/
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M.E:V")50,#'1Y$:64;@SQ4 H<&F5,GV>'/S]O/.>WG5X-^SZZV1#QBRB -G
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M)(P2. !R._B>'CS%>'JX=4/4TF ]E?U1Q0/DPIOQR8;7YEP<8]3YO83X_/\
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M2U<./P;,TR/>6Y,IE7'Q4I6UXO383CV94='BYC'J,X^:_'.$_E8\JL^9/B!
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MLLMEK/R_Z;8=-H>U_61C_P!VGI][(IRO'CC,AJ2C.?.VO&)/''DX^8D?9BH
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MKMFI4J=!$WJL6JHR&9-:N=F")AF:V63 <*X*B,C[&-#EQRF3W]F/,#G'I%7
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M&WIC6%&,4^#KRR4.DV?7^I.P)$_,1JEKX#1A39J?L7:YW7$^^TPV4J[9;<4
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MJ1LEY2),8_K"H;+:&&' TT3D)0%*4K*$[.VM:E!3A63*6NNXVW=K[^)1>O\
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MIO\ \A7KZ)N/W-ZKC9_E:U_2,+[RU7U0><"UU_3BE8(]B>FTW>FTFM@,6^J
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MG478<4K!L@I\51Z15:4/=V7:)FP[3EK:$NUG%S]HQA$>>A J,3?7$AJA0HC
MAA0F/AW$E>.6Z)TF07K/?&Y+,^.N-:+3;K2RJ_W!R^7'&H'+C,+VH6XR'DB.
MW(6IMHM--IC(5&1M!Q0JNG=#]R8ONG'8C]KEMR[_ 'R[7R0C2]J9TW:0K2C5
MH@)CZ4<FN1U&4[%;2\\'WWES'!,<V"TDUB]V>M5?V-NBZVH$20=K]B359L1]
M3<E/CABH@&50)WOC;4B>1"2V7Q4\K*:P\6(0I1;/BJ;E:L#UU>FKGJN[7.V3
M5/PYZ;>XVX@NH)";9#0IAXN!+CS\5Q"XSTAU.W)>:7).=[D[/Z,]/R;'H>Q6
M:\6]N-/MBKLRZRX&'4@KO-P<3)CAI3K4:-.:6W+CQ&E[$.,^U#  8V1F;[*>
M791.V[B*!TH9+J9VMY>M%Q<A3X\ZOOC'&E"AD0K&8?'R,%I#Z5+!$?=7'&X[
MQ2#/97!DP2FY?Z.]TNB[I=;>(2'K>N+UB3<EQU[V.ZVI*68R9J4%)#Y65=3=
M4,["Y#126W$N<_\ ]+&T686.Q75=Q<CW9F:8D2T(E-[B7'>0MR1,5;U*2M*H
MP;"#.82=DN-QGDK#K2V-_'.M:X1IQ2G%*<4K7T6]JY[-X)#LLPGW0T$Q]$I<
MV <@-WF!*.-3!TAV+,CP*[#]<^<=:D,N-I2#&DO6RGS,>HE259O:=.7M2P@6
M]T$\RI;*$-GN><6XEMA6>!2\IM0/Q2,\*MAO-L"2HRDD 9 2AU2E@\06D);*
MW01Q!:2L$8(X$&L52'X0=[+2/:I=58WV?D0T5M!J-?8>H-J3Z8[.?P_Z=>2F
M-4W;6DXPEMI^0F356 Z$/M,_&,RTR(S%>G1M]4VE268Y<42-PF6PI:4#_P"H
MIU*S$"3A6$]9+N$DEL H*J4ZCMB5*!6^$ #]:8[J0I1_J):4D221PRHL!K)V
M=X5!0&+76W\(:]G32]2ZTUE9YF[@1>AZQJ(8\?>U3*)5\Y:Q5=@M6+(F2&,D
M3DETD=;GOMSBP(0Q*=D>\/NL8<4I-4="WI0VD*AN9)VDH5+!;[]I2XB4$#_\
M:W,]F21GQ_*:WI.RI$E&!\4J$;X_=L@25*&>Y:4[/]; %3OUH_"!>I/:;L]2
M^N%$U]NRNM7]Z8'J^P[Q6Q<,62MC:,.BP:0%6+6TO"AF&VY>6SY=0R -]!"S
M"($9QV1'\Y^C+C MSL];C;P8"5O!I#J&FVB<%6_DICE3@44IW263ME6&UK5A
M*OJ+J.)*F-Q A31=REK;6VMU;F,@;I@O)"-D*)<+OQ0,K0E.TI.]WF'UD-.*
M4XI3BE.*5JX]I#[5+5?LTI>E6=H:KVIL.)N=^ZM0)^NXU?4P"324UE4QN:[8
MRX6)+GSOI/&<A#X\Q#F(\.9(?<:3AE+U_LE@=O8?#,AMIQE;*$ME"G%.%X.G
M:(204-HW6"K"R2H!*3A6+3<[JBVEK>,E:%H<6MPK#:4!LMC9!4DA:U;9(3E(
M2$DJ4,ISJC*?A*Q';-Q;U1TVZ,[+V9L:V(P/UNWL.X P<DK8$I<F2(\ZCU)F
MPO2XS N+-DH1!O<62^ZUA&<L-XRXK*OS?+B-+E7.8ZW'CI*Y2FHV[92D@!!3
M+D.;205J2%*7") Y(5G(L7Y6ID.)8A,-*>>4$L)6_O75$94O,=E&RHA 44I3
M* )QE0 (,0;9_".NXU9I&L;*&]G_ %?7J-@@2EA$V38M_MUM 6P563DBLV<M
M7 P6MT$F*&03\.2-6\3+$L17T82IR8CR.NW.)T:M/OR8Z9<B8['<;:>9CJC1
MU17'FDO--NN*3+#RUM*"P$ML$IXA.<@44C6BFFFGBU'C-.H6XTX\EYX2$-++
M;BVT)5'W20L%)RMT _UB,$XJ;,_"!.]]#V'M*2/ZZZ;UKM2TKJ]8L$FZ8N%O
M73@M#&RFAM7K@MLS6XC26+!8+;9)3YAX[YIUJEQO00U%C*3<8/1:V^EMYOK,
MUEP;;:TR6D,*2K]G;#;&]6"!^TAQDD@\..*H96O TIQM;D>,MLE+B3'<4]M)
M''9*WBA)SV*;= ';GC7;*]F]V-V)VRZ8:1WUM2N!:W=KL G-FD5XI'(B#DNN
M&2%7F6B&Q'88P!182 :8076'<R7J\XXL8N9*PPEY>K]2VGX#O<^U[1)BN(!!
M2I(076D/AM.VI:EI;2XE*7%'*P-KCG)SJRW 76V1)X_9D(44JRDE8;<6T5J"
M4I2E2U()*$C"2<<.0SCY8JNE.*4XI3BE=83\)]_H ZQ?OAM7^2E\WMT$_+%]
M^C8_WH5J7I;^3;3_ (Y[[N:T(ZUV-[2C4W76C;&UR5;$Z)K-5HURJ[$";I@P
M8^A&E^SEZN53N)/73LV?LF?4ZMV/MUP1,LQJK.AGITMH&7G2*_&&1&MM3X6A
M[C>I<*:@N79^1+C/E:;FTWUJYV*+&D1D30A$)$B198T8H8;?#@0@NMH#REJ.
MN(LK54*UQY45>[MS3,=]G85 <<ZO!N\A]E]<4J5*4RU='WPIUQDMDJW:U%I*
M0*/1=N^T1V727]44BM/S:\,&4_29W.-4ZVK9N1&MFD-NZ1H%<M]R+UT0<G/N
M:2M6R*A5IQTRY\,&)B3(<J*8CBIZ_67;=%P9:;C*?"'EKDW1G_XA-?:2J/=;
M==)CT>,T\XR@?"D>%(D(::!<7MI4E39<2/B--U/+CF'':4II*&+>[_P<1IQ2
M7H$V!&:??<:0XK_@'I3#*EN?$3LE*DN!"CP&O:$]JX<#9<"^U>J6\A<Q4EOQ
MMNFJ*@.!L,BY:"V-;[@6IKM(Q7+.8/1=(T%91=@'K2/DD,W*&N*8FYES/LZ.
MT\I<%<.0_&;C.))ZO<Y1<>9$:\0HT9N4)>_8:95=)@;#*\N);ZLK:;24I^1J
M:\)3+1)99?4^@\'X,?=MNE^W2WWUL&/NGEN)@1RO>IP@JZPG96K:5:!#O#W@
M+ +) /V0K8 ]C:,5PO*L.K*H8PT<DE=FV\V2A3R%1>^$WG,G:^Q2,TS"<CG&
M8Y5B2IQO-9K3X2I;TKI5IYE;++;+K!;>;2S<)#>6DMP8S2%H1(&\B;-NAH2V
MH%HJ;4G!W[Z7?!6H=0+:=0Z\MUMT.-++L-E8#BERWW%I4I@[$C,V4M2TD.!*
MP3P99+>#SM=L# Q1IX$99#)=BL*+.C)K8Q+TZ,F9"95/6QB+AV9$6B5%;R[Y
MY$9:7VL+:5A6<J#[)<W0>:+N%'=AQ!<PA6RL[ .UA*@4J.,)4,'!X5CY:="-
MLMN!&4C;*%!&5 *2-HC&5)(4GCQ!!'"J/SUKXIQ2G%*G?JU_6<ZY_OWU#_J#
M7N6F_P#R%>OHFX_<WJN-G^5K7](POO+5?2[[.=@0_6[6$J^D1BSI&42BUZL@
MD2/=$%#TZ/,ELHE2_3>5%@184";.F/(9=6I$;$9I.'Y+2L?FAK[6<;0NGW+P
M_'5+?<?;A0(@7NQ(F/(=<2'7=E1;9;:9>>=6$J)#>[2-M:37Z"]%O1W,Z3-5
M-:?C2DP(S45VXW2>IO?*BV^.XRRM3+.T@/2'7Y###+:EH2%.EU9+;2P=?U7]
MHIM:M6^LXW72-?\ U<VO-<7D]091#!.K,6D&)L,!TO&FV$XYEV$++QI,H81'
M@YD]AF=-#OS(S#:7=,6_INU%!N4#\JK39A8[CU%77+.X]UBWHN,2-.97)0[-
MEJVFHTIMQR.^S$=>0AUV*MU"!M=$77^C;I*YV>Z?D/?=1?E+:#<DBWZA:C&+
M=G+5.EVY]$-QBW0$[#TN&ZTU+C2)[$=QR.Q-0PZXHIV)W[LEI_6-OQ1[F?.C
MCK8>IV(F\/UYL>R5JL +S8SE2J9R[7:LU(Q2Z((-6"M'X$8E<CX*&W@.0F27
MF(,9R3CIRN,L'\.S.>['.OQK+LKI[<!J-7Z*>L,HF1KI6W@D6+7&S*'#ME5!
M%A ,W8Z05OM/K(J\@PQ6PUV(6*5":;A#E6*O.3'F63HER8I@^_O[\>XU+;%F
MK<I,A<:P@Y"(;A-F6M@M >3%>"OQXQAJ0IN0K##@F3+BQR;;N4J@/R8[4K#3
MCS:5*BJ<5OU'!BS1HO<*T.$UQZ9&/SY1L<W&#RX#33TV$1<S(\(LZ,T^PMV"
M[Y9:?78QZ/F>:PM2O;6[M3[C&ARZK9P5@9GA ]DB_"B<28\X L$;$P&7S&9=
M5):'EHN?7@27FFVY*,*RTI64JQA2K<;W%K1^X2Z'%MD&?:!S8=TK!&L$"<4,
M@_C8F!63AF!#D@PGO+VJ+["7@L2AJBDPK(J9B.2.5^*54JYOII3L12,[-LK6
M(0>$/)%YGQT7[J+'%H^)8J>1D>]>C!A$XN<21\J2MIB;'SAZ,XXWG"N*5Q0E
M_I-DF7(>!M(0K,UX7C@KNQ#(,.JK!:76@MQCPRZL+PB*MVL6(,90XI66?=)R
M,Y<PXV^AI2N?'MM5EJ#HBV:OR5V%I#P!,<R.>4<9=8E2FG@Z6Y*LDVG(T&;(
M0Y"P^A;$.4ZG.6X[JD*5^6K?4WFH3[-HKKK!(N[7QSS1L:XU//,K>;>"0G$R
M<HE%VG(TAMT:PIR:VMAY"V<*:7A*E>'KA48[99Z1::XPT!E-03CKQL8TV&FO
M.,,LPRRURDI'2G79,9IJ/,RR\XY(80A&5.MX4I7JG76K#WW(CQF+(G,3P(V2
M-%X>-E8<BRG6:T'<GB@[4\C @/F7O=9)69&8%C&F)TXI,ACQT^5&4KFM6:MO
MBIIYBP W@8W,])$RT6@."H"A:W&R:9I%$A4.+D<XRZB?A]YO,1;3B9'IJ0K&
M%*B2=V9T</V6/U ]?8CVQ"A2MA8->'![(6P\3ME5M%Y!Q<F!8:8!9R]3Z<=L
MDYU\HTP%$)$S#;HYJR5O)94X.,]G^P_&I0Q=*=F,+FXME:5#-LSY 64DZ+5'
M,,"F'))-X6]B5EL@T.CLNOSG(BGDQ&6G'9&6T(4K"HKA4[8M#V"+"&J3;Z_9
MQUDK :Z!'A!2+*<(5.PL(DA+ U$0Y[X@6396G,64\PVVXOS->.'4+0E2KSXI
M3BE.*4XI6ORIR]P;?WW/JVZ-5W5O5VH+]>"%,.9$!!.OKJ8CVRPE=;W.R(+'
M!Q:P0:13<U8'3X-<K]DB3-@NEKQ8%C7 5<F1/HX X$9('FX<1YSSXCN[ZCCG
MW\>/#GV<#COK8'SYJ:<4IQ2G%*<4K!WL1N:@)V?K/45E,)K;=4V!3-NWZ6<]
M&(,<I%:#6ZQ4PB+6E]Y\DN5N2OTBO1HJ8S<I\XG$* Q+EKB-O_0!P3CGP''M
M//T#/I!Y5!(!QZ>'OS/#AGCPYUG%SYJ:<4IQ2G%*<4J$MA]=M%[.+(L^P];5
M4^9BM(PX;FQEPYKL>*C&&D$YL%^$X1C1FD^5ILFN2RPSC*$)0WXIYBE[T1I&
M_P D3[W8K?-E-I3M2W4*:=4AL?%$AUE;2GVVTC"4R"XA"<I "<BLYTWTD:]T
MM$5:]-ZFNUOA/+5LP6'$OL(=>5E:HK$AM],9UU9RI<5+3CBSDDJXUC\2WY-L
M,E6D^E=. 6"37D)#E=A)AMC=*:OC_/'DBR(#"8MD*M)4MZ*,#-/Q'',XDH29
M0U/B-X7(UB[-<_)3HKM<.:Y" BR+V&DL:4T^CN;6RC=SI"02IN/%2MLJ.\2)
M00\T-B1NCYBW-#7/3A>[A;F[DHS8FG"\N5KG53@Q\9YN0LO6R(LA*'I4Y;;R
M4C=*,)3D9Y5O-]&Y&-@Z?V,=NSVP[G7[ZU>=JWBXR9R3)M0.'F35 5+"1FI(
M<-7H!_"'7A;K[&6XJ6E-RWFHD08U1#HD6+UIF^2[LJ]W6%>$W;4=VNCCW6I9
MB-%RW1+5%;0N-%A,3 E2HREHV6@DI=6EIJ.FXKZ>&SIW66FK?8D:<LEQT^NP
MZ2L5E:CF%!3/?#5WGWR<ZIJ9.N4BW%2$2T-N!3VV%,MK>>E+SGNU+K.QJC8Z
M)<AGQFIVT1- V(3F9/@))""+*H\Z"Y,%RH1!AJ2PM;+JHLMAW+:U(]3"59QG
M<TB.Q+9<C26D/,.IV76G!M-N)R"4+3R4@D *2<I4,I4"DD'GF)+DP9#4N&\Y
M&E,*VV7VE;+K2\%(<;6.*'$@DH6G"T*PI!2H C#0'[,GI%5WTN5G1X^NQL.*
M=<%![7>80AYQ7AX96/19LLMH1G'CAJ-AAE7CE+C:T?DXPF[]&>B+[*1+N=D1
M(=1R"9MPCM*Y8VF8TMELXQR"0"."LCA6R+#TR])&FH+EOLVHUQ8[F,ERW6F6
M\CGG8D3(+[P)SS*R4D904G)-'M/6GI>!VIK?5$W1RI-@V5 MY45,&&K*R)%1
MJ:/CD)BS><6^'(0U/0\J- 3"AD,+EM^22VPTOU\8C<-!]%</4-BTX[I .3;\
MS<Y$=UB3-3&CHM;*'W#+/PDTXE+P46V=TT]EQ.RX$(.V,ZM72;TVW#2>IM7,
M:\+5NTQ(LT26Q*A6Q<N6Y>I#L9E,$&S/-*5'4@.R"\]'(95M-*<6G=G*+[.6
MA\T^+05ZEHKU1A2E3HH=^OP9#;)!>$8<(IEO-N3\DGD--M/D%2E3'V4)8>?6
MSC".;"3HK2*+:W9QIRSFVM.*=;BK@L.(2\K 4_M+0IPOK"4I6^5EU:$A"EE(
M K5*^D;7B[P]?SJ[4";N^VEAV:U<Y++BHZ"2B/L-.(93&0I2EMQTMI8;6I2T
M-I623)]?KE?J8F(!JX0370D!O#4(2$'Q1@Z*WC_XL0X;3+#?CGYJRE&,J5XJ
M5G*LYSR_0X4.W1FX<")&A1&1LM1HC#<=AL=R&FDH0G/,X2,GB>-8Q<+E<+M+
M>GW2=,N4Z0K:?F3I+TN4\KO<??6XZLCD-I1P. P*K7*JJ*G%*<4IQ2NC_P"U
M)]A);-/V;L+VIT"W1&.N$-<6_P"-9MRK]8ME 9Q^4-C6@97:\"U\7AKK<2S$
MYI,=[U8$P:S4O4D&"D0<(D/,[ST%K*R/&+:+[%6N9(4XDW%?56XVT-XX%/NO
M2&E)*VTI20A"UNOJV&T$K0FM6ZMT[=T)?N%HD(1'92C$) ?4\4G=HPVAME:2
M$K)/QE)2AH;2U@)41A[U%VM5.I>O(VL]Q=6NPLHMO;80:]S3\&H0PCY&)IV5
M5;OH>-KNO6L$R4O3X_8D4_*MTD1;*0S&K=GPRE%K\J1^=B7:QQKZ^9UCO%@;
MCVZ$8Z&5/J< 5/$B/<U37F'2B(DQ%M"*'(\HE]C:S'.5U@]OO$JU-")=K;>'
M'YLD/*=#6QD0RR_ 1%9=;"I!$E#AD%#\<!IW&'L!%0UVIWIJ'9]$+Z_U;I^R
MZL(1]RQ=IRJF3UO3&9 &(5U?7*1:Q<[8<.<O81%.+N$58H2+% ?P?3<UH/36
M2M2%2;!?-/:>?M\I$J=+A3VE6U4$/MRWREYQ$YZ4PZF&IL0T'JKNX465@M=6
M!9242'$LVF\WM$QA3$1B7$<3-3++*X[0+2%0VF'4&2E9DJP^WO4;Q'QQ((<4
M%LH+NR3\'SZ=6*W=G!W9*S57<-?":8<L:*S91HFK"->S;*7JI.M3P%J(GSD6
MX3EO"+'.]$=4*H2CHDM,_&S@R.O,=_".ES4=MC65VQ0'[,^_.4RF6PEUUZ<P
MVT^W(0MM$=I<=DA;*,F5(;64J.Z96>(RGHZLL^1=6[M-:N;345+BHSRVT-17
MEN-+94E:WEI>=!2ZK CLK2%#]8ZD?%/>#YS'6]Z<4IQ2G%*<4K%3N7T\U+WD
MT>8T/N))B+7")<)8!UAK& +-NJYX!-3+AEJR3L *PQ14Q]C,L.0?9@>O,!$R
MHI3J(Q"0E=TL]WEV2<W<(1;W[04 '0I32@H8(6A*T;0[0"K@H!0PI*2*&X6^
M/<XJXDG;W2R"2V4I6".6RHI5CQP.(RDY22#U(]E^R7[,]+.X&;'U=BB+F!#0
MI^-#0[=LH:;V_L&19:(5K)LA$J=#JH$T$D5,D9FR7CI4*$I !; J03NC\9U]
M]&]XW2GIZ[V-%NU(A]F1)W*9JH$#,= 9E-/)^*])?4MM:6TAPA2W%I*]EI!(
M36I)&@+S;KJJ;8W&G660\8J)DO#RB['6V3M-L-)#B5+)0"$H20C+BADUE99M
M3^VI*UBR69[I;J6-FT5PU7$U*NWC5S9JJ#'(ZA[,2#7Y]WGC/HM.P]/(EZJ&
MD.RK-/DLD)SD22SX2/!BX]&"'F&?RFN2MP^T]UA^'/+;ZPH+4I3J(R'-^G"$
M-R'0$L(2I" I)&SZ/0M>K:==-C@I+K3C6Y:DQ-ME!24!*6U/J1NE94M;+:B7
ME*"E;*AQ@C8/LK/:?=X-OZXMN[-$:>T@.J@J.#FFK!L85+J12I9LA*WQ1\ZE
M:TMAZRH-1TV D)*OBX]2(V:1Y"%C,,VATQ:IUXA:_P!":5MLZ-:KM<[HY(6I
MU#;4)Q$AN1N$1E+3*G1V62T=RAUL.*D(8&4,-E@-QT6R3H[5M_G17KA;X-O0
MP@-*<<E(6PM@.K?2DQXCSCNV XIM90&%/*PMUP.EQY7;VT+J8)HO3>N=25X1
M3P8VBUB &5 H%=F5.G9)X2J4<( JZ2.V@F+B&#<DB76P4LMA**D3GWB1LI.<
M?G/\YW6X/76Y3;B^[)><EOK=VY;R9$G8_9:0\\AIA#BFVDH;VFV&6\( 0TV@
M)0-V6^&W;X46$TVRVB.REO9CM%EG: RXIMI3CJT!;A4LA;KJ\J)6XM1*C+G+
M?593BE.*4XI76$_"??Z .L7[X;5_DI?-[=!/RQ??HV/]Z%:EZ6_DVT_XY[[N
M:ZXM<[\[2JVNNM>O E;:&ZTT6.@56\,"5P A_<@V/V$LO8=ZL3]LA*P/V?1
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MY!D6J7:RRK"<U2( @Z+'OT78FXMAM% !$? )JV=7Z:O7XZYD(VN2-?;H,G6
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M=#Z/> =XI1/-6V +9CK7[RY #VJ._'BS,MX1)'RQ,[&<-$HN7)/ _9Y.SU5
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MK7'CR$L]A_I]4KG1NMVJZO?VY4>SC@LUR5 G95[Z*@$#90D#$2TK_P"8Q(%
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M94HDUYW!8[[21(B\5 5BT JN1<F;&ID(>Y,M!RDNQG&B)*DJ:<PMZSU1STK
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MVAN2$GE@;>Z;[C&9U!:]"VIP+LO1S9HNFXY0,(D77=MOWZ>I(.$R9,TI8E8
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M;I;*Y<=B[EJ!&I"+**URBV#=)$U5+%T>@=BFB4U#;.O[:,"$9P<*=-.U/$Z
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M$(1GBL&KQ2+^9*;?$T58HJYJU,&5UY;2EI?1%;2SN'Y4AK<=2C1%)<0Y,?\
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MV=@!K;/%&RMS P'-VLA)M<6[,2[C<;8AB6AZVB.7GG6"B,[UA!6CJ[NT2O9
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MX"37;N/T@V4CZ]D7&S;,MI(=<":"U6&T(?0;#*R[-N+HH<J=GLX]F.SGGO\
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M\<!CRYQV=_(^YKG5JU6[LF3[)WOLJ$AL[3UQU;N[833YJKD!L+14J3!&*C'
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MXI3BE.*4XI3BE.*4XI3BE.*4XI76$_"??Z .L7[X;5_DI?-[=!/RQ??HV/\
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M=8_U(A/XXG_RURD_22G?-.)];/?N-5_Z']M^?4[ZAC_Q2GXVZQ_J1"?QQ/\
MY:X_22G?-.)];/?N-/T/[;\^IWU#'_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[
M]QI^A_;?GU.^H8_\4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'
M_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\ %*?C;K'^I$)_
M'$_^6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_P"*4_&W6/\ 4B$_CB?_ "UQ^DE.
M^:<3ZV>_<:?H?VWY]3OJ&/\ Q2GXVZQ_J1"?QQ/_ ):X_22G?-.)];/?N-/T
M/[;\^IWU#'_BE/QMUC_4B$_CB?\ RUQ^DE.^:<3ZV>_<:?H?VWY]3OJ&/_%*
M?C;K'^I$)_'$_P#EKC])*=\TXGUL]^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_
M\M<?I)3OFG$^MGOW&GZ']M^?4[ZAC_Q2GXVZQ_J1"?QQ/_EKC])*=\TXGUL]
M^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_\M<?I)3OFG$^MGOW&GZ']M^?4[ZAC
M_P 4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'_ (I3\;=8_P!2
M(3^.)_\ +7'Z24[YIQ/K9[]QI^A_;?GU.^H8_P#%*?C;K'^I$)_'$_\ EKC]
M)*=\TXGUL]^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_P#+7'Z24[YIQ/K9[]QI
M^A_;?GU.^H8_\4I^-NL?ZD0G\<3_ .6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_X
MI3\;=8_U(A/XXG_RUQ^DE.^:<3ZV>_<:?H?VWY]3OJ&/_%*?C;K'^I$)_'$_
M^6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_XI3\;=8_U(A/XXG_RUQ^DE.^:<3ZV>
M_<:?H?VWY]3OJ&/_ !2GXVZQ_J1"?QQ/_EKC])*=\TXGUL]^XT_0_MOSZG?4
M,?\ BE/QMUC_ %(A/XXG_P M<?I)3OFG$^MGOW&GZ']M^?4[ZAC_ ,4I^-NL
M?ZD0G\<3_P"6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_XI3\;=8_U(A/XXG_ ,M<
M?I)3OFG$^MGOW&GZ']M^?4[ZAC_Q2GXVZQ_J1"?QQ/\ Y:X_22G?-.)];/?N
M-/T/[;\^IWU#'_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\
M4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'_BE/QMUC_4B$_CB?
M_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\ %*?C;K'^I$)_'$_^6N/TDIWS3B?6
MSW[C3]#^V_/J=]0Q_P"*4_&W6/\ 4B$_CB?_ "UQ^DE.^:<3ZV>_<:?H?VWY
M]3OJ&/\ Q2N:/]K>3Q+9^*Z/@J@Y7C$CX??)#<M",YQA3C.)-6<9<6C'BK#2
M\M8<SC"<O-8SY\>K/])*1O$]8TDR6<@+W-X6EP)[2G;MZDJ('$).R%<MI.<C
MPD?T/XI97U37;X? );ZQI]M3*E <$KW5V2M(4>!6G;*1QV%XV3LTT)V)UQV+
MJ[UCH4Z0B2-<9CV&M%FVHQ^O2Y"%K81/C,O2&78LM+3JH!&&_(A2\,OMI=1*
MC2XL??>CM;V/6]O5.L[RPXPI")L"2E+<V$XL$H#S:5+0IMT)467VEK:="5I"
M@ZVZVWR]T@]&^INC:ZHMNH([9:DI6Y;;G#4MVW7)ELI#BH[JT-K0\R5H$B,^
MVV^R5MK*"RZRZ[.W,OK :<4IQ2G%*U@^T_\ 9P9]I!K_ %A1L;CQISZN+B5M
MGQ3.OL[!^,?$PN0_N'N6+M2?A_H>/O'O7O<WU/\ Q>[M_P#EYG>A-:_D5,GR
M_@WX2Z[&;C[OKG4]UNW=YM[7596WG]G9V48YY/*L2U=I8ZIC1(XG=1ZJ^M[;
MZMUG>;;91L[/6(^SCGG*L\L#G6E__A:5_MR)_P -6?O\YLW\_?\ RK_ZW_[3
M6!_FA/S@'U4?XC3_ (6E?[<B?\-6?O\ ./S]_P#*O_K?_M-/S0GYP#ZJ/\1I
M_P +2O\ ;D3_ (:L_?YQ^?O_ )5_];_]II^:$_. ?51_B-/^%I7^W(G_  U9
M^_SC\_?_ "K_ .M_^TT_-"?G /JH_P 1I_PM*_VY$_X:L_?YQ^?O_E7_ -;_
M /::?FA/S@'U4?XC3_A:5_MR)_PU9^_SC\_?_*O_ *W_ .TT_-"?G /JH_Q&
MG_"TK_;D3_AJS]_G'Y^_^5?_ %O_ -II^:$_. ?51_B-/^%I7^W(G_#5G[_.
M/S]_\J_^M_\ M-/S0GYP#ZJ/\1J_-6?@SZM:;.USL;/=))K% OE0NWP?[.V1
MWQ;Z*V >=^&?$/KRG>X^_P#N'NOOGN4SW7U?7]UD>3TETD_IQZ]!FPOR9W77
M(DF+O/AG;W?6&5M;>Q\%IVMC;VMG:3M8QM#.140^BDQ)<65\/!SJTEB1N_@P
MHV]RZES8VOA!6SM;.SM;*L9SLG&*[47-!5N&G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M$7M7[<9D[4UU1%O/(KX
M:A)M4>-A2DLOF+"?."I<E:,>"'5L0JW#9CK7YE,>M+2WY,/N^IR#_2,N4IS4
M-DLY6H0HMG%Q0WDA"Y4V;+C..$<E%#4%I""<E&TZ$XVU9[[_ *(]GA-:2U)?
MTH0JXS=0FTN.X!6W"MMN@2V6DJ/QD!Q^YOK<2G <V&5*VBVC9U2<YUKK6LKN
MJNLZCL>=MA=KKL*T*INL95J BBMU3KX0\9:LM=&(^*6AZ<.A#H?N9*7A3L^4
MW&PYEOQSA?DYL7H\L-MOCNHS<835P-KL#EQAQI%U%FC+E)GP8Z>L7!;S#3#6
M[?<!4\ZEO:(_K;-:EZ6-47C33&D4VFXOVL7K53-IGRXEC.HIB(2[7<I2NJ6I
MN/)?DO;Z*R0B.RITI"L#9VJR2AZ&Z^K@;7L 014;2[5!6CUN@C.^8(*CT^V7
M=FVXNU7C;3:FCPMC;&N"1BH,A<F4MR4Y(@-/N.M.XYG3>C]%EG4<V)'MEP5;
M8VDE*B2M8,P[3;+C=D7+X6M[>H4NL19X85&CEE9<=*G"XRE:E)4*UF_K_I%3
M(TC;ITR\6E-WEZ[2B?"Z/Y$^^WJT6)=G^ KJ[I-;$B=;%2DS)0D-):92EE+4
MA3:4+0:QMV?I"IP^T4O2]5.1J179<^O1FRUU)9<& )!:J#3T]ALW*:&X,C,3
MI3\*L$WDQ&CK#PMS$Q3,M)%W!;_I*W-=(+NE;=+;M,)QZ$VF1=7]IB&N3;H\
MQY EN)8ZTQOG%M6]]0:3,0J,=Z4.!]6R]+:ZN[W14SK>[0';[<FH]R=5$L<7
M9E7!N'=Y5OCN*@M*E=2E=79;?NL5LO*@+1+3N0XR8J+ZC]/BJG;/5(4MB>>D
M%-&PZT:L8BS5!\:C:%CM )Y2QZU3 I:&RH&IV85#D+0)<BM-I!%'R6"$&/=T
M=&4@JN%N:<0],7(TBU E3HT^VK8&H9T^(K+)+L22T@Q"IV3%?N$8H2!#D+?W
MS3=A<Z98@3:[L\RY'M[437C]SA6V7;+PW).E+;:IZ F0 S.AOK3/2AF'-C6J
M8AU:C<(K<7JS[M!C]3A),:U9 FX0\ZH_"MN%YAR33K$.?@1].-5IZQ(>$+=?
MF/.SF[%AT6F*I_U68[7K>C*DNQ85&CHYC/L(G1-31GK:8NI93LM=KFLK91I=
M,!4X*C%:W%J=$X*CALKVDH3M[#CBFVK@YTN2XLI=LG:,FQ[QUS1T)F U>K;)
M1(<UHJZ(MRD3$I;90B.JV%$LO!O96XLM[;32'GZB#Z9RCEM2 B[#0\'+1-7S
M:G98=%L<F&5B[8$8+UV4<6^]"$51N.TI+<Z',/S#KRUX4(#%$MRO=_>'T7KF
M7(0V[V%1I+6GWK=/;M$Y;4AO4<;K4)R6I:FHUN#:"$NLNS')BR?^%B2-E>Q3
M3^FIJ!9S<7=.*1-B/:K8N]K>OUL;?B/:0F&'<F8"6T/S+NMQ0*V'V+>S;T $
M3)T0J:WE8QU+#'8^O!$.SP*S9']?6 S9F$*</F+?8A6W[30<HIM>FDPJI[<$
M<*C3)\6!);F8@QER(HR?.D>[*J1T<19B++&:N#$"<NRS)4] *IDFYSH^I[C9
MMFUPGGXA>2TQ&0Z\VTM+NZ;*VX[SSF[JC/2]-@.:CFO6N1=+8WJ*WPK6XH)M
M\*S6V5HVTZ@"KU<F(L[JZI$J6XQ'=D-*8+[J6G94=AO>#'NLZ3G'MB7VD3[!
M& C=9#+D?N%FG@S[*X5?I3WN\^;&JY&"+L:R$V0Y#CP@A&&+GH?F(;()@^D_
MEO"[?I1V9>[Q:7IJ(;%@8NDRYSWHDQ):A6E6P\ZW;WVH\XO.K4TAJ(^U&>"W
M0E\,[*]G8EUUPQ;]-Z?OL>W.7"3JB59;=9;7'G6]8?N-\1O([#MUC/R[8F.P
MVEYQ^=&?EQU-LJ5&,C;;"Y3U]U1C;).21U;V=&(!Y):J!:Y8X=$MJALZ;;1C
MA&*BP2B;0@765CW$I'$("2QDT[,4IP.**CT9G9R*R]'3=]F.,0;^AZ*N3;HD
M&<U9[D6'G;E',AH37'TQH\!3) 9?8$F5++A*HT>2PDO5BFHNEMW3,!J3<]+.
MQYC4.[SKE;7[_9Q*88L\I,9TVYJ*N9,NB9*2J3'D&%"@H8 3-F0Y"@P.+*ZH
MRX]7?()V"&?N+>J96WV*2V$+^:161EOE4XHW](59P-:G-SXV7!S&6E*GHPZE
M](]"&GI'DYT=.-V];WPU%5=$Z=<U,FTIB2<KM[%R<MDA/7CA@/!YLJ81LDO
M+V]P$I4YZM=+3+EV;C'3LU%E5JYK1B[ZJ=#PW=)5E9O417P:,RE,*8=")+FT
M!')06S(*EH;Y?V2E2[\QK )M.M%;N*-DPFP!.05BA,U-0*L$K0=(C)[T=<:U
M#1K <@*\S&1<Z49Q$9CP%#Y*R4?T_-N7+RC3\34,"3=HTJ1%O4;JDYI-N,.
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MU6T"2++2FVF9#;;#"6K-"U?J.WJFJBS@#<)JKG(W\"WRTIN2]YM7"(F7$?3
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MG%*<4IQ2G%*<4IQ2G%*<4JT[A>*U0AXXK:ITD<.*V$#58DQD09+,I-V<DR'
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M,7A1R4=$EF.2B(?99E(0O&4^?W>3*BNI5C+<B'*E0Y"'8TEYIQ2L-+WTDB;
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F@T2'U,'! PYY9^.Q%CO$I<> V_-<CQH["Y+CBFF&F\I;2J*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>business5a.jpg
<TEXT>
begin 644 business5a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )U:^$ <#A"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@P.2LP,# P.$))300E       0^J?1#3F_36!^($EZOG
M#>6#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           H4   =C          $                          0
M         '8P   H4                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   H4     4F=H=&QO;F<   =C    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   *%
M   %)G:'1L;VYG   '8P    -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !CA"24T$#      ,'     $   "@    -P   >   &
M<@   ,   8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
MP,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0
M@ -P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0
M($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @
M0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4
M,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<
M34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!0
M8'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W
M,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;
M7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]56+]:
MLW)Q.GL&.XUNOL%;K&Z$-VN>=COS7.V+:0,W"QL['=C9+-];OD01]%S7#Z+F
MIF6,I8Y1B>&1&A9,,XPR0E,<48FR'SQCK["8L<8YFS;SYO<BVA^T.K)8!.Z;
M@Z?#3>NH_YHX,!HOOAO'\WXS_H?<HU?5?#>UQ]:T$.>WBKLYS>]*S/N6;8C?
MQBZIY_#N#MX2<3H'4,NCJ>/6RQ[ZKW^G947%S2'#Z8:Z=KF?27=+,Z?]7\#
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-#4V1U*&MK?Q)B<H,T135%5B8V1G:'.%I<;_Q  = 0$  00# 0
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M!(>P[;\@YI<1QLXL[D==M^X)P:K]ZO9\NVK@D)3U$;H=ZS:PHL6X'7F62"2
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M6JLT0)DBLPR,X=N+B9(US0.(@;EP Y^7L*_HN>_;VU^]R=W_ *GUL_-](O\
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M(Y YL390^23L[XQU#*_<,+8@U[7M9+P<7'1DIDM+8A\;@+)>*02OW:6AXCV
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M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7JK_:Y_I\?"*M'3[^U]I_\
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MEMBZF(R80F><<?SA]V\4PE1ME9>;CK^[5;49J-PBAK7EJ[%:!L.:/<Z1MG9
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M#H#KP1H-.VMW&WJ<U2/VQM&KD[O2]65FD:DONW[<>32Q5EISMMN1872$UVD
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M:AIBVD*6G8>*G9[I0ZA':IXZY6D,:M$VHYD5@N6( YDR#((H5ZK>1?Z==>-
MTO3MPJCN[+.#UQK'7=IV39;!LD:L_!U5LD%N2O8J-2?V181FH@4K;-9 [&/U
M'74T0"M%M'I+VI@[(?DJ>(K5;*Z!=4]L6&[7&V:[-Q+OL.[!MB6J]4?:NWM8
MWB7;@6LV=-0R0ZWZWOE5L%>C2=6L(I)H-72 H'8@N7$'QI*2ZY(418>1\E_T
M6(Q2 _&AAXH61U=J33Z@]:NFR*H'@4_0I6*:TK,!BJU<14"O7W5I&&P[1]K
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MWX?6'YZZ/^D'?YOQX2=!>=>&_"V_F3P0]*'F'JCU3:_L)[\3K#\]='_2#O\
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M8L?#NND?I!W^;\IX2M!'LU9A?PMOYE0=$72>?_0/5'JFU_87CWXG6'YZZ/\
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MK:M[%O;%4CL&-D4;!';+ZD]4FCU<9<.&M:E;-OS#@>):6NZUPC;![8[_ +S
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MS"D ]Y&4Y@?Z:J?W>GX)[8'L_P#?;IWY?[ F_P"/']>_P?X>/L<,KV]\V/\
MP&QS.^_\;_5]7,I]E[A0.(Z(RGB(VS53Q[=N^/3\$]L#XMMT[] FOX/[M[/;
M^?C['#*[_OFQ_9M_D-GEXN7VWGR\OI3[+S#>9&3]=U?I_P!'_P#GZ%Y_!/[
M^=RG?E_L";_+_P#?_)[/@^7\W'V.&5Y?]IL=R_\ Z-G\?VW<^3M[%7[+S"D;
M]Y.4YCQYJIXQX_UA^7LY)^"?V#\[=._/[A&\^WXO[MCX/SY_@X^QPROG/0W_
M -AL^GGOUO;SW[%0?JO,-L-M$90#?<#X:J  $[_)_;S)^<I^"?V#\>W*?^7^
MP)OX?^?]OR?^SPS3['#*GMU-C_+_ )#9._DW^V^+Q*OV7F&/;HC*'_YU4YCG
M_P"K_3Z?'Y>3/DG]@?%MNG?!X>T$;_TWP>'C[/'_ +:_8X97SGH?@-GR;?QO
MT=G8J']5YA1MOHC*'<@?NU4_0/J\B?@G]@?!]]RG_H$U_#_=_C_IX\?8X9;;
M;OFQ^W^PV?:\_IW5?LO,+R_[$93T?LU4[>W?]SQY/I]&R\?@G]@_.W3O;\/]
M@3?^'^O^WY/B^+/Y./L<,J1MWS8_\!L]N^_\=MXM^SM\7C3[+W#$_O(RFXY_
MNW5\>XWW^#^1V'Y/2O/X)_8'SN4_\O\ 8$W[?R__ !_R_%[?S\?8XY;SGQYY
M'MHV3V\OXWR?F\93[+S#'MT1E#V[?LW4\>^_^CSVCM/CY\D_!/[!^=RGY_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>business6a.jpg
<TEXT>
begin 644 business6a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *4*^$%8CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L
M   0 !.$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         !.$))30/T       2 #4    ! "T    &
M !.$))30/W       <  #_____________________________ ^@  #A"24
MT$"       $     $   )    "0      X0DE-!!X       0     .$))30
M0:      ,U    !@             "NP   ^@          0
M             !              /H   "NP                     !
M                       !     !        ;G5L;     (    &8F]U;F
M1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&
M5F=&QO;F<          $)T;VUL;VYG   "NP    !29VAT;&]N9P   ^@
M &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&
MEC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6
MT    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6
MT    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   KL     4F=H=&QO;F<   /H     W5R;%1%6%0    !
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M   *    !P   !X   T@   !]) !@  ?_8_^(,6$E#0U]04D]&24Q%  $!
M ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M  245#('-21T(                  /;6  $     TRU(4" @
M                                                     18W!R=
M   5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<E
MA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M!P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _
M@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3
M@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@24
M5#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                           %
MA96B        #S40 !     1;,6%E:(                     !865H@
M      ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "
M2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M           !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                          9&5S8P         N24
M5#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W
M!A8V4@+2!S4D="                             &1E<V,         +%
M)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
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M(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q
M33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B
M<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K
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M/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*
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MP,#Q48$Q,5$Q,8$0P,# P,#!$,#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M" #@ 4 ! 1$ _\0 'P ! 0 " @,! 0$           @'"00& P4* 0(+_\0
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MCD'34TKY337$CT)?I_N(-Q#<J/?Z7)6;RTE!@G/X/P]'@>,CQ^%\?-G/X/\
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M\U+_ %ZFS]W#GY\>_8SXYQ\GQ4WAC&,^;[NIK\N<YSG'EQ_<X^;QQX>.?$.
M^ L> LY\V \!?L'V0HR!G)^N.M74P AX"E0;W1@L\W 4XS\" )SH)N38"88
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M:139\^E(9><VDC2C9VAS/:'AWJ>#-C6XI\M[8RN*][:F8!:(:)N9\_Z.=?\
M2'7_  R0P6E'RS'UC?LQA&E^,V6(9.HC,6A#)B/0Z%QG#8Q1U$CC\?;?3X"K
M6(W&5/JQ2>XRR2R!?@E23<?CC\^/S_/CYL_-GG1IQ9D&K?,/Q-G\ABS/IRPU
MK$?3)7!7AYF\H"L&PL)>6](KPE.<0MZST:M?E*WE9)\JA62(PK ^?+)U#(&E
M9ULTE+#%DDAE49@[">_.B-L+>9C,WA+'XI&&O*LTKU]]D+TM2MK2V)<&JUBH
MX("2A> \A[5C.,_-G&?\&?'G[QQQQQSUCTRL\D9W:.R%J;7U@?FQ>ROC&\H4
MSFT/+.Z)34+FU.K:M*.1N#:XHCST:Y"K)-3*TIQI!Y1A1@P9Q,W:U:Z-#SB1
M-5"4PV2##F@>L/B"L(2C=\/#5"%E9MCKAR3LA:SVBW5PX+X A6^F]920M:KB
MY!A;(I.0CQZ9H?I";7 Z>-T]U?,J8R89L(RLAT-5PH".>Y3Y29F@HAF+98,R
MKU/.4?P@R@]J^IYRD]:]7_!\R"IUIUU66)$[>44-3AML0&-%PR!V<.LX6*P8
M3$B$YZ1/&8C,!,N7^.,*5*J5)DK0T+TB!.0I4DDIP%'G '@?7#K>TSU?IY#2
MU?T/6KPP^QX>SRN23:O:]?IU9X:_>@R*#N5IR)-$FOX<O$1>RDKG&U[NB,,9
M%Z%$M; I5:8L_&=W?6K7M\M$R]'"DZL,O0<;5Q$J[R8'&$UR(8XM0'M9S4V6
M@G;"YNVI<-Z@Y&0%"^$93IS!%$9++^]Y"FL_3;I=KDQW#'G6*J=D&N[VN#QJ
M;M^R4:J2<,2N(5L\R*2PR-BB$=K&&0ISRVR>5O\ *'"42&./4WD,D7^V'^3.
M*M,D&GM7.I.JPI?6U@YUJH3,\IMC;(Q44T^*& 8E571MDP8%D8*]?\1_VK#6
M9FP:;[(;8\J;D;9Z4W*(DC)@\B]6UZ6Z>LGPHPSZJ:Y->)NM>W*98;Z3K=)B
M5KY)(8]+9"LD6"(V##RH?)5$8K)7<UP]8&XO\:8'=7DUP9V]0GYDMT]U+GSR
MT2*<ZPZ^3)_8)D]V*QO<IINO']U:)_)52%;(YNVN#K'52I'+']:UMJQZD*<T
MMU=%;>A4K59YZ0@PNC......:I]N=Z]1M-=PZ :K8I^3K[ROEFA5&16\8XQU
MEDU@B5IW&UQB.0%6Y2B?QFQI(RJ[)&BDD@C58Q.=G1UO2?#"0MZ% 2!5G&3[
MWKZ@Q-YFP9?!]AHQ7T69MG7V.7&Y5ZP&UW:Z'4N<L%6VH76(6^;+9H\KS;.D
M*.!Q- [0]B4R-[P X@!+2M0.*GP23O%HN)G-T0?-9MQDU\'2ZQ(9(-; U]6@
MK?A+A7-'M&QRURE 1V\7 P,#]3CRFED?=66</11HB%[(Z%M3\C-;<8WEW?IK
MG6F;)FTOC<ZD%5 5:?E4[B,1>.1&5.Y.UVM;ULDQYG+_ &[:4'KYD4!BS$J
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M!4=(I(_4M_V+$HTLA5',#W#ZY^$C$-S<F^9NK/"9+(H@<IF13^D7-3TO6*D
MY",M[*V/4;2M<:X4[6E"U PBB]7U%#&& P2/C<7)W-:HS&T!3<V)#W5X5KG5
9R4!()")0N<5BE8K/$8>><,P8L\RKQS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>business7a.jpg
<TEXT>
begin 644 business7a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %F:^5S0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!N;?/
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              =@   7_          $
M                 0             %_P   =@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   =@     4F=H=&QO;F<   7_
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   '8     %)G:'1L;VYG   %_P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      ,
M  $   "@    ,0   >   %O@   +Y  8  '_V/_M  Q!9&]B95]#30 "_^X
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MF:LPN>?V@&-+B6-:QA ;/M;+_<[V+S?_ )Z]6AI/U>Z=#@2#IP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( +H"70,!$0 "$0$#$0'_Q  ?   !! (# 0$
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M?Z#=HFEKWM8WL;V)L.F_+'+ZUIBV5O(J$-324ME3J9+2FTA\#P%*6%]J0[W
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M=\=L.RVZ_ NJWZ)<M+1.;IM?I4"LP&ZG3YE*J*(=2BM3(R9U,J#,>= E!EY
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M#SI?>1 BQXB'7U?G/.)CM-AQT^KBP5''GYYZ1P0P@B&*.($LQ$:*@+,;EB%
M!8G?403?F=SC''%%$"(HTC#-J8(H34WBVD#4?,W/AC?]W3_PEY]2"E)5Z85V
MI2/+C@ _;KN5!MSV)(LQ N>MKV)\+\L9 +;]?&PN?U>7+H.N.7@HPH<DJ&"H
MG*L'/&?3SXQY>FA4&][[\]SOY>SV8>_V<MO(;6M[;XR&DI((*N#D#/'EV\X
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M7+CR[?WH-OBYWQ81\5Y;+NB56XN+Q1CGU_/B_A;GUY80I/TDCV:,3/C5O>S
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M!-_X?66_^KJFW_W=]_O;'?\ J'_3W_@OASV?A'2?_DM]>,_PS_1G_P ;NO\
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M/'E^'M]@?=_MW_Z-<'T:\$G?\'Z/_I5/\HQU_JK?W05__E'S0_\ B[A_?_\
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M=R;S'?WI2O)Q1B. H?+R/'&3)CFU1HY NX)L+CE?D"6\#UQ*28M%&Y NZD[
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M?V]&VSJRE:D<[E7F,]N>>*,?0>0SY^?&NRS@VN.8ON+?7_-8[VQV6IU6VM<
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MLHX(6H8ZX:S.[Z)Z]Z"EATQ0N!453QM+ C,H:(:F9;-IN),[A69H$@GE=)C
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MZ5;\_MI"NUGPH41+3RE/( *BT<AOU4"E0P2D>?ISJ/4UL [52&U.]U[I)VL
M20;#QM>Q'UQLBX.SF"JES%Q3>K".<EA4)JL],UAI()^B;&PMR-[X5]X_[(W@
MY,8!+3*:4X>X%!"6Z/3TGX#ZDI( SP"==,B[M&$/,F4'KL)9+;]1]9QY_E2]
MAPKER/;4]9F9 !N+M5GJ+7%CT( ZWPVMKKFI]J77'GU?WCP#,]X CM!U?@J>
M;6?A[VP5 H)QWYY2!W'REYK2R5M&8X= 8!3WC8;7L+V-KB_2V]KC?$/.\KJJ
M^A:GIQ'VCP,5U.54#0P%S8VW;F1U Q.MZ$;G;_7)<]LDKI5W5*E(I*IP]T?[
M8-#CQ'O>6"75,_QT1[L)*BM/:H8[CBDB=:'):>EJ 1-3)(9 G?6[S:AI8V!N
MK#E:U[''7AG(J_A7T3O49IV6B&B82&GD$NPS2=@0 %)(+KS /.W(XV9FRE\5
M:I0*7%:I)F2ZC&B-!VI-M-EZ4]X+65J:40"M0!."!SQC72+.Z&)&9NW 6-FL
M(P20%'@UM[7M>^-37BC*J>FFK)'G$$-/)*Y6!G;LXU+L0H().E;@&US;KMAZ
MU3I#W@MRYJ#1*DW:J9U<9GNT\,UX.H4B"V5/AUQ,8)01Z?"0>?OUA3BG*IX)
M73UHB,H#>$+>Y%K=^_(^(OTOBCI?2?PM7Y=7UU.^8-3T#TZU!>C(<&<Z8]"%
MB6%[WM8CP..[;'HYWDO-%S,T=%II7;-,JM?J EUXM(5 B2$MNADIB+[WR<D)
M44IQDE0\CBS7C#)Z%J0S"J(JYX:.'1!J/;2*UKC4;+<&[';:W7&;-/2-PY1F
M*24YBRR(C=VEL54*K%RKNE](=.ZNIR>0.&74NF+=!I^J-+;MPKB5$1G FM)[
M?$#WA802QDI[@KD < >8U8Q\0Y>5C8"HLR"WS8ZBX!&H;[V/U7MB3#Z1.&V6
ME8-7@34YF0&C:Y309">9((4C;<7'0<G*]TW;DT9FK466S03,<AI2GPJPVXW_
M !R \C"O=LG*%IR<  Y'VZB?+M%,\$R=OH1]3 Q@'2-CL9/$';>][^V#'Z0>
M':KU>KC>N[+M3]*CD#74Z6N 3;O GW[##'K>PFX%N4R/,J#='2RNHPV4"/56
MI#G>Z<)RD,)^2B>>[Y ^6IJYY12.0!-NDFYCV-A<"X<^%AT'UXMLOXUR+-*I
MZ>D>J>1:>21A)3/$H":;F[,+&Y %QCOW2HTVW*+:DFI)9#5)-3<EEIPN'M7(
MC8"  %+.7 3Y8YSSYP\JD2HFKHTU!JCLA&"!^B&)O8V&R[;;WY#&Q<"9S1P\
M0K5L9&B6:)S9+W AD7K[CX;VWPC6SMW<EPR4,T]N%WJIK-4'CRTM8B.>$4G\
MQ>%?QB<I \P0#QJ5/F5+"A#]I='>%M* C6E[V)(OTWYD>%L0\YS[+Z::HJIF
MF[.6OGC73$S=YY'90;';NBY-_#>UAAS2NGO<*Y%NQJ:S1E.E7'CU9ME(P0HG
M*F#CA)]!R,:QP9[10@%NV%@+VC!YW\'^(YVWY7Q2/QMD67*LM4]6JD  I3.Q
M/3:QZWY'EMAH5+I9W4HD6CRIR;>+3];3';\*M-K67 5E04GP., *R3D9&, \
MZF?A+EK-(H$X(BO^:(!OR_3L>M^?C<[XF4?I"X=S&2IBIGKB\%*9GU4K*.S!
M"['QN1MUZ&W)R4C8J^XLQZH/IHR(\9;D9TBJ(4H./-^&TD!+'YI6I(4K((!)
M^PQ*C/*%X>S7MBUU-NS'1@2/I^1VW_7C'4\790R10*U69)D[5!ZJ]M*$LQ+%
MMC939>I&Q)P_6^FS<RD[A[?61+;H K<6Z(:GD,UIIR($SVH\MG$@QQW?Q3K9
M7A [2HI\P2($G$&724>95"F?LYJ4A"T)#7C#J;J&-MP>=]A<8IQQ[P_4Y%F^
M=PM6&A]1F:[TC+*3 S1O:/5SU@A06%^MMAB0*QMQ<E*O2=39:8(E4YRH4R4&
MI(=:]ZC2'8[O8X&QXC?BH4$+&.\?$.,8IHJJ*2C73K(D*3*2+=QD!%P=P;6Z
M=WSWQ7TO$66U.505L32B"=(9X]<15Q'+&LBW35L=+#4+G>X'*^(GJ^V=S5=O
M=RE16X!DF#;*<.3 VVI:V [@.%'JEL\$#*N$D9SJ[IZZ"G.332%@D#U+266Y
M"LQ ( .^YMXCKYW=/Q%EL!X=F=YBE3-7!-,1)/9N5:XN" "=CN;?7']!VLNN
M@]]-J"*?[R\QXS:6IR7D>"M#322I:6P4DN(5Y\X^>,:G5><T<S*\?:V!%P8R
M-P6)-BUB+'8?9B[GSNAJP)H3+H5]!)C*FZ,6-E9M^GV^-^;'3'NA6JJX_ ;H
M"17%&1#\6L):5F.V?$+B"PHHRVV2!DYSC@DDR!Q'EL4*!NW.@%3\V-P3:P[P
MN ;6MXF^VPAS<?</4<4BSO67HM*3E*9B 9#90K<CN=]R.=AS."J[+7L_2*G,
M;12BQ"A34/D5%).8C#@="!X63RVKMP1W>GGG6.'/*$2Q@]L2TBVO&  2P )[
MU_@-CS\Y$/$^5I54T+&</4/$T8,#<IG71<WL-R-6VV^VV$B_:1-I=L;>Q9#:
M/$%J0R2VX%(&&HZ?,E.22%>9'D/73+IXVK,S<'NO5LPL.A9_?;<>SXXON&\O
MJ,YJ,\J*)5,=-F!CD+L([.YE90-72RGH+XB:VG#0*_"JD])]T1+COJ#)2XZ$
MQW M7P]P3GD$#N&<$$ZN*NU72S01D:FB9!>X4%@;;[FU^HZ<P<;%FF0UXHRF
MF/6\<BH.U7225%^0ZWV-O8.>%VY;@I]<KB*G"\8QHX4P[XS2$.%TO%U20@.J
MR!D?$%%./UC6&BII:6F["33K:Q7220 %"WN5&^W@+WM?EBLH,CKHJ.1&$8*R
M!3:86-DTV%U!.WE;?<89U<6:Y="'8??VRY)2TAX!"O@92%A9&><@D'/GCRSJ
M9#:GI '-RBG40=@-5["]C?EM[QYVF2Y?4^L4] %45!;LRM^Z2;DW/Z("WY"_
M(^6'YLA<,*V+PD?6*)!2VB2VKW="7"GNFPB5]JEM]R4=JB<=RC@ )/I7Y]!)
M4T2=GIVDC8:MN22> VOJVN0+7WZ8JL_R&OS6&OIJ01&2BCJ*N822!%$%,DPE
MTL0;GO"W4]ZQVMB6KJONA39>XT2,):G9D^E)8\2+V9+;<9:DJ*G0$'M02"<Y
M/D1QBHIJ"H497*=&A$EU6>^S$A; #>Y(]EM_$ZKDV25\@R2G7LA*(IUVE4+?
MYTCO%1M;>_M-KB^(=K5<AN5-FK]KHB/MQJ<G+22LR64I#B2VAQ9",).',X^8
M'EJ[I8'6%H+@NI:4V8@!6)/,@7M<7%O"QQM[9!7T66B:98Q&:J:)2LRO=@&8
M[6!%K&_.]C[1PM.*[>.Y5&I='(5*+-80D2#X+1\*G2Y3H+@[BDI;95CX<*7\
M(QR=<UC"DRV>25>Z.Q/=W-C*B@V)\6%_ $GPQ49C+'EN45-35&T2O!J* LW>
MFBC6P%B3J=;^_H+XM%MEMA<U5W!W*I<9$%4MBU[:2X7)12C$E"@DI5V*)402
M%'MXR",'.M7S&LA^3<M?O6-35'<;]UKVL-CSY7Z&Y.-%X@XERR@RG):F9IA#
M-75BH4B+'5&23<:A8 ["Q-^5L0)NY39E#=J$&<EL28DZ3$>#*PM'BL2I+"BD
MC&1W-$YP.!GUXO<EE28!DO;2"+WN+JI/3_&VY]<;EP]+'7QP34Y)CE@2:,L"
M&[-XTE!(MMW3RN+';IAJ[/T:H7S=EH630D,JKE7F/QH@EN>[Q X(\J8I3C^%
M%(+3*SD(/Q82<#RGYK*E'25=5*#V2(K$)WB02B"PV W;<7V\,2>(JR')LJS'
M.*TN**DA229D4N]NT1-HQ;5NXWN -[]+/CJ"LJLT?<JW:+/3%%0B6_26GBQ(
M+C07'JL^(I*5]J>X>*V0"$C(Y. 3BMX?J(ODZIE%]#U,KC;<*\4;#8$W[N_\
MXQ#X'K(,[R&NS"AUM3+4ULA:4"-]"4\,I.@WYJZ<SO?8>,>U6CS#4*_;* V*
MI%E,M.I4O^)[T$RCVN\93X9R"4CXN,<:FQU$0CIZPEA$Z,RG3ON=.X]MA[<>
MJ<-QMGN1BAR_>:>.#3VA$:$I)+*W>/(:58W.Q]F.ZMV/7*DS&#(C)#184HKE
M(0%%MOL)3A+N0%8XS@\GC.#BI\YHE9P3(;ECM&>18\[V\/9RM<&^)U/Z,.)X
M@7=*%0;V'KB-])M7TE4J3N-@;CD3<;.MO:JZH$&DN24TT)J5.5+B=LQ*UJ9"
M%I)7\.$J/((]",\# U4R\3Y6TLZ U ,,O927A-@P.^FQ)(!'[!L<>H4GHDXO
MIZ'+))$RW164(J*<)6J6,;(1OL0"0>5R%OXXCY%EUB,BD)>3&!3/<4>Q\+_.
M4M9 PG(!XQDG& /,\7@S.FD%0%+W$2WNA&Q%ASZ@\_?X"^@C@_.*098)EI^_
M6.%"U",02=1V47 N!;PN!??"/)I,Y^4XVEM ]WJ12M1=XRAXCX1@D@G(Y &#
MG/ &IJ5$2HFY[T08;="!UY7M[SY[G&H5N2UBSYE,533#/5]KWA<:&D8V!M<;
M6V%C<XEE>VMS2:_:"&VX8549DY$7NE 94RVT%>(>TA(&?/!!Y&/352F;4G85
MC R$0HFJR<PQ(%KG?<=2+8\].<T4=)7NQ>T,<32$1W(U:[V%[,=AX>(OA]2>
MF_<F0IT-MT+.%R?]EVA_% $XR8YP>1ZC)SJ,G$&7@*#VQL+&\?AU_.#P/3]5
MZ)>/.'T"%Y*L7=8!^22'YPVL+7N.O2P'7"!/Z?=PE4"HY;HW\7[NE9%6;./Y
M0D8P&1GG[1GG'IK*O$.7]JC?/@ L3\U:]P>A8D^8&V)\7%^3FL@C#U1:82%+
MTSVL$N23<@;#XV&(XN",[1(D&E3<>]MRO#6&UAQ 4M ">U0 ]02>,^G/)U/I
MG6I=IXQ\VP!4$6-P3MSVZ>7/D0,;1E52CO6SK?LY:25%N"INQ4'8W/38\O,7
MPET.@5&KPZ\Y"0VI$>J-MK+CO9\3G>L8&#D8P,X!],<@ZRU%5#3O LA8-)$Y
M%AMW2!S]_P!1\-\5360PO2K+J&J$[*"U[$7VWL?/H/.V&Y)M:JM2%/K3'!_B
MTG+ISA 2%<!./[T8.<GSQSJ2M3&RV!/+P\;D&_MV\.M\39*ZGF?4NO<"_=ZZ
M=)^K?D/'#ZO*RJY":LYYY,8)E6K1IS)2]GN9?\?PRH=A[592<IS^W!Q!H:V!
MFK5&KN5DZD$?VNGEN;C?F-]N7+%5EN:4DJYC%&7U19A/%)=;?.(!J%M[CO B
MQ]G*V.X;;71)CTI+3<%1N4RV:852T#*X*@'P_P!R1X0\^Q6%E0X  \^C9K2*
M9K]I:E[,RV3I)]'3OOTN+#SO;$FFS^@IXLTB<RAXDIQ):%F U,66Q! :X^'7
MRV+HM*L4BV8#\I,8-HN2'2%=CX6KWAIM7=V\#N0%-J[5GA?'PX5KK25T%15N
MB:R32M-NMAI+#8F][V8;6(%_$&T&CKJ>>L=(R]_5'GW! ",P&]R;$"VQ!M[L
M2#0K5JU\V\BVZ&(_UC%93'=]\?$5GO<=7*20Z4KY#;*R?ASW<8^5=-514%::
MB?5V<I+(4&IK!-!!6ZVWY;GW8J*[,*?*ZAJ^J[3U=F,A,:ZW MV1[NQ-V91L
M?/Q&.VD]-&YL272I[PM_P:A5&:4QBM(*O>0ZV4A8\#*4X'F>/UC66;B/+GCD
M4">XC9A\T>H(MNW6WCUQBGX\R"2.IIE]=[2DII*V6]*UA!H.X)(!-]K7N>0Z
MX<,WIFW-F5F<RPBWBXQ-DH<S6DX*TNJ"L$Q^1P2!QY<:PP\09>(DN)]D7;L@
M""0-MWW-[\_/VXKAZ0N'(*6"65J\+-"C):D<[,HM?<V.XOOA0JFQU],5)EI;
M=')84VI934VU\%(Y&& I6<C@ 9Y\N=1DSFC6-P>W!((MV=MSTOKL.8WYV/NQ
MQ2<89/4TQEC>J".&"DTSK]$G8[FW+G?E[\1K:VU]UUR3=3L)J!VTRX*K2I7C
M2TM$RTK_ +P=BNY 0/SCV\CG5C59K1P+2!NTO)!#*MEOW"+;W(WOX7OS&V-D
MS7-J/+AEJU+2JU90TU= $C+@T\B@H6((*M9@--[]//#'G657:1*?H$T14U!E
M:FU>%(#K?<I ?&%@)!'8XGT.#^Z?'F%--&M2FLQ$7[RV;8E=QO;<&W/$Z+,:
M:>)*J,NT+ ,"4(8B^G<$D_2!&YV'+:]W18M%GIH;Z2&LPZU(4[_&8^%IMKN[
M>.?+@9'.><ZK\QJ(A4J"3\[3J$[IYL6M?[/?[<1LUJ8FJD)#=^E15V!WNUKG
M[3]0Y8_3#]F+MI9N\OL4NF';V][FJ%ET>O69!>IEXT>KP*'7+4O2B;VSZ_MU
M<=OU"J,RJ8+AHM_TNVJA08=2A5"!5*O'ATR93:C'F.07[Z@%J2$&U['XW)]^
MWWZXNLN%J2(?Y7_6.)1NOV0>TUY0X3]=WIWGEWJW=M#W"K.XJW+$1==Q7W33
MU'3:I7J@(]H1Z/#B7)6^IF]*A5+:HU*IUO-4ZE4.W:? B4A,]F9,Q,^_(^T?
M?^C$)=.WL1+(V@CRZ)<F\%W5JV;.O&]U;.TNGP;-#].L6[MC4;)O+O.H.V5!
MFU.\'J<XBJ.+8DO4:E3:!2ET)N'&J]?@RF&^_3V_<;?K]F[MH7L7>G&!7IB[
M>WLW5C56WGZ4?J&ES=O&Z3;3@M:2W"D/6A#M--(@5BNW*]3MPZ[4GJ<P_?$Z
MEM-74W7H=7N-ZMOO]^O3"_/;]7C?[V]^^-ZZ/8A=-]VBU'*G?^Y;\RTJW?MP
ML2)4';JJ1:S5=S;6V0LZ]?PCHE8LJ?;U:I53H>RX8AT&;2'*'257G6138+,>
MEV['IK'/W]GMQ[+4ZFQ*53:?2H389A4N#%I\-I 0A+46'';C,-I0TAMI(0TT
MA*4MMH0GM 0A*0$C@B_PMT\OV8>'EB MV>FK;+=VZ[4NZYZ'%>K-L34&2XN,
MV_&N2A^[R$+H-=C*6A$N&V]($F$\<R84AK^+4N._(9<TWB'@7A_B3,LMS3,J
M.&2LRZ4-K= XK*6Q$E+4@FSQ=[4FH'LV!9>=L;_PIZ2^*N#LISG)LGS">"BS
M:$JHCE:.3+JS5&R5]$X[T<A1&BFC6T<R278:U5ALCI2Z<<#.SEC_ /W0@?N[
MQ@>7H/(:[?B^X)_BODV_/\CC_9OS.'XU/2/8 <:<0 "UK5\NP%MAX#88R.E+
MIQ&?[C=C<Y\Z0V?/[U']OGY\ZX/H]X(:U^%\G.D@C\D06(Y';[_# ^E3TC$$
M'C/B"QYCU^6Q]N^_V8FZ-1:9#I3-$B1&XU*CP6Z9'A,=S33$!F-[HU%9\,I6
MTTU& 9:"%)4VA*>Q0(!UMT$4=-''% @BBA1(XD466..,*$11T50JBW6V]\:'
M/+)52S3U#M--4222S2R$L\LDK,\CNW,L[.Q)/4DXBIWIWV9>V8;Z>7+&I_XF
MVJ!&MEJQVYE69@M4>'(:F1&&Y[-0;K3<F-.89GL5-%234V9[2)K<Q,I(=%DF
M9UZ9B,U6I<5X<R"H*QLVME"$E'1HVN@T69"-!*VL2,06H:1J3U%H5-*$"=E=
M@-*FX[P8/<'O7U7+=XF^^$>Q.EC8/;6I0ZQ9NW=/I=4A*O\ <;GR*G7ZU*>D
M;IN6P[N',GNUVJU)53GW8JS;935IU1,J6XU2FF&GFF79+;^:ISK-*M)(YZMS
M'(:0NB)%"I%")A2*!#&FE8!/+V86P&J_,"W2'+:*G*M% JLO;$-=F.JH""9S
MJ)!>18T5G(+$+8FQ(/5:W2GL)95DWOMS;%A)I5F;C4?\'+OHS=R7=(%1MM%-
MET>-;,2?+K\BJ4*VH%*GSJ=2K>H$VET:DPIDJ/3(41I]U*DN<YE-/35,E26G
MHY#+3R&* %)B58S,!$%EF9D1FEE5Y&90S,2 <=8\KH8H9J=(2(:B,0RH996U
M1#7:)2SL8X@'<".,J@#, NYQW5KI7Z>[@J5'JU3VKMI4V@T2V;<I:H2)M)C,
M4*S;PH-_6O2W8%*EPH$V)1+OMBA5J"U-C20V] 3'/="?E1G^(LXS.$,(ZR9=
M<D\K$Z7;M*FGDI9V#.K,O:T\TD;A2 5<FVJQ'+970.P<TL8(CCA&D%!V<4L<
MT:%4*J0LD:,"03MIOIVPCW)T==-MW(0U<6U]-J325;Q*=;76+FCMS1O]*$[=
MUJJ(B5N.FK,7E.;C3I,>IB6Q2YL"ERZ$W2Y%*ISD7+!G^;TQ!AK74CU K=(7
M"_)@"T&D/&P7U=046P&I&=)-:NP/$F5T$MNT@U6]:W[24$BM;75!BK@L)6L2
M&N%TKITA5M6?>WV8NT.Y]$HEJ696ZCM1;#3U_N79%IL!=WU^YU[FP+<I-Y51
MN]+IK$FZZ;<%6H]LQ*=+?G52O6Y4"Z*I6+5J==@4FJ0+?+N,\SHI))JA17RZ
M8%IM9CABI_57EEIK4\<0A9899I)$THDBL>Y(JW&*VNX=I:I(HHG:FB76'"AY
M)9%D01R 3M)VJET558:F1@NZ$[XLI,Z-^FJH7<Y?4W:ND/7,[";AKEIJ5PL4
M_P 9FT#8+%;;MV-6&;;8NR-99_!B)>;%(:NN'14HI\2L,1VT(341\09S'!ZN
MM<XB[02!=$+.H[<5/9"9HS-ZN9U$KT_:=@\EV>-F))L?DJ@,IF-..U(-V#R
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MP+\P<?-4,,L7#&2O-')&CU^9JC2HR*^FH[X5F #%38L!< VU6VO#3:2:JV$
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M*PI0YP#G@D#SX/.O0( =%03<7A 4F^Y%MAXD=1SVQ\[9DRM+E>EU8QUC,X#
MZ$8'2S6/=4D[$V!N+$WQ'7":A-'EW5-U22<?$#(5R#Z@^F,@CR/'-]<]C#S/
MS* ^5@I-_KY^>/*<Q%ESS;3>?,6&UM2DRV(\18W',$ 'PQ;:*RM%Q[:*6VM(
M,ZM%*E(*02&V,]I*0,CY@DCC/.M0C/Y+F>_]CI[;\[,WV7Z8^9YV4T&=@$$B
M&$D @DB[G?<FQ\Q[,6A:KE%;+JG*O3$!,1R,2N?%0 ^0<LDJ= \88_U+\_U(
M&.*?0Y_1;=0>6]MM_P#)/+ZSN,>63T%<W9A:*K;\M27NT\I^;!W>P4]S_&Y
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M7\^>U Y-AY $#KOO<\F41FELCC(=F#[3@1\<#)],\\#/GJ]B-JV;I\U +D$
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M,\^A_9]FN#N&OT)M\=_/RVVN=_$=(R!64 OWO5)-N=MB1L/COOC?IR5"YYP
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MRY([*Y#[BW7ELI0 EI3BU*66QGX4D]HS@#&MGID19JI$541:8L$4 *&U&YL
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M))&2M6,<@8Q@ #5M3TD#YM/4LA,O8TMFU-MI!46%[<K<P0;;BY).@-G>8P\
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M)Y.,U#$E7'4B<:Q#1R/& 2NEHT!0W4@D#?9K@WW&+7+D2K@D$_>[.A:1 "5
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ML^UWUB0,%""YVTB]]/,<N9'7&N>CN,YU0<19X2*;Y"J,OA6F%Y6JO7DG747
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MU=0N6(,E1$IM](=Y;'X<C?EOAXNV@A=#DW']8%)8N%F 8WNW?WI>27@YX_>
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M_.Q]Z30 $4ZN\UR>Z+M?8"^V-=XNS/+:C/,I,&8T$R"MRT%HJNG< @;W*RL
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MZ="$J2VP9DZ45!B'&2XH%Z4[V++;+84ZL(40DI2HC#)/#"8Q++''VTJPQ!F
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M2J)ID;US,X-<<T@++J@&F][%0%V-@"X"4WSN9&:)2T=HKL<7'"AV%TA\>(4
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M:$K2X]VE!'PDCL&",@A (.,$^NT<CF7)R7;?*LN!N=B"5%FZD[VY7N>7,8^
MDBB.6^E(-#%(8_2%QNJ*ZW,(56*B)AW%!*;6(^CX6PA;NTZ%3-HMH94&*Q#D
M5JW:I)K#T=I+3M2?8JT-MEV<X@]\A3#?<AI2\J0DK _..K#AZ:6;B#B5)7>1
M*:LACIUD<LL*-%(66(&X4.;%@NS&QZ#$3T@T5)E_HG]$\M#!#2R9MP]73YE)
M31)"]?41UU*L<E6T=NW>%2Z1O)J*#4!8-O!-MI3+7(5)!>4(Y 4Y\1 2II(2
M,YQPH@'G \\ZVRI)0+I.D:P-NH_IY^?C;'B67Q1-1YFVA-J&J=21>SA5L?;[
M-[; WQ9W;*F4U_9/=Z2_!C.R8=Z6^U%?<90IUIM4B*"E"U@E(/<4A /(QP?/
M5!F;L,VRO2["]++< VO=)"?=R.W0V\ /'<]JJE.,>&8(YY%BFRFO>6-6(1V2
M-M)*C:Z[V)%@+V/A7^^&&15ZR\IIM+C41KM6!\226$@%)&<$$\?(^7&!JZH&
M/JT*W/>8W]@<W\/=X^-['&YY>["GI[,QN[ [G<:CSOSVZXE!#7OUEVI/FH]Z
MF1[AM&F-2G\./,P?#9*H32UY4F*'%.E32<(^(\<@ZIPQCS&KBC)1&I*R9T7Z
M#2EB.T8#8O8  \P/ [8K8V,.99@D1,2-09C.Z1W4-)IEM*PV4MI"]X]XX^B6
MP=J-L*KM0BMU*P+.J%7IS$Y^GU29;],D5&"\:K,07H\IV.7FE*0E""I*T**$
M@*^$#7A>99CF$.>14T5;5102N%DA29UBE7L4:S1J;&QNPN"+FX/7'PW7<2\0
MQ9EFL$>=9HD+>HJT25U2L;+IC!&E9 K WTL"#O>W7$I[)[>6'XM0?-FVR7<R
M4>(:)32OM\2*LIR65' 4 1QZ#'&=4_%.85\,</95E5'=EOHF=+C3*-R"-R1O
MO<\[$[XC09GF68YAZM75]95PK1]JL<]3/)&'$D:JX5GV95=P#T#'D#BS-+LN
MT&)22S:]OLE05W%JCP$%?PG 5V,)SYGSSZZ\^K<WS3L'/RC6[6L34S76["Y!
M#?8/VXOZ6BI9)T66!)19N[(.T4V4D=V0L/?SZ\\+M0H5%0Q<#3=)IZ&GZ#)8
M>93$80VZRXP4K:<2E&%-J!*5)5D$'!!'&J^EKZV1LL,M74.RYG$P9I78@AK@
M@D\QM[^N^)-914M,F;/3TL$)3*YBIBC"%6$9(*Z0 #=0018W (L0#B"KILBS
M10:<T+4M\-%B$2V*/!PI0<9[5*(9&2.>2<C)/&M^RW,LP>LJM5;5,%EE"WJ)
M" H5M@NH[<K 7%P ,:)7U%13P99405$\,TU,C2RI-(LCEXP6U-JNVJY#$[M>
MW(XX779%G.5BG.N6M;RW$OQ^U:J7#[AB(0,?Q6> !@?8,\9.N^69C7FEFO6U
M1[LG.9[CYP#J=MB1MTY8Q9C5U=+6-!35,\$+Q1AXH99$1M0B)#*&( 9B6/+O
M&^Y%CH7?2*8QL_=L2/ ALQ$5HO",TRVACO;C1^TAM*0GN 0D XX[ !Z:YHIY
MGXIRUVED=SES*69B6LSO<%COS-_._/%IE$\K92\C2N93G,2AR6+:2D=@&.]K
M%NN^XZXHE0[5MJ8=I%RZ!1I#L^9<7OIDT^,\N2AIQ24)=4XV2L-I 2@*R0".
MWC /I51-*GRL$D=>R2F[.S$:"RB]K':Y-V\?@1L4^;9I%^$219A6QI''0A!'
M42HJ74&]E-A<W-^=^>V.&YMLV]/E36IM#I$MJ+2I#<9N5#9=3';81*0RAA*T
M%"$M(PEM(QV@ # &N:":41HPD<%G740Q!).FY)YFYW)\=]L=N'<SS*FC0P5U
M7"9:M6E,4SH9'=H]18A@26-R6L3>_OCANU;9B6-;WNM!H["'H#I>2W C-AY;
M<\ =_:WA1 )P5Y&/V:FB:5ZJ76[,=2[LVKF@))U7(OL>E[[^&+Z?-\U?.\P+
MYC7,R5 "7J96[)3#N%!( Y&X '0D8GF1;]"@6E18\&CTV)&=K2RMEB.RTA9=
M;!5WI"4I)7SE1'S)/.JB.:4U<]Y7-H+B[$V.KH.@\CS^&-+6NKJG,:R6HJZB
M:5:8 /)(SL-!%@"3>POL!\,-6B6_0DU"H)32*=VJJ1!'N[1\EJSD!."<?9C/
MS&I4LLHC4B1@>SO?<7V!N>E]S:VQOOORL:NNKG@@+U52Q6 !;R,2!:^VHDCW
M<O'PU+VMZA*ZD'Z0NBTURE/.VJVNFF&R8CK;U)AAQMR/V!I3;I*N]*DX5DDY
MU&R^>9LA$S2N9NSJB)2QUW69PIU'<E5V'.PVV'*TR^OK(^ HIXJN:*9&S"TP
ME<2*1.6NC@Z@XN""IN.AQ4:JW)<$'8?J$A0JW58D.E]7AI-.BLSI2(\.DLJ>
M88IT9KQ.R/#9;92VB,V$-(0VA*6P ,[(M)329UDLCT\)DDX5:1I#&NMI&LYD
M9K LS'O$[FY-SX^O^ITC<6>CL-3P-Z]Z*H<QK 5UBIKF5=5;4!A:2K?M)%,I
M#,0S=X@WQ4.[WGXFX-UB*\ZPH.4PA3*E-Y)IT=7(&,D$D\C&,'/.MGID1\NH
M]:JP^?OJ ('SK6MN;'E?>]_=CT/+0LF4T#.H?NR@ZN]RE8  ^P>9Y ^&))?E
M2ZS':E522]49,>D-QF'IKBWUL1F6NYEMM3A4M*&U*44)S\)4<#GFA)[*5HX[
MHO:FZKL"=5M^0O;]6^YQ610049=::*.%)*AI9%A4('E<]]B% !9M(U,1N+;D
M"^/MYV2WXWUZ?O89]!MV=/0NJ1N!<M_698+M/L:SK.OR^ZI;%Q;B;B*N*GV9
M;-_/1;6J%SOPJ</JANJS(K+DI"&!(0IX9])RW^!4^_)3RY<VVYFUCT_FQZ/E
M0_(8;<N__P!=O"WMPA5OVH7791:=/F6]5=M-VI558V.K+%9VRV^N2Z;$L)=9
MZ?+UNI>VUPP)%HVI<%,O[?K?"UK;M^VI3UTWA27+5W A4>SVJ'=<-EV1/Q8_
M?[^S]6+-;#=>W4O??57:FV9OZSMR]J*SO]N+8<*X:'MO2Z0Y>U MZCP(USMT
ME%$N*OR[7H6VU>B52OVK.KD^1<ERV%5K>N.Z#,I5PT&>_P 7^_/^CZ]O;A]_
MO[>6/?S^ORUSA@TPQUK23CC/"AZ<$XQYD<>><'75A>PZ=1;GNO7F"-R#[3S
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M2W:174K:Q4"$#>VX(/@+8UP>B_AE:*LR\#,/5J]X'J5-4A+-3,'A*L8"R!6
M)"D!A<&XVPS6_HZOL\6I%0EML;VI?JC+D>6H[H+*5LNJ[U)0D4)(0KOY"QG
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MWS4Y5)DN;*4-V7O]7FE7C^&/J'"$'O4$HY"1CDXUL4>1T41@([4FFBB@B)8
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M8@"]KD[7)L!?ES(QV>,@#)) ^9& 1\\^7RQSSD:XOSL"0!>^UB.>QOT&Y/+
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MTXK;J2J$^9_ASQ37TJBU(QBOZNFK3#F^!+<2TJHCR3.99JBDARNO>HHS'ZU
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M9.RL$9VB4D_.'&W#M2D6FFDI5,M!/23)4BHGB5YZ@3M41DS&0R ,ZB[ DBY
MN57T9J?3!:]<V!VWV D75N%:5 VXM^QZ'3JUMC=U3L&XWF[(MQ%O16U5>CXD
MBGS607I< Y9?=2RXX/$901J"YS4)FM5FPBIYYZJ>IE9*V%*N(^LR&1M43C2S
M VL2!8[BQQ?MEL+4%/EY:5(H(X$1H7,4@,*Z00PN1<&YN#M<6Y7:%=Z5YU#Z
M8-Z-@=K-Q[[DUO<^U;VH=*O7>.[J[N-4*!.O2W4VS(=349934DTR#$[Y,2GQ
ME(2Q.<>DMD+>6H9XLZ$F=Y?FM;2P=G1U4$TE/001T:N*=Q(@5$"I],"YY%>8
M-L8WRS1EM70TTTMZB&:-)*B1I&4RJ5)U<QL=K#8\L55W']FI5+EI]X1K3NNS
MZ(F#MITC;=;34*I6_49=L1Z+TP7A4-P*A;^X$*&[%<J5O;A7-.[:BBFK]Y:B
MM-RGF9<AM33][2<9I"],:FEJ9BU9Q%65\D<H6<2YU#%21ST,ANL4U+%&KH)+
M@FX  %Q63\.F1)E26*WJ^5T\$<JEHM.7,\Q[8+9V$LLKZMR&YD"^+!;7]/>X
M&VUE]5M^;AU:+=&\'42Y5;HN.D;-4MVGT>AM6]MK&L*SK5VYBW14(3U3KK-)
MI++GUW7IM&^N:_,;,M-,AQVW$U-=F\%749#3TD314.2B&*&3,76269FJS5U,
M]48E<"-Y'*K&JOHC%@&^CB=2Y?-3PYI+42*]5F)DDD6FC98H], @AC@4D,;(
MH+7(9F)).HW/EGL?T6[S]1=&NZS+^HM1VIM/;_H;MCI5VJO&K;/W5M9495PU
MBZH]T7/)J]KW36G[@K3S$.UZ52[XJM"EP[?G.7-6*?;51G@2*E*WK,N)<OR>
M2":CD&835?%,^>YA"E?3596*.G$%,(IJ:,TB*IFFDIT>/M R1B6)%%AK=%D]
M77=M%4HU/%%E(R^GE--+2AV>:.=F>.9S+(S,FF=A\VP+!'+&^+GV7[/&]D7/
MMO>-_P!Q6,_,HN_]F[T;@4BEU;=R]47)#VCVVN6S]H:"FX-T+HN";/DV[<%R
M2*^]+12K<@LTV-3:.S393],:J+VN5'&$+0UL%-!57FR>JRRCE=*.C%.*^OCJ
M:]A#0Q01QB2&(1@ZY6D=I)#I$A&+6'()0U.\\L)*UT-74W,]09A2T_94RZYB
MSDHUSW@ J:8P.X"8RJOLNMTFJ1MS4*%N9:,Z^*;2.H^C[BFKS-T[7M:IR^H_
M<MW<"OW30T[<7+;%?EO0XJQ;=5M*H5&G4>YZ6&F7:C1U0V7C,7CFD::LOE\\
M=,[Y-)0V6CGF1,IHUIEIYUK8JF-59]<\<BQF2*:S@-< 1VX:J E.14HTR)6Q
MU 5YX(W%9*79XVBL^I5"*RW"ON"=\7%WIZ4;RKEB=)-H[,5FS*+&Z7-PK&NZ
M!0=P&+JJ%N5JGV-85=LRWV''H%3GW&Y*M^35HM?IT>?59:JA)IK46I5A"EKF
MJU_+\_ACJL_J:^*KF;/:6JB::F>**>%JJHCJ)+ATB0B8(8Y;)';4Q"@$KBWJ
MLKE>GRN&E>&(9;/!(%E5G1E@B>)5 #,>[J#*"S6*J=1*W-#K5Z,NJVP]Y]K*
M;9U0V\KMU;4;7]0^X=T;M;B61=B=L+NWAZL=V:Q(N$VR*6^J8Q<MG6C2:3(7
M!+\M/U=X=&FJ8C5M%3C;34<29)4Y57M4+6HE95Y-1PTE/4P^O199D-".R[6R
MV[*HJ6>X5;L;:>\AO119/F4553+$:=Y:>DK:B2>>GE-,^89I.RRO&]M.N*$*
M+&]E-B+&V)ML?V7#-L;>[R6%-W#8FR;TZ2[1Z6-N[U307#<%E4V%%O2M7W7G
M(SLD,-1KQW O.35UT*DS(Z&Z' ATI^>\\A,I%74\<25%3EU2E'H%-Q%4\05E
M/K AJI9!!#2J+@C5!20A#="O:,[:1R,^+AL115,#3J>TRV'+*6958RT\4?:R
MR$FX!#U$KLK(RLJ:5'(8KYN'T:;I[(V]MQN#,HKEZ[CT?>[8RMC\7%K;X;]V
MA#M+8NS;\IEI4W<6A7#N#.OE=#^L[RK-1M][;VT4Q[-JQH-+F1JA BLUV-:T
MO$=%F<]?3]HM'32Y3FL1:HDR[*YWJLUJ86<4<T5&M-=5C43+5SWGB,S:HW(1
MJ^;)ZFC@II"AJ)4K**8B..KKXU6DC:-3/$\S5!UAKKV$;"$JH:ZC#SV5Z)^I
MMZQ.GW=V#4K$VZWCAW]U@;O7W;.X-KUIF-2;IZGS)HEL7-"MZW*D\Y3[ALNR
MV8K+EJ5&K*1$<J\NFRJT7Z:XJ7AS3B3)HZK.,M K:W+GILBRZDJ:26-S+2Y+
M*M1-')+4*K-%4S*;21)=@ P0@XR4N2YD(:.I1HH*I:C-*N:*I6RI-7HT44B"
M$$7C6TFAR""UFL=P^('LVMW;3LN%2;#W>MJDW);/2ULOT\6Y/7$N"G,S3;^Z
M+NZ._DRHU2FE59H,;>*>M%+;JUO]]Q4B.A,\O*GLL.MQ9>,Z.IJ9'J:"I>";
M.\RS=T$D+,IEH5H<K0!H]+_)Z+JTR:D<DBUK6D)PY411!(JR-73+Z6B5A&Z$
MVK#65Y9E.H+5L=+!;,.>US=5VT]GKN[MO,VHK?X?V'=-;M/JZW.ZD[U1<"MP
MZM'KT:]-LY.V%HQ8-;N.L7/=LRM[>T2013U7-6JFU4G0W)FU,+:4A_'7<7TE
M6M?$M-5PQ5609?D<10P1=DM/5I55=H:=8X$CK)(TUE$&A2X )..U+D-33FG8
MRP2/%F=9F$AD,TNKMH'BI4#R'M&[ E0>T9C8:K],-*D^S:WQL"TK1INW&YNU
M4JYZGTU7UT[[I5V_[3N2KL4N1N9N+<>Y-Y[E;9P84UI*Z[5*G=E5A2*+<)C0
M9;4*BOR)JD0UPG9,G&F75-14RU5!7) F>T.<T4%'4"*\67T45'34-4S7<JB0
MJPFC+2!F:R:B2>J\/UD,42P3TA>3+I*"J%1&\B*9JB6>6HA4&^MNV92C$ A5
M_1L [*Q[-:JQK1W1MAB^J1*MNZ?R/+)@2:C1JO5;F@=/O2O'MF97[-6Y!:7+
MDW%N!5*17IY;I/AQ4R*K&/\ &OM%I4:+C334T50*5TFIUXDJ6*N CYQGW:)%
M4D,P44U)&^BSW<[M>W/(_#H:&HB[74DRY9!9E%_4\N%C&#INLE1])B/HLH/.
MU[@=(MC753H^\^\=]4&?:MT=1F[=1W)8M2K,JBUFU+#I-NV]M_MG0Z]#428-
MPN6;:5.N"OTYPE^D5>O2Z-(P]37!JASZK@D^3,NI766#)\NCHS.A#1SU4DDE
M76RQN"0\7K4\D<3 V:.-7%]=S995!*OKE9.K)+F%49Q&ZE'B@1%AIXG7]%Q&
MFMA8$,Y! M87"U08M\&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#
M3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!
MIA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@
MTPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP
M:88-,,&F&#3'!Y'V'!ICG!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!
MIA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@
'TPP:88__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>business8a.jpg
<TEXT>
begin 644 business8a.jpg
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M5&-VHM+4U>)8>)(C)"4F)V$R0E)B@:&U_\0 '0$!  $$ P$
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M-X.;O-:\ENH(U U!')>/+6WT,7DK\36/DI8^Y;C9)KN/?6KR3,:_=+7;CG,
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MPN_A[^^/1?YCO?\ 44]267_HU_GQ^ZG_ %1=%?O^>_4[OO"?X7?P]_?'HO\
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M:CMUY:$:*[G#/'GHU9[!?O(WO'1*;?NQ7BA5'E,2+S'GY'F_.Z?SJF'K-9X
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MM9:QBKNF3C&)H6LCL]9J8TR,JNGK&.MC[L?!J,EKP[HABD<RVXG@-/@DMU
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M(B(B(B(L!ND^F!X,]=OEFZ9T+B&QZ[7&P9M5B,M=-["$U(6/,5F%[XU%U_H
MH-!G8B1V8^'1X^)\%MO&NN,>W;VYA1V^VMQM."A2RW!J5H>KP1&AC)=R#>+^
M%Q)J<DKV;SB[1[W<RNLQ,))+=23J3J>WL[^Y9?\ ,^:TOCU$K7,^=B' %*J$
M'8;7@[I8T=<@0MY+\S9G<M8B)8W.SF1)?<^-($9;V,;XTPYAO3337&K]ZUD[
MD]^[*)K5E_$FE$<4(>\-#=1' R.)G@M T8QHY:Z:DE5@!H '8.SM/UJNLY]F
M,Y_S?IKR+E8?2O-'GV*QO9P]$ZX?PS(Z_(E5YFIC:W;8-0X8Z-9Z'?9]<OMA
MJ!&&!'NG:XS #/MZ7PF_8Q$>-3OCMYND')F[*W>L"O+;QL!<W&-9,;+[%9]G
M+B0T:;)Z<%F-TT@AG+Y033C;!*YUK0-WZ.(--=''3>Y::'1O:>9'+L[>?/L5
M?<\\D*9TN[9IP$):X\2>QTZ14+H18KVM3OFG&;P&YQT[%<R/L9"R1-JM<ST$
M1[+77*U@]IK+*5G)D1$>GZ^.[@[5"IUJ:6L7,./%FHPS]9I^FM26]CS.'P1P
M.%BK"^7^33V.#JR.QPI7M8N0X..@!\>A/8=TZ'3GKR/>!KVC4*VP?S6IEBQ7
M(M>YEUHS8;X/I=DYE58T;G$<OTBB] K'3KE5;Y7Y1'I$*OB01"M<ANQ%X?=S
M=3M@[>.''DJW$)V$-#F>^792W!QW3W\;%#3?;@R%ASKSHJ%RE8H5;%.=L=!\
MTDS)\G4C#ZD5FL_>E?'.Z."5[>-\'31KN>FGL>8(<0?9=S3VZ'\BJKFWEKSG
MJQ^JCZD&N;M7O66(5*Z1.@ HE-LMD=YD'Z_O4X+'U1.W*.9CT,M(*.R"=1@@
MLRJ]9!+9G<D.9C3/->V;O8Z&S)9EJBQ3U?;HL?,ZU! +\N,%EYX JNB-R-L8
M$=E\V[/!(8A'(7-!X<1H#H>0/+37373MU[/R::@A91+'U6B(B(B(B(B(B(H>
MWJC_ &=O=?X?-?ZH.?J>_0O[FFS7Q9?[>RB^=73K[JNU7QX7_;N(6 "VBM2(
MB(B(B(B(B(B+?YZ%W[+\GON?C?Y3J2B[Z)3V&QGRMH?JPBEMZ%GV>W/R=FOK
MSZD&*+*ETB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(L4+EXG5^T,%\C
M+Y<JB5/S.TQRYL.U6Y4Y^H]_W".]&J45LP$(1(3+TJLUHD ,MQ]R@<F!@O.N
MD(3A ?-R.KM'/7,7$IU;,<#,48HI388QMG#"9M&RXQ31O>6ML6(YHBX1RQS/
M #'ACV4%@Y\R-=[7L['^R'9^3EXQ^5?BO^+FM"L4*P\^Z =$- 3=I?IU<("Z
MW/"U2N=>[92>P]Z"1GMPNQ0L[>G:K/" )Y68],ID$_.T$R=7M84R"GV@-R!\
M%VG#*9H:XM3LDG;+9GQF)MXO#3.'%$<0IBPR69D30RT^%AE:1O,>W-#J">1.
M@Y: .<'._+STT'<#H%3 +PJ#U?:I$J[U:]C;/S,11:?RNQ;C*3-<I7/>=5/J
MM'K%0W&2:UL/L7Q5<[';FIYLPTX2)$8-3(RL[[@GFB?HFVJEL"U'/CJDE?(2
M6[61@XEMHM7KUG'6[%H2-G$D&L^+K%D41$<;'V6-T$P,;<TTT<01H >7(#70
M=AUY$\SW ^+G5/+_ !&I/)#=.=K%FM;E)YV\P7HW/B6P60* VO3E GB[UDR9
M:$L6$@Z]1AY#34?,(;PFS=KM)7?1[60$A@?/D-I;>2BM"Q7K"W>#H[=V,2MD
MFK'(R940<(R&!@%M[#Q&QAYBK5X]01*^8&!NFA.@[!XM=-W7O/+Z23XUE@L<
M5:(B(B(B(B(B(BA[>J/]G;W7^'S7^J#GZGOT+^YILU\67^WLHOG5TZ^ZKM5\
M>%_V[B%@ MHK4B(B(B(B(B(B(BW^>A=^R_)[[GXW^4ZDHN^B4]AL9\K:'ZL(
MI;>A9]GMS\G9KZ\^I!BBRI=(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B*#+ZPGE!1>>>HSY%TXP%MLLD'<Y1B3(&0P[L%
MSY?P_FA-KXAR4<AO[?!8FM:.?&1V_8[JYC7X>F-=]IK]$FTE&AT>[/U)HK;I
M(1E=YT<<)8=_-Y*0;I=.QQ\%X!U:.>NFHYF O33@;EWI,VFLQ25FQRG#[HD?
M*'C<P&+C.H;"]O-S"1HX\M-=#R&M#]&IS+YNWO\ !]?^DBV/ZK\;[Q>^:K_>
M5JWU+Y#WZG\Y/]W3]&IS+YNWO\'U_P"DB>J_&^\7OFJ_WE/4OD/?J?SD_P!W
M3]&IS+YNWO\ !]?^DB>J_&^\7OFJ_P!Y3U+Y#WZG\Y/]W3]&IS+YNWO\'U_Z
M2)ZK\;[Q>^:K_>4]2^0]^I_.3_=T_1J<R^;M[_!]?^DB>J_&^\7OFJ_WE/4O
MD/?J?SD_W=/T:G,OF[>_P?7_ *2)ZK\;[Q>^:K_>4]2^0]^I_.3_ '=/T:G,
MOF[>_P 'U_Z2)ZK\;[Q>^:K_ 'E/4OD/?J?SD_W=26_S.OVRL=@F^7>M<''H
M&:]%X1M,]]QQ[&'<%7>PX8^3?(29#X6=/=SWQWQOQ/P?AM? ^,]N_P ".7H@
M<Q6RK-D^KLG9P'9S?XS8VZ\48C=W=R6373ANWM=W34::\])2>AIQ=C&OVSX[
MX7\9NSV[PG/=IPSF][>WXX]->(--->PZZ<M9-RC<I4(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B+YO7KS?NL'E=_&\2_L
MY<A4HNCKVFX?_4/M6\H9=*WM^S_QXS[&QRU"+-EKQ$1$1$1$1$1$12]/S*5^
MV'G7]Q^-7Y?O2TKTP^PV>^5E?JQRD-T">SVJ^3A/KRRF&+2*D4B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(OF]>O-^ZP>
M5W\;Q+^SER%2BZ.O:;A_]0^U;RAETK>W[/\ QXS[&QRU"+-EKQ$1$1$1$1$1
M$12]/S*5^V'G7]Q^-7Y?O2TKTP^PV>^5E?JQRD-T">SVJ^3A/KRRF&+2*D4B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(O
MF]>O-^ZP>5W\;Q+^SER%2BZ.O:;A_P#4/M6\H9=*WM^S_P >,^QL<M0BS9:\
M1$1$1$1$1$1$4O3\RE?MAYU_<?C5^7[TM*],/L-GOE97ZL<I#= GL]JODX3Z
M\LIABTBI%(B(B(B(B(B(B(B(B(B(B+%3S@M%CI?BCVJTU$X5K5D#5>/)$G0D
MZ0-*C9&QT2QL_"G17&I$9W++KK6=VG-=O@.;Z^WV;9PKKA(HYLK2BF8R6-\I
M#XWM#F.&X\Z.:=01J >?C"UMTP9&_B.C7:W)8NY9Q]^ICHY*URI,^"S7D-RJ
MPOBFC+7QN+'.:2T@[KB.PJ*W^C%\K?\ Q&=G_&):/^I+:/I/BOZNI^3Q_NKY
MO^NKTE_]^;5_KS(?\Z?HQ?*W_P 1G9_QB6C_ *DGI/BOZNI^3Q_NIZZO27_W
MYM7^O,A_SJ\37;O*&-6N>VX[YE=!&!+S.OT65O#Z%=34NL[4,!6+"X.(,PYN
MD>59+!%M0V*'"1Y>K$<A+@Q#Q8,XX2]T>(TL69;$,>&@<^ 5R-ZO$P2\>26/
M?:2TD11F)Q?(0=6AQ8UVC=[*F[8=(L>/P>4N=*V;K5,Q-FXI#%F\M;DQYPM'
M'7W03MAE#)+]Z/)5XJM2.4,CGEABNV:CG6.J]A*Z]Y6#;E:P);RT[)#KM,HX
M+HAZPZ6JXNE(E>L\&H/A8.]6>/176K5L2O5<KY0'(+,QA1=V?JZ7=AP<RWN!
M4Q3H8I&8FHZ2>=]:./A1!CI(W3![N*&.!BW8))&R!A+V!IW 7:#OEVIZ2Z^6
MR5*STF[4QT,3AZ6>NWAD<FZQ'0R,.*?4A..?<C<W)=8S-"C8IR66,KVG3!UE
MT4/%?7&QKS0R4TJD?RUZ?,O!C!4G3 +%XNV(%JJ@H_& ;6'0V^19P)W([.3R
M@L7-';/."PI3>?('3LC(!+S[N%W>*<36; W<;-(88=Z*5\;I.'N!IWPW=#7/
M#@-Y[=T.;O.;>#<Z6>LC&Q])NT,N8M=9L8BDS+9809/&5KL=(WQ<?.P53.73
M6*U:: O=7J63-)!,:\-BT70_(/RCIC(,H&\L>P6VNGWK! B%VKC<0[FIBJD\
M##D)R!*,2'/B,8?'$QDS#WMFB2L%R3&'$=9PR'[*V/Q<YD:_%5(I(Q&XL,43
MP62LWXW!P8!KR<US=/!>QP!<W=<<7SNW/2-B64[%3I+VHR="Z^]!%:;E,I4<
M+6-L"O<A=!+9>[<&_!8KS!_X:M9A=)'7L":M#;+]&+Y6_P#B,[/^,2T?]27J
M])\5_5U/R>/]U8]ZZO27_P!^;5_KS(?\Z?HQ?*W_ ,1G9_QB6C_J2>D^*_JZ
MGY/'^ZGKJ])?_?FU?Z\R'_.ICW/)<HAS^C3YTAZ7-FTZLRYDN0YL[(E2I(6$
M](D/N[YSNZ\\[ONXZYOG.V^^VVVV<YSG*T_8 ;8G:T -;-*  -  'N  'B '
M(!?53!RR3X3#S3/?+--BL?++)(XN?)))4A>][W'4N>]Q+G.)))))YE5BNE75
M$1$1$1$1$1$1$1$1$1$1=?*+"X3F&9I(?$>SKC?#4J9&CN9TVSG&N^-'7--L
MZYSKMC&WL]F<ZYQC/MQE5!CW#5K7$=X:2/S@+HDLUHG;DMB")V@.[)+&QVA[
M#NN<#H=#H=-.2X_U0@/W\#_A.%_?KGAR>]O_ $7>94=>I?#*OE$7[Z?5" _?
MP/\ A.%_?IPY/>W_ *+O,G7J7PRKY1%^^GU0@/W\#_A.%_?IPY/>W_HN\R=>
MI?#*OE$7[Z?5" _?P/\ A.%_?IPY/>W_ *+O,G7J7PRKY1%^^GU0@/W\#_A.
M%_?IPY/>W_HN\R=>I?#*OE$7[Z?5" _?P/\ A.%_?IPY/>W_ *+O,G7J7PRK
MY1%^^GU0@/W\#_A.%_?IPY/>W_HN\R=>I?#*OE$7[ZY44H,G;[-0B,"8YII\
M9LW%EQY&^NF,XUSOMHRYOMKIC;;77X6<8Q[=L8]OMSA<%CVC5S7-'9J6D#7N
MYA=D=FO,XMAGAE<!O%L<K'N#=0-2&N) U(&O9J0/&N<J5W(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B+YO7KS?NL'E=_&\2_LY<A4HNCKVFX?\ U#[5
MO*&72M[?L_\ 'C/L;'+4(LV6O$1$1$1$1$1$1%+T_,I7[8>=?W'XU?E^]+2O
M3#[#9[Y65^K'*0W0)[/:KY.$^O+*88M(J12(B(B(B(B(B(B(B(B(B(BPU]0C
M.-?#+ON=LXUQBH1O;G;.-<8_^8@OZ^<YQC'_ /.5?MF*\]K/8RO6AEL3RSEL
M<,$;I99'"*0D,C8'.<0 3H 3H">P+573<US^BG;1K07..+CT &I/\NJ'D H<
MOQS/VYG[ZW_Q+>WJ9VC_ *AS'ZMN?\*^6?5;'O$OZ#O,GQS/VYG[ZW_Q)ZF=
MH_ZAS'ZMN?\ "G5;'O$OZ#O,KN4;LT^CXI+6*W1K3#H5FN]N"C[7',2HCIV\
M5^JU^3+GX#V((^YL!Q3@IBM;17X;L VVY-EN$&L1HT;R3[&[0S\?_P!&ST1G
MBAA>Z+'V 1'!)+(&MWZKQ^$XSVRZAP<S1H#>9.3X;:#(X<8AHPV.R46%R.7R
ME2#)UKTD3KF8HXVC)+-U6[3>XTABJEK'F)\3H+C732.G:(XX^UU[4+;E'2;7
M/*=\MN3U@BWF)*L/12@JT5\OK3R$,7+?,7\E9VY8RXU=Z[Z&V[)@K*.DMFIL
MJ4%BQ1#%'J,VETC;Z59W=A$9@(Q3F.BD89FEP#*3(BUT,H@,?#W0QNK0'DO/
MJ&T3FR7;#=F*/&RSKT>9BDL[16:V1HVABIXJ\K[>:L9%LM?*XY^8%QN0ZS)=
MG+99)*D<=5G?N>4UXVE.F6H%.BVMAXFW7;=&9+:%Z>!*G(9]^K5Z-O8' 7N6
M/+BOQ8&Y@07+QAQ4M$]Z.9DQW8G6-A,YH&'"9TPD-,D)Q]C=ED:QT8ED=U82
M;Y:X%P8]C"YC#NC0AWL=MWM&976VX^E'DV/L-H9..O=%K%4[-R*Z_'48W7'4
M^J,DC?%";56U:CKV;,767;['16SOW2W;W@1&U"5>I!@FQF1  5C<O@;H1L1+
M<H;)[[V$Z?);2ISV(D7#>)^L.,/&CHL:,WEEYZ1Z:^Q^T5??/I+G)GO# Z27
M&V-XMB;N1MTCK1MT:-3KNZESG$GF ,?S64NYGJL8Q57&5:AMR0TL='>ZN+%Z
MP;%NRXWK=Z<RS.X46@F$4<%>O''&TL>]]N_CF?MS/WUO_B7I]3.T?]0YC]6W
M/^%6+JMCWB7]!WF3XYG[<S]];_XD]3.T?]0YC]6W/^%.JV/>)?T'>93J^8?X
MM.>?Y?\ Y&J7ZWZ>/V@'_K9_RJ.EQKF6[3'M+7LLSM<UP(<US97AS7 Z$$$$
M$'F"-"OL3L\",!@P1H1A\8"#V@]2AY%5RO,KPB(B(B(B(B(B(B(B(B(B(HN_
MK$_98B?Y'Z?_ /[]R6SMC_Q4_P#MDW_C@7SJ]%1[IE;_  MBOVW*K5.LJ4;%
M=#BH.HV?K'/:W>6#4NLV"W  9&& E1H!&7@N4BCF8^I&4U(T'Q]WI.GRR6U$
ME2FHV'<16?E&S;K?ENOFBJ6)("QLL<,CVND!<UNXTN)W01O$ >"TD G34Z:@
MY%LE3QF1VEP=#,,MRX^]DZ5.>*E)'!/+UJS' V,3R-D$$9=(.+*V*61L8<(V
M;Y:YO?Q:E2G^5]1-Z1#CEUJMZJ8P>_M,8; Q*\:?L<?:,W!T:<FD2LI\7KL[
M+DR6(\)AAIJ/%E/2WI$;J,TXMU&%T8@F@F<X;IXCI&-C.I=R:U@#N0:-7$DD
M@- /N9C,0[9S:.V(KCLMC<UC:T#S,QM**A;=D&&-L(:Z6>S(^JTNEDD9'#&Q
MK612/E=)'?/G/$N=VQNJUPJ)(,S-J-S[I!&U0RTYDA995HZI I)/G\*(_M("
M0M-Q9;Y((D11FYMBR5TM(E2B$.3@0.\5F]8AXLK'M+>/8K-B+&EL0BK&9E@D
M:/<=YN\\.>(W1RL#6M(WW9C@=D,%DQC:%FK.R4X?!Y^QD8K,S)\A)DMI(,18
MPD,3N)4B::UGAU7Q5G7&7Z%J226>&058.?5.1<OL4#DMCDU',?7M5GY92Y@"
M">L.('.];O>.T4HI8@3THE)+2"+T?F8BQ5V/:R!P2SK)/L3812(X.=&TRV[4
M;K<8F!ZE%:F;(8X]ZQP(:<S8Y &A@:#9='(8FL=J(]US3O!W?C-EMG;\&S%^
M3&;@VNR6S>(EI0W;PAP(S&8VMQ-B_2=)8DLR3OCV>JWZ+,E/<K,#[S)8;$3H
M'U\#]L8QMMC&<;8QG.,;8_6SC&?9[<?_ &S^OA7X=@\2TN>1(UUT/;W_ )5X
M1%N&]%O[(OI?\BI/^G-%6'[9_B^K_;!_X)E*?T)?M[V@_P )6/MC#J2TM;KZ
M HB(B(B(B(B(B(B(B+&'R;[1>.,!JP5I]->L Z7*L9"\65^J7NV Z'3ZO6YI
MH@;*P: -(EL..OMQFXK6V--Y,9DEJ/8(DFXH^1D& Q5/*RV([5H0/:V!E2N+
M%.M-<M6)VQ,BC?=DCBT WMXZZ-<Z/?<R,N>VA[BT @:]NIT)  !))TYKI>2>
M1IOI/1H 1T'7&Z-=-?([Z@C(@G.EF=,>-'8J[QH_)/:.Q\#9D*]D3CUFK;PK
M>/J$$P&!Y'8K,)Z2(?9DL'%0HOEXLYN53@Q<BEC8V(G/8N?*0MAT/$8ZFR$5
MYQ)O&:5Y?&(V1D/-<2?%H=[30\_ =NG7Q<]>7=^56>J'F#U*\D.654/1Z% M
M/>*9ROJO.IA(Q87@-<HO4N?=UZ)$#71F-"TGD;6$A\3:"2YH9^",G3+KJ3AP
M/DM2F1#ETL[,8^HS(69;=U];#VLCCKS8XH!-/<Q]W$472U"YY9'6E?EC*QDH
M?(QE0QO?O66NAX#R=  /" <#KR (<>?>?!\7;KKXE5/#/, [V>?RRQZTD0"Y
MIV(LQ3JPWL8F3;L*MF. C^]R)AO3$)@,]7W(+5KJC+</X$QJ8$"'-I,F/:'1
M5>\^7V9AQ3,A ;<DU_&1.M6"(FLJ2UO3E^&:V$[[I1-O&O9)?JPMEEA#6FN)
M9S7EVATT!.@[===T.[NSM'^6OCT&>"P]=B(B(B(B(B(B(B^;UZ\W[K!Y7?QO
M$O[.7(5*+HZ]IN'_ -0^U;RAETK>W[/_ !XS[&QRU"+-EKQ$1$1$1$1$1$12
M]/S*5^V'G7]Q^-7Y?O2TKTP^PV>^5E?JQRD-T">SVJ^3A/KRRF&+2*D4B(B(
MB(B(B(B(B(B(B(B(L+?42^PK\@?]CXG]) :V'T3^Z)LM_;Y/V.RM9],?N9;7
M_P!VL_;:JADKZ"KYIHB(B(B(B(B(B(B*>;RW_%ESG_82H_T?'KYE9K\<Y;^\
M[_[5*OK'@OQ'AO[JQW[)"J[5L5U1$1$1$1$1$1$1$1$1$1$46OUD9F&/+43I
MEO.W_P!':=M[?A>S]<_<\>SV?!S_ )E)'HFV!.TNR\N1&5%+=RUNMP>H]8UX
M4%-^_P 3K<'LN+IN[G+=UWCKH/G[Z)W'"UTCUI3,8_\ \9QC=WA;_9<RAUUX
MC.W7LT_S6J#WEC[3G_UX_P"%;.]:$_\ < _51_B*CMZ2CX4?F!_S+DPC\L;,
MB$1SLJ 0@26)L&="E.Q9D*9%=T?BRXDICXM^-)C/MZ/,/L[Z.LNZ:.-[Z[ZX
MSCAW0_O-+79]KFN!:YKL3JUS2-""#D="".1!Y$<BNR+%R5Y8IX+TL,\,C)89
MHHW1RQ2QN#XY8I&6&OCDC>T/8]A#FN <T@@%<Z#<30S=S:"0)1</3X!22VR0
MDMM2R(I]R2-FRVM-]=),F"^\^[$?>QN['<?>W9WTV=WSM2[H=:X:.SS#HUS
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M;K6!O2RO(7N$X+9J]-ZE<Y8NXV$E:[-I*,R9$TP?,F!-B-$)19W;<MC8W80
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M9US^FNZ"Q/6D$M:>:O* 0)()'Q2 .Y$!\;FN (Y$:Z'QK@@$:$ CN/,+K1]
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MQ)>QOV29"_,7.FNVY7/;(QYDLS/+F3;O%:XN>2YLNXSB-.H?N-W@=T:- .P
M?Y#Q=B[&V4:DWV#'%WFGU:Z#8DMN?%'6ROB;'!C3F<;:M38\0Q$F1V9;6NVV
M&Y+;>KVF-ML:[XQG/MHKV[5-[I*EFQ5>YI8Y]>:2![F'M8YT3FDM/C:20?&$
M(![0#\8U7&.\YY[:) ^79J)3+%*$#YH@5).U<(7D#!1*/\D(C![Q"#(<A#R$
M7_W:;"C;-1I4?_V+[3C?ZE50WKM</;!<M0-D>V200V)8Q)(QV\R1X8]H<]CO
M":YVKFNY@@\T(![0#\?Y>W\ZYFE*INF<9TJ59TS@_'M>,Z 16N<6F)$:@1;+
MC.(F/8?C06&84<QC_P"(LQ&6H[<G5EO33%!M6CVV9S^!-;G-)_\ QW.+W0>R
M_F7.)<8O8%Q+BW4DIH.X=_9X^S7\W)>@?0:()(64L+I52&E+GG;-P)#ZX'AD
M+7G;5W3;-EF1H;<D[G;1][3;)1R5[=7G=<^W#F^,U/N6Y&01R6K,D=705HWS
MRO97 TT$#7.+8=-!IPPWL'<$T'/D.?;R[?C[UZ _-^=UX8+"U^A4L&&"&,V(
M*)#U8&,&"+!EM]G)T7 A06(L QEJ3):R3B--3<MR']/C_@NN8VYDO79I))9K
MEJ666+@2R26)9))8=0>#(]SRY\6K6GAN)9JT'3D$T'<._L\?>JT7E7*(B(B(
#B__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>business9a.jpg
<TEXT>
begin 644 business9a.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2104&AO=&]S:&]P(#,N,  X0DE-! 0
M    )#2^DF@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              M    =D          $
M                 0             '9    M
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   M      4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   +0     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      9S@
M  $   "@    /0   >   ')@   9L@ 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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MHF'U8@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5&)G=(6EM$B"@X:5_\0 ' $!  $% 0$               $" P0%!@<(_\0
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MX!\MO_&&NM^8T]^NVW']NHX?=)YQ^2^76[>^%3OYNY_-L=L1[Z!;?\T5:WW
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M#WT&VCR^A#6Q\@]U$ITV\/U)Z?ITT^ ?+1_UAK1V_N&G_P#7WZ_8X?=)YO\
MDOEWC_MA4^K]S]6]O7B/?0;9U^A#6N>_^%,G]_\ 4G?3X!\MZND-;_L, _\
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M &^CJOA]TIF_Y+Y=\HU/V?KZ^SJQ/OH-MZCB*M<M]M[3*[[AM_S3R'<?O:?
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M_P!VEO\ ]:+!\GML[_FU[+DMN\^5?S=1<^WN:._T^;'@N>6[\YO_ #KF'/\
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M.YZMKR4=2%961BNH+(K1MITLU]+A38JCL-KD*Q&PQR*FHIVA(0Q@+^R$I1,
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M'(=3[?/YO;<#"YY7V[,!\-O/D/\ /R\?, ';;4 ;GU^/]@[#;GMAO]> #S\
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MPL=/?C-/DZB^SX? ?[F^W]J)]O\ XKF'VG$_2-<)V_[0+^7[NYW^6=A^'?\
M#J/A8Z>VOWS7R=[:*_\ P^'P'^YM\43_ "KF'VG]O7BOU+@^X:J?::_:*U"J
MH3T!*LY6'6-<YAX"4DQ7(LS.+1:553<]E8I#=THDH100[!RF =AP\Q]TGIGF
ME#59?79@LE'5P205,8H*2/7$XLPXB0*R;7-U((YW'7G97[D70')LQHLTH,LF
MAK:"ICJJ61LRK9%2>)KQL8Y)V1[-8A6!%^K%UY7X:L%Y;M"5HR-&*/Y\D4TB
MB+DM$G#]F/9JNEFQ/0VD@T3'99VZ'ON[%0_:$ICB4@ 7!R'IUTIZ.41R_)ZT
M049GDG:,T=-/]^D6-7;B31.PN$C\$,% &PN;'8])/<VZ'=+,R&:9[0255<*>
M.E$B5U53C@0M*T:<.":-#I:60ZBI8DFY-A;&GTC7"=]@%_GY/?#]F//ESZA\
MFMW\+'3WXS3Y.HOL^-!\!_N;?%$_RKF'VG#Z1KA.'^\"_P 5[GOQ3 ?IX:?"
MQT]^,T^3J+[/A\!_N;?%$_RKF'VG$_2-<)WV 7Z?Y=SO\L]?OCI\+'3SXS3L
M_%M%]G]?+#X#_<V^*)^W\:YA]I]7+#Z1KA.W_:!?X?=Y.]?@]N>G+P\^773X
M6.GGQFGR;1>+_N_C^?#X#_<V^*)^S\:YA]I]?/#Z1KA.^P"_S[G?5_SS^G/U
MZ?"QT]^,T^3:+[/\^(^ _P!S;XHJ/E7,?M/C]K#$?2-<)WV 7Y]?U]SW+_\
M,_@YB/7ST^%CI[\9I\G47V?$_ ?[FWQ1/\JYA]IQ/TC7"=O^T"_7_+R=]?\
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M'S#@:X3N7Z@+\O\ IY.^O_GGGTY;^?@/(9^%CIY\9I\FT7V?$_ ?[FWQ1/\
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MJM=5456M:=I3#^_R2%=)EE_!MJOX5[;9[US..RPTPQ^3+^B)CG)FWAW[!S%
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MWZ=;$7W'7U;]6V-ATE);.:L6Y+"N_P#H(6%KW W-B;&^_7OCRB](6^N*>?\
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M;ZXI]T4_/]8Z7'8/7]> 4><>)?,>7MY<?I>_H<@YCV/BV$QC#M"86#<QA-L
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MQU.9$,:D@. UV73X7=^DANQK<?&Z=VI9LCG?2AF%>,2P$BW]<A\YN>'YY/\
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M-K>?R]>&F)W]0^GT>W.V/TP_T./^Z'BWV^PF%_\ ][)_Q_)SUY=[I?[WD_\
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M'$JX9HS'9])5@A661I#?=\N2/@HM/)$98X5#DAV5<PJ+RRZ=#G1 T9#DK<,
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MA0RR[ITY6.=9PY75.95==4YU553&44.8YA$9550!4 10  % 4     #8
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M((6EB"K',U.'$#2H$0+(T98:5-[C$K4U"HL:RD*$,8)"&01DEF192#( 2Q+
M-8W%[VQ4K5Q#YAND;+P]AMY%XR>7G'DTTCJU4*\G*2%GL%,M5CE'QJY 1*CF
M7G;'CRF3$M+JG-)OWL U5<NU.^> YI@RRBIV1XH2&3A!"\LTI188IX(40R2.
M5CBBJ9TCC4A$5R% L+5RU=5,K*\I(8L6"JD89G>-W8A% U.T,;,UKL44D[8M
MB]Y4OF3%FR]UFT9=9L]E9054(2OPJCZ:G3-#3MBFCP$5%FL%HG3,&)INT3HR
M-AES-&PR,FY%%/LWJ6DIZ._<R&.XC4 R2R!(X@XBBC$KN(XHQ(X2--**#95
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M_P T'GY=/?-T?^.*']+_ %<.\V<?%]1^C/UXCWN+CL^U5S/\T'GY=/?-T?\
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M57,WS0>?ET]\W1_XXH?TO]7#O-G'Q?4?HS]>'O<7'9]JKF;YH//RZ>^;H_\
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MS)^@4QS(J*( DX260.HD>Y%--"Q>&0QL4DC8@ DI(A1UW!V*D@VW\8Q2R*X
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MVEX=2N@ZJB&"+5QI-*M3T\5.D[1&Z23+PN+'(=+1RL3=E 7%H4JW0ZOP"Q_
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MN:JJ5M;KM<P4P(DE/.S,8HC:PDO8-HIDVPY0RF*S2;D58^!4-L%<A@49Q9R
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M31J2Q )TV#^"W@[7-C+NE649B[4^4YOE=?)&AD:&@K:>ID1%<(SND$LA"JY
M+D  E03<V/52R)BE:>]RZ5ZI:EC"2/#^T1+-#'F/;9)<S52-".*Z%T+XCDIT
M#-.Z!P"Q#)F3 X" 5MT=S-*45K9-F2T9BX_=344XIN"1<2\<Q\+ALINKZM-K
M[B]C2G3')GK.]ZY]E35QG-,:-<PI6JNZ%D,+0]SB3B\42+PS&4#B3P"+X^MD
MOF+J>_+%6RZ5"MR9VZ;HD?-V"*C'IVJIU4T7)&SQP@L9!8Z"Y$UNP!#G15*!
MA%,X%HI.C^8U\1GH,HS"MA5RAEI:2>>,.%5G77$CIJ564E200""-B+U5_2_*
M,KF%/F>>Y7ETYC6405N84M+,8W+*L@CGDC;0Q1@'MI)5@"2"!WYVT4&KQS&7
MLEEK<!%2HD"-DIB9C8^/?F40%TD5F[=+IH.!4:@+@G<G-VD?Z87<O,+=-DU5
M6RR04>75=7/!JXT5-33321!6X;&5(T9D ?P-3@ /X-[[XOU?26AR^""JK\UH
MJ*GJ;"FGJZN"GAJ"T?%589)759"T8U@(3=/#&V(:6FA/JVM<65DKCJJMBKBZ
ML:$S&JP;8K50$G KRA%C,DP05$$UA,L'=G$I3[&$ U#Y-51U:T,F75D=<Q&F
MCDIY%JF+@E L!7B,74:D 4@KN.O%,?2>@FH7S2+-:&7+(B_$S!*RG>BCX;\.
M0O4JYA31)X#W?P6-C8XX5FWXZNJSUO4;96+.M'II+/TH&;C991FDNH<B*CDC
M%=<Z)%5$U"D.<"E,9,Y2B)B" 55F25N7B-J_*ZVB24D1/5TTU.DK  NL9E1=
M;*I4L -M0ZSB*#I1EV:/-'EF;Y?7R4VDU$='64]2\ 8$(9DB=FC#6(4L #;;
M;<4Z*R)B:<F6U?A;Y2I:==K.$&T/&V:&>R2R[5-99PBDR;NSN%%$4FSA50A$
MS"F1%4Q@ J9Q"[/T=S.F@-549-F,-*J*[U,M'/'!&CV$;O+)&JJKLR*K?RBZ
MV)N,6*?IEDM74I14N?Y54UDKO''2PYC22SR/&&,J1Q)*SN\81RZJI*JCEK:3
M9/9$Q35Y-:$L5YI<',-P1%Q%2UEAX^1;@X1(LW,NS>.47"95D%"+)&,G]6F<
MBA0$IRB,4_1[,ZR!:JCR?,JJG8MHFIZ.HEB;0Q$FEUCX;!&!#Z6.FQO:UL*W
MIEDN73M39AGV5T-3'HXD%5F%)!*G%0R1AXY95=>(@UKJ4:E\);CG=;ZSUFKN
MHJ-E[##P[R<.NE"Q\I+,6*\JHV%'OTXQ!TJB=XJF#A#O"-BG. K)%$-U"[VZ
M:@K9XYYJ2DJJB&E56J9((99XZ=&U:6F:-"(5.A]+2$ E2 ;[8O5V<9;334T%
M=74-)45KNE''45,%/-62)IUK DKJT[(&0LL89EUCP;D8N],_; 1[.VVWB ]?
M(0]6P[^O5D&Y(MRZ[CT;$FXZ[BW83B_U WYX^FIPPTPPTPPTPPTPPTPPTPPT
MPPTPPTPPTPPTPQU7+LC<H_4F5/\ W*9.HCY"8?J2_&._38!W#5MY G46/4 .
M?7SY#%V*(R,!<*+[LQ%AYN9\V+!G&\Y-D,W46,U9FW S9L8R?>D'<!*X5#8Z
M@" [&( D2,&X&3'6JJXZJI\$LZ1=:1G3JYVUO^$>?(67Q=>.AH'H*!A+H2><
M6M+*%8(;C>-#<*0?Y1NWC VQ9@X[1$1$$$P$>8CV2CT^$/\ B.M2,E7_ ">_
M6>5_/?J[+[=>^.@'2=[_ (9MR #6'Z_-L,1]#M+ZRG]S+^;J>\J_Y+UGZ\3[
MYW_QS_KX?0[2^LI_]POY-.\J_P"2]9^O#WSO_CG_ %\/H=I?64_N9?S=.\J_
MY+UGZ\/?._\ CG_7P^AVD'_L4_C3+^33O*O^3]9^O#WSO_CG_7QWX^G.8IP5
MU&JJLER]%&YQ3$Q=]Q(H4 ["J8B ;IJ%,0=@W =@VNP99+3L'A,D4@&S(UKV
MOLRFZL-[6/5?&+59W#6QF&KCCGC/\F2S%3RU*Q-T:QV9;'G;;&3(Z2>E(1*2
M1 3[;>D(EV*/+EVTMQ$#<MQ,0>R(\@(&M_#++8"9=]KLHVOVD=5_%MXL<I4T
ML )>EDN+_O3L"P_S7V!'8& -N9.+@*8#!N40$!\0UE8UQ!!L=B,3IB,-,,-,
M,-,,-,,?!5RBD&YC"//;8A3''?\ _J @'QB&J2RC:^]KV\6*UC9^0\5R; 6\
MN*4YE7( (-60F'P.X,)"^.P]@@")@Y;\CA\(:QWG>QX4>KJ!)L.76!OZ^7GM
MF14<9L9IPO:J ,?]8D"_;L;8MA\-F? )0>BS3'?<C(I43;#Y*F ZX" #_<J%
M$?@WU@RFOEV#F'_1@#T%KG?EXO':PVU.N4P&YIQ4.-@T[ZAR_P 1=*$$[[J>
MSGBSG-%.\4,LZ,HY6-U5<G.X4'KU.J)C>8AUY[^'+6L?*7E):7B2,0;L[LQ\
MP+$>?F,;N+/U@71 L<*<M$02-0+;6":=QCK_ $.TOK*?W,OJ_P#A_3?5'>5?
M\EZS]>+_ +YW_P <_P"OA]#M+ZRG_P!POY-.\J_Y/UGZ_;YGOG?_ !S_ *_M
M[<L3]#M(?_8IA_\ T+\'B&G>5?\ )>L_7[=>'OG<?RS_ *]_FQ'T.TOK*?W,
MOYNG>5?\EZS]>'OG?_'/^OA]#M+ZRG]S+^;IWE7_ "7K)_\ W8>^=_\ '/\
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MP99*28P].3?9)-2?ZKW(W.P##;KVQ<2,IVNR5PV41,(<Q*(*DW^'8IPW_P!
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M$N,JKFSI*:G:AI,NGJR4[JAJLPJJ:GC!C)?@5$.754D^F4*BB2FI]49:0E6
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M(I)=6)3AU;MX-B'53>UP>9SW.:G*\QZ+4D$<+QYYG<F6U32I(S10IE68UP>
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MZGU':V.2R/.*VOZ1],\LJ.%W+D=;DT%#H0"7AUN2TM;/QW!)=^Z)'*WMI0J
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MJCI:@<-@" )HI%4\F U+X)&.0Z#9/6Y'T?CH,P1$JES//JDA)%E BK\ZKJZ
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M(%=F*B8$68N%CBF1,RA>CZ)P9=4Y]20YKP.XG@S)I>Z94A@UQ9762P%Y'DC
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M-.B$E M0::DS^2HS8PS<*-:$Y-FD*FH3B(9XNZY:=>%IE^^&.319"ZYB -@
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M:O*1TE&,T[)D:&")L;MO';XO'[=O+LWY8@*2&(M90"UR ;%@HL"06-R+A02
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M88:88:88:88:88MVWO(F/JMD?SS3T^"8P,N\FF(H)N@>1+:/<K2346RIB(N
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MA-5JTX9B(M1N1G=LA.Z[.@LW*LH>,0I-KG2%;*&$/1EO;"(9&,L4IC=T"B0
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MJ'&2N%F-.RT:*C7T7LQ+T[1 S(A.3DA0(?LN@!;F.Y1G,LU&95$%1WLRB@X
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?3##3##3##3##3##3##3##3##3##3##3##3##3#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_26.jpg
<TEXT>
begin 644 image_26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &)J^8I@X0DE-! 0      %D< @   @  ' )0  AR<C,V,# S,AP"!0!
M36EC<F]S;V9T(%=O<F0@+2!#;VYT97AT7R!&;W)M(%,M,2 M(%)%5DE3140@
M1DE,12!W:71H(&%D9&ET:6]N80 X0DE-!"4      !#&Z';X_:9NV#^JR=Q'
M;,A8.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M            R@   F<    & &< ,  S &T .0 Y     0
M           !              )G    R@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    R@    !29VAT;&]N9P   F<    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ,H     4F=H=&QO;F<   )G     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    %.$))300,      X3     0
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ML_I@R^CUAUCG[=EXVZ P_AVUW_;G_@BL7U]3=EXSZ+:V8K9^TUD2YW]1T?\
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M6GJF!P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(B-187&!,CAV=Y&V&!DD1U*6L;2UP? S-C<Y0D138M7_Q  = 0$  @(# 0$
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M%+\9RM?VKCQ<NP8^]W^>9^'Q'PWQ!,O9R!B0'K?OP; _O;FJHA9!2FVFH^#
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M<X4>.,9DYS :1AMM#:<82E"<)2G'T2E..V,8_9C&,8Q^SJ[54*H4> H  'L
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MY1,%1)CR6BVFOGY/XIX2&E/\<^XB7\VQZB/PKD^"1IU_;/'/36\-4_D0V12
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MXLX_/CGY>V?YW6<?3';/?Y8^?Z_V]:=:G.OBDE ICS\R:F$Q^ BLGY*RC ^
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M_)PK#OM_/ZGP[X]#9EO-Z?S]#,7@SW7?\SVWK>I^C\W4OZ:&/]GNV>[QX_:
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MW=^%.]83<%1$3- ^U(KMXJ!)+@8ENI\B\P[(Q+A*$N9#/')$$E(8[++Z I<
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MC#VF'&=<<6(VX8!*Q^5K1'RXP[Q STMV1U&O>R9'AIPE?:)I.Y-:ZAV1%D(
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M$K V.@VV\5<@D \10LS %S(5BB\E $D17L3Q2W.SQZAR4O&P61 3R7ESX-Y
M5D<QN%*D^5.0,C/'Y(V#PD#%'^3<.')3YRK*'1L,!D,"N?5QD5U\TT=--:9Q
MYL9QG\?^OQ[XZ::Q#&:$U!#[%/VS&42%#V')8(R99FFW?=K=+:PR84T.MU0
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MB<8)26*55DC8 @E74'R/&L-TCD;J'8FP;1J^I6\64NE/<-;FHC 4D+C"HPM
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M@:1$&A&!=4SZ#F#9QDJ,9,B!AL2R73'1?2LHYUKLK'XF)4C)"EE;XN.<ER"
M/0K@E!ZF(_@@9XC(@2+(RL\<C8&%(2"HC./GGE*I ^G+)\ ' 7(_BSO;:^R]
MX.9JNO=K4[:%2AZYJB2V?MW8,73=$(:I>:_9,R6BHJO2M1O1Y=D>-N<-.MD,
M39IAJ864DX2.B(TA?E*YBD3'&1F<B?\ &QC9(E5%4E>VT960Y&58R!B"5P>0
M.'1LED55!B\(.:R,S,6 )=74IGEAEX<%PISK\"YU??>O+_X:%>KM>UW-;+U;
MJ3==<MM8)MDZ/3;(#7-<ZKJDN% WQ=+^)11Y:61YR#-DZ6@=TL3,)(M"B%NR
MXWL9Q+/63)G@U-)(RM@.&EK*%N"'\)*R$ DD<HP6XHQ 7J1>,$4;$!A41 $#
M(]$%8,D>X#*?D25<K^)00<F67BIMG=>IN6X^S2*52-C\E#J<55Z[7IB=L]5H
M<;JR&K:-?15GL[4;59B?.DK'"'25SD(".B\!Q\LF)KY!*XH>5+\I4A(P,.RU
M2U;YY1HSJU+B)2C&3@8Z1 TA(8N[D*%"C782&<D@JGPQI0007"M\2QD(8%.0
MDJ6XI@KQ10S,2=;>.?%RV5#>,5MJR:AH.I@ZCKFU4L,2(W5L[>UDLEEMTM42
MI29C9F_!Q(E,I P%7<88BQ0G;#9S#@2IU,.W71!3^Q6*K/AF'?C2()@#$8=9
MG[C @L1)'$%0<D\,Y]7#CUD<C'D#,;LY?/XB4[>$7!" AF);/+P%Q@MGI(_'
M/EF_0].:$<@M-1E TQR7UQM,O92K_9CIF_:TH.]6-HQ4-%4AK7[6*U=/A#+#
M,TJ2L9D*J6C4!19CP4V[)P76@ %+D$?#T\<)'AN31T+48<'(PI)$F,<E) \X
M)/:6/^$X_P#6'9_ /I#U2U+*?.<Y7CD97B?/Y2N"U;LB%YCVK=0053D=:;!T
M/K;6$TZ1892.N-9G]86_;UH%+!KR*R?$V&)L+>R@PG'G;1!%Q#D84_[*22ZR
MWGL20K%/"1A7FBG1E&261#"T; E> XGF' <$X4J!E]?'P>R1[IWE?)P.+\'4
MJ IR>2%6!*C# @^"#@P#BIMZKZ)T9$5R0H9NXN/O(78.\Z[&RLG,L4"VAW:W
M[G:.JDI/-5PF:A"3=<;@DF1ID:MR*82X!AN9#EHIEUPKZTK!J9D!^[H*2CF1
MFP&[-NAHY2C -C[V,R1$KZE #A2Q XLJR-4%B5$M7/4QL 25[E8]3'R4D9RC
M\) ">)8E,LJZRB15^5>R]>;Y:NP>GJ7*WBK#UK46IY1*=KT>";&BY!N<)VW.
MD5:ONVEK8ATA\'G(",BC8:NU6/"<C52<R=*^IU%1CU8E+2H[(PXJ(5[>8%9<
MMR?$I:4@E#(HC\)D_<DL./*(")TY*0S]YN[B;!)7"<HPL8(#"-BY!? Z'Q:X
M_P"S]8;3G;2_2(#1.J"]>JK*M)U'=MXV_4Y._?>4&49O5;A+-7X"N:LA(>':
MF(.-AJ>&&JQBV!!%AB(AZO1;*^>?#@EVY-$R<CDQJO=$@+$DL9.<9(#%4[7@
M>LYXD99" !Q$@? "ARW:X$*/ [?&7)(!/=QY"YU89U\URT=--'331TTUL]-&
M<]_+CO\ 7\?]G?MU\P/I[>1^GZ_I_/\ 3]=,?\/U_7^K40.37#>D<FYFI3EB
ML%@KLA5QW8U;L+D-U$G"OE9,=!<9.9=;&);?4ZL60:POTO7<P^*5A+.&J1ZK
M]#;!U8K[-<KE=+E::RT1-2-)0B"5:NWR3FH:G:.H5EAF61I##4H&"B5Q+#.!
M&J75TKZW[AZ4T5ZM]JMMLN=+=G2J5*\3HU)7QQ=A:A)*=T:6)XPBS4SE0_;7
MMRPYD+]HY!\?7=OZ'*TU6K"Y4<#CU]F'+>R06$L>M+'P%%S"6G4%$@/L#-I=
M=QEUQHEL<S+)2F,L.YCJ9TU?>W3J78MHN9LW9BM4=!--W9Z=XK0T7P])7A&6
M62GDCB57D7FZ2K'/VYBG;;#=->HR[)ZAP[YNML6]&26YR5T,?:AG62ZB3OU=
M$74Q1U,;R,44\$>)Y(!)%S$J;.)F@Y;CGJEB@S5I3:I!R9DILDD9LAF*CW)#
M R/AL.R4M3Z0F\"^Y<6M#&2#BBR/;,^IA/7SHUTYK.F&SDVY7W<7BJ>OJKA+
M)"LJ4=*U2(E^$HEF/=,"]GNL[I$9)Y97[2<B-=G6/J)2=3MY2[DH;0;13+0T
MMOBBE:*2LJEIC*WQ=<\($9J&[O:55:01T\,,?=<IR/#K'B1JK5&UK=N"LL3"
MK1;G95;C$@>P_$0C<X>F2EFH,)D(=8Z"RDX[9*(,6.QW''6VVISS<-I]%]F[
M-WC>M[VE*]KM>6K&,-341O0VY;C4+4UJ6^!((G19IE4*:B6H:&',4152<_=U
M]9-Y;PVA9-DW:2A%GLBT85Z:FD2MN#6ZG-)1O<)Y)Y5D:&$DGLQ0B24"20,P
M7$H<H3G.<YQ\\_C\_P /EC^SJV\?KDZJG6[&.V.V/ICY8Z::.FFCIIHZ::.F
MFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::X5#L*<0ZII"G6_/Z;BL=UM
M^KVPYAM6?FC#F,8PO"<XPK&,=^_;'337-TTT=--'331TTT=--'331TTT=--?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_5.jpg
<TEXT>
begin 644 image_5.jpg
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M 0$! 0$! 0$! 0'_P  1" $Z E(# 1$  A$! Q$!_\0 'P !  (!!0$! 0
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MT2W7*?=;K#MJVZ[S;%U8F94EV7<HL4)33,7<-DA!+$U1IUW=-@@H3BCMB-9
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M=ZX+(*3;:CM9-5%-MN+Q7 VK#O8WY1UOVCL?775$[K"/NG:=:L^O8 $15]K
M*V<KEBKH<\='V*V35)L26W0(D>O$:+!=)%"PN+*A?$?5MT [/:LN\O4&%,U
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M3"&X@*<]PVW)"E)7*$C:IN$P3:$O"K#=L?$;(]+\0$[2T82M FO4>F6/9FP
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M@A/$0$F[013/G77Q8-<;VJVP]DD-;$*5JK7^GK/N\E=!VU-0;,G"*K4T+E$
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M;:8D?3NA5,F/DR^6^[-?+<*P7%V.U+9^39TY]([)D,AIM9417-H1DQU43(<
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M5TNC .$<4G6A9D7>6'^S.,DZUNA<52!3*TE:@>F1BCR(<0\"@QW4ZR)QE*#
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MV$5!-"9?L.H?9^*'$F),.1[+[;;S7NLK]MUM#B/):4JPI6IC(*K!V&L9$UP
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MC2-FMMO@%:YK-VKF"YR\S39&VJ@(3=B@.HAK))/3TG*K #$ZME+D:15PU0G
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ME"7P@D/** 941@A%ASH)@S,#=(Z/]6V_3+K[D\9"@A*^ L"CIO&H@&Z "4
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M!PR4G5%JL+=)$R%"<EM7;?R&91,N1]VK;A-&W%-'7([CB''2.X^L9_B^125
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M'%;WKKFPH-AM)M'Y"+M<*R5EB-7NYP+:U<+?#2?.CP5GSY&YMT,I#H-H_-D
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MV7%L.I6VXI.>;=*,^=;[%:S@3)4$Y.J+!#?DQ'W8SPQ7Y:[X-ZR0'NW$%&W
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M.*4XI3BE8^V1JRB[;"QJ]?@[Y@5$FNSX[40Y8*[*;?DBB8&>U@G62H<FJ 5
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MO:QU.*4XI3BE.*4XI3BE.*4XI44N[]'CUDH[L9RK-4[#&?G*KGD5BN9CY_\
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M%.;N9.,H,A$C$MP:&8JQT:S(4W%\IUU3D;]=A;::27];9;1D!5B,J*TD0X"
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MF"K0ZZV6H1]P7(FF)3-5Q*3LNPZZ+GMP18UOBV%K!R8'$01<6R@](QVK=;@
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M.G,G*]2ZH'(2B)&1,>@@!C'Q&$QT\4ROJY8X?16_M'7+25RER2-AUX&F%I)
MD8P;CO$A1^":+S* 0G'0Q\1.@&0)Y4_5FO)L<X$G#RT"540\B!,C.L*6M49[
M/CM]ZU&'.GW6=Q<?.=/51N/%!/UYD9'21BA/@)='G:TF2'@$:>T%DG9NO",F
MDSK1(@.V:;5_A@DHN\/@PF(ZIROQZ_IX^>N4/=6>OUE0027U@!<=*3GB4V;"
M>*B"CLR6=VI8R#C98.1@$XS9<GO'<.#<:-+9C'!FRKD"+LS09V<.=4RO?R_E
M[DKBHO3WK5"=DO0]3 (BI$YD@RB-,.L1Q"X]V:V.S#K,5HLB-4PK=Z;>M&*_
M661(+YL2.2,CL_4!Q)!3*K\>&/CU\TKD(/5+KN-+1#4'5-:CS1V:LX,0G!!0
MT5,I<JE2Z\7$!7)RPPH_%=UOK]N;81T",<-1*96H!L@1@AX,=E3*_'I]ZUF:
MN5BOU$?($UH5$##I1VTV>1#A(4AEX_=K,7N=K*KPI2LYEG;2?,G)Z_/R<G$9
M+B4H2K"<*BN>XI3BE.*4XI3BE.*5%[P'-V"F6L'6C\BJV,O73(X!9HB&G)%?
M-S!\A@4:::>:?9>4,G+8F99=9=;>PSEI;:TKSC*E1O3M_7LW6U6N,J%@4:FP
MWQUL!X5ZE5R\5Z;)KUXK3N<YSG+E>M@LP'4O.?[WX+#R?-#B<YE4POQR[*A%
MRG=_+A63.14TXI3BE8TW1;+%0M/;7O-0'BR]LIFM;U;*P*.?-LA2=AKM7*&
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M45OM.H>F+5,9PI]PAD[9X"JFW;=/":!:;?'(D46GKHX;+K[Z"HD+K;R@).R
M/T-JF$%VONDOZ/>B9C06NTW &=07417=WG5I-DY?;M* %0WV+*RW(8C1B/:
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M_P E./>GJ7WT^G^Q/ZUM._P'N/\ N&XR'WI?UD_R4X]Z>I??3Z?[$_K6T[_
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M%QIP4-LQ7[T@)"3P6K1QLV7'&G14'&C-MP"^R P)1,5\1)%1?%*VHT=.,$8
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M=%.Z>/E0RXI+Z8L.SQ(:Y6&&.EH8^40H92+E=J"AOAE1GACN3AY\YSX<.%1
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MDY;,O5NBXRMNRXTN/%LUPL*.:B>CBS,1IJ.Q<$<;?>+;C0'SP*,F+&[M+?\
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M/S678_\ QW4_[S63\&<?4]:Y_#-.?V^=_"Z?59=&?XOU?^B[9_&Z?FLNQ_\
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MGU671G^+]7_HNV?QNGYK+L?_ ([J?]YK)^#./J>M<_AFG/[?._A=/JLNC/\
M%^K_ -%VS^-T_-9=C_\ '=3_ +S63\&<?4]:Y_#-.?V^=_"Z?59=&?XOU?\
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M !W4_P"\UD_!G'U/6N?PS3G]OG?PNGU671G^+]7_ *+MG\;I^:R['_X[J?\
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MPJ-?&)("V50LV&J!Q-FN>@-(R+5K2PNZX'O3F*_;=X$J_9MC-B(PRQ5C7S9
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+')#JEJ5*N*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
